Caly: Es gibt doch noch Hoffnung !!! - 500 Beiträge pro Seite (Seite 4)
eröffnet am 26.09.02 16:02:50 von
neuester Beitrag 24.02.03 12:00:21 von
neuester Beitrag 24.02.03 12:00:21 von
Beiträge: 2.507
ID: 639.234
ID: 639.234
Aufrufe heute: 0
Gesamt: 86.716
Gesamt: 86.716
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 29 Minuten | 6247 | |
vor 34 Minuten | 5007 | |
vor 37 Minuten | 4148 | |
vor 43 Minuten | 3758 | |
vor 29 Minuten | 2585 | |
heute 14:53 | 1943 | |
heute 15:18 | 1918 | |
heute 13:07 | 1476 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.177,64 | +1,38 | 235 | |||
2. | 2. | 1,1100 | -19,57 | 118 | |||
3. | 3. | 0,1905 | +0,79 | 97 | |||
4. | 5. | 9,3450 | +1,08 | 63 | |||
5. | 4. | 171,59 | +0,83 | 54 | |||
6. | Neu! | 0,4250 | -1,16 | 39 | |||
7. | Neu! | 11,905 | +14,97 | 36 | |||
8. | Neu! | 4,7750 | +6,47 | 35 |
1 minute gehandelt!!! 33 trades und kurs 14,1 cent bei kanpp 190.000 stücken...uffff
Last 10 trades
Time Price Volume Exchange Info
09:32:15 0.139 26100 OTCBB
09:32:08 0.141 10000 OTCBB
09:31:31 0.141 9600 OTCBB
09:31:31 0.141 4600 OTCBB
09:31:31 0.141 200 OTCBB
09:31:21 0.140 1000 OTCBB
09:31:21 0.140 1000 OTCBB
09:31:21 0.140 16900 OTCBB
09:31:18 0.140 1000 OTCBB
09:31:16 0.139 20000 OTCBB
09:31:05 0.140 4000 OTCBB at Bid
09:31:05 0.139 5000 OTCBB at Bid
09:31:57 0.141 5000 OTCBB at Ask
09:31:54 0.139 6000 OTCBB at Bid
09:31:51 0.140 5000 OTCBB
09:30:49 0.140 10000 OTCBB
09:30:45 0.139 200 OTCBB at Bid
09:30:45 0.140 1500 OTCBB
09:30:39 0.140 4000 OTCBB
09:30:39 0.140 800 OTCBB
Time Price Volume Exchange Info
09:32:15 0.139 26100 OTCBB
09:32:08 0.141 10000 OTCBB
09:31:31 0.141 9600 OTCBB
09:31:31 0.141 4600 OTCBB
09:31:31 0.141 200 OTCBB
09:31:21 0.140 1000 OTCBB
09:31:21 0.140 1000 OTCBB
09:31:21 0.140 16900 OTCBB
09:31:18 0.140 1000 OTCBB
09:31:16 0.139 20000 OTCBB
09:31:05 0.140 4000 OTCBB at Bid
09:31:05 0.139 5000 OTCBB at Bid
09:31:57 0.141 5000 OTCBB at Ask
09:31:54 0.139 6000 OTCBB at Bid
09:31:51 0.140 5000 OTCBB
09:30:49 0.140 10000 OTCBB
09:30:45 0.139 200 OTCBB at Bid
09:30:45 0.140 1500 OTCBB
09:30:39 0.140 4000 OTCBB
09:30:39 0.140 800 OTCBB
da begreift doch mal einer die Amis?????!!!!
danke nachmal an alle, die vorhin ihre stücke in panik rausgeworfen haben!
(das musste mal sein)
(das musste mal sein)
Einen dankeschön an alle die für 0,11 verkauft haben.
Salut
Salut
@ js
"trotzdem"? versteh ich nicht.
und daß der gewinn/verlust bei CALY ziemlich unabhängig vom umsatz ist, habe ich unten schon angemerkt, du selbst hast es in #1474 gesagt. es sei denn, du meintest er spiele im bezug auf eine investmententscheidung keine rolle, das kann dann ja wohl nur ein witz gewesen sein.
"trotzdem"? versteh ich nicht.
und daß der gewinn/verlust bei CALY ziemlich unabhängig vom umsatz ist, habe ich unten schon angemerkt, du selbst hast es in #1474 gesagt. es sei denn, du meintest er spiele im bezug auf eine investmententscheidung keine rolle, das kann dann ja wohl nur ein witz gewesen sein.
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.14 0.003 (2.19) 0.139 (50) 0.141 (50) 09:35
Day Volume Last Size Open High Low
366,100 10,000 0.141 0.141 0.139
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-+ 49
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.14 0.003 (2.19) 0.139 (50) 0.141 (50) 09:35
Day Volume Last Size Open High Low
366,100 10,000 0.141 0.141 0.139
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-+ 49
09:39:10 0.141 2500 OTCBB at Ask
09:39:07 0.141 5000 OTCBB at Ask
09:39:01 0.139 5000 OTCBB at Bid
09:38:25 0.141 25000 OTCBB at Ask
09:36:56 0.141 5000 OTCBB at Ask
09:39:07 0.141 5000 OTCBB at Ask
09:39:01 0.139 5000 OTCBB at Bid
09:38:25 0.141 25000 OTCBB at Ask
09:36:56 0.141 5000 OTCBB at Ask
ja danke für alle Panik-Leute!!!
lächerlich!!
wer hat schon gute Zahlen erwartet bitte ?!?!
der Weg zu 0,22 EUR steht offen!!!
lächerlich!!
wer hat schon gute Zahlen erwartet bitte ?!?!
der Weg zu 0,22 EUR steht offen!!!
Last: 0.139
High: 0.141
Low: 0.139
Open: 0.141
Change: +0.00
Volume: 401,300
Bid: 0.139
Ask: 0.145
09:41:12 0.139 24000 OTCBB
09:41:03 0.139 10000 OTCBB
09:41:03 0.140 10000 OTCBB
09:41:52 0.140 5000 OTCBB
09:41:52 0.140 2600 OTCBB
09:40:49 0.140 700 OTCBB
High: 0.141
Low: 0.139
Open: 0.141
Change: +0.00
Volume: 401,300
Bid: 0.139
Ask: 0.145
09:41:12 0.139 24000 OTCBB
09:41:03 0.139 10000 OTCBB
09:41:03 0.140 10000 OTCBB
09:41:52 0.140 5000 OTCBB
09:41:52 0.140 2600 OTCBB
09:40:49 0.140 700 OTCBB
@LOSS_PRO
Im Prinzip ist es egal wie man Resultate erzielt:
ZBS: Angepeilter Gewinn 1 MIO
Man kann 100Mio Umsatz haben, Reingewinn zbs. 1 MIO
Man kann 10 Mio Umsatz haben, Reingewinn zbs. 1 MIO
Wer arbeitet besser ????????
Beide haben das ZIEL erreicht!!!!!!
JS200
Im Prinzip ist es egal wie man Resultate erzielt:
ZBS: Angepeilter Gewinn 1 MIO
Man kann 100Mio Umsatz haben, Reingewinn zbs. 1 MIO
Man kann 10 Mio Umsatz haben, Reingewinn zbs. 1 MIO
Wer arbeitet besser ????????
Beide haben das ZIEL erreicht!!!!!!
JS200
09:46am ET
0.142
0.01 (3.64%)
Day`s Range: 0.139 - 0.142
Day`s Volume: 725,400
Avg. Volume: 2,215,966
JS200
0.142
0.01 (3.64%)
Day`s Range: 0.139 - 0.142
Day`s Volume: 725,400
Avg. Volume: 2,215,966
JS200
Ich glaub das nicht 0,1460 im Ask
david
david
09:48:55 0.143 5000 OTCBB
09:47:40 0.142 5000 OTCBB
09:47:26 0.143 1000 OTCBB at Ask
09:46:49 0.142 5000 OTCBB
Last: 0.143
High: 0.143
Low: 0.139
Open: 0.141
Change: +0.00
Volume: 584,900
Bid: 0.141
Ask: 0.146
09:47:40 0.142 5000 OTCBB
09:47:26 0.143 1000 OTCBB at Ask
09:46:49 0.142 5000 OTCBB
Last: 0.143
High: 0.143
Low: 0.139
Open: 0.141
Change: +0.00
Volume: 584,900
Bid: 0.141
Ask: 0.146
leute, ich glaube es sind nicht die zahlen, die den kurs stabilisieren. es ist der anstehende conference-call, auf welchem die zahlen als grundlage genommen werden sollen, alsp auch wieder ein blick in die zukunft...
mittlerweile ist der kurs bei 0,143. spanne 0,143 -. 0,144!!! 93 trades bei 751.000 stücken
mittlerweile ist der kurs bei 0,143. spanne 0,143 -. 0,144!!! 93 trades bei 751.000 stücken
09:50am ET
0.145
0.01 (5.83%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 802,100
Avg. Volume: 2,215,966
JS200
0.145
0.01 (5.83%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 802,100
Avg. Volume: 2,215,966
JS200
09:50:29 0.144 10000 OTCBB
09:50:29 0.145 10000 OTCBB
09:50:26 0.145 5000 OTCBB
09:50:29 0.145 10000 OTCBB
09:50:26 0.145 5000 OTCBB
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.145 0.008 (5.84) 0.144 (50) 0.145 (50) 09:50
Day Volume Last Size Open High Low
802,100 6,200 0.141 0.145 0.139
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+-++ 100
100 trades!!!!!
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.145 0.008 (5.84) 0.144 (50) 0.145 (50) 09:50
Day Volume Last Size Open High Low
802,100 6,200 0.141 0.145 0.139
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+-++ 100
100 trades!!!!!
laß mal überlegen... hmmm, die mit den 10 mios vielleicht?
da es sich bei CALY aber um verluste handelt, wäre dir 1 mio verlust bei 100 oder 10 mio umsatz lieber?
da es sich bei CALY aber um verluste handelt, wäre dir 1 mio verlust bei 100 oder 10 mio umsatz lieber?
Bid: 0.144
Ask: 0.180
09:52:32 0.145 2600 OTCBB
09:52:52 0.145 5000 OTCBB
09:51:28 0.144 15700 OTCBB
09:51:28 0.144 4300 OTCBB
Ask: 0.180
09:52:32 0.145 2600 OTCBB
09:52:52 0.145 5000 OTCBB
09:51:28 0.144 15700 OTCBB
09:51:28 0.144 4300 OTCBB
company news
--------------------------------------------------------------------------------
CALY - Calypte Biomedical Corporation (OTCBB : CALY)
--------------------------------------------------------------------------------
CALY Reports Q3 EPS (2c) vs (5c) Last Yr. on Rev $493K
THURSDAY , OCTOBER 24, 2002 09:20 AM
Calypte Biomedical Corporation (OTCBB:CALY) today announced financial results for the third quarter ended September 30, 2002.
For the third quarter of 2002, Calypte recorded revenues of $493,000 compared to $1.5 million in the third quarter of 2001.
The net loss attributable to common stockholders for the quarter was approximately ($1.5) million, or ($0.02) per common share, compared to a net loss of ($1.7) million, or ($0.05) per common share for the three months ended September 30, 2001.
GUIDANCE
No forward guidance was provided by the company in the above referenced press release.
JS200
--------------------------------------------------------------------------------
CALY - Calypte Biomedical Corporation (OTCBB : CALY)
--------------------------------------------------------------------------------
CALY Reports Q3 EPS (2c) vs (5c) Last Yr. on Rev $493K
THURSDAY , OCTOBER 24, 2002 09:20 AM
Calypte Biomedical Corporation (OTCBB:CALY) today announced financial results for the third quarter ended September 30, 2002.
For the third quarter of 2002, Calypte recorded revenues of $493,000 compared to $1.5 million in the third quarter of 2001.
The net loss attributable to common stockholders for the quarter was approximately ($1.5) million, or ($0.02) per common share, compared to a net loss of ($1.7) million, or ($0.05) per common share for the three months ended September 30, 2001.
GUIDANCE
No forward guidance was provided by the company in the above referenced press release.
JS200
nach den nachrichten in der letzten zeit und den news hat der kurs einfach nachholbedarf. aber ich glaube nicht, daß die 0,20 lange halten würde, wenn es denn so käme, denn so gut waren die zahlen jetzt nicht und aufgrun´d dessen die zahlen für das nächste quartal auch nicht!!!
umsatzsteigerung: 50 - 75% geplant
umsatzsteigerung: 50 - 75% geplant
company news
--------------------------------------------------------------------------------
CALY - Calypte Biomedical Corporation (OTCBB : CALY)
--------------------------------------------------------------------------------
CALY Conference Call Today at 11:00 AM ET
THURSDAY , OCTOBER 24, 2002 09:27 AM
Calypte Biomedical Corporation (OTCBB : CALY) will host a conference call today.
Date: Thursday, October 24, 2002
Time: 11:00 AM ET
Subject: The Company will discuss its 2002 Q3 earnings.
Location: The call will be webcast live and can be accessed from the Investors section of the Company`s website at www.calypte.com. A replay will also be archived on this website.
JS200
--------------------------------------------------------------------------------
CALY - Calypte Biomedical Corporation (OTCBB : CALY)
--------------------------------------------------------------------------------
CALY Conference Call Today at 11:00 AM ET
THURSDAY , OCTOBER 24, 2002 09:27 AM
Calypte Biomedical Corporation (OTCBB : CALY) will host a conference call today.
Date: Thursday, October 24, 2002
Time: 11:00 AM ET
Subject: The Company will discuss its 2002 Q3 earnings.
Location: The call will be webcast live and can be accessed from the Investors section of the Company`s website at www.calypte.com. A replay will also be archived on this website.
JS200
berlin stellt 0,14 - 0,16 , so wie fra. na dann kauft mal schön zurück...eine gewisse schadenfreude kann ich momentan nicht verhehlen...
ich sagte es ja schon,
caly hat trotz schwächeren umsatzes, verluste verringert!!!
und das wird vom markt honoriert. umsatz ist heute nicht mehr alles.
man muß mit dem vorhandenen das bestmögliche erzielen und ich finde cataldo hat das ganz gut gemacht. das sollte an dieser stelle auch mal an jene gesagt werden, die ständig genörgelt haben. caly hat sich und das meine ich allen ernstes stabilisiert. ich bin schon auf die conference call gespannt. ihr wisst ja, bei 0,15 kaufe ich nach. unter umständen daher schon heute.
ich verstehe nicht alles an der börse, aber der heutige verlauf ist bis jetzt ganz normal. caly hat wirklich keine hororzahlen gebracht.
..... und einige experten unter euch verstehen aber leider nicht sehr viel.......ohne jemanden beleidigen zu wollen.
mfg. bittermoon
caly hat trotz schwächeren umsatzes, verluste verringert!!!
und das wird vom markt honoriert. umsatz ist heute nicht mehr alles.
man muß mit dem vorhandenen das bestmögliche erzielen und ich finde cataldo hat das ganz gut gemacht. das sollte an dieser stelle auch mal an jene gesagt werden, die ständig genörgelt haben. caly hat sich und das meine ich allen ernstes stabilisiert. ich bin schon auf die conference call gespannt. ihr wisst ja, bei 0,15 kaufe ich nach. unter umständen daher schon heute.
ich verstehe nicht alles an der börse, aber der heutige verlauf ist bis jetzt ganz normal. caly hat wirklich keine hororzahlen gebracht.
..... und einige experten unter euch verstehen aber leider nicht sehr viel.......ohne jemanden beleidigen zu wollen.
mfg. bittermoon
läuft suppi
gruss - allen noch investierten - fhr
gruss - allen noch investierten - fhr
wenn wir die 0,14 heute halten, bin ich schon zufrieden...
10:00am ET
0.14
0.00 (2.18%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 1,226,900 innerhalb 30 Minuten
Avg. Volume: 2,215,966
JS200
0.14
0.00 (2.18%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 1,226,900 innerhalb 30 Minuten
Avg. Volume: 2,215,966
JS200
Merkwürdig, merkwürdig! Bin zum gleichen Preis mit 3/4 der verkauften Hälfte wieder rein. Irgendwie gefällt mir die Reaktion nicht so richtig. Trotzdem ist das Volumen für die erste halbe Stunde recht hoch - und das bei steigendem Kurs!!!
...so, ich klinke mich erst einmal aus! Schönes Wetter, draußen! Ich hoffe, daß sich der Wiedereinstieg nicht rächt! Also, bis heute abend!
bio
bio
@bio
dito
dito
wachstum at least 50-75% auf deutsch zumindest 50-75%
ich sehe caly demnächst bei 0,2.
china alleine macht das nicht aus.
da kommen noch weiter news.
vielleicht sogar noch heute.
wie wäre es mit USA und Canada
mfg. bittermoon
ich sehe caly demnächst bei 0,2.
china alleine macht das nicht aus.
da kommen noch weiter news.
vielleicht sogar noch heute.
wie wäre es mit USA und Canada
mfg. bittermoon
10:29am ET
0.141
0.00 (2.91%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 1,382,600
Avg. Volume: 2,215,966
JS200
0.141
0.00 (2.91%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 1,382,600
Avg. Volume: 2,215,966
JS200
So und bei 0,14 wieder raus .Das macht Spass hier.
Salut
Salut
So jetzt sitzen alle schön brav auf den Stühlen in der Conferenz und lauschen.
0 Trade seit 10 Minuten
JS200
0 Trade seit 10 Minuten
JS200
@LUX2001
Ech hat Menz net soss wir ech och dru gaang
JS200
Ech hat Menz net soss wir ech och dru gaang
JS200
verhaltener optimismus vor dem conference-call!!!
kurs bei 14,1 cent. 178 trades. spanne: 14 - 14,2 cent umsatz:knapp 1,4 mio. stücke.
ich glaube, entweder geht es nach dem conference call richtig hoch oder runter. die aussichten/ergebnisse, die dor gehandelt werden dürften elementar sein. das die vergangenheit auf gut deutsch scheiße war, wissen alle. auch die zahlen fallen nicht schwer ins gewicht, wenn die perpektiven stimmen. sollten sich optionen auf neue investoren/absatzmärkte herauskristallisieren, sehen wir ganz schnell die 0,20, ansonsten die 0,10...
meine meinung!!!
kurs bei 14,1 cent. 178 trades. spanne: 14 - 14,2 cent umsatz:knapp 1,4 mio. stücke.
ich glaube, entweder geht es nach dem conference call richtig hoch oder runter. die aussichten/ergebnisse, die dor gehandelt werden dürften elementar sein. das die vergangenheit auf gut deutsch scheiße war, wissen alle. auch die zahlen fallen nicht schwer ins gewicht, wenn die perpektiven stimmen. sollten sich optionen auf neue investoren/absatzmärkte herauskristallisieren, sehen wir ganz schnell die 0,20, ansonsten die 0,10...
meine meinung!!!
alle halten den atem an. es ist spannend. der conference-call läuft!! wer ist live zugeschaltet und kann aktuell berichten, was gesprochen wird?????? habe leider nicht die zeit!!!
der kurs in amiland verharrt auch. seit 10 min. kein umsatz. derzeit glatt 14 cent(16.56h), glatt 200 trades. 1.638.900 st. gehandelt. 14 cent auf 14,2 cent....
ruhe, absolute ruhe.........
der kurs in amiland verharrt auch. seit 10 min. kein umsatz. derzeit glatt 14 cent(16.56h), glatt 200 trades. 1.638.900 st. gehandelt. 14 cent auf 14,2 cent....
ruhe, absolute ruhe.........
Können zur Telefonkonferenz nicht lediglich (potentielle) Investoren zugeschaltet werden ?? Oder kann da jeder zuhören ?? MfG X 99
kann jeder rein, bin auch drin.
Gefakt
Gefakt
...und alle halten die Luft an.pilgern wir gen norden oder nach süden????????
mfg fieldi.
mfg fieldi.
Net Loss von -5 auf -2Cent?
Hab ich das richtig gehört?
Hab ich das richtig gehört?
also wenn ich es richtig verstanden habe, dann gibt es das ergebnis des 2. tests durch die who in 2 wochen detailliert auf deren webseite?? bisher "under construction"; übrigens: nancy hat ´ne geile stimme...
also ich lausche weiter jetzt geht´s um china
also ich lausche weiter jetzt geht´s um china
kann mir bitte jemand realtime kurse reinstellen?
habe keine verbindung.
danke
mfg. bittermoon
habe keine verbindung.
danke
mfg. bittermoon
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.14 0.003 (2.19) 0.14 (50) 0.142 (50) 11:27
Day Volume Last Size Open High Low
1,781,200 3,000 0.141 0.145 0.139
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+-+- 219
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.14 0.003 (2.19) 0.14 (50) 0.142 (50) 11:27
Day Volume Last Size Open High Low
1,781,200 3,000 0.141 0.145 0.139
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+-+- 219
Calypte verkündet drittes Trimester und Neun-Monat finanzielles Results;Management erwartet aufeinanderfolgendes Ertrag- im vierten quartalwachstum von mindestens 50 to75% ALAMEDA, Calif., Okt 24, 2002 (GESCHÄFT LEITUNG) -- Calypte Biomedical Corporation (OTCBB:CALY), der Entwickler und der Marketingspezialist der einzigen zwei FDA-anerkannten Tests des Antikörpers Hiv-1, die auf Urin benutzt werden können probiert, sowie ein zusätzlicher Test des FDA-anerkannten Antikörper des Serums Hiv-1 westlichen Flecks, verkündete heute finanzielle Resultate während des dritten Trimesters und neun Monate beendeten September 30, 2002. Während des dritten Trimesters erzielte die Firma zahlreiche Meilensteine, denen Management hilft Position Calypte für langfristiges Wachstum glaubt. Vollendungen Jahr umfassen bis jetzt: -- empfangene Finanzierung von über $7 Million, nachdem die Firma seine geschlossenen Pläne aufhob und seine Betriebe wiederbegann. -- Rehired 100% des oberen Managementpersonals, der dem Wiederanlauf von Betrieben folgt. -- wieder aufgenommenes Geschäft mit allen Versicherungsgesellschaften des Calypte`s Premier US nach dem Wiederanlauf, der 9 der oberen 10 Versicherung Versorger miteinschließt. Die Versicherung Fördermaschinen sind fortgefahren, Erwerbe durch die Hauptlabors abzuschließen. -- schloß einen neuen Vertrag mit einem Verteiler für westliches Fleckgeschäft des Serums. -- empfangener erster Auftrag für Burkina Faso in Westafrika. -- geförderter Besuch durch Dr. Luc Montagnier zu den chinesischen Gesundheitsämtern. Dr. Montagnier, Weltgrundlage für AIDS Forschung und Verhinderungpräsidenten, Co-entdeckte Hiv-1 und entdeckte Hiv-2. -- vermittelt und Anfang Oktober, schloß einen zweijährigen Verteilung Vertrag mit einem chinesischen pharmazeutischen Verteiler, ZYPute, für die minimalen Erwerbe, die ungefähr $3 Million zusammenzählen. Empfing den ersten kommerziellen Auftrag für 100.000 Tests. -- zuletzt hinzugefügt von 50 Zuständen Genehmigung durch die zuständige Aufsichtsbehörde Liste für die Lebensversicherungprüfung des Urins Hiv-1. -- leitete eine einleitende UntersuchungsSitzung der vorrichtung Befreiung (vor-Pre-IDE) mit der Nahrung und der Droge-Leitung (FDA), mit einem Ziel der Beschleunigung des FDA-Annahmeprozesses für den schnellen Urintest. Die Firma plant, die IDE Anwendung im Dezember 2002 einzureichen und US klinische Studien im Februar 2003 einzuleiten. -- abgeschlossene Phase eins, die auf drei Calypte Urintests mit der Weltgesundheitsorganisation (WHO) prüft. -- konzentriert auf das Entwickeln der strategischen Bündnisse und das Wieder.aufnehmen der Auswertungen von Urin HIV prüfend mit Schlüssel, einflußreiche Kunden. -- stellte die Resultate der Möglichkeit zur Schau, die auf den schnellen HIV Urin-Test bei der Vereinigte Staaten Konferenz auf AIDS, in Anaheim, Kalifornien prüft. -- gesicherte FDA-Zustimmung für und eingeführt einigen Herstellung-in Verbindung stehenden cost-reduction/saving mißt. Anthony Cataldo, Calypte`s der Executivvorsitzende, angegeben, "unser Ziel für das Viertel sollte eine Bargeld-begrenzte Firma mit einem hervorragenden Produkt nehmen und fängt an, eine Welt-Kategorie Marketing- und Verteilungsplattform zu errichten. Unter unseren bedeutendsten Meilensteinen war das Unterzeichnen einer neuen Verteilung Vereinbarung in China, das minimale Kaufauftraganforderungen umfaßt, und hat uns einen neuen Auftrag von diesem großen und erweiternmarkt bereits geholt. Wir trafen auch die FDA beschleunigen die Entwicklung unseres schnellen Tests des Urin-Hiv-1 in den Vereinigten Staaten. Zusätzlich führen unsere inländischen Verteilung Partner auf ihrem Marketing und Verkäufe Programmen."durch Cataldo fuhr, "fort, obgleich die Trimesterresultate durch die Tatsache, die wir durch die meisten unseres Warenbestands im zweiten Viertel während der Abschaltung Phase verkauften, wir erwarten Resultate des 4. Viertels, um bedeutenden Fortschritt in unserer Wiederaufnahme zu reflektieren ausgewirkt wurden. An diesem Punkt nehmen wir aufeinanderfolgendes Einkommen Wachstum von mindestens 50 bis 75 % während des 4. Viertels."vorweg Während des dritten Trimesters von 2002, notierte Calypte Einkommen von $493.000 verglichen bis $1,5 Million im dritten Trimester von 2001. Der Reinverlust, der allgemeinen Aktionären für das Viertel zuzuschreibend ist, war ungefähr $1,5 Million, oder $0,02 pro den allgemeinen Anteil, verglichen mit einem Reinverlust von $1,7 Million oder $0,05 pro allgemeinen Anteil für die drei Monate beendeten September 30, 2001. Nancy Katz, Calypte`s vor
haltet uns bitte bez. news aus dem conference-call auf dem laufenden!!!!!!!!!!!!!!!!!!!!!!!!
11:31am ET
0.142
0.01 (3.64%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 1,792,200
Avg. Volume: 2,215,966
JS200
0.142
0.01 (3.64%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 1,792,200
Avg. Volume: 2,215,966
JS200
es wurden bis jetzt die allgemeinen info darfgesetllt, die wir schon kennen. die ausblicke seitens caly sind durchweg gut und langfristig.
zur zeit gerade frag-antwort; jetzt gerade zu den reservesplitz....
to be continued
zur zeit gerade frag-antwort; jetzt gerade zu den reservesplitz....
to be continued
eine wichtige frage war gerade, ob sich die steigerungen von 50-75% auf noch dieses jaht beziehen; die antwort war :ja.....
sorry für meine rechtschreibung, aber ich möchte euch schnell informieren und doch alles mitkriegen
11:44am ET
0.143
0.01 (4.37%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 1,927,400
Avg. Volume: 2,215,966
JS200
0.143
0.01 (4.37%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 1,927,400
Avg. Volume: 2,215,966
JS200
SUPER 3007t, weiter so, vielen dank. das gesagt scheint gut anzukommen kurs derzeit 14,3 cent und es wird schön in das ask gekauft!!!! spanne 14,2 auf 14,3.
berichte bitte weiterhin!!!
berichte bitte weiterhin!!!
@3007t
is schon ok, und danke schonmal für den Service...
in USA gibts schon die ersten Trades:
24.10.2002 17:10 .1420 2000 Trade
24.10.2002 17:10 .1400 5000 Trade
24.10.2002 17:10 .1400 5000 Trade
24.10.2002 17:10 Best Bid .1400 5000 .1420 5000
24.10.2002 17:10 Best Ask .1400 5000 .1410 5000
24.10.2002 17:10 .1410 2000 Trade
24.10.2002 17:10 .1410 500 Trade
24.10.2002 17:11 Best Bid .1400 5000 .1410 5000
24.10.2002 17:11 Best Ask .1400 5000 .1420 5000
24.10.2002 17:11 .1420 15000 Trade
24.10.2002 17:12 .1410 35000 Trade
24.10.2002 17:12 .1420 3500 Trade
24.10.2002 17:12 .1410 25000 Trade
24.10.2002 17:13 Best Bid .1410 5000 .1420 5000
24.10.2002 17:13 Best Ask .1410 5000 .1420 5000
24.10.2002 17:15 .1410 1600 Trade
24.10.2002 17:15 .1420 11300 Trade
24.10.2002 17:22 Best Bid .1400 5000 .1420 5000
24.10.2002 17:22 Best Ask .1400 5000 .1420 5000
24.10.2002 17:22 .1410 5000 Trade
24.10.2002 17:23 .1400 5000 Trade
24.10.2002 17:23 .1420 1000 Trade
24.10.2002 17:26 .1400 10000 Trade
24.10.2002 17:26 .1400 10000 Trade
24.10.2002 17:26 .1420 1000 Trade
24.10.2002 17:27 .1420 1400 Trade
24.10.2002 17:27 .1400 3000 Trade
24.10.2002 17:30 .1420 10000 Trade
24.10.2002 17:31 .1420 1000 Trade
24.10.2002 17:34 .1420 10000 Trade
24.10.2002 17:36 .1420 20000 Trade
24.10.2002 17:36 .1400 28000 Trade
24.10.2002 17:37 .1400 18000 Trade
24.10.2002 17:37 .1410 2000 Trade
24.10.2002 17:37 .1410 4000 Trade
24.10.2002 17:37 .1410 2000 Trade
24.10.2002 17:37 .1410 10000 Trade
24.10.2002 17:37 Best Bid .1410 5000 .1420 5000
24.10.2002 17:37 Best Ask .1410 5000 .1420 5000
24.10.2002 17:39 .1420 5000 Trade
24.10.2002 17:39 .1420 5000 Trade
24.10.2002 17:40 .1420 1200 Trade
24.10.2002 17:42 .1420 5000 Trade
24.10.2002 17:43 .1420 5000 Trade
24.10.2002 17:43 Best Bid .1420 5000 .1420 5000 MMMcl
24.10.2002 17:43 Best Ask .1420 5000 .1420 5000 MMMcl
24.10.2002 17:43 .1420 7000 Trade
24.10.2002 17:43 Best Bid .1410 5000 .1420 5000
24.10.2002 17:43 Best Ask .1410 5000 .1420 5000
24.10.2002 17:43 Best Bid .1410 5000 .1420 5000
24.10.2002 17:43 Best Ask .1410 5000 .1430 5000
24.10.2002 17:44 Best Bid .1420 5000 .1430 5000
24.10.2002 17:44 Best Ask .1420 5000 .1430 5000
24.10.2002 17:44 .1430 3000 Trade
24.10.2002 17:44 .1420 5000 Trade
24.10.2002 17:44 .1430 5000 Trade
24.10.2002 17:44 .1430 7500 Trade
24.10.2002 17:45 .1430 13000 Trade
24.10.2002 17:45 Best Bid .1420 5000 .1430 5000
24.10.2002 17:45 Best Ask .1420 5000 .1440 5000
24.10.2002 17:45 .1430 10000 Trade
24.10.2002 17:46 .1420 14200 Trade
24.10.2002 17:46 .1440 25000 Trade
24.10.2002 17:46 Best Bid .1410 5000 .1440 5000
24.10.2002 17:46 Best Ask .1410 5000 .1440 5000
24.10.2002 17:47 .1440 20000 Trade
24.10.2002 17:47 Best Bid .1420 5000 .1440 5000
24.10.2002 17:47 Best Ask .1420 5000 .1450 5000
24.10.2002 17:47 Best Bid .1430 5000 .1450 5000
24.10.2002 17:47 Best Ask .1430 5000 .1450 5000
is schon ok, und danke schonmal für den Service...
in USA gibts schon die ersten Trades:
24.10.2002 17:10 .1420 2000 Trade
24.10.2002 17:10 .1400 5000 Trade
24.10.2002 17:10 .1400 5000 Trade
24.10.2002 17:10 Best Bid .1400 5000 .1420 5000
24.10.2002 17:10 Best Ask .1400 5000 .1410 5000
24.10.2002 17:10 .1410 2000 Trade
24.10.2002 17:10 .1410 500 Trade
24.10.2002 17:11 Best Bid .1400 5000 .1410 5000
24.10.2002 17:11 Best Ask .1400 5000 .1420 5000
24.10.2002 17:11 .1420 15000 Trade
24.10.2002 17:12 .1410 35000 Trade
24.10.2002 17:12 .1420 3500 Trade
24.10.2002 17:12 .1410 25000 Trade
24.10.2002 17:13 Best Bid .1410 5000 .1420 5000
24.10.2002 17:13 Best Ask .1410 5000 .1420 5000
24.10.2002 17:15 .1410 1600 Trade
24.10.2002 17:15 .1420 11300 Trade
24.10.2002 17:22 Best Bid .1400 5000 .1420 5000
24.10.2002 17:22 Best Ask .1400 5000 .1420 5000
24.10.2002 17:22 .1410 5000 Trade
24.10.2002 17:23 .1400 5000 Trade
24.10.2002 17:23 .1420 1000 Trade
24.10.2002 17:26 .1400 10000 Trade
24.10.2002 17:26 .1400 10000 Trade
24.10.2002 17:26 .1420 1000 Trade
24.10.2002 17:27 .1420 1400 Trade
24.10.2002 17:27 .1400 3000 Trade
24.10.2002 17:30 .1420 10000 Trade
24.10.2002 17:31 .1420 1000 Trade
24.10.2002 17:34 .1420 10000 Trade
24.10.2002 17:36 .1420 20000 Trade
24.10.2002 17:36 .1400 28000 Trade
24.10.2002 17:37 .1400 18000 Trade
24.10.2002 17:37 .1410 2000 Trade
24.10.2002 17:37 .1410 4000 Trade
24.10.2002 17:37 .1410 2000 Trade
24.10.2002 17:37 .1410 10000 Trade
24.10.2002 17:37 Best Bid .1410 5000 .1420 5000
24.10.2002 17:37 Best Ask .1410 5000 .1420 5000
24.10.2002 17:39 .1420 5000 Trade
24.10.2002 17:39 .1420 5000 Trade
24.10.2002 17:40 .1420 1200 Trade
24.10.2002 17:42 .1420 5000 Trade
24.10.2002 17:43 .1420 5000 Trade
24.10.2002 17:43 Best Bid .1420 5000 .1420 5000 MMMcl
24.10.2002 17:43 Best Ask .1420 5000 .1420 5000 MMMcl
24.10.2002 17:43 .1420 7000 Trade
24.10.2002 17:43 Best Bid .1410 5000 .1420 5000
24.10.2002 17:43 Best Ask .1410 5000 .1420 5000
24.10.2002 17:43 Best Bid .1410 5000 .1420 5000
24.10.2002 17:43 Best Ask .1410 5000 .1430 5000
24.10.2002 17:44 Best Bid .1420 5000 .1430 5000
24.10.2002 17:44 Best Ask .1420 5000 .1430 5000
24.10.2002 17:44 .1430 3000 Trade
24.10.2002 17:44 .1420 5000 Trade
24.10.2002 17:44 .1430 5000 Trade
24.10.2002 17:44 .1430 7500 Trade
24.10.2002 17:45 .1430 13000 Trade
24.10.2002 17:45 Best Bid .1420 5000 .1430 5000
24.10.2002 17:45 Best Ask .1420 5000 .1440 5000
24.10.2002 17:45 .1430 10000 Trade
24.10.2002 17:46 .1420 14200 Trade
24.10.2002 17:46 .1440 25000 Trade
24.10.2002 17:46 Best Bid .1410 5000 .1440 5000
24.10.2002 17:46 Best Ask .1410 5000 .1440 5000
24.10.2002 17:47 .1440 20000 Trade
24.10.2002 17:47 Best Bid .1420 5000 .1440 5000
24.10.2002 17:47 Best Ask .1420 5000 .1450 5000
24.10.2002 17:47 Best Bid .1430 5000 .1450 5000
24.10.2002 17:47 Best Ask .1430 5000 .1450 5000
jetzt 14,4 cent und 14,3 auf 14,4 cent!!!!
............
jetzt 14,5 cent und 14,3 auf 14,5cent gestellt..........
............
jetzt 14,5 cent und 14,3 auf 14,5cent gestellt..........
11:49am ET
0.145
0.01 (5.83%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 2,049,600
Avg. Volume: 2,215,966
0.145
0.01 (5.83%)
Day`s Range: 0.139 - 0.145
Day`s Volume: 2,049,600
Avg. Volume: 2,215,966
schöne 20.000er blöcke immer. leute, das sieht gut aus!!! das wird was, wir bleiben heute bestimmt deutlich über 14 cent im schlußkurs!!!!! der conference-call kommt wohl gut an!!!!
abschließend hat sich cataldo noch mal für das interesse bedankt, er sei mit dem q3 ergebnis ?? und mit den erreichten fortschritten sehr zufrieden, ist optimistisch für die zukunft und will in zukunft auch weiterhin alle investierten umfassend informieren.
hauptinteresse scheint im moment in china zu liegen. die fragen zu finanzierung habe ich leider nicht so ganz mitbekommen. vielleicht könnt ihr aushelfen...
greetings 3007t
hauptinteresse scheint im moment in china zu liegen. die fragen zu finanzierung habe ich leider nicht so ganz mitbekommen. vielleicht könnt ihr aushelfen...
greetings 3007t
die Konferenz ist zu Ende
jetzt heißt es anschnallen die OTC zeigt ihr wahres Gesicht
Caly steigt und es wird sehr schnell hochgetaxt!!!!!!!!!!
mfg jojo
jetzt heißt es anschnallen die OTC zeigt ihr wahres Gesicht
Caly steigt und es wird sehr schnell hochgetaxt!!!!!!!!!!
mfg jojo
11:52am ET
0.146
0.01 (6.56%)
Day`s Range: 0.139 - 0.146
Day`s Volume: 2,152,000
Avg. Volume: 2,215,966
JS200
0.146
0.01 (6.56%)
Day`s Range: 0.139 - 0.146
Day`s Volume: 2,152,000
Avg. Volume: 2,215,966
JS200
dann: auf einen preis pro test wollte sich caly nicht festlegen; er soll aber nich so teuer sein (was immer das bedeuten mag). die instis, die dort angerufen haben, klangen alle sehr fröhlich und haben sich mit den antworten, die meiner meinung nach gut fundiert waren, zufrieden gegeben. es wurde sogar gescherzt.
ich denke, dass wir als nächstes so in ca. 2 wochen mirt einen bericht über die testergebnisse der who zu rechnen haben. dann sehen wir weiter.
3007t
ich denke, dass wir als nächstes so in ca. 2 wochen mirt einen bericht über die testergebnisse der who zu rechnen haben. dann sehen wir weiter.
3007t
nochmal für alle warmduscher, die heute zu 11cent verschenkt haben:
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.147 0.01 (7.30) 0.145 (50) 0.147 (50) 11:56
Day Volume Last Size Open High Low
2,182,000 5,000 0.141 0.147 0.139
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+-++ 266
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.147 0.01 (7.30) 0.145 (50) 0.147 (50) 11:56
Day Volume Last Size Open High Low
2,182,000 5,000 0.141 0.147 0.139
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+-++ 266
Da muss was ziemlich großes laufen.
Ask 0,147
david
Ask 0,147
david
also die erklärung in den steigenden kursen liegt dann wohl in den allgemein für glaubwürdig gehaltenen sehr guten zukunftsaussichten.
@biologist
hast du zeit gehabt, die conferenz zu verfolgen, wenn ja, sei doch bitte so nett und ergänze entsprechende informationen.
trotzdem: bahnbrechend neues gab es meiner meinung nach nicht.
schönen abend noch allen zusammen
@jojo
gibt´s dich noch??
3007t
@biologist
hast du zeit gehabt, die conferenz zu verfolgen, wenn ja, sei doch bitte so nett und ergänze entsprechende informationen.
trotzdem: bahnbrechend neues gab es meiner meinung nach nicht.
schönen abend noch allen zusammen
@jojo
gibt´s dich noch??
3007t
11:59am ET
0.147
0.01 (7.29%)
Day`s Range: 0.139 - 0.147
Day`s Volume: 2,203,900
Avg. Volume: 2,215,966
JS200
0.147
0.01 (7.29%)
Day`s Range: 0.139 - 0.147
Day`s Volume: 2,203,900
Avg. Volume: 2,215,966
JS200
Die Verkäufer zu 0,11€ werden staunen
12:04pm ET
0.148
0.01 (8.02%)
Day`s Range: 0.139 - 0.148
Day`s Volume: 2,217,000
Avg. Volume: 2,215,966
JS200
12:04pm ET
0.148
0.01 (8.02%)
Day`s Range: 0.139 - 0.148
Day`s Volume: 2,217,000
Avg. Volume: 2,215,966
JS200
Hallo 3007t
mich gibt es noch !!! Dich aber auch !!
habe Heute mein Depot geleert und für alles Caly gekauft bin 100% in Caly
alles andere ist mir Wurscht
NO RISK NO FUN Caly hat mir schonmal gutes Geld gebracht und jetzt hol ich mir wieder was ab.
mfg jojo
mich gibt es noch !!! Dich aber auch !!
habe Heute mein Depot geleert und für alles Caly gekauft bin 100% in Caly
alles andere ist mir Wurscht
NO RISK NO FUN Caly hat mir schonmal gutes Geld gebracht und jetzt hol ich mir wieder was ab.
mfg jojo
so jungs, wir sind auf tageshoch...
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.148 0.011 (8.03) 0.148 (50) 0.149 (50) 12:07
Day Volume Last Size Open High Low
2,236,900 10,000 0.141 0.148 0.139
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-+ 279
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.148 0.011 (8.03) 0.148 (50) 0.149 (50) 12:07
Day Volume Last Size Open High Low
2,236,900 10,000 0.141 0.148 0.139
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-+ 279
12:08pm ET
0.149
0.01 (8.75%)
Day`s Range: 0.139 - 0.149
Day`s Volume: 2,246,900
Avg. Volume: 2,215,966
JS200
0.149
0.01 (8.75%)
Day`s Range: 0.139 - 0.149
Day`s Volume: 2,246,900
Avg. Volume: 2,215,966
JS200
ASK 0,15
12:09pm ET
0.15
0.01 (9.48%)
Day`s Range: 0.139 - 0.15
Day`s Volume: 2,255,900
Avg. Volume: 2,215,966
JS200
0.15
0.01 (9.48%)
Day`s Range: 0.139 - 0.15
Day`s Volume: 2,255,900
Avg. Volume: 2,215,966
JS200
@jojo
hatte ich auch vor, mich dann aber nicht getraut und meine kauforder zu 0,11 wieder gestrichen, na macht nichts: hoffentlich hält der trend an....
3007t
hatte ich auch vor, mich dann aber nicht getraut und meine kauforder zu 0,11 wieder gestrichen, na macht nichts: hoffentlich hält der trend an....
3007t
ASK 0,1510
0,15ist geknackt
0,151und ask 0,154
steigende kurse bei hohen umsätzen nach der konferenz; also wurden die zahlen und aussichten gut aufgenommen oder sehe ich das falsch??
3007t
3007t
@3007t
ja, kann kaum anders interpretiert werden....
AktieX
ja, kann kaum anders interpretiert werden....
AktieX
so was wie heute habe noch nicht erlebt,alles zu 0,11 verkauft,und wieder zu 0,15 eingestiegen mit 50000st.
und alles wird gut...
habe wie besprochen bei 0,15 nachgekauft.
allen bashern zum trotz prophezeie ich euch in bälde die 0,20.
ich weiss ihr habt mir vor 3 wochen auch nichts geglaubt.
alles wiederholt sich irgendwann..
dilution und wie dieser sachen alle lauten mögen gehören heute bei otc werten zum alltag.....
geduld war und ist meine devise!
ADVR ist der nächste kandidat! 0,09 ist ein gelegenheitspreis.
mfg. bittermoon
habe wie besprochen bei 0,15 nachgekauft.
allen bashern zum trotz prophezeie ich euch in bälde die 0,20.
ich weiss ihr habt mir vor 3 wochen auch nichts geglaubt.
alles wiederholt sich irgendwann..
dilution und wie dieser sachen alle lauten mögen gehören heute bei otc werten zum alltag.....
geduld war und ist meine devise!
ADVR ist der nächste kandidat! 0,09 ist ein gelegenheitspreis.
mfg. bittermoon
15,4 cent und 15,3 zu 15,4 gestellt
12:35pm ET
0.154
0.02 (12.40%)
Day`s Range: 0.139 - 0.154
Day`s Volume: 2,699,300
Avg. Volume: 2,215,966
JS200
0.154
0.02 (12.40%)
Day`s Range: 0.139 - 0.154
Day`s Volume: 2,699,300
Avg. Volume: 2,215,966
JS200
12:36pm ET
0.155
0.02 (13.13%)
Day`s Range: 0.139 - 0.155
Day`s Volume: 2,725,300
Avg. Volume: 2,215,966
JS200
0.155
0.02 (13.13%)
Day`s Range: 0.139 - 0.155
Day`s Volume: 2,725,300
Avg. Volume: 2,215,966
JS200
15,5 cent...
sind womöglich positive dinge über die finanzierung gesagt worden?????
gibt es bald instis, die sich zu dieser aktie äußern??? wohl erst dann, wenn die pleite außer reichweite ist!!!
sind womöglich positive dinge über die finanzierung gesagt worden?????
gibt es bald instis, die sich zu dieser aktie äußern??? wohl erst dann, wenn die pleite außer reichweite ist!!!
so, woe die makler sonst runter taxen, so taxen sie diemal hoch...unglaublich!!!
15,5 zu 15,6
sollten wir doch vor dem we die 0,20 sehen. liegen noch einige news in der pipeline??? also, ich ´kann das ganze gar nicht mehr einschätzen...
15,5 zu 15,6
sollten wir doch vor dem we die 0,20 sehen. liegen noch einige news in der pipeline??? also, ich ´kann das ganze gar nicht mehr einschätzen...
12:41pm ET
0.156
0.02 (13.86%)
Day`s Range: 0.139 - 0.156
Day`s Volume: 2,777,700
Avg. Volume: 2,215,966
JS200
0.156
0.02 (13.86%)
Day`s Range: 0.139 - 0.156
Day`s Volume: 2,777,700
Avg. Volume: 2,215,966
JS200
kommt bald kaufpanik??? die makler ziehen den kurs gut hoch!!
was ist zum reversesplit gesagt worden????
was ist zum reversesplit gesagt worden????
12:44pm ET
0.157
0.02 (14.59%)
Day`s Range: 0.139 - 0.157
Day`s Volume: 2,876,900
Avg. Volume: 2,215,966
JS200
0.157
0.02 (14.59%)
Day`s Range: 0.139 - 0.157
Day`s Volume: 2,876,900
Avg. Volume: 2,215,966
JS200
12:45pm ET
0.158
0.02 (15.32%)
Day`s Range: 0.139 - 0.158
Day`s Volume: 2,889,600
Avg. Volume: 2,215,966
JS200
0.158
0.02 (15.32%)
Day`s Range: 0.139 - 0.158
Day`s Volume: 2,889,600
Avg. Volume: 2,215,966
JS200
nach diesem Chart war auch nichts anderes zu erwarten
wenn das so weiter geht dann schaffen die esda drüben heute noch bis 0,20 0,22 so in etwa
100% darf man doch auch mal erwarten macht ja jede Neue Markt klitsche
ASK 0,16
100% darf man doch auch mal erwarten macht ja jede Neue Markt klitsche
ASK 0,16
1:01pm ET
0.16
0.02 (16.78%)
Day`s Range: 0.139 - 0.16
Day`s Volume: 3,096,200
Avg. Volume: 2,215,966
JS200
0.16
0.02 (16.78%)
Day`s Range: 0.139 - 0.16
Day`s Volume: 3,096,200
Avg. Volume: 2,215,966
JS200
@ jojobada
0,20 wären fast etwas viel für heute
lieber etwas langsamer aber kontunuierlicher
wäre vieleicht besser
kunokuhn
0,20 wären fast etwas viel für heute
lieber etwas langsamer aber kontunuierlicher
wäre vieleicht besser
kunokuhn
@Kunokuhn: Meine Meinung !! MfG X 99
sind auch kaum Käufer bereit über 0,16 zu zahlen
es wird etwas dauern die letzte Handelsstunde wird es zeigen
und die nächsten Tage sowie Wochen !!!
es wird etwas dauern die letzte Handelsstunde wird es zeigen
und die nächsten Tage sowie Wochen !!!
kurs?
@3007t
Habe die Konferenz leider nicht mitverfolgt, bin aber soeben angenehm überrascht worden. Eine Hälfte meiner Position habe ich allerdings zu 0,13 verkauft, eine dreiviertel davon danach zum gleichen Preis wieder eingekauft - noch mal Glück gehabt, nur die Maklerkosten!
Meine Prognosen für Q3 waren viel zu hoch angesetzt, aber die meisten Anleger sehen die Ergebnisse und Prognosen offensichtlich SEHR POSITIV. Am wichtigsten scheint den meisten wohl der reduzierte Verlust zu sein, sowie die Aussichten für das Q4. Bei mindestens ca. 50-75% Umsatzzuwachs wären das dann wohl zwischen ca. 750.000 und 875.000 USD.
Gruß
bio
Habe die Konferenz leider nicht mitverfolgt, bin aber soeben angenehm überrascht worden. Eine Hälfte meiner Position habe ich allerdings zu 0,13 verkauft, eine dreiviertel davon danach zum gleichen Preis wieder eingekauft - noch mal Glück gehabt, nur die Maklerkosten!
Meine Prognosen für Q3 waren viel zu hoch angesetzt, aber die meisten Anleger sehen die Ergebnisse und Prognosen offensichtlich SEHR POSITIV. Am wichtigsten scheint den meisten wohl der reduzierte Verlust zu sein, sowie die Aussichten für das Q4. Bei mindestens ca. 50-75% Umsatzzuwachs wären das dann wohl zwischen ca. 750.000 und 875.000 USD.
Gruß
bio
realtime:
0,159
Ich glaube morgen werden viele Gewinne einsammeln.
Tiefe als 0,12€ kann es aber nicht gehen (I hope).
david
0,159
Ich glaube morgen werden viele Gewinne einsammeln.
Tiefe als 0,12€ kann es aber nicht gehen (I hope).
david
HotStockChat.com Daily Update 24 October 2002
Daily AUDIO UPDATES ARE BACK!!!!!!!
After a few months of a dead market, things are beginning to heat up again. So, we decided to bring back out daily updates of the market in text and audio.
Stocks mentioned in today`s update include: COVD, HQNT, EDIG, CALY, IBXG, IMDS, ERHC and GTEC... (see our disclaimer below on GTEC...)
--------------------------------------------------------------------------------
HotStockChat.com Updates
Current Interviews:
Ruby Mining Company (Admiralty Corp) (OTCBB-RUBM)
Current Profiles:
Defense Industries International, Inc. (OTCBB-DFNS)
Mondopolitan Corp (Pink Sheets-MDPN)
Sec2Wireless, Inc. (OTCBB-TRVL)
Upcoming Interviews/Profiles:
Sticky Web (Pink Sheets: SIKY)
VIP*ComLink (Pink Sheets VIPM)
--------------------------------------------------------------------------------
If you have questions for management of HotStockChat.com, please email us…
This email is sent to an all opt-in list. If you wish to be removed from the list, reply to this email with the word "unsubscribe" either in the subject line or in the body of the message. We will promptly remove you from the list.
Disclaimer… PLEASE READ:
HotStockChat.com received $5,000 cash for the profile of RUBM. HotStockChat.com received 400,000 free-trading shares for the profile of TRVL. We expect to receive $4000 cash for the profile and coverage of MDPN. We expect to receive $3000 cash or free-trading stock for the profile/coverage of DFNS. We expect to receive compensation for the profiles of SIKY, and VIPM. Details of the compensation will be published as soon as we have finalized the compensation package. HotStockChat.com was compensated 10,000 free-trading shares for the profile and coverage of GTEC. HotStockChat.com purchased 10,000 shares of RUBM in the open market 1 Oct (we still own the stock). We also purchased 40,000 shares of OPUS in the open market 1 Oct and still own all 40,000 shares as of this emailing. More information on our disclaimer page.
HotStockChat.com is not a registered investment advisor or a broker dealer. HotStockChat.com has been advised that the investments in companies discussed are considered to be high risk, and use of the information provided is at the investor`s sole risk.
HotStockChat.com has also been advised that the purchase of such high-risk securities may result in the loss of some or all of the investment. The information provided by the companies mentioned in this report and on the web page may include information provided by outside sources, such as research reports, public filings or computer databases. All information is obtained from sources believed to be reliable, including company press releases, SEC Filings and other sources. HotStockChat.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information or the disclosure by the companies reported on. Investors should not rely solely on the information presented. Rather, investors should use the information regarding companies as a starting point for doing additional independent research on the companies in order to allow the investor to form his or her own opinion regarding investing in the companies that are reported on.
Factual statements made by the companies reported on are made as of the date stated and are subject to change without notice. The receipt of this information shall not create, under any circumstances, any implication that there has been no change in the affairs of the company reported on since the date of review. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies mentioned in this report or on HotStockChat.com’s web site. HotStockChat.com makes no recommendation that the securities of the companies mentioned or reported on should be purchased, sold or held by individuals or entities that learn of the companies through HotStockChat.com.
Investing is not for everyone and should not be entered into unless a complete analysis is considered and all risks understood. IF any companies, individuals or other entities mentioned by HotStockChat.com pay or compensate HotStockChat.com in any way, shape or form, it will be noted on our disclaimer page.
JS200
Daily AUDIO UPDATES ARE BACK!!!!!!!
After a few months of a dead market, things are beginning to heat up again. So, we decided to bring back out daily updates of the market in text and audio.
Stocks mentioned in today`s update include: COVD, HQNT, EDIG, CALY, IBXG, IMDS, ERHC and GTEC... (see our disclaimer below on GTEC...)
--------------------------------------------------------------------------------
HotStockChat.com Updates
Current Interviews:
Ruby Mining Company (Admiralty Corp) (OTCBB-RUBM)
Current Profiles:
Defense Industries International, Inc. (OTCBB-DFNS)
Mondopolitan Corp (Pink Sheets-MDPN)
Sec2Wireless, Inc. (OTCBB-TRVL)
Upcoming Interviews/Profiles:
Sticky Web (Pink Sheets: SIKY)
VIP*ComLink (Pink Sheets VIPM)
--------------------------------------------------------------------------------
If you have questions for management of HotStockChat.com, please email us…
This email is sent to an all opt-in list. If you wish to be removed from the list, reply to this email with the word "unsubscribe" either in the subject line or in the body of the message. We will promptly remove you from the list.
Disclaimer… PLEASE READ:
HotStockChat.com received $5,000 cash for the profile of RUBM. HotStockChat.com received 400,000 free-trading shares for the profile of TRVL. We expect to receive $4000 cash for the profile and coverage of MDPN. We expect to receive $3000 cash or free-trading stock for the profile/coverage of DFNS. We expect to receive compensation for the profiles of SIKY, and VIPM. Details of the compensation will be published as soon as we have finalized the compensation package. HotStockChat.com was compensated 10,000 free-trading shares for the profile and coverage of GTEC. HotStockChat.com purchased 10,000 shares of RUBM in the open market 1 Oct (we still own the stock). We also purchased 40,000 shares of OPUS in the open market 1 Oct and still own all 40,000 shares as of this emailing. More information on our disclaimer page.
HotStockChat.com is not a registered investment advisor or a broker dealer. HotStockChat.com has been advised that the investments in companies discussed are considered to be high risk, and use of the information provided is at the investor`s sole risk.
HotStockChat.com has also been advised that the purchase of such high-risk securities may result in the loss of some or all of the investment. The information provided by the companies mentioned in this report and on the web page may include information provided by outside sources, such as research reports, public filings or computer databases. All information is obtained from sources believed to be reliable, including company press releases, SEC Filings and other sources. HotStockChat.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information or the disclosure by the companies reported on. Investors should not rely solely on the information presented. Rather, investors should use the information regarding companies as a starting point for doing additional independent research on the companies in order to allow the investor to form his or her own opinion regarding investing in the companies that are reported on.
Factual statements made by the companies reported on are made as of the date stated and are subject to change without notice. The receipt of this information shall not create, under any circumstances, any implication that there has been no change in the affairs of the company reported on since the date of review. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies mentioned in this report or on HotStockChat.com’s web site. HotStockChat.com makes no recommendation that the securities of the companies mentioned or reported on should be purchased, sold or held by individuals or entities that learn of the companies through HotStockChat.com.
Investing is not for everyone and should not be entered into unless a complete analysis is considered and all risks understood. IF any companies, individuals or other entities mentioned by HotStockChat.com pay or compensate HotStockChat.com in any way, shape or form, it will be noted on our disclaimer page.
JS200
2:13pm ET
0.16
0.02 (16.78%)
Day`s Range: 0.139 - 0.16
Day`s Volume: 3,515,300
Avg. Volume: 2,215,966
JS200
0.16
0.02 (16.78%)
Day`s Range: 0.139 - 0.16
Day`s Volume: 3,515,300
Avg. Volume: 2,215,966
JS200
2:33pm ET
0.161
0.02 (17.51%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 3,814,700
Avg. Volume: 2,215,966
JS200
0.161
0.02 (17.51%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 3,814,700
Avg. Volume: 2,215,966
JS200
2:34pm ET
0.162
0.03 (18.24%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 3,824,700
Avg. Volume: 2,215,966
0.162
0.03 (18.24%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 3,824,700
Avg. Volume: 2,215,966
wie ist heute die stimmung im kindergarten?
muß ja schöner sein als eine kiste gummibärli!
muß ja schöner sein als eine kiste gummibärli!
auch nicht von schlechten eltern.
nortel kommt von 0,43 vor 2 wochen!!!!!
HEUTE 1,06 spitze war bei 1,2
ihr wisst ja, ich habe seinerzeit zu 0,47 gekauft und bin aber wieder zu 0,5 raus.
damit meine ich nur, bei etwas mehr geduld wäre da eine nette summe zu machen gewesen.
bin aber trotzdem zufrieden
nortel kommt von 0,43 vor 2 wochen!!!!!
HEUTE 1,06 spitze war bei 1,2
ihr wisst ja, ich habe seinerzeit zu 0,47 gekauft und bin aber wieder zu 0,5 raus.
damit meine ich nur, bei etwas mehr geduld wäre da eine nette summe zu machen gewesen.
bin aber trotzdem zufrieden
@XANDA 1
Lass uns doch spielen!!!
Warst du nicht eingeladen????
JS200
Lass uns doch spielen!!!
Warst du nicht eingeladen????
JS200
@BITTERMOON
Hier sind weitere
INSP
2:46pm ET
6.20
0.96 (18.32%)
Day`s Range: 5.30 - 6.23
Day`s Volume: 627,292
Avg. Volume: 1,955,518
DNAP Kommt von 0,018
2:43pm ET
0.038
0.01 (22.58%)
Day`s Range: 0.031 - 0.0399
Day`s Volume: 1,571,800
Avg. Volume: 1,541,106
JS200
Hier sind weitere
INSP
2:46pm ET
6.20
0.96 (18.32%)
Day`s Range: 5.30 - 6.23
Day`s Volume: 627,292
Avg. Volume: 1,955,518
DNAP Kommt von 0,018
2:43pm ET
0.038
0.01 (22.58%)
Day`s Range: 0.031 - 0.0399
Day`s Volume: 1,571,800
Avg. Volume: 1,541,106
JS200
noch ein netter fall gefällig?
newkidco (nkcif)
habe euch vor ca.3 wochen aufmerksam gemacht. (damals 0,14 )
heute +35%
auch nicht schlecht, oder?
mfg. bittermoon, der auf keinen fall pushen möchte, sondern euch nur auf interessante aber auch riskante papiere hinweist!
newkidco (nkcif)
habe euch vor ca.3 wochen aufmerksam gemacht. (damals 0,14 )
heute +35%
auch nicht schlecht, oder?
mfg. bittermoon, der auf keinen fall pushen möchte, sondern euch nur auf interessante aber auch riskante papiere hinweist!
3:09pm ET
0.152
0.02 (10.94%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 4,050,100
Avg. Volume: 2,215,966
JS200
0.152
0.02 (10.94%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 4,050,100
Avg. Volume: 2,215,966
JS200
iss doch nich so schlimm js200
hier hast´n keks "KEKS"
el geduldo
M1
hier hast´n keks "KEKS"
el geduldo
M1
@js200
bei holdings (dnap) habe ich meine probleme (zweifel).
frage mich aber bitte nicht warum?
außerdem sage ich dir ganz offen und ehrlich, dass ich bei diesem kurs keinen mut hätte, einzusteigen.
das ist so ähnlich wie bei medical services groups.
zu insp kann ich nur sagen, chart sieht ähnlich aus wie bei nortel. nur bei nortel war der einstiegskurs zum zocken wesentlich interessanter.
außerdem kann ich mich gut an einen ausspruch eines brokers erinnern, der über nortel gemeint hat, wenn die pleite gehen sollten, dann geht der gesamte telekommarkt pleite.
mfg. bittermoon
bei holdings (dnap) habe ich meine probleme (zweifel).
frage mich aber bitte nicht warum?
außerdem sage ich dir ganz offen und ehrlich, dass ich bei diesem kurs keinen mut hätte, einzusteigen.
das ist so ähnlich wie bei medical services groups.
zu insp kann ich nur sagen, chart sieht ähnlich aus wie bei nortel. nur bei nortel war der einstiegskurs zum zocken wesentlich interessanter.
außerdem kann ich mich gut an einen ausspruch eines brokers erinnern, der über nortel gemeint hat, wenn die pleite gehen sollten, dann geht der gesamte telekommarkt pleite.
mfg. bittermoon
@BITTERMOON
Bei INSP wurde Leider RVSplitt 1/10 durchgeführt, darum die schwache Reaktion.
JS200
Bei INSP wurde Leider RVSplitt 1/10 durchgeführt, darum die schwache Reaktion.
JS200
15:23:59 0.158 1000 OTCBB
js200
auch ein grund für mich, die finger davon zu lassen.
änlich wie bei cmrc.
auch ein grund für mich, die finger davon zu lassen.
änlich wie bei cmrc.
Der SCHLUSSSPURT NAHT
JS200
JS200
@BITTERMOON
Hatte vorm Splitt ein paar Tausend, jetzt nicht mehr!!!!!
Was mich zur Zeit am meisten ärgert ist LAMP, keine NEWS, rein gar nichts???
Was man einerseits verdient, geht mit Lamp verloren, schade!!
Was mich noch aufregt sind diese Werbebanner, nach Anmeldung müsste WO diese doch sperren, was meinst du dazu???
JS200
Hatte vorm Splitt ein paar Tausend, jetzt nicht mehr!!!!!
Was mich zur Zeit am meisten ärgert ist LAMP, keine NEWS, rein gar nichts???
Was man einerseits verdient, geht mit Lamp verloren, schade!!
Was mich noch aufregt sind diese Werbebanner, nach Anmeldung müsste WO diese doch sperren, was meinst du dazu???
JS200
js200
über lamp weiss ich zu wenig, kann dir nichts dazu sagen.
was machen die eigentlich?
die werbebanner sind leider wirklich nervig - wenn wir aber weiter das internet bedienen wollen, müssen wir uns damit abfinden. vergleichbar mit den 7 minuten werbepausen bei den privatsendern. heute spricht mann auch nicht mehr darüber.
übrigens bei uptotrade.de stellen sich die banner nach einer gewissen zeit ständig automatisch rein. auch nervig
das mit dem sperren habe ich auch schon versucht. hilft nix.
mfg. bittermoon
über lamp weiss ich zu wenig, kann dir nichts dazu sagen.
was machen die eigentlich?
die werbebanner sind leider wirklich nervig - wenn wir aber weiter das internet bedienen wollen, müssen wir uns damit abfinden. vergleichbar mit den 7 minuten werbepausen bei den privatsendern. heute spricht mann auch nicht mehr darüber.
übrigens bei uptotrade.de stellen sich die banner nach einer gewissen zeit ständig automatisch rein. auch nervig
das mit dem sperren habe ich auch schon versucht. hilft nix.
mfg. bittermoon
@BITTERMOON
Einmal angemeldet müsste doch reichen
Wie siehst du den Schlusskurs, ich tippe 0,160
JS200
Einmal angemeldet müsste doch reichen
Wie siehst du den Schlusskurs, ich tippe 0,160
JS200
js200
was meinst du mit einmal angemeldet?
sobald du bei wo etwas abfagst kommt der banner und der lässt sich leider nicht verhindern oder sperren.
davon leben diese firmen, sonst müßten wir geld dafür bezahlen.
schlusskurs heute? alles ist möglich nur bitte über 0,155
eine ganz wichtige hürde.
mfg. bittermoon
was meinst du mit einmal angemeldet?
sobald du bei wo etwas abfagst kommt der banner und der lässt sich leider nicht verhindern oder sperren.
davon leben diese firmen, sonst müßten wir geld dafür bezahlen.
schlusskurs heute? alles ist möglich nur bitte über 0,155
eine ganz wichtige hürde.
mfg. bittermoon
15:52:22 0.154 9000 OTCBB
15:52:12 0.156 3000 OTCBB at Ask
15:52:53 0.155 15000 OTCBB at Bid
15:50:45 0.156 10000 OTCBB at Ask
15:49:29 0.155 9000 OTCBB at Bid
15:49:25 0.155 4000 OTCBB at Bid
15:49:24 0.156 30000 OTCBB at Ask
Volume: 4,201,000
Bid: 0.153
Ask: 0.161
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: 12.4%
15:52:12 0.156 3000 OTCBB at Ask
15:52:53 0.155 15000 OTCBB at Bid
15:50:45 0.156 10000 OTCBB at Ask
15:49:29 0.155 9000 OTCBB at Bid
15:49:25 0.155 4000 OTCBB at Bid
15:49:24 0.156 30000 OTCBB at Ask
Volume: 4,201,000
Bid: 0.153
Ask: 0.161
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: 12.4%
@js200
0.162
0.162
@FHR
nee, beide daneben
3:59pm ET
0.156
0.02 (13.86%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 4,518,800
Avg. Volume: 2,215,966
JS200
nee, beide daneben
3:59pm ET
0.156
0.02 (13.86%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 4,518,800
Avg. Volume: 2,215,966
JS200
@js200
abwarten
abwarten
Last: 0.156
Close: 0.156
High: 0.162
Low: 0.139
Open: 0.141
Change: +0.01
Volume: 4,528,800
Bid: 0.153
Ask: 0.156
15:59:28 0.156 2000 OTCBB at Ask
15:59:23 0.154 7500 OTCBB
15:59:02 0.156 2000 OTCBB at Ask
15:57:41 0.154 10000 OTCBB at Bid
15:57:03 0.155 5000 OTCBB
15:56:07 0.152 100000 OTCBB
15:53:23 0.156 3000 OTCBB at Ask
15:53:12 0.155 5000 OTCBB at Bid
15:53:09 0.156 38000 OTCBB at Ask
15:53:49 0.156 3000 OTCBB at Ask
Close: 0.156
High: 0.162
Low: 0.139
Open: 0.141
Change: +0.01
Volume: 4,528,800
Bid: 0.153
Ask: 0.156
15:59:28 0.156 2000 OTCBB at Ask
15:59:23 0.154 7500 OTCBB
15:59:02 0.156 2000 OTCBB at Ask
15:57:41 0.154 10000 OTCBB at Bid
15:57:03 0.155 5000 OTCBB
15:56:07 0.152 100000 OTCBB
15:53:23 0.156 3000 OTCBB at Ask
15:53:12 0.155 5000 OTCBB at Bid
15:53:09 0.156 38000 OTCBB at Ask
15:53:49 0.156 3000 OTCBB at Ask
@steffen
komm noch mal nachbörslich
komm noch mal nachbörslich
war nicht so schlecht die gesamte sache
möglicherweise gibt es aber morgen einen kleinen rücksetzer.
ich gehe aber in der nächsten zeit von weiter steigenden kursen aus.
allen ein gutes nächtle...
möglicherweise gibt es aber morgen einen kleinen rücksetzer.
ich gehe aber in der nächsten zeit von weiter steigenden kursen aus.
allen ein gutes nächtle...
gute nacht
well done
Noch ein 100.000der Block zu 0,153, der 2te
JS200
JS200
gut´s nächtle @all
16:07:43 0.153 100000 OTCBB at Bid
15:59:28 0.156 2000 OTCBB at Ask
15:59:23 0.154 7500 OTCBB
15:59:02 0.156 2000 OTCBB at Ask
15:57:41 0.154 10000 OTCBB at Bid
15:57:03 0.155 5000 OTCBB
15:56:07 0.152 100000 OTCBB
15:59:28 0.156 2000 OTCBB at Ask
15:59:23 0.154 7500 OTCBB
15:59:02 0.156 2000 OTCBB at Ask
15:57:41 0.154 10000 OTCBB at Bid
15:57:03 0.155 5000 OTCBB
15:56:07 0.152 100000 OTCBB
der letzte 100.000 ist gecancelt (XNOL)
nicht ausgeführt !!!!!!!
Gute Nacht
mfg jojo
nicht ausgeführt !!!!!!!
Gute Nacht
mfg jojo
@JOJOBADA
Wie kommst du auf gecancelt
ZUR ZEIT UMSATZ
3:59pm ET
0.156
0.02 (13.86%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 4,618,800 ??????????????????
Avg. Volume: 2,215,966
EFFEKTIVER UMSATZ 15°°H59
3:59pm ET
0.156
0.02 (13.86%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 4,518,800 ?????????????????
Avg. Volume: 2,215,966
ALSO JOJO, sag mir nicht er wäre gecancelt
JS200
Wie kommst du auf gecancelt
ZUR ZEIT UMSATZ
3:59pm ET
0.156
0.02 (13.86%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 4,618,800 ??????????????????
Avg. Volume: 2,215,966
EFFEKTIVER UMSATZ 15°°H59
3:59pm ET
0.156
0.02 (13.86%)
Day`s Range: 0.139 - 0.162
Day`s Volume: 4,518,800 ?????????????????
Avg. Volume: 2,215,966
ALSO JOJO, sag mir nicht er wäre gecancelt
JS200
Morgen werden wohl die nächsten mit kalten füßen kommen und verkaufen
Bleibe investiert,und werde morgen nachlegen.
Gruß spekulativ
PS: Kann schnell auf 0,3 hoch laufen.
Bleibe investiert,und werde morgen nachlegen.
Gruß spekulativ
PS: Kann schnell auf 0,3 hoch laufen.
@speku
du schwerenöter 0.30
gruss fhr
du schwerenöter 0.30
gruss fhr
@fhr
du bist noch nicht so lange an der OTC ? sonst wüßtest du wie schnell es gehen kann
Na eventuell wirst du es bei Caly erleben dürfen.
Gruß spekulativ
du bist noch nicht so lange an der OTC ? sonst wüßtest du wie schnell es gehen kann
Na eventuell wirst du es bei Caly erleben dürfen.
Gruß spekulativ
@speku
danke für den hinweis -
danke für den hinweis -
Gern geschehen
Gruß speku
PS: Wo ist denn der spinner LUX ??? der doch bei 11cent alles gekauft hat.
Gruß speku
PS: Wo ist denn der spinner LUX ??? der doch bei 11cent alles gekauft hat.
der hat noch schule
Sind nicht Ferien ?
The Calypte Mission
Our mission at Calypte Biomedical Corporation is to develop and market in vitro diagnostic testing solutions that make positive contributions to public health and healthcare worldwide. Our urine-based testing algorithm is designed to be safe, cost-effective, and painless, while our serum-based tests offer proven solutions in a traditional format. We believe that by offering both unique urine-based and traditional serum-based testing solutions for HIV infection and other chronic diseases, we can create more opportunities for better healthcare worldwide.
liest sich sehr überzeugend !
Our mission at Calypte Biomedical Corporation is to develop and market in vitro diagnostic testing solutions that make positive contributions to public health and healthcare worldwide. Our urine-based testing algorithm is designed to be safe, cost-effective, and painless, while our serum-based tests offer proven solutions in a traditional format. We believe that by offering both unique urine-based and traditional serum-based testing solutions for HIV infection and other chronic diseases, we can create more opportunities for better healthcare worldwide.
liest sich sehr überzeugend !
Unsere Mission an Calypte Biomedical Corporation ist, in-vitrodiagnoseprüfenlösungen zu entwickeln und zu vermarkten, die positive Beiträge zum öffentlichen zum weltweiten Gesundheitswesen und healthcare bilden. Unser Urin-gegründeter prüfenalgorithmus wird entworfen, um kosteneffektiv, und schmerzlos zu sein sicher, während unsere Serum-gegründeten Tests nachgewiesene Lösungen in einem traditionellen Format anbieten. Wir glauben dem, indem wir einzigartiges Urin-gegründet anbieten und traditionelle Serum-gegründete prüfenlösungen für HIV-Infektion und andere chronische Krankheiten, können wir mehr Gelegenheiten für besseres healthcare weltweit verursachen.
So muß nun leider weg,bin aber gegen 19Uhr wieder bei euch
Kurs wird dann wohl bei 0,18 stehen.
Gruß spekulativ
Kurs wird dann wohl bei 0,18 stehen.
Gruß spekulativ
PS: Immer an die Zukunft denken die an der Börse gehandelt wird.
@ALLE
Von Gestern
CALY
CALYPTE BIOMEDICAL CP
0.156
+0.019 +13.87%
Daily Commentary
HOLD
Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/15/2002 (9) days ago, when the stock price was 0.129. Since then the stock gained 20.93% .
Today the stock closed higher with a higher high and a higher low. A bullish gap occured, which may indicate an upward break out.The volume is extremely high. The security price is trending up.
Candlestick Analysis
Today’s Candlestick Patterns:
Long White Candlestick
Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!
Stock Quote
Last 0.156
Previous Close 0.137
Change +0.019
% Change +13.87%
Volume 4,628,800
Stock Activity
Open 0.141
Day`s High 0.162
Day`s Low 0.139
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -29.09
6 Month % Change 524.00
12 Month % Change -42.22
Stock Statistics
50 Day Close MA 0.119
200 Day Close MA 0.164
65 Day Volume MA 2,200,822
JS200
Von Gestern
CALY
CALYPTE BIOMEDICAL CP
0.156
+0.019 +13.87%
Daily Commentary
HOLD
Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/15/2002 (9) days ago, when the stock price was 0.129. Since then the stock gained 20.93% .
Today the stock closed higher with a higher high and a higher low. A bullish gap occured, which may indicate an upward break out.The volume is extremely high. The security price is trending up.
Candlestick Analysis
Today’s Candlestick Patterns:
Long White Candlestick
Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!
Stock Quote
Last 0.156
Previous Close 0.137
Change +0.019
% Change +13.87%
Volume 4,628,800
Stock Activity
Open 0.141
Day`s High 0.162
Day`s Low 0.139
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -29.09
6 Month % Change 524.00
12 Month % Change -42.22
Stock Statistics
50 Day Close MA 0.119
200 Day Close MA 0.164
65 Day Volume MA 2,200,822
JS200
wenns denn so kommt - was will man mehr - erster kurs ( a bullish gap ) - kommt gut zum wochenende
@FHR
Kannst du nicht lesen
DA STEHT == VON GESTERN ==
Die Analysen sind immer vom Tage vorher , also GESTERN
JS200
Kannst du nicht lesen
DA STEHT == VON GESTERN ==
Die Analysen sind immer vom Tage vorher , also GESTERN
JS200
na klar hab ich das gelesen - das ändert aber doch nichts an der aussage - bullish gap ( auch für HEUTE )- oder hab ich da keine 100K order gesehen - GESTERN - gruss fhr
@FHR
DIE 2 Orders lagen TIEFER
Eine vor Handelsschluss und eine danach
Schlusskurs war 0,156 Dollar
#1624 von js200 24.10.02 22:13:20 Beitrag Nr.: 7.678.145 7678145
Dieses Posting: versenden | melden | drucken CALYPTE BIOMED. DL-,001
Noch ein 100.000der Block zu 0,153, der 2te
JS200
DIE 2 Orders lagen TIEFER
Eine vor Handelsschluss und eine danach
Schlusskurs war 0,156 Dollar
#1624 von js200 24.10.02 22:13:20 Beitrag Nr.: 7.678.145 7678145
Dieses Posting: versenden | melden | drucken CALYPTE BIOMED. DL-,001
Noch ein 100.000der Block zu 0,153, der 2te
JS200
@js200
wait and see bullish 0.198 schlussspurt 22.00 - schlusskurs wird steffen71200 posten um 22.02 genau mit 0.20
reicht das jetzt mit meiner profi analyse - gruss fhr
wait and see bullish 0.198 schlussspurt 22.00 - schlusskurs wird steffen71200 posten um 22.02 genau mit 0.20
reicht das jetzt mit meiner profi analyse - gruss fhr
leute, ich fürchte, heute vor dem we werden kräftig gewinne mitgenommen...wir schließen heute bei 13,9 cent oder drunter...
bei den amis weis man nie - siehe gestern - gruss fhr
@FHR
GAP UP nicht möglich, da 2 x 5000 im ASK zu 0,156 und 1 x 5000 im Bid zu 0,155
JS200
GAP UP nicht möglich, da 2 x 5000 im ASK zu 0,156 und 1 x 5000 im Bid zu 0,155
JS200
ja, das stimmt..spanne momentan 15,5 zu 15,6 cent...ich erwarte trotzdem ein absinken im handelsverlauf auf unter 14 cent. hoffentlich vertue ich mich. zu oft werden bei caly die gewinne mitgenommen...
schon wieder 20.000 vorbörslich zu 15,6 cent gehandelt, wenn ich es richtig sehe...spanne 15,5 zu 15,6...
tja, was soll man dazu sagen...ich denke aber nachwievor, daß der einbruch noch kommt!!!
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.159 0.003 (1.92) 0.155 (50) 0.159 (50) 09:37
Day Volume Last Size Open High Low
244,700 9,000 0.156 0.159 0.155
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-+ 29
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.159 0.003 (1.92) 0.155 (50) 0.159 (50) 09:37
Day Volume Last Size Open High Low
244,700 9,000 0.156 0.159 0.155
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-+ 29
moin moin,
auf der mauer, auf der lauer, liegt ein kleiner CALY. auf der mauer, auf der lauer......
sorry mir war grad danach
gruß
M1
mein KZ heut über 0,14€! sonnst grich isch plaque!
auf der mauer, auf der lauer, liegt ein kleiner CALY. auf der mauer, auf der lauer......
sorry mir war grad danach
gruß
M1
mein KZ heut über 0,14€! sonnst grich isch plaque!
bis jetzt keine gewinne mitgenommen,
noch eine stunde weiter so,
und sehen wir die 0,17
noch eine stunde weiter so,
und sehen wir die 0,17
hallo berlin, hallo frankfurt!
aufwachen es geht bergauf bevor es wieder bergab geht?
wills nicht hoffen!
OTC eröffnet im + das stimmt mich positiv! und euch?
Gruß
M1
aufwachen es geht bergauf bevor es wieder bergab geht?
wills nicht hoffen!
OTC eröffnet im + das stimmt mich positiv! und euch?
Gruß
M1
Wieder recht hohes Volumen zu Handelsbeginn mit steigenden Kursen ! Viel Glück allen (noch) investierten........MfG X 99
naja, kurs stagniert...kommt der einbruch ab 16.00h????
volumen jetzt deutlich geringer...
kurs bei 15,5 cent spanne nur noch 15,4 - 15,6. leichtes minus. wie erwartet!!!!
volumen jetzt deutlich geringer...
kurs bei 15,5 cent spanne nur noch 15,4 - 15,6. leichtes minus. wie erwartet!!!!
Time Price Volume Exchange Info
09:54:03 0.151 4600 OTCBB
09:54:56 0.151 5000 OTCBB
09:54:56 0.153 5000 OTCBB
09:52:17 0.155 10000 OTCBB at Ask
09:52:53 0.155 9000 OTCBB
09:51:48 0.154 5000 OTCBB at Bid
09:51:13 0.158 10000 OTCBB
09:50:29 0.157 1500 OTCBB at Ask
09:50:29 0.158 1500 OTCBB at Ask
09:48:37 0.159 12500 OTCBB at Ask
Jetzt gehts bergab !!!!!!
09:54:03 0.151 4600 OTCBB
09:54:56 0.151 5000 OTCBB
09:54:56 0.153 5000 OTCBB
09:52:17 0.155 10000 OTCBB at Ask
09:52:53 0.155 9000 OTCBB
09:51:48 0.154 5000 OTCBB at Bid
09:51:13 0.158 10000 OTCBB
09:50:29 0.157 1500 OTCBB at Ask
09:50:29 0.158 1500 OTCBB at Ask
09:48:37 0.159 12500 OTCBB at Ask
Jetzt gehts bergab !!!!!!
wie befürchtet, jetzt geht es bergab!!!
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.152 0.004 (2.56) 0.152 (50) 0.153 (50) 10:04
Day Volume Last Size Open High Low
376,900 4,500 0.156 0.159 0.151
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+--+ 47
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.152 0.004 (2.56) 0.152 (50) 0.153 (50) 10:04
Day Volume Last Size Open High Low
376,900 4,500 0.156 0.159 0.151
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+--+ 47
Last: 0.152
High: 0.159
Low: 0.151
Open: 0.156
Change: -0.01
Volume: 401,900
Bid: 0.151
Ask: 0.153
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: -2.6%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Quotes provided by S&P Comstock
10/25/02 - 10:07 a.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
10:06:00 0.152 7400 OTCBB
10:05:24 0.153 8500 OTCBB
10:04:37 0.152 10000 OTCBB
10:04:37 0.151 15000 OTCBB
Hält sich wirklich gut kein großes Anzeichen für Gewinnmitnahmen !!!
Mal abwarten was der Tag so bringt
High: 0.159
Low: 0.151
Open: 0.156
Change: -0.01
Volume: 401,900
Bid: 0.151
Ask: 0.153
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: -2.6%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Quotes provided by S&P Comstock
10/25/02 - 10:07 a.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
10:06:00 0.152 7400 OTCBB
10:05:24 0.153 8500 OTCBB
10:04:37 0.152 10000 OTCBB
10:04:37 0.151 15000 OTCBB
Hält sich wirklich gut kein großes Anzeichen für Gewinnmitnahmen !!!
Mal abwarten was der Tag so bringt
Das Gap von Gestern könnte halten !!!
JS200
JS200
hallo zusammen, war eine Woche weg im Urlaub.
Na wer sagts denn...Caly kommt und wie die kommen werden.
Kurse nächstes Jahr von 4 - 5 Dollar sind, glaube ich,
nicht zu hoch.Wie sagten bzw. schrieben einige von Euch...
Die Zukunft wird an der Börse gehandelt.. und die Zukunft
macht halt Caly.
meine Meinung
Na wer sagts denn...Caly kommt und wie die kommen werden.
Kurse nächstes Jahr von 4 - 5 Dollar sind, glaube ich,
nicht zu hoch.Wie sagten bzw. schrieben einige von Euch...
Die Zukunft wird an der Börse gehandelt.. und die Zukunft
macht halt Caly.
meine Meinung
HALLO
Das war ja eine nette Woche für Caly,und seine Aktionäre!
Habe mir heute weitere 10.000 Stück ins langzeit Depot gelegt ( 0,14 €!
Ich hoffe nicht,dass wir die 0,10 € nochmal unterschreiten.
Schönes Wochenende allen.
Newman8
Habe mir heute weitere 10.000 Stück ins langzeit Depot gelegt ( 0,14 €!
Ich hoffe nicht,dass wir die 0,10 € nochmal unterschreiten.
Schönes Wochenende allen.
Newman8
@newman8
dito
@alle
stell bitte mal jemand realtime rein - mein consors funktioniert nicht - danke
dito
@alle
stell bitte mal jemand realtime rein - mein consors funktioniert nicht - danke
@js200
du hast Post.
Gruß spekulativ
du hast Post.
Gruß spekulativ
13:30:09 0.139 1000 OTCBB at Ask
13:26:22 0.139 5000 OTCBB at Ask
13:24:46 0.139 5000 OTCBB at Ask
13:26:22 0.139 5000 OTCBB at Ask
13:24:46 0.139 5000 OTCBB at Ask
@fhr
post
post
hallo @all
wer kann mir sagen woran das lieg:
1. OTCBB CALY USD €0,156 $0,139 -0,017$ -10,90% $239.221 Stck.:1.654.200
25. Okt 19:06
und eine 1/2 std. vorher lag der kurs noch bei 0,136$ bei gleicher stückzahl (1.654.200)
wie kommt das ?
danke
M1
wer kann mir sagen woran das lieg:
1. OTCBB CALY USD €0,156 $0,139 -0,017$ -10,90% $239.221 Stck.:1.654.200
25. Okt 19:06
und eine 1/2 std. vorher lag der kurs noch bei 0,136$ bei gleicher stückzahl (1.654.200)
wie kommt das ?
danke
M1
Eventuell hochgetaxt ?
I dont no.
Gruß speku
I dont no.
Gruß speku
@steffen
danke
@speku
du hast post
@morphoys1
wo hast du das her ??
danke
@speku
du hast post
@morphoys1
wo hast du das her ??
danke spekulativ!
noch andere vermutungen?
oder gar wissen???
M1
noch andere vermutungen?
oder gar wissen???
M1
@morphoys1
vieleischt liegt es daran
Time & Sales most recent back next
CALYPTE BIOMEDICAL - OTC BB: CALY
Rec. Time Action Price Volume Exch.
1:30:17 PM Trade (at Ask) 0.139 1000 OTC BB
1:26:30 PM Trade (at Ask) 0.139 5000 OTC BB
1:25:54 PM Trade (at Ask) 0.139 5000 OTC BB
1:22:05 PM Trade (at Ask) 0.139 2100 OTC BB
1:06:49 PM Trade (at Ask) 0.139 3500 OTC BB
1:05:06 PM Trade (at Ask) 0.139 800 OTC BB
12:59:23 PM Ask 0.139 5000 OTC BB
12:59:09 PM Trade (at Ask) 0.138 4900 OTC BB
12:54:18 PM Trade (at Ask) 0.138 10000 OTC BB
12:50:26 PM Trade (at Ask) 0.138 5000 OTC BB
12:50:11 PM Trade (at Ask) 0.138 10000 OTC BB
12:50:07 PM Ask 0.138 5000 OTC BB
12:50:05 PM Trade (at Bid) 0.136 30000 OTC BB
12:46:10 PM Trade (at Bid) 0.136 2000 OTC BB
12:42:41 PM Trade (at Ask) 0.139 4200 OTC BB
12:41:02 PM Trade (at Ask) 0.139 1500 OTC BB
12:40:13 PM Trade (at Bid) 0.136 40000 OTC BB
12:39:47 PM Trade (at Ask) 0.139 20000 OTC BB
12:39:37 PM Trade (at Ask) 0.139 5000 OTC BB
12:31:19 PM Ask 0.139 5000 OTC BB
most recent back next
1:57:08 PM EDT - Friday, October 25,
vieleischt liegt es daran
Time & Sales most recent back next
CALYPTE BIOMEDICAL - OTC BB: CALY
Rec. Time Action Price Volume Exch.
1:30:17 PM Trade (at Ask) 0.139 1000 OTC BB
1:26:30 PM Trade (at Ask) 0.139 5000 OTC BB
1:25:54 PM Trade (at Ask) 0.139 5000 OTC BB
1:22:05 PM Trade (at Ask) 0.139 2100 OTC BB
1:06:49 PM Trade (at Ask) 0.139 3500 OTC BB
1:05:06 PM Trade (at Ask) 0.139 800 OTC BB
12:59:23 PM Ask 0.139 5000 OTC BB
12:59:09 PM Trade (at Ask) 0.138 4900 OTC BB
12:54:18 PM Trade (at Ask) 0.138 10000 OTC BB
12:50:26 PM Trade (at Ask) 0.138 5000 OTC BB
12:50:11 PM Trade (at Ask) 0.138 10000 OTC BB
12:50:07 PM Ask 0.138 5000 OTC BB
12:50:05 PM Trade (at Bid) 0.136 30000 OTC BB
12:46:10 PM Trade (at Bid) 0.136 2000 OTC BB
12:42:41 PM Trade (at Ask) 0.139 4200 OTC BB
12:41:02 PM Trade (at Ask) 0.139 1500 OTC BB
12:40:13 PM Trade (at Bid) 0.136 40000 OTC BB
12:39:47 PM Trade (at Ask) 0.139 20000 OTC BB
12:39:37 PM Trade (at Ask) 0.139 5000 OTC BB
12:31:19 PM Ask 0.139 5000 OTC BB
most recent back next
1:57:08 PM EDT - Friday, October 25,
#fhr
hab mir zufällig die zahlen gemerkt!
weil ich einfach mal lust dazu hatte und dabei iss mir das aufgefallen! (war auch nicht das 1. mal) hab mir nur vorher keine gedanken drüber gemacht!!
und! es ist ganz sicher KEIN vergucker gewesen sonnst hätt ich euch nich gefragt!
M1
hab mir zufällig die zahlen gemerkt!
weil ich einfach mal lust dazu hatte und dabei iss mir das aufgefallen! (war auch nicht das 1. mal) hab mir nur vorher keine gedanken drüber gemacht!!
und! es ist ganz sicher KEIN vergucker gewesen sonnst hätt ich euch nich gefragt!
M1
#fhr
auch ne möglichkeit!
wann iss heut eigendlich schluß? 22Uhr oder Früher?
hoffendlich über 0,14$ (nur für meine psysche!)
danke!
M1
auch ne möglichkeit!
wann iss heut eigendlich schluß? 22Uhr oder Früher?
hoffendlich über 0,14$ (nur für meine psysche!)
danke!
M1
22.00
sieht wohl nicht danach aus! (über 0,14$)
berlin schon -18%
na ja hauptsache über meinem EK! und der liegt bei 0,09€
gruß
M1
berlin schon -18%
na ja hauptsache über meinem EK! und der liegt bei 0,09€
gruß
M1
neue kurse an der otc ??
@M1
dann kann man doch beruhigt zu schauen wie es runter geht ( leicht runter geht ) bin dabei auch völlig entspannt
Gruß speku
dann kann man doch beruhigt zu schauen wie es runter geht ( leicht runter geht ) bin dabei auch völlig entspannt
Gruß speku
man(n) wir warn heut schon an den 0,16€ dran und nun das
M1
der sich ne flasche Dornfelder gönnt!!!
M1
der sich ne flasche Dornfelder gönnt!!!
#1677
?????
was meinst DU?
?????
was meinst DU?
Die werden wir schon wieder sehen,nicht heute aber nächste woche bestimmt.
Gruß speku
Gruß speku
fhr meinte Realtime Kurse
@speku
deine entspanntheit kommt vom bier
@m1
dornfelder - lecker - vom aldi ?
deine entspanntheit kommt vom bier
@m1
dornfelder - lecker - vom aldi ?
@fhr
das weiß du doch,kaufst doch nur beim ALDI ein
das weiß du doch,kaufst doch nur beim ALDI ein
@speku
mehr geht auch nicht - bei dem gezocke hier
mehr geht auch nicht - bei dem gezocke hier
Na da bist du aber noch gut dran,wenn es so weiter geht,werde ich meine Sachen nur noch bei der Tafel holen
tschüss bis kurz vor 22.00
Steffen hast du noch realtimekurse für uns ?
Danke und gruß speku
Danke und gruß speku
Hallo Caly-Freunde,
ich muß mich heute doch wieder melden!
Es wird versucht, den Kurs wieder nach unten zu drücken. Das gleiche Spiel wie gehabt.
Leider fallen die meisten darauf rein.
Ich beobachte Calypte schon sehr lange. Bin auch investiert!
Es gibt nur eine Lösung:
nicht mehr verkaufen, sondern nur noch kaufen!
Dann können die "Verkäufer" hinterher laufen und teuer bezahlen oder sich ärgern!
Schönes Wochenende und viel Glück!
diegutefee
P.S.: Bin viele Jahre im Management tätig gewesen.
Wer weiter kommen will, muß ein "Schwein" sein.
Wer reich werden will, muß schlauer sein als die anderen.
Steuern muß man nur bezahlen, wenn man Aktien verkauft aber
nicht, wenn man sie kauft!
ich muß mich heute doch wieder melden!
Es wird versucht, den Kurs wieder nach unten zu drücken. Das gleiche Spiel wie gehabt.
Leider fallen die meisten darauf rein.
Ich beobachte Calypte schon sehr lange. Bin auch investiert!
Es gibt nur eine Lösung:
nicht mehr verkaufen, sondern nur noch kaufen!
Dann können die "Verkäufer" hinterher laufen und teuer bezahlen oder sich ärgern!
Schönes Wochenende und viel Glück!
diegutefee
P.S.: Bin viele Jahre im Management tätig gewesen.
Wer weiter kommen will, muß ein "Schwein" sein.
Wer reich werden will, muß schlauer sein als die anderen.
Steuern muß man nur bezahlen, wenn man Aktien verkauft aber
nicht, wenn man sie kauft!
#fhr aldi iss nich nur lecker sondern auch GÜNSTIG nicht BILLIG!
die haben einige leckere weine, aber dornfelder iss halt sowohl günstig als auch lecker! und dazu noch ne selbstgemachte pizza (mit zutaten von aldi natürlich)!
#speku
glaubst du wirklich an kurse um 0,16€ nächste woche?
na ich weiss nich! aber ich bin guter hoffnung!
stand in den zahlen nicht auch was von Forschungen für den HIV2 test?
gruß
M1
die haben einige leckere weine, aber dornfelder iss halt sowohl günstig als auch lecker! und dazu noch ne selbstgemachte pizza (mit zutaten von aldi natürlich)!
#speku
glaubst du wirklich an kurse um 0,16€ nächste woche?
na ich weiss nich! aber ich bin guter hoffnung!
stand in den zahlen nicht auch was von Forschungen für den HIV2 test?
gruß
M1
Time Price Volume Exchange Info
14:31:19 0.137 2000 OTCBB at Ask
14:22:57 0.137 500 OTCBB at Ask
14:21:44 0.137 1000 OTCBB at Ask
14:01:05 0.135 3600 OTCBB at Bid
14:01:55 0.135 9800 OTCBB
13:59:36 0.135 5000 OTCBB at Bid
13:59:11 0.135 5000 OTCBB at Bid
13:57:14 0.135 21000 OTCBB at Ask
13:57:12 0.135 29000 OTCBB at Ask
13:57:12 0.135 10000 OTCBB at Ask
ciao
Westfalica
14:31:19 0.137 2000 OTCBB at Ask
14:22:57 0.137 500 OTCBB at Ask
14:21:44 0.137 1000 OTCBB at Ask
14:01:05 0.135 3600 OTCBB at Bid
14:01:55 0.135 9800 OTCBB
13:59:36 0.135 5000 OTCBB at Bid
13:59:11 0.135 5000 OTCBB at Bid
13:57:14 0.135 21000 OTCBB at Ask
13:57:12 0.135 29000 OTCBB at Ask
13:57:12 0.135 10000 OTCBB at Ask
ciao
Westfalica
erst mal !
bis kurz vor 10
M1
bis kurz vor 10
M1
Last: 0.137
High: 0.159
Low: 0.132
Open: 0.156
Change: -0.02
Volume: 1,901,000
Bid: 0.131
Ask: 0.149
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: -12.2%
14:34:41 0.137 1000 OTCBB at Ask
14:31:19 0.137 2000 OTCBB at Ask
High: 0.159
Low: 0.132
Open: 0.156
Change: -0.02
Volume: 1,901,000
Bid: 0.131
Ask: 0.149
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: -12.2%
14:34:41 0.137 1000 OTCBB at Ask
14:31:19 0.137 2000 OTCBB at Ask
Time Price Volume Exchange Info
14:44:06 0.139 2500 OTCBB at Ask
14:34:41 0.137 1000 OTCBB at Ask
ciao
Westfalica
14:44:06 0.139 2500 OTCBB at Ask
14:34:41 0.137 1000 OTCBB at Ask
ciao
Westfalica
14:55:20 0.139 1000 OTCBB at Ask
14:55:12 0.139 4000 OTCBB at Ask
14:55:12 0.139 4000 OTCBB at Ask
kein handel ab 14:55:20 bis jetzt.....
@steffen
und was sagt uns das ?
Gruß speku
und was sagt uns das ?
Gruß speku
speku,
nüscht!
15:30:20 0.137 8000 OTCBB at Bid
15:29:00 0.139 52000 OTCBB at Ask
15:26:02 0.136 2000 OTCBB at Bid
hehehe!
nüscht!
15:30:20 0.137 8000 OTCBB at Bid
15:29:00 0.139 52000 OTCBB at Ask
15:26:02 0.136 2000 OTCBB at Bid
hehehe!
15:30:20 0.137 8000 OTCBB at Bid
15:29:00 0.139 52000 OTCBB at Ask
15:26:02 0.136 2000 OTCBB at Bid
Last: 0.137
High: 0.159
Low: 0.132
Open: 0.156
Change: -0.02
Volume: 1,973,000
Bid: 0.135
Ask: 0.142
15:29:00 0.139 52000 OTCBB at Ask
15:26:02 0.136 2000 OTCBB at Bid
Last: 0.137
High: 0.159
Low: 0.132
Open: 0.156
Change: -0.02
Volume: 1,973,000
Bid: 0.135
Ask: 0.142
15:34:03 0.139 4000 OTCBB
#1697
das caly das falsche invest ist
das caly das falsche invest ist
15:37:52 0.139 21000000 OTCBB
steffen tippfehler ???
15:40:52 0.269 65210000 OTCBB at ask
trading halt !!!!!!!!!
@steffen712000
15:37:12 0.139 21000000000000 OTCBB
Gruss
15:37:12 0.139 21000000000000 OTCBB
Gruss
steffen du bist besoffen
15:43:11 0.439 6540 OTCBB geht schon was
Date Time High Low Close Volume
10/25/02 15:27:42 0.136 0.136 0.136 2,000
10/25/02 14:55:20 0.139 0.139 0.139 5,000
10/25/02 14:44:06 0.139 0.139 0.139 2,500
10/25/02 14:36:50 0.139 0.139 0.139 2,500
10/25/02 14:34:43 0.137 0.137 0.137 1,000
10/25/02 14:31:21 0.137 0.137 0.137 2,000
10/25/02 14:22:57 0.137 0.137 0.137 500
10/25/02 14:21:46 0.137 0.137 0.137 1,000
10/25/02 14:01:56 0.135 0.135 0.135 9,800
10/25/02 14:01:06 0.135 0.135 0.135 13,600
10/25/02 13:58:14 0.135 0.134 0.135 104,000
10/25/02 13:58:05 0.134 0.134 0.134 5,000
10/25/02 13:53:50 0.135 0.135 0.135 5,000
10/25/02 13:53:31 0.136 0.135 0.135 40,000
10/25/02 13:52:05 0.136 0.136 0.136 50,000
10/25/02 13:49:14 0.137 0.137 0.137 2,000
10/25/02 13:46:39 0.137 0.137 0.137 10,000
10/25/02 13:42:21 0.139 0.139 0.139 600
10/25/02 13:30:10 0.139 0.139 0.139 1,000
10/25/02 13:26:23 0.139 0.139 0.139 10,000
10/25/02 13:22:00 0.139 0.139 0.139 2,100
10/25/02 13:06:44 0.139 0.139 0.139 4,300
10/25/02 12:59:02 0.138 0.138 0.138 4,900
10/25/02 12:54:11 0.138 0.138 0.138 10,000
10/25/02 12:50:58 0.136 0.136 0.136 30,000
10/25/02 12:50:19 0.138 0.138 0.138 15,000
10/25/02 12:46:02 0.136 0.136 0.136 2,000
10/25/02 12:42:34 0.139 0.139 0.139 5,700
10/25/02 12:40:04 0.139 0.136 0.136 65,000
10/25/02 12:31:59 0.137 0.137 0.137 5,000
10/25/02 12:31:05 0.139 0.134 0.139 41,300
10/25/02 12:29:35 0.135 0.135 0.135 5,000
10/25/02 12:27:20 0.135 0.135 0.135 21,000
10/25/02 12:24:03 0.135 0.135 0.135 3,000
10/25/02 12:22:58 0.132 0.132 0.132 15,000
10/25/02 12:21:36 0.135 0.133 0.133 20,000
10/25/02 12:20:34 0.135 0.133 0.135 60,000
10/25/02 12:18:54 0.135 0.135 0.135 20,000
10/25/02 12:16:12 0.137 0.137 0.137 6,500
10/25/02 12:14:29 0.135 0.135 0.135 6,500
10/25/02 12:10:20 0.135 0.135 0.135 15,000
10/25/02 12:09:05 0.135 0.135 0.135 2,500
10/25/02 12:07:53 0.135 0.135 0.135 17,000
10/25/02 12:06:46 0.136 0.136 0.136 5,000
10/25/02 12:02:32 0.135 0.135 0.135 1,000
10/25/02 12:00:24 0.135 0.135 0.135 700
10/25/02 11:59:34 0.135 0.135 0.135 26,000
10/25/02 11:57:52 0.139 0.139 0.139 200
10/25/02 11:55:27 0.139 0.139 0.139 2,300
10/25/02 11:55:12 0.140 0.136 0.136 63,600
10/25/02 11:50:53 0.141 0.141 0.141 5,000
10/25/02 11:50:12 0.138 0.138 0.138 4,000
10/25/02 11:42:11 0.141 0.140 0.140 200
10/25/02 11:40:59 0.138 0.138 0.138 2,500
10/25/02 11:39:36 0.141 0.138 0.140 21,000
10/25/02 11:31:51 0.141 0.138 0.138 13,400
10/25/02 11:25:12 0.140 0.140 0.140 10,500
10/25/02 11:22:03 0.141 0.138 0.140 140,800
10/25/02 11:19:28 0.140 0.140 0.140 10,000
10/25/02 11:18:39 0.141 0.140 0.140 34,600
10/25/02 11:16:09 0.142 0.141 0.141 25,800
10/25/02 11:14:21 0.142 0.142 0.142 17,500
10/25/02 11:03:34 0.145 0.145 0.145 6,000
10/25/02 11:00:42 0.145 0.145 0.145 6,200
10/25/02 10:59:40 0.142 0.142 0.142 20,000
10/25/02 10:57:10 0.143 0.142 0.142 28,400
10/25/02 10:53:31 0.147 0.143 0.147 18,600
10/25/02 10:49:52 0.146 0.143 0.145 38,600
10/25/02 10:46:55 0.143 0.143 0.143 20,000
10/25/02 10:46:02 0.147 0.144 0.147 27,300
10/25/02 10:43:44 0.144 0.144 0.144 10,000
10/25/02 10:43:03 0.148 0.144 0.147 30,200
10/25/02 10:41:32 0.148 0.148 0.148 12,400
10/25/02 10:39:59 0.148 0.148 0.148 2,000
10/25/02 10:38:38 0.148 0.148 0.148 4,000
10/25/02 10:35:52 0.146 0.146 0.146 9,000
10/25/02 10:32:54 0.147 0.146 0.147 7,000
10/25/02 10:31:07 0.148 0.147 0.147 7,000
10/25/02 10:28:43 0.148 0.148 0.148 1,000
10/25/02 10:27:29 0.147 0.147 0.147 13,100
10/25/02 10:22:35 0.147 0.147 0.147 20,000
10/25/02 10:22:05 0.146 0.146 0.146 16,000
10/25/02 10:20:26 0.147 0.145 0.147 70,000
10/25/02 10:15:45 0.145 0.144 0.144 30,000
10/25/02 10:14:09 0.145 0.145 0.145 7,500
10/25/02 10:13:09 0.150 0.149 0.149 12,200
10/25/02 10:11:34 0.152 0.150 0.150 23,500
10/25/02 10:10:16 0.151 0.150 0.150 40,300
10/25/02 10:07:50 0.151 0.151 0.151 6,500
10/25/02 10:07:15 0.152 0.152 0.152 17,400
10/25/02 10:05:28 0.153 0.151 0.153 38,000
10/25/02 10:03:44 0.155 0.155 0.155 10,000
10/25/02 09:54:07 0.153 0.151 0.151 14,600
10/25/02 09:52:22 0.155 0.155 0.155 19,000
10/25/02 09:51:52 0.158 0.154 0.154 15,000
10/25/02 09:50:33 0.158 0.157 0.157 3,000
10/25/02 09:48:40 0.159 0.159 0.159 12,500
10/25/02 09:42:18 0.159 0.159 0.159 5,000
10/25/02 09:39:35 0.159 0.157 0.157 23,600
10/25/02 09:37:34 0.159 0.159 0.159 9,000
10/25/02 09:36:49 0.159 0.155 0.159 10,500
10/25/02 09:34:58 0.159 0.159 0.159 400
10/25/02 09:34:16 0.159 0.157 0.159 85,800
10/25/02 15:27:42 0.136 0.136 0.136 2,000
10/25/02 14:55:20 0.139 0.139 0.139 5,000
10/25/02 14:44:06 0.139 0.139 0.139 2,500
10/25/02 14:36:50 0.139 0.139 0.139 2,500
10/25/02 14:34:43 0.137 0.137 0.137 1,000
10/25/02 14:31:21 0.137 0.137 0.137 2,000
10/25/02 14:22:57 0.137 0.137 0.137 500
10/25/02 14:21:46 0.137 0.137 0.137 1,000
10/25/02 14:01:56 0.135 0.135 0.135 9,800
10/25/02 14:01:06 0.135 0.135 0.135 13,600
10/25/02 13:58:14 0.135 0.134 0.135 104,000
10/25/02 13:58:05 0.134 0.134 0.134 5,000
10/25/02 13:53:50 0.135 0.135 0.135 5,000
10/25/02 13:53:31 0.136 0.135 0.135 40,000
10/25/02 13:52:05 0.136 0.136 0.136 50,000
10/25/02 13:49:14 0.137 0.137 0.137 2,000
10/25/02 13:46:39 0.137 0.137 0.137 10,000
10/25/02 13:42:21 0.139 0.139 0.139 600
10/25/02 13:30:10 0.139 0.139 0.139 1,000
10/25/02 13:26:23 0.139 0.139 0.139 10,000
10/25/02 13:22:00 0.139 0.139 0.139 2,100
10/25/02 13:06:44 0.139 0.139 0.139 4,300
10/25/02 12:59:02 0.138 0.138 0.138 4,900
10/25/02 12:54:11 0.138 0.138 0.138 10,000
10/25/02 12:50:58 0.136 0.136 0.136 30,000
10/25/02 12:50:19 0.138 0.138 0.138 15,000
10/25/02 12:46:02 0.136 0.136 0.136 2,000
10/25/02 12:42:34 0.139 0.139 0.139 5,700
10/25/02 12:40:04 0.139 0.136 0.136 65,000
10/25/02 12:31:59 0.137 0.137 0.137 5,000
10/25/02 12:31:05 0.139 0.134 0.139 41,300
10/25/02 12:29:35 0.135 0.135 0.135 5,000
10/25/02 12:27:20 0.135 0.135 0.135 21,000
10/25/02 12:24:03 0.135 0.135 0.135 3,000
10/25/02 12:22:58 0.132 0.132 0.132 15,000
10/25/02 12:21:36 0.135 0.133 0.133 20,000
10/25/02 12:20:34 0.135 0.133 0.135 60,000
10/25/02 12:18:54 0.135 0.135 0.135 20,000
10/25/02 12:16:12 0.137 0.137 0.137 6,500
10/25/02 12:14:29 0.135 0.135 0.135 6,500
10/25/02 12:10:20 0.135 0.135 0.135 15,000
10/25/02 12:09:05 0.135 0.135 0.135 2,500
10/25/02 12:07:53 0.135 0.135 0.135 17,000
10/25/02 12:06:46 0.136 0.136 0.136 5,000
10/25/02 12:02:32 0.135 0.135 0.135 1,000
10/25/02 12:00:24 0.135 0.135 0.135 700
10/25/02 11:59:34 0.135 0.135 0.135 26,000
10/25/02 11:57:52 0.139 0.139 0.139 200
10/25/02 11:55:27 0.139 0.139 0.139 2,300
10/25/02 11:55:12 0.140 0.136 0.136 63,600
10/25/02 11:50:53 0.141 0.141 0.141 5,000
10/25/02 11:50:12 0.138 0.138 0.138 4,000
10/25/02 11:42:11 0.141 0.140 0.140 200
10/25/02 11:40:59 0.138 0.138 0.138 2,500
10/25/02 11:39:36 0.141 0.138 0.140 21,000
10/25/02 11:31:51 0.141 0.138 0.138 13,400
10/25/02 11:25:12 0.140 0.140 0.140 10,500
10/25/02 11:22:03 0.141 0.138 0.140 140,800
10/25/02 11:19:28 0.140 0.140 0.140 10,000
10/25/02 11:18:39 0.141 0.140 0.140 34,600
10/25/02 11:16:09 0.142 0.141 0.141 25,800
10/25/02 11:14:21 0.142 0.142 0.142 17,500
10/25/02 11:03:34 0.145 0.145 0.145 6,000
10/25/02 11:00:42 0.145 0.145 0.145 6,200
10/25/02 10:59:40 0.142 0.142 0.142 20,000
10/25/02 10:57:10 0.143 0.142 0.142 28,400
10/25/02 10:53:31 0.147 0.143 0.147 18,600
10/25/02 10:49:52 0.146 0.143 0.145 38,600
10/25/02 10:46:55 0.143 0.143 0.143 20,000
10/25/02 10:46:02 0.147 0.144 0.147 27,300
10/25/02 10:43:44 0.144 0.144 0.144 10,000
10/25/02 10:43:03 0.148 0.144 0.147 30,200
10/25/02 10:41:32 0.148 0.148 0.148 12,400
10/25/02 10:39:59 0.148 0.148 0.148 2,000
10/25/02 10:38:38 0.148 0.148 0.148 4,000
10/25/02 10:35:52 0.146 0.146 0.146 9,000
10/25/02 10:32:54 0.147 0.146 0.147 7,000
10/25/02 10:31:07 0.148 0.147 0.147 7,000
10/25/02 10:28:43 0.148 0.148 0.148 1,000
10/25/02 10:27:29 0.147 0.147 0.147 13,100
10/25/02 10:22:35 0.147 0.147 0.147 20,000
10/25/02 10:22:05 0.146 0.146 0.146 16,000
10/25/02 10:20:26 0.147 0.145 0.147 70,000
10/25/02 10:15:45 0.145 0.144 0.144 30,000
10/25/02 10:14:09 0.145 0.145 0.145 7,500
10/25/02 10:13:09 0.150 0.149 0.149 12,200
10/25/02 10:11:34 0.152 0.150 0.150 23,500
10/25/02 10:10:16 0.151 0.150 0.150 40,300
10/25/02 10:07:50 0.151 0.151 0.151 6,500
10/25/02 10:07:15 0.152 0.152 0.152 17,400
10/25/02 10:05:28 0.153 0.151 0.153 38,000
10/25/02 10:03:44 0.155 0.155 0.155 10,000
10/25/02 09:54:07 0.153 0.151 0.151 14,600
10/25/02 09:52:22 0.155 0.155 0.155 19,000
10/25/02 09:51:52 0.158 0.154 0.154 15,000
10/25/02 09:50:33 0.158 0.157 0.157 3,000
10/25/02 09:48:40 0.159 0.159 0.159 12,500
10/25/02 09:42:18 0.159 0.159 0.159 5,000
10/25/02 09:39:35 0.159 0.157 0.157 23,600
10/25/02 09:37:34 0.159 0.159 0.159 9,000
10/25/02 09:36:49 0.159 0.155 0.159 10,500
10/25/02 09:34:58 0.159 0.159 0.159 400
10/25/02 09:34:16 0.159 0.157 0.159 85,800
fhr,
los ich stelle meine 390K zu 1$ in den ask!
kauf`se weg !!!!!!!!
los ich stelle meine 390K zu 1$ in den ask!
kauf`se weg !!!!!!!!
geht los
@steffen712000,
hab gesehen das du heute im Board von
Deakin Financial Services Group Limited (WKN 910.424) warst.
Bist zu welchem Kurs soll man nachkaufen, hast du mir einen Tipp.
Danke Jasmin
hab gesehen das du heute im Board von
Deakin Financial Services Group Limited (WKN 910.424) warst.
Bist zu welchem Kurs soll man nachkaufen, hast du mir einen Tipp.
Danke Jasmin
Latest Quote
Last: 0.137
High: 0.159
Low: 0.132
Open: 0.156
Change: -0.02
Volume: 2,012,500
Bid: 0.130
Ask: 0.138
15:50:35 0.137 20000 OTCBB
15:50:27 0.138 2500 OTCBB at Ask
15:49:29 0.137 10000 OTCBB
15:46:21 0.137 900 OTCBB
Last: 0.137
High: 0.159
Low: 0.132
Open: 0.156
Change: -0.02
Volume: 2,012,500
Bid: 0.130
Ask: 0.138
15:50:35 0.137 20000 OTCBB
15:50:27 0.138 2500 OTCBB at Ask
15:49:29 0.137 10000 OTCBB
15:46:21 0.137 900 OTCBB
jasminBe,
mein EK liegt bei max0,11 min0,9 sprich 0,10€. fett dabei-ohohoh.....
ich selbst höre nun auf einzukaufen! in ausi kaum handel! in deutschland heute umsomehr
raten tue ich garnüscht, doch vorsichtig empfohlen bis 0,13! voll die chance..... modell und konzept = TOP!!!
schau mal auf meinen FTP, dort findest du so einiges von mir zusammengetragenes ich schicke dir die adresse per BM- ok? erbitte bestätigung.....
ciao erstmal, muß katze füttern und weggeflogene firstziegel suchen und gegebenfalls eine neue im dunkeln auf`s dach schrauben
1/4 stunde.....
mein EK liegt bei max0,11 min0,9 sprich 0,10€. fett dabei-ohohoh.....
ich selbst höre nun auf einzukaufen! in ausi kaum handel! in deutschland heute umsomehr
raten tue ich garnüscht, doch vorsichtig empfohlen bis 0,13! voll die chance..... modell und konzept = TOP!!!
schau mal auf meinen FTP, dort findest du so einiges von mir zusammengetragenes ich schicke dir die adresse per BM- ok? erbitte bestätigung.....
ciao erstmal, muß katze füttern und weggeflogene firstziegel suchen und gegebenfalls eine neue im dunkeln auf`s dach schrauben
1/4 stunde.....
das nenn ich freund?!
ich genieße Dornfelder und steffen wird besoffen!
also nur 0,139$ naja neue woche neues glück!
gut´s nächtle @all
zum wohl alle miteinander!
M1
ich genieße Dornfelder und steffen wird besoffen!
also nur 0,139$ naja neue woche neues glück!
gut´s nächtle @all
zum wohl alle miteinander!
M1
16:00:04 0.137 25000 OTCBB
15:55:32 0.138 3800 OTCBB at Ask
15:55:56 0.138 15000 OTCBB at Ask
15:54:44 0.138 7000 OTCBB at Ask
15:53:05 0.137 5000 OTCBB
ciao
westfalica
15:55:32 0.138 3800 OTCBB at Ask
15:55:56 0.138 15000 OTCBB at Ask
15:54:44 0.138 7000 OTCBB at Ask
15:53:05 0.137 5000 OTCBB
ciao
westfalica
@steffen712000,
Danke!
Warte auf Post von dir.
Danke!
Warte auf Post von dir.
16:00:02 0.137 25000 OTCBB
15:55:30 0.138 3800 OTCBB at Ask
15:55:54 0.138 15000 OTCBB at Ask
15:54:42 0.138 7000 OTCBB at Ask
15:53:03 0.137 5000 OTCBB
15:55:30 0.138 3800 OTCBB at Ask
15:55:54 0.138 15000 OTCBB at Ask
15:54:42 0.138 7000 OTCBB at Ask
15:53:03 0.137 5000 OTCBB
wurden die ausgeführt?
16:04:47 0.159 8000 OTCBB
16:04:28 0.159 27000 OTCBB
16:04:47 0.159 8000 OTCBB
16:04:28 0.159 27000 OTCBB
jasmin, potschta! (post)
watt`n hier los ??????????
16:15:55 0.136 9300 OTCBB at Bid
16:12:16 0.135 60000 OTCBB
16:12:00 0.136 5000 OTCBB at Bid
16:08:38 0.150 5000 OTCBB
16:04:45 0.159 8000 OTCBB
16:04:26 0.159 27000 OTCBB
16:15:55 0.136 9300 OTCBB at Bid
16:12:16 0.135 60000 OTCBB
16:12:00 0.136 5000 OTCBB at Bid
16:08:38 0.150 5000 OTCBB
16:04:45 0.159 8000 OTCBB
16:04:26 0.159 27000 OTCBB
@steffen712000,
hast du deine Ziegel wieder gefunden
Was ist denn heute los??????
16:15:55 0.136 9300 OTCBB at Bid
16:12:16 0.135 60000 OTCBB
16:12:00 0.136 5000 OTCBB at Bid
16:08:38 0.150 5000 OTCBB
hast du deine Ziegel wieder gefunden
Was ist denn heute los??????
16:15:55 0.136 9300 OTCBB at Bid
16:12:16 0.135 60000 OTCBB
16:12:00 0.136 5000 OTCBB at Bid
16:08:38 0.150 5000 OTCBB
klaro jasmin!
was geht den bei den amis ab ???
mein klaro galt der ausführung
ziegel war pfutsch! erstzziegel paßt nicht, hab erstmal folie druntergeschoben.... morgen ist auch noch ein tag
ziegel war pfutsch! erstzziegel paßt nicht, hab erstmal folie druntergeschoben.... morgen ist auch noch ein tag
Steffen habt ihr bei euch so ein Sau wetter ?
Gruß speku
Gruß speku
weltuntergangsstimmung
es pisst und pfeifft durch alle ritzen! bin ein geschoß höher geflüchtet.....
mal ehrlich : SCHEIßWETTER !!!!!!!!!!
es pisst und pfeifft durch alle ritzen! bin ein geschoß höher geflüchtet.....
mal ehrlich : SCHEIßWETTER !!!!!!!!!!
@steffen712000,
ich wünsche dir trotzdem ein schönes Wochenende
Du hast Post, aber das hast du bestimmt schon gemerkt.
ich wünsche dir trotzdem ein schönes Wochenende
Du hast Post, aber das hast du bestimmt schon gemerkt.
Na dann wünsch ich dir ein gut Nächtle darüber.
Gruß speku bei dem alles ruhig ist bis auf die kinder
Gruß speku bei dem alles ruhig ist bis auf die kinder
solch ein massiv-foligranuiegeldach habe ich dennoch nicht! und wenn es so ein teil wegweht... ohoh!
...dann nützt der beste regenschirm als passant nüscht-gelle!
danke speku, werd`s überleben - hehehe!
PS:ääääääähhhhhhmmmmmmmmmmmm N8
...dann nützt der beste regenschirm als passant nüscht-gelle!
danke speku, werd`s überleben - hehehe!
PS:ääääääähhhhhhmmmmmmmmmmmm N8
@spekulativ,
du hast schon Kinder?
Und dann hast du soviel Zeit für deinen PC (Aktien)?
Na, dann mußt du eine liebe Frau habe.
Gruss JasminB
du hast schon Kinder?
Und dann hast du soviel Zeit für deinen PC (Aktien)?
Na, dann mußt du eine liebe Frau habe.
Gruss JasminB
jasmin,
hast immer ein passendes bildchen parat -was?
N8 und schönes WE (die woche ist auch schon wieder rum!)
PS: uhren umstellen nicht vergessen ---> 1h ZURÜCKSTELLEN
hast immer ein passendes bildchen parat -was?
N8 und schönes WE (die woche ist auch schon wieder rum!)
PS: uhren umstellen nicht vergessen ---> 1h ZURÜCKSTELLEN
@steffen712000,
du hast schon wieder Post!
du hast schon wieder Post!
@steffen712000,
schlaf gut bis dann
schlaf gut bis dann
jasmin,
hast 2x POST !
PS: hast du das bett für mich aufgedeckt? ooooooops......
hast 2x POST !
PS: hast du das bett für mich aufgedeckt? ooooooops......
@steffen712000,
echt Super deine Infos
echt Super deine Infos
wann iss eigentlich euer TERMIN?
ta ta tata, ta ta tata.......
gruß und schön das es sowas noch gibt
M1
ta ta tata, ta ta tata.......
gruß und schön das es sowas noch gibt
M1
@morphoys1,
ich Versuche nur nett zu sein.
@steffen712000 versteht es bestimmt richtig!
Gute Nacht Deutschland
ich Versuche nur nett zu sein.
@steffen712000 versteht es bestimmt richtig!
Gute Nacht Deutschland
jasmin,
wann war doch gleich unser termin? ...ich denke zur 1$ - FETE ?
time will tell
PS: habe DEAKIN gerade nochmal aktualisiert schau ruhig nochmal rein....
wann war doch gleich unser termin? ...ich denke zur 1$ - FETE ?
time will tell
PS: habe DEAKIN gerade nochmal aktualisiert schau ruhig nochmal rein....
@steffen712000,
auf welcher Insel
Gruss
auf welcher Insel
Gruss
@jasmin, weiß ich doch!
@steffen, wo soll die noch gleich stattfinden?
hier oben oder bei euch da unten?
gute nacht alle und nehmt nicht immer alles so ernst
M1
p.s. die amis haben wohl kurz vor 4 noch mal ne line gezogen
@steffen, wo soll die noch gleich stattfinden?
hier oben oder bei euch da unten?
gute nacht alle und nehmt nicht immer alles so ernst
M1
p.s. die amis haben wohl kurz vor 4 noch mal ne line gezogen
GOZO
#steffen
hast du einen abküfi? (GOZO)
oder insider?
M1
hast du einen abküfi? (GOZO)
oder insider?
M1
Gute Nacht ihr Zwei
PS: Hab es auch nicht Böse gemeint.
Gruss JasminB
PS: Hab es auch nicht Böse gemeint.
Gruss JasminB
morphosys,
"abküfi" ???????häääääääää?????? was ist das denn ?
"insider" ???????häääääääääääää???????
"abküfi" ???????häääääääää?????? was ist das denn ?
"insider" ???????häääääääääääää???????
N8J.
abküfi für abkürzungsfimmel ahaaaaaaaaaaaaaa jetzt hats geklickt
nööööööö
nööööööö
M1,
du kennst GOZO nicht? die gaulitaner um malta? mittelmeer? victoria? xlendi? brit. kolonie ?
na klickts?
geile insel hmmmmmmmmmmmmm
du kennst GOZO nicht? die gaulitaner um malta? mittelmeer? victoria? xlendi? brit. kolonie ?
na klickts?
geile insel hmmmmmmmmmmmmm
steffen
also du schreibst "GOZO" richtig? richtig!
ist das:
a) dein abkürzungsfimmel (abküfi) oder
b) ein Insiderwitz mit J.
gruß
M1
also du schreibst "GOZO" richtig? richtig!
ist das:
a) dein abkürzungsfimmel (abküfi) oder
b) ein Insiderwitz mit J.
gruß
M1
malta uff hab ich grad nich auf der pfanne gehabt aber klar nix wie hin!!!
M1
M1
N8 leute!
o.k
angenehme träume
M1
angenehme träume
M1
Wünsche euch allen ein schönes Wochenende.
Gruß spekulativ
Gruß spekulativ
Von Freitag
CALY
CALYPTE BIOMEDICAL CP
0.137
-0.019 -12.18%
Daily Commentary
HOLD
Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/15/2002 (10) days ago, when the stock price was 0.129. Since then the stock gained 6.20% .
Today the stock closed lower, close to its low (sign of weakness) with a lower high and a lower low. The volume is normal. The security price is trending up.
Candlestick Analysis
Today’s Candlestick Patterns:
Long Black Candlestick
Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!
Stock Quote
Last 0.137
Previous Close 0.156
Change -0.019
% Change -12.18%
Volume 2,157,300
Stock Activity
Open 0.156
Day`s High 0.159
Day`s Low 0.132
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -48.30
6 Month % Change 389.29
12 Month % Change -49.26
Stock Statistics
50 Day Close MA 0.119
200 Day Close MA 0.163
65 Day Volume MA 2,185,026
JS200
CALY
CALYPTE BIOMEDICAL CP
0.137
-0.019 -12.18%
Daily Commentary
HOLD
Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/15/2002 (10) days ago, when the stock price was 0.129. Since then the stock gained 6.20% .
Today the stock closed lower, close to its low (sign of weakness) with a lower high and a lower low. The volume is normal. The security price is trending up.
Candlestick Analysis
Today’s Candlestick Patterns:
Long Black Candlestick
Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!
Stock Quote
Last 0.137
Previous Close 0.156
Change -0.019
% Change -12.18%
Volume 2,157,300
Stock Activity
Open 0.156
Day`s High 0.159
Day`s Low 0.132
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -48.30
6 Month % Change 389.29
12 Month % Change -49.26
Stock Statistics
50 Day Close MA 0.119
200 Day Close MA 0.163
65 Day Volume MA 2,185,026
JS200
Hi bin neu im Caly-Forum bei euch.Habe seit einiger Zeit Teile an Caly.was steht next week an, up or down??
Gruß 2502
Gruß 2502
Guten Morgen @all
Wollen WIr doch mal hoffen das Cataldo und Co noch ein
Paar gute Nachrichten auf Lager haben um uns die Zeit
bis zum Jahresabschluss zu versüssen
auf ein bis zwei Vertragliche abschlüsse kurz bis mittelfristig hoffe ich noch
einen schönen Tag Wünsche ich Euch noch
mfg jojo
Wollen WIr doch mal hoffen das Cataldo und Co noch ein
Paar gute Nachrichten auf Lager haben um uns die Zeit
bis zum Jahresabschluss zu versüssen
auf ein bis zwei Vertragliche abschlüsse kurz bis mittelfristig hoffe ich noch
einen schönen Tag Wünsche ich Euch noch
mfg jojo
im Ariva Board stehen lustige Dinge: Caly soll von Morphosys ???? übernommen werden ????? Weiß jemand was ??? Is n Scherz oder ??? MfG X 99
deswegen hat morph auch die 360.000 aktien an xoma verkauft
so eine kl. Kapital erhöhung ist immer hilfreich bei
übernahmen
an jeder Story ist was dran wieso nicht !!
so eine kl. Kapital erhöhung ist immer hilfreich bei
übernahmen
an jeder Story ist was dran wieso nicht !!
@jojoba
Kann das sein dass du mehr weisst als der Rest der Gemeinde hier? Wäre doch nett wenn du deine "spekulativen" Gedanken mal etwas ausführlicher gestalten könntest. Was hat Morphy von der Übernahme außer das eine größeres Abschreibungspotential aufgebaut wird?
Bin durch anraten von mfierke auf caly aufmerksam geworden und möchte ein paar mehr Infos bevor ich größer einsteige, oder gibt es noch einen anderen Tip von dir?
moon1
der nach Infos sucht
Kann das sein dass du mehr weisst als der Rest der Gemeinde hier? Wäre doch nett wenn du deine "spekulativen" Gedanken mal etwas ausführlicher gestalten könntest. Was hat Morphy von der Übernahme außer das eine größeres Abschreibungspotential aufgebaut wird?
Bin durch anraten von mfierke auf caly aufmerksam geworden und möchte ein paar mehr Infos bevor ich größer einsteige, oder gibt es noch einen anderen Tip von dir?
moon1
der nach Infos sucht
Hallo
Caly kann doch erst zum Übernahmekandidat werden wenn
Umsatz generiert wird
Caly war bis dato nicht interessant weil
die Strukturen nicht stimmten sowie zu wenig bzw. nicht ausreichend Cash vorhanden war
wenn Caly es schafft soviel Verträge zu schliesen das am ende mehr als eine schwarze null steht
dann wird Caly für alle biotechs bei der jetzigen MK
sehr Interessant werden !!!!
hier wird Zukunft gehandelt ich denke schon das da noch
was kommen wird
mfg jojo
Caly kann doch erst zum Übernahmekandidat werden wenn
Umsatz generiert wird
Caly war bis dato nicht interessant weil
die Strukturen nicht stimmten sowie zu wenig bzw. nicht ausreichend Cash vorhanden war
wenn Caly es schafft soviel Verträge zu schliesen das am ende mehr als eine schwarze null steht
dann wird Caly für alle biotechs bei der jetzigen MK
sehr Interessant werden !!!!
hier wird Zukunft gehandelt ich denke schon das da noch
was kommen wird
mfg jojo
Was is jetzt los ???? In Frankfurt Brief: 12,14 ; Geld 12,00 Euro ???? Wohl leider nur ein Systemfehler...... MfG X 99
realtime bitte von der otcbb - danke
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.133 0.004 (2.92) 0.133 (50) 0.136 (50) 09:38
Day Volume Last Size Open High Low
83,000 7,000 0.136 0.136 0.133
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-- 18 4,611 0.4375 0.0156
Prev Close VWAP Avg Day Vol
0.137 0.1349 N/A
JS200
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.133 0.004 (2.92) 0.133 (50) 0.136 (50) 09:38
Day Volume Last Size Open High Low
83,000 7,000 0.136 0.136 0.133
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-- 18 4,611 0.4375 0.0156
Prev Close VWAP Avg Day Vol
0.137 0.1349 N/A
JS200
Calypte Biomedical Corp.
Date Time Price Volume Exch Type Bid BSize BEx Ask ASize AEx Cond
Vl: BSize: ASize:
28.10.2002 14:58 Best Bid .1330 5000
28.10.2002 14:58 Best Ask .1330 5000 .1360 5000
28.10.2002 15:30 .1360 100 Trade
28.10.2002 15:30 .1330 100 Trade
28.10.2002 15:30 .1360 100 Trade
28.10.2002 15:30 .1360 1700 Trade
28.10.2002 15:31 .1330 6300 Trade
28.10.2002 15:31 .1360 3000 Trade
28.10.2002 15:31 .1330 10000 Trade
28.10.2002 15:31 .1360 2900 Trade
28.10.2002 15:31 .1360 700 Trade
28.10.2002 15:31 .1360 3100 Trade
28.10.2002 15:31 .1360 3000 Trade
28.10.2002 15:31 .1360 4400 Trade
28.10.2002 15:31 .1360 1600 Trade
28.10.2002 15:33 .1360 10000 Trade
28.10.2002 15:34 .1360 10000 Trade
28.10.2002 15:34 .1350 13000 Trade
28.10.2002 15:34 .1350 6000 Trade
28.10.2002 15:38 .1330 7000 Trade
Date Time Price Volume Exch Type Bid BSize BEx Ask ASize AEx Cond
Vl: BSize: ASize:
28.10.2002 14:58 Best Bid .1330 5000
28.10.2002 14:58 Best Ask .1330 5000 .1360 5000
28.10.2002 15:30 .1360 100 Trade
28.10.2002 15:30 .1330 100 Trade
28.10.2002 15:30 .1360 100 Trade
28.10.2002 15:30 .1360 1700 Trade
28.10.2002 15:31 .1330 6300 Trade
28.10.2002 15:31 .1360 3000 Trade
28.10.2002 15:31 .1330 10000 Trade
28.10.2002 15:31 .1360 2900 Trade
28.10.2002 15:31 .1360 700 Trade
28.10.2002 15:31 .1360 3100 Trade
28.10.2002 15:31 .1360 3000 Trade
28.10.2002 15:31 .1360 4400 Trade
28.10.2002 15:31 .1360 1600 Trade
28.10.2002 15:33 .1360 10000 Trade
28.10.2002 15:34 .1360 10000 Trade
28.10.2002 15:34 .1350 13000 Trade
28.10.2002 15:34 .1350 6000 Trade
28.10.2002 15:38 .1330 7000 Trade
danke
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.136 0.001 (0.73) 0.133 (50) 0.136 (50) 09:41
Day Volume Last Size Open High Low
88,000 5,000 0.136 0.136 0.133
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+--+ 19 4,632 0.4375 0.0156
Prev Close VWAP Avg Day Vol
0.137 0.135 N/A
JS200
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.136 0.001 (0.73) 0.133 (50) 0.136 (50) 09:41
Day Volume Last Size Open High Low
88,000 5,000 0.136 0.136 0.133
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+--+ 19 4,632 0.4375 0.0156
Prev Close VWAP Avg Day Vol
0.137 0.135 N/A
JS200
Jetzt rauscht Caly Richtung Süden.
$ 0,130
david
$ 0,130
david
$ 0,128
$ 0,125
$0,120
@Calypter
..........ausverkauf ......
aber keine Panik bei 0,08 dürfte erst mal Schluß sein
und dann von vorne , das selbe Spiel.
Gruß Dr.B
..........ausverkauf ......
aber keine Panik bei 0,08 dürfte erst mal Schluß sein
und dann von vorne , das selbe Spiel.
Gruß Dr.B
$ 0,119
$ 0,1270
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.127 0.01 (7.30) 0.121 (50) 0.127 (50) 11:12
Day Volume Last Size Open High Low
538,200 4,000 0.136 0.137 0.119
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+++ 85 6,332 0.4375 0.0156
Prev Close VWAP Avg Day Vol
0.137 0.1287 N/A
JS200
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.127 0.01 (7.30) 0.121 (50) 0.127 (50) 11:12
Day Volume Last Size Open High Low
538,200 4,000 0.136 0.137 0.119
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+++ 85 6,332 0.4375 0.0156
Prev Close VWAP Avg Day Vol
0.137 0.1287 N/A
JS200
hi leute!
kann mir mal jemand den link zum "ariva-board" reinstellen?
danke
kann mir mal jemand den link zum "ariva-board" reinstellen?
danke
Kann mir jemand Amilandrealtimekurse reinstellen - Danke - MfG X 99
bittermoon -danke...
11:55:26 0.128 2500 OTC BBS at Ask
11:47:50 0.128 3800 OTC BBS at Ask
11:55:26 0.128 2500 OTC BBS at Ask
11:47:50 0.128 3800 OTC BBS at Ask
mich hauts auf`n arsch- hehehe
hier zitiert aus dem arivaboard:
*325
"habe soeben mit einem Freund aus Kulmbach auf geht´s 27.10.02 18:16
telefoniert - er hat mir bestätigt, das Hammer-News ins Haus stehen und der Kurs in Kürze erst richtig explodieren wird ===> er hat mir hinter vorgehaltener Hand ein mögliches Kursziel von 1000 € ( in Worten = dausend !!! ) genannt.
Mein Tip an alle - kaufen bis 1,00 € was das Zeug hält, wer hier nur 1 Stk. vor dem genannten Kursziel abgibt, ist total verblödet !!!
Angeblich soll CALY von MORPHOSYS übernommen werden, wenn das wahr ist, kennt der Kurs ( und mein Lachen ) kein halten mehr!!
Gruß ( und noch einen schönen Sonntag )
AUF GEHT`S "
.....nicht schlecht! mir reichen allerdings schon KZ 500 hehehe
hier zitiert aus dem arivaboard:
*325
"habe soeben mit einem Freund aus Kulmbach auf geht´s 27.10.02 18:16
telefoniert - er hat mir bestätigt, das Hammer-News ins Haus stehen und der Kurs in Kürze erst richtig explodieren wird ===> er hat mir hinter vorgehaltener Hand ein mögliches Kursziel von 1000 € ( in Worten = dausend !!! ) genannt.
Mein Tip an alle - kaufen bis 1,00 € was das Zeug hält, wer hier nur 1 Stk. vor dem genannten Kursziel abgibt, ist total verblödet !!!
Angeblich soll CALY von MORPHOSYS übernommen werden, wenn das wahr ist, kennt der Kurs ( und mein Lachen ) kein halten mehr!!
Gruß ( und noch einen schönen Sonntag )
AUF GEHT`S "
.....nicht schlecht! mir reichen allerdings schon KZ 500 hehehe
11:59:13 0.123 11900 OTC BBS
11:59:59 0.123 10000 OTC BBS
11:59:58 0.125 9400 OTC BBS
11:59:58 0.125 2500 OTC BBS
11:58:40 0.123 2500 OTC BBS
11:58:40 0.123 2500 OTC BBS
11:58:40 0.125 2500 OTC BBS
11:58:40 0.125 2500 OTC BBS
11:58:21 0.124 5000 OTC BBS at Ask
11:59:59 0.123 10000 OTC BBS
11:59:58 0.125 9400 OTC BBS
11:59:58 0.125 2500 OTC BBS
11:58:40 0.123 2500 OTC BBS
11:58:40 0.123 2500 OTC BBS
11:58:40 0.125 2500 OTC BBS
11:58:40 0.125 2500 OTC BBS
11:58:21 0.124 5000 OTC BBS at Ask
Derjenige (auf gehts) der im ariva-board von dausend ausgeht hat wohl kalte Füße bekommen und is ausgestiegen (vgl. letztes Posting im ariva-board) - soviel zu Freunden aus Kulmbach - MfG X 99 (dem heut nicht nach Grinsen ist)
x99,
der will doch aber unter 0,10 wieder rein hehehe
der will doch aber unter 0,10 wieder rein hehehe
company news
--------------------------------------------------------------------------------
CALY - Calypte Biomedical Corporation (OTCBB : CALY)
--------------------------------------------------------------------------------
MOVER(-): Calypte Biomedical Trading Lower In Session
MONDAY , OCTOBER 28, 2002 12:08 PM
Calypte Biomedical Corporation (OTCBB: CALY)
- Last Trade: $ 0.12800
- : $ 0.00900
- % Change: -6.56934%
- Volume at Publication: 631,600
- 20-day Average Volume: 2,586,155
Recent company news:
10/24/02: Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, today announced financial results for the third quarter and nine months ended September 30, 2002.
Recent Knobias stories:
10/24/02: CALY Reports Q3 EPS (2c) vs (5c) Last Yr. on Rev $493K
Technical analysis:
- Below 2 of 4 moving averages
- Near-term support price: $ 0.12000
- Near-term resistance price: $ 0.16200
JS200
--------------------------------------------------------------------------------
CALY - Calypte Biomedical Corporation (OTCBB : CALY)
--------------------------------------------------------------------------------
MOVER(-): Calypte Biomedical Trading Lower In Session
MONDAY , OCTOBER 28, 2002 12:08 PM
Calypte Biomedical Corporation (OTCBB: CALY)
- Last Trade: $ 0.12800
- : $ 0.00900
- % Change: -6.56934%
- Volume at Publication: 631,600
- 20-day Average Volume: 2,586,155
Recent company news:
10/24/02: Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, today announced financial results for the third quarter and nine months ended September 30, 2002.
Recent Knobias stories:
10/24/02: CALY Reports Q3 EPS (2c) vs (5c) Last Yr. on Rev $493K
Technical analysis:
- Below 2 of 4 moving averages
- Near-term support price: $ 0.12000
- Near-term resistance price: $ 0.16200
JS200
bei DAUSEND macht das dann nochmal ein paar Prozentchen, so ein Schlitzohr,gelle......MfG X99
12:14:00 0.124 5000 OTC BBS at Bid
12:08:27 0.128 10000 OTC BBS at Ask
12:08:27 0.128 10000 OTC BBS at Ask
Last: 0.128
High: 0.137
Low: 0.119
Open: 0.136
Change: -0.01
Volume: 702,900
Bid: 0.124
Ask: 0.128
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: -6.6%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Quotes provided by S&P Comstock
10/28/02 - 12:30 p.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
12:24:56 0.128 5000 OTC BBS at Ask
High: 0.137
Low: 0.119
Open: 0.136
Change: -0.01
Volume: 702,900
Bid: 0.124
Ask: 0.128
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: -6.6%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Quotes provided by S&P Comstock
10/28/02 - 12:30 p.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
12:24:56 0.128 5000 OTC BBS at Ask
unglaubliche panikverkäufe!!!!!
seit 19 Uhr 09 will jeder raus!
seht euch mal den umsatz seit diesem zeitpunkt an!
mfg. bittermoon
seit 19 Uhr 09 will jeder raus!
seht euch mal den umsatz seit diesem zeitpunkt an!
mfg. bittermoon
15:14:05 0.128 2500 OTC BBS at Ask
15:12:46 0.126 1500 OTC BBS at Bid
15:11:01 0.126 10000 OTC BBS at Bid
15:09:12 0.128 10000 OTC BBS
15:08:08 0.126 10000 OTC BBS
15:06:21 0.127 5000 OTC BBS
15:06:20 0.128 10000 OTC BBS
15:05:15 0.127 7000 OTC BBS
15:00:29 0.127 10000 OTC BBS at Ask
14:59:22 0.127 5000 OTC BBS at Ask
15:12:46 0.126 1500 OTC BBS at Bid
15:11:01 0.126 10000 OTC BBS at Bid
15:09:12 0.128 10000 OTC BBS
15:08:08 0.126 10000 OTC BBS
15:06:21 0.127 5000 OTC BBS
15:06:20 0.128 10000 OTC BBS
15:05:15 0.127 7000 OTC BBS
15:00:29 0.127 10000 OTC BBS at Ask
14:59:22 0.127 5000 OTC BBS at Ask
@BITTERMOON
2:40:16 PM Trade (at Bid) 0.124 1000 OTC BB
2:25:21 PM Trade (at Bid) 0.124 15000 OTC BB
2:22:44 PM Trade (at Ask) 0.128 700 OTC BB
1:10:45 PM Ask 0.128 5000 OTC BB
1:10:45 PM Bid 0.124 5000 OTC BB
1:09:43 PM Trade (at Bid) 0.123 900 OTC BB
1:09:43 PM Trade 0.125 900 OTC BB
1:08:28 PM Trade (at Ask) 0.128 1700 OTC BB
Von Panik keine REDE, abwarten auf den Schlussspurt und morgen wieder hoch
JS200
2:40:16 PM Trade (at Bid) 0.124 1000 OTC BB
2:25:21 PM Trade (at Bid) 0.124 15000 OTC BB
2:22:44 PM Trade (at Ask) 0.128 700 OTC BB
1:10:45 PM Ask 0.128 5000 OTC BB
1:10:45 PM Bid 0.124 5000 OTC BB
1:09:43 PM Trade (at Bid) 0.123 900 OTC BB
1:09:43 PM Trade 0.125 900 OTC BB
1:08:28 PM Trade (at Ask) 0.128 1700 OTC BB
Von Panik keine REDE, abwarten auf den Schlussspurt und morgen wieder hoch
JS200
wie eine schaukel ist caly.
rauf und runter ohne dass sich das ganze
bewegt.
der einzige der kohle macht ist quwatschtaldo
rauf und runter ohne dass sich das ganze
bewegt.
der einzige der kohle macht ist quwatschtaldo
15:47:58 0.126 700 OTC BBS
15:45:28 0.127 20000 OTC BBS
15:45:23 0.126 16000 OTC BBS
15:45:52 0.126 15000 OTC BBS
15:37:42 0.126 10000 OTC BBS
15:45:28 0.127 20000 OTC BBS
15:45:23 0.126 16000 OTC BBS
15:45:52 0.126 15000 OTC BBS
15:37:42 0.126 10000 OTC BBS
Von GESTERN
CALY
CALYPTE BIOMEDICAL CP
0.127
-0.010 -7.30%
Daily Commentary
HOLD
Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/15/2002 (13) days ago, when the stock price was 0.129. Since then the stock fell -1.55% .
Today the stock closed lower with a lower high and a lower low. The volume is extremely low. The security price is trending up.
Candlestick Analysis
Today’s Candlestick Patterns:
Black Candlestick
Today a Black Candlestick formed. Sellers were in control but the selling pressure was not very strong.
Stock Quote
Last 0.127
Previous Close 0.137
Change -0.010
% Change -7.30%
Volume 1,017,600
Stock Activity
Open 0.136
Day`s High 0.137
Day`s Low 0.119
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -43.30
6 Month % Change 353.57
12 Month % Change -51.15
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.163
65 Day Volume MA 2,182,542
JS200
CALY
CALYPTE BIOMEDICAL CP
0.127
-0.010 -7.30%
Daily Commentary
HOLD
Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/15/2002 (13) days ago, when the stock price was 0.129. Since then the stock fell -1.55% .
Today the stock closed lower with a lower high and a lower low. The volume is extremely low. The security price is trending up.
Candlestick Analysis
Today’s Candlestick Patterns:
Black Candlestick
Today a Black Candlestick formed. Sellers were in control but the selling pressure was not very strong.
Stock Quote
Last 0.127
Previous Close 0.137
Change -0.010
% Change -7.30%
Volume 1,017,600
Stock Activity
Open 0.136
Day`s High 0.137
Day`s Low 0.119
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -43.30
6 Month % Change 353.57
12 Month % Change -51.15
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.163
65 Day Volume MA 2,182,542
JS200
hallooooooooooooooooooooooooooooooo
keiner mehr da?
hab ihr nen anderen spielplatz gefunden?
habt ihr caly schon aufgegeben?
52€ in frankfurt, wer hat den da sooooooviel geld übrig/nötig um so etwas zu tun?
keine new´s, hab ich was übersehen vergessen oder so
nix zu erzählen jojo,steffen oder bitterm.................?
na ja dann wart ich mal auf 15:30 MEZ
vielleicht seit ihr ja dann wieder gesprächiger
gruß
M1
keiner mehr da?
hab ihr nen anderen spielplatz gefunden?
habt ihr caly schon aufgegeben?
52€ in frankfurt, wer hat den da sooooooviel geld übrig/nötig um so etwas zu tun?
keine new´s, hab ich was übersehen vergessen oder so
nix zu erzählen jojo,steffen oder bitterm.................?
na ja dann wart ich mal auf 15:30 MEZ
vielleicht seit ihr ja dann wieder gesprächiger
gruß
M1
Hallo Morph
Wir sind alle da nur ein bischen unsichtbar
Wir warten auf die Eröffnung und ein Paar
guten News
vieleicht kommen am Donnerstag wieder gute Nachrichten
wäre ja nicht das erste mal
viel Glück noch
mfg jojo der nicht in Datasave angaiert ist 100% Caly
Wir sind alle da nur ein bischen unsichtbar
Wir warten auf die Eröffnung und ein Paar
guten News
vieleicht kommen am Donnerstag wieder gute Nachrichten
wäre ja nicht das erste mal
viel Glück noch
mfg jojo der nicht in Datasave angaiert ist 100% Caly
Wir sind da, im Hintergrund.
Habt Ihr gesehen ----EXEL-NASDAQ----EXELIXIS---TOLL
JS200
Habt Ihr gesehen ----EXEL-NASDAQ----EXELIXIS---TOLL
JS200
hallo miteinander,
bin auch im hintergrund unD warte ab!
ich glaube, caly wird die nächsten 2-3 wochen zwischen 0,105 und 0,14 pendeln. wichtig wäre die marke nicht zu unterschreiten sonst gibts nochmal die 0,08.
beim nächten versuch die 0,15 zu knacken wird dies auch gelingen..... und dann sehen wir die 0,18......0,20
da bin ich mir sicher!
wichtig wird sein welche wichtigen news caly bringen wird.
heute würde ich mal als schlusskurs 0,135 tippen.
mfg. bittermoon, der 0,2 noch vor weihnachten sieht!
bin auch im hintergrund unD warte ab!
ich glaube, caly wird die nächsten 2-3 wochen zwischen 0,105 und 0,14 pendeln. wichtig wäre die marke nicht zu unterschreiten sonst gibts nochmal die 0,08.
beim nächten versuch die 0,15 zu knacken wird dies auch gelingen..... und dann sehen wir die 0,18......0,20
da bin ich mir sicher!
wichtig wird sein welche wichtigen news caly bringen wird.
heute würde ich mal als schlusskurs 0,135 tippen.
mfg. bittermoon, der 0,2 noch vor weihnachten sieht!
Gute Nachrichten wären schön.
Gruß spekulativ
Gruß spekulativ
wem schenk ich denn die 1800????????
in völliger selbslositgkeit
gruß
M1
@bitter...
ich denke eher: leider nur knapp über 0,12€ wenn überhaupt!
aber ich hoffe ich bin nur ein mensch und irre mich!
he was schreib ich da ? natürlich bin ich ein mensch
in völliger selbslositgkeit
gruß
M1
@bitter...
ich denke eher: leider nur knapp über 0,12€ wenn überhaupt!
aber ich hoffe ich bin nur ein mensch und irre mich!
he was schreib ich da ? natürlich bin ich ein mensch
o.k
dann schenk ich sie mir zum feierabend eben selbst!
bis morgen
M1
dann schenk ich sie mir zum feierabend eben selbst!
bis morgen
M1
11:17:27 0.123 2100 OTC BBS at Ask
11:17:09 0.123 40000 OTC BBS at Ask
11:16:43 0.122 25000 OTC BBS at Bid
11:15:05 0.123 10000 OTC BBS at Ask
11:10:13 0.121 1000 OTC BBS at Bid
11:09:46 0.123 30000 OTC BBS at Ask
11:17:09 0.123 40000 OTC BBS at Ask
11:16:43 0.122 25000 OTC BBS at Bid
11:15:05 0.123 10000 OTC BBS at Ask
11:10:13 0.121 1000 OTC BBS at Bid
11:09:46 0.123 30000 OTC BBS at Ask
Nicht viel los heute...gibt mir jemand aktuelle Amilandkurse - Danke - MfG X 99
Last 10 trades
Time Price Volume Exchange Info
12:10:44 0.122 800 OTC BBS
12:02:36 0.123 10000 OTC BBS at Ask
12:00:29 0.123 1000 OTC BBS at Ask
11:17:27 0.123 2100 OTC BBS at Ask
11:17:09 0.123 40000 OTC BBS at Ask
11:16:43 0.122 25000 OTC BBS at Bid
11:15:05 0.123 10000 OTC BBS at Ask
11:10:13 0.121 1000 OTC BBS at Bid
11:09:46 0.123 30000 OTC BBS at Ask
11:05:09 0.122 4500 OTC BBS
Time Price Volume Exchange Info
12:10:44 0.122 800 OTC BBS
12:02:36 0.123 10000 OTC BBS at Ask
12:00:29 0.123 1000 OTC BBS at Ask
11:17:27 0.123 2100 OTC BBS at Ask
11:17:09 0.123 40000 OTC BBS at Ask
11:16:43 0.122 25000 OTC BBS at Bid
11:15:05 0.123 10000 OTC BBS at Ask
11:10:13 0.121 1000 OTC BBS at Bid
11:09:46 0.123 30000 OTC BBS at Ask
11:05:09 0.122 4500 OTC BBS
Last: 0.121
High: 0.128
Low: 0.121
Open: 0.128
Change: -0.01
Volume: 461,100
Bid: 0.122
Ask: 0.123
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: -4.8%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Quotes provided by S&P Comstock
10/29/02 - 12:30 p.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
12:22:10 0.121 2000 OTC BBS at Bid
12:21:51 0.121 5000 OTC BBS at Bid
12:21:56 0.121 20000 OTC BBS at Bid
12:20:26 0.123 10000 OTC BBS at Ask
12:10:44 0.122 800 OTC BBS
12:02:36 0.123 10000 OTC BBS at Ask
High: 0.128
Low: 0.121
Open: 0.128
Change: -0.01
Volume: 461,100
Bid: 0.122
Ask: 0.123
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: -4.8%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Quotes provided by S&P Comstock
10/29/02 - 12:30 p.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
12:22:10 0.121 2000 OTC BBS at Bid
12:21:51 0.121 5000 OTC BBS at Bid
12:21:56 0.121 20000 OTC BBS at Bid
12:20:26 0.123 10000 OTC BBS at Ask
12:10:44 0.122 800 OTC BBS
12:02:36 0.123 10000 OTC BBS at Ask
13:51:38 0.122 1000 OTC BBS at Bid
13:40:52 0.123 2800 OTC BBS at Ask
13:34:10 0.123 5000 OTC BBS at Ask
13:30:37 0.122 50000 OTC BBS
13:30:33 0.123 60000 OTC BBS at Ask
13:27:33 0.122 26000 OTC BBS at Bid
13:27:28 0.123 50000 OTC BBS
13:26:49 0.122 50000 OTC BBS at Bid
13:40:52 0.123 2800 OTC BBS at Ask
13:34:10 0.123 5000 OTC BBS at Ask
13:30:37 0.122 50000 OTC BBS
13:30:33 0.123 60000 OTC BBS at Ask
13:27:33 0.122 26000 OTC BBS at Bid
13:27:28 0.123 50000 OTC BBS
13:26:49 0.122 50000 OTC BBS at Bid
CALYPTE BIOMEDICAL - OTC BB: CALY
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.127 0 (0.00) 0.124 (50) 0.13 (50) 15:57
Day Volume Last Size Open High Low
1,013,600 5,000 0.128 0.128 0.121
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+-++ 103 9,841 0.4375 0.0156
Prev Close VWAP Avg Day Vol
0.127 0.1231 N/A
JS200
Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
-- -- -- -- -- --
--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.127 0 (0.00) 0.124 (50) 0.13 (50) 15:57
Day Volume Last Size Open High Low
1,013,600 5,000 0.128 0.128 0.121
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+-++ 103 9,841 0.4375 0.0156
Prev Close VWAP Avg Day Vol
0.127 0.1231 N/A
JS200
es ärgert mich das ich so genau gelgen habe mit meinem tip un ter: #1799
nacht alle man(n) und natürlich auch frauen!
es ist ja bald auch wieder donnerstag
gruß
M1
nacht alle man(n) und natürlich auch frauen!
es ist ja bald auch wieder donnerstag
gruß
M1
Guten Morgen @all
das wird noch kommen ich weis es einfach das ist das ganze Ziel von Cataldo und Co und es ist auch die Logische Schlussfolgerung das es diese Teststreifen von Caly gibt !!
ich der jede nur Erdenkliche Wirtchaftssimulation auf den Rechner geübt habe und denoch wie jeder andere Leergeld
an der Börse gelasen hat.
deswegen ist Caly mein 100 % Investment !!
und diese Nachricht wird unserer aller Depot bald bis ins unermessliche füllen !!! lacht nur wer zuletzt lacht lacht am besten die Nachricht wird schon bald kommen ich fühle es einfach.
mfg jojo
Cataldo schließt Vereinbarungen mit Pharmaunternehmen nach
dem Motto – „Zeig mir wer Krank ist und ich Verkauf Ihm mein
Medikament“ der Teststreifen, weltweit im Einsatz würde dieses
möglich machen und die stark gebeutelten Pharmakonzerne die
alle durch Kassenverordnung und der Wirtschaftskrise zu leiden haben,
in nur kurzer Zeit wieder die Kassen auffzüllen.
das wird noch kommen ich weis es einfach das ist das ganze Ziel von Cataldo und Co und es ist auch die Logische Schlussfolgerung das es diese Teststreifen von Caly gibt !!
ich der jede nur Erdenkliche Wirtchaftssimulation auf den Rechner geübt habe und denoch wie jeder andere Leergeld
an der Börse gelasen hat.
deswegen ist Caly mein 100 % Investment !!
und diese Nachricht wird unserer aller Depot bald bis ins unermessliche füllen !!! lacht nur wer zuletzt lacht lacht am besten die Nachricht wird schon bald kommen ich fühle es einfach.
mfg jojo
Cataldo schließt Vereinbarungen mit Pharmaunternehmen nach
dem Motto – „Zeig mir wer Krank ist und ich Verkauf Ihm mein
Medikament“ der Teststreifen, weltweit im Einsatz würde dieses
möglich machen und die stark gebeutelten Pharmakonzerne die
alle durch Kassenverordnung und der Wirtschaftskrise zu leiden haben,
in nur kurzer Zeit wieder die Kassen auffzüllen.
für alle die es noch nicht kennen
vieleicht solltet Ihr Euch mal Gedanken machen und nicht
flachsen !!! Der Teststreifen von Caly ist ein Riesenmarkt nicht weil er Aids heilen kann nein weil er den Pharmariesen zeigt wer Krank ist und diese verkaufen Ihre Medikamente an die noch lebenden weil diese an ihrem Leben hängen
ich geh jetzt schlafen hatte Nachtschicht !!! bis gleich
Die Gedanken sind frei
Die ganze Wahrheit über Caly und Cataldo !
1983 Wenn nicht schon früher, begann der ganze „Horror“ Aids eine
Immunschwäche Krankeit brach aus Dr. Montagnier und seine Kollegen
fanden als erstes den HIV1 und 1985 den HIV2 Aidsvirus.
1995 Erst 10 jahre später begann massive Aidsaufklärung
mit viel Erfolg in den reichen aber nicht in den armen Ländern
2000 Condomi geht an die Börse, expandiert, und verkauft nicht
nur Kondome, verschenkt sie auch an Drittländer, in dem das Aidsvirus unaufhörlich wütet.
2001 Safer Sex ist lt. einer Studie wieder out. Werbemaßnahmen zur richtigen Verhütung sowie zur Bekämpfung von Aids werden aus finanziellen
Gründen zurückgestellt.
Scheinbar ist Aids so hart es auch klingen mag, eine profitable Einnahme
vieler Pharmaunternehmen Weltweit
In den letzten Jahren gab es von seiten Betroffener sowie Aidshilfen
und den Regierungen großes Bestreben gegen die Pharmaindustrie,
die die Medikamente mit immensen finanziellen und zeitlichen Aufwand
erforscht und hergestellt haben, diese so teuren Medikamente für die
Armen der Armen zu verbilligen, was aber leider nur im geringe Maße
gelang.
Wenn man bedenkt, daß Aids bis zu zehn Jahre im Menschen schlummern
kann,um dann erst auszubrechen, dann könnte es zu einem Zyklus kommen,
der folgendermaßen ausehen kann.
1985 bekannte Aidsrate 300000 Tsd
1995 bekannte Aidsrate 17.000000 Mio
2005 vermutliche Aidsrate 25.000000 bis 27.000000 Mio
Safer sex war verstärkt von 1995 bis 2000 in den reichen aber nicht
in den armen Ländern, weil es dort an Aufklärung und Geldmittel
fehlte und noch weiter fehlen wird. Es werden in den nächsten zehn Jahren
ganze Völker von Aids bedroht bleiben, sogar ausgerottet werden, wenn
nicht in den nächsten zwei bis drei Jahren ein Gegenmittel gefunden wird.
Die Armut wird weiter ansteigen ganze Industrieländer werden stillstehen
Die Wirtschaftslage in solchen aidsbetroffenen Staaten ist heute schon kurz
vor dem Erliegen.
Zur Zeit sollen es lt.Berichte 20.000.000 Menschen sein die mit Aids inviziert
sind die Dunkelziffer wird aber deutlich höher sein da der Test von Calypte
nach der entscheidenen Phase und aus Geldmangel in der Vergangenheit
weltweit noch nicht zum Einsatz gekommen ist.
Aids, eine lukrative Einnahmequelle für die Pharmariesen ?
In den westlichen Ländern, wo die Kassen die Kosten für eine Behandlung
übernehmen oder der Infizierte sich für eine kurze Zeit selbst vom ersparten
über Wasser halten, kann weil es hier überwiegend die Reichen und den
Mittelstand betrifft, die vom Aids Virus betroffen sind.
Die Pharmaindustrie ist deshalb gezwungen die Preise für Aidsmedikamente
Stabil zu halten, um ihre Kosten zu decken,die nicht gerade Unerheblich
sind.
Anthony Cataldos Plan könnte deshalb folgendermaßen aussehen:
Cataldo beobachtet Firmen mit einem guten Produkt, aber wenig
Cash, Mindestens sechs Monate vorher hat Cataldo schon sämtliche
Pläne in seiner Schublade, wie er Caly übernimmt und weltweit zum
Erfolg führt um mit einem minimalen Einsatz ein Maximum an Gewinn
zu erwirtschaften.
Cataldo kauft sich für knapp fünf Mio Dollar bei Caly ein und ist
Vorstand bei Caly.
Anschließend fliegt er mit seinen Beratern nach Barcelona, um
nicht nur Vorträge zu halten, auch um wichtige Personen wie
Dr. Luc Montagnier zu treffen und sie auf seine Seite zu ziehen,
was ihm auch gelungen ist .Montagnier, Mittendecker des Aidsvirus,
z.Z. Präsident für Weltweite Aidsforschung, hat sich bereit erklärt,
bei Calypte als Berater zu fungieren.
Reversibel Splitt von 1:2 bis 1:10 wurde vor wenigen Tagen vorgeschlagen,
sowie die Aktienzahl von 200Mio auf 400Mio zu verdoppeln
Der Aktienkurs von Caly verliert in nur drei Tagen 50%
Cataldo stellt den RS zurück der Kurs stabilisiert sich bei 0,25$
Cataldo teilt mit, daß er am 25 Juli eine Konferenz einberufen wird, um
weltweit Investoren zu finden, die sich an Caly beteiligen.
Cataldo strebt den Ausbau der Produktion sowie die weltweite
Vermarktung der Teststreifen an.
Dies hat Licenzabkommen mit Versicherer zur folge
Um hier schnellstmöglichen Profit zu erzielen.
Der entscheidene Punkt ist, daß Cataldo den geraden Weg
geht, um den größtmöglichen Profit zu erzielen
Wenn du deine Gegner nicht besiegen kannst, so Verbünde dich mit ihnen;
muß Cataldo wohl denken, denn ein Speicheltest ist in Vorbereitung.
Die Konkurenz schläft nicht und um die ca. 78 Mio$ Einsatz für
den Teststreifen von Caly wieder einzufahren, erfordert es
gerade jetzt hartes Durchsetzungs Vermögen ausreichend Cash sowie
gezielte Werbemaßnahmen mit einem bekannten Schauspieler.
den Cataldo schon engagiert hat.
Cataldo rechnet mit weiteren Investoren, um die Expansion weltweit
voranzutreiben.Cataldo hat Euch noch nicht erzählt, das er die
Aktien von 200 Mio auf 400 Mio Erhöhen will, nur um Kooperationen
sowie Übernahmen dami tätigen will. Um die Produktionsstätten
Auszubauen bzw. sich in eine einzukaufen um die Masse von
Teststreifen zu erreichen, die er braucht um die ganze Welt damit zu
Versorgen
Cataldo kann nicht aus dem „Nähkastchen“ plaudern er würde
dem Kurs nur die Fantasie rauben und Euch die Spannung nehmen
die Ihr Tag ein Tag aus, mit Caly erlebt
Cataldo wird jede noch so kleine News zu einer positiven Ad-hoc
ausbauen um Euch und Euer Geld anzulocken damit sein Traum
von Caly und dem reichtum sich verwirktlich.
Cataldo schließt Vereinbarungen mit Pharmaunternehmen nach
dem Motto – „Zeig mir wer Krank ist und ich Verkauf Ihm mein
Medikament“ der Teststreifen, weltweit im Einsatz würde dieses
möglich machen und die stark gebeutelten Pharmakonzerne die
alle durch Kassenverordnung und der Wirtschaftskrise zu leiden haben,
in nur kurzer Zeit wieder die Kassen auffzüllen.
Cataldo schickt Nancy Katz nach China, Von diesem Treffen erhoffen
sich viele einen weiteren Absatzmarkt in Höhe von mindestens
zwei bis drei hundert Millionen Teststreifen
Cataldo, der sein Ziel verfolgt und seinen Weg mit oder ohne Euch
gehen wird, wird mit allem Ihm zu Verfügung stehenden Mitteln
und Kontakte, Caly wieder an die Nasdaq bringen wollen, um
weitere Aktienkäufer sowie Fonds und Banken anzulocken.
Cataldo, der sicherlich Fonds und Anteile an solchen Pharma-
unternehmen hält, wird Caly schnellstmöglich zum Erfolg
bringen um seine Taschen aufzufüllen mit jeglichen
Beteiligungen die er in der Vergangenheit und Zukunft
getätigt hat.
Cataldo wird auf den Markt reagieren, er wird nichts unversucht
Lassen, aber auch nichts tun, was in irgendeiner weise schädlich
für den Aktienkurs sein wird, deshalb hat er auch den RS zurück
genommen.
Cataldo wird Caly mit oder ohne Euch zum Erfolg bringen,
Anschließend wird er Caly Gewinnbringend abstoßen
und sich aus diesem Geschäft mit weiteren Millionen Dollar
in den Taschen zurückziehen und das nächste Projekt
starten.
In erster Linie ist es ein Leichtes, über das Thema Aids zu schreiben,
und zu Posten sowie zu Reden, wenn man selbst davon nicht betroffen ist.
Wir jagen alle dem Profit hinterher, im Grunde genommen sind wir alle nicht
besser als Cataldo, denn er holt sich das Geld von denen, die eh kaum was
haben, zumal Ihr wißt, wie schwer es ist, an anderer Leute Geld zu kommen.
Sollten wir jetzt Aktien von Condomi kaufen, damit sie weiterhin die Möglich-
keit haben, Kondome an die Armen zu verteilen,um die Ausbreitung von Aids
zu stoppen ? Sollten wir Aktien von allen Firmen meiden, in Zeiten von
Unterschlagung und Korruption ?
Jeder von uns sollte selbst entscheiden und einen Mittelweg finden.
ich werde wohl weiterhin in Caly investiert bleiben, weil ich mich wohl
kaum von all den Menschen die nach Macht und Reichtum streben,
unterscheide nur um mich persönlich zu bereichern und mir
materiellen Wohlstand leisten zu können. ??
Ist es das was wir wollen oder gibt es noch was anderes im Leben,
was uns mehr bedeutet vielleicht, Gesundheit, ein langes Leben,
unsere Familie, Wie lange noch sollen wir dem schnöden Mammon
hinterher laufen, der Eigentlich nur eine angenehme Begleiterscheinung
ist und das Leben einfacher, aber nicht sinnvoller macht.
dies ist meine Persönliche Meinung, dies ist keine Aufforderung zum Kauf
oder Verkauf der Aktie mit der WKN 909402 Calypte, dies ist die Erkenntnis
die ich aus den Gegebenheiten durch Caly und Cataldo in der Vergangenheit
und Gegenwart erfahren habe.
jetzt könnt Ihr mich in der Luft zerreißen, vierteilen oder foltern.
Es bleibt Euch überlassen, mich zu verurteilen und zu kritisieren.
Ich Wünsche allen Kranken auf dieser Erde nur das Beste.
Sollte ich etwas Vergessen haben, so bitte ich um Mittteilung
korriegiert mich zensiert mich alles ist erlaubt denn die Gedanken sind
frei.
Mit freundlichen Grüßen jojo
Caly die Gedanken, sind bei dir
die Gedanken das sind wir
Caly wie weit gehst du noch auf und ab
Caly halt durch und mach nicht schlapp
Caly bald wirst auch du wieder auferstehn
denn wir können schon das Licht am Ende
des Tunnels sehn.
denn Hilfe naht und ist nicht fern,
es braucht Zeit und die geben Wir dir gern
weltweit wirst du Anerkennung finden
und diese wird auch niemals schwinden
auf uns kannst du immer zählen
halt nur durch du wirst schon sehn.
Es wird bald Aufwärts gehn
vieleicht solltet Ihr Euch mal Gedanken machen und nicht
flachsen !!! Der Teststreifen von Caly ist ein Riesenmarkt nicht weil er Aids heilen kann nein weil er den Pharmariesen zeigt wer Krank ist und diese verkaufen Ihre Medikamente an die noch lebenden weil diese an ihrem Leben hängen
ich geh jetzt schlafen hatte Nachtschicht !!! bis gleich
Die Gedanken sind frei
Die ganze Wahrheit über Caly und Cataldo !
1983 Wenn nicht schon früher, begann der ganze „Horror“ Aids eine
Immunschwäche Krankeit brach aus Dr. Montagnier und seine Kollegen
fanden als erstes den HIV1 und 1985 den HIV2 Aidsvirus.
1995 Erst 10 jahre später begann massive Aidsaufklärung
mit viel Erfolg in den reichen aber nicht in den armen Ländern
2000 Condomi geht an die Börse, expandiert, und verkauft nicht
nur Kondome, verschenkt sie auch an Drittländer, in dem das Aidsvirus unaufhörlich wütet.
2001 Safer Sex ist lt. einer Studie wieder out. Werbemaßnahmen zur richtigen Verhütung sowie zur Bekämpfung von Aids werden aus finanziellen
Gründen zurückgestellt.
Scheinbar ist Aids so hart es auch klingen mag, eine profitable Einnahme
vieler Pharmaunternehmen Weltweit
In den letzten Jahren gab es von seiten Betroffener sowie Aidshilfen
und den Regierungen großes Bestreben gegen die Pharmaindustrie,
die die Medikamente mit immensen finanziellen und zeitlichen Aufwand
erforscht und hergestellt haben, diese so teuren Medikamente für die
Armen der Armen zu verbilligen, was aber leider nur im geringe Maße
gelang.
Wenn man bedenkt, daß Aids bis zu zehn Jahre im Menschen schlummern
kann,um dann erst auszubrechen, dann könnte es zu einem Zyklus kommen,
der folgendermaßen ausehen kann.
1985 bekannte Aidsrate 300000 Tsd
1995 bekannte Aidsrate 17.000000 Mio
2005 vermutliche Aidsrate 25.000000 bis 27.000000 Mio
Safer sex war verstärkt von 1995 bis 2000 in den reichen aber nicht
in den armen Ländern, weil es dort an Aufklärung und Geldmittel
fehlte und noch weiter fehlen wird. Es werden in den nächsten zehn Jahren
ganze Völker von Aids bedroht bleiben, sogar ausgerottet werden, wenn
nicht in den nächsten zwei bis drei Jahren ein Gegenmittel gefunden wird.
Die Armut wird weiter ansteigen ganze Industrieländer werden stillstehen
Die Wirtschaftslage in solchen aidsbetroffenen Staaten ist heute schon kurz
vor dem Erliegen.
Zur Zeit sollen es lt.Berichte 20.000.000 Menschen sein die mit Aids inviziert
sind die Dunkelziffer wird aber deutlich höher sein da der Test von Calypte
nach der entscheidenen Phase und aus Geldmangel in der Vergangenheit
weltweit noch nicht zum Einsatz gekommen ist.
Aids, eine lukrative Einnahmequelle für die Pharmariesen ?
In den westlichen Ländern, wo die Kassen die Kosten für eine Behandlung
übernehmen oder der Infizierte sich für eine kurze Zeit selbst vom ersparten
über Wasser halten, kann weil es hier überwiegend die Reichen und den
Mittelstand betrifft, die vom Aids Virus betroffen sind.
Die Pharmaindustrie ist deshalb gezwungen die Preise für Aidsmedikamente
Stabil zu halten, um ihre Kosten zu decken,die nicht gerade Unerheblich
sind.
Anthony Cataldos Plan könnte deshalb folgendermaßen aussehen:
Cataldo beobachtet Firmen mit einem guten Produkt, aber wenig
Cash, Mindestens sechs Monate vorher hat Cataldo schon sämtliche
Pläne in seiner Schublade, wie er Caly übernimmt und weltweit zum
Erfolg führt um mit einem minimalen Einsatz ein Maximum an Gewinn
zu erwirtschaften.
Cataldo kauft sich für knapp fünf Mio Dollar bei Caly ein und ist
Vorstand bei Caly.
Anschließend fliegt er mit seinen Beratern nach Barcelona, um
nicht nur Vorträge zu halten, auch um wichtige Personen wie
Dr. Luc Montagnier zu treffen und sie auf seine Seite zu ziehen,
was ihm auch gelungen ist .Montagnier, Mittendecker des Aidsvirus,
z.Z. Präsident für Weltweite Aidsforschung, hat sich bereit erklärt,
bei Calypte als Berater zu fungieren.
Reversibel Splitt von 1:2 bis 1:10 wurde vor wenigen Tagen vorgeschlagen,
sowie die Aktienzahl von 200Mio auf 400Mio zu verdoppeln
Der Aktienkurs von Caly verliert in nur drei Tagen 50%
Cataldo stellt den RS zurück der Kurs stabilisiert sich bei 0,25$
Cataldo teilt mit, daß er am 25 Juli eine Konferenz einberufen wird, um
weltweit Investoren zu finden, die sich an Caly beteiligen.
Cataldo strebt den Ausbau der Produktion sowie die weltweite
Vermarktung der Teststreifen an.
Dies hat Licenzabkommen mit Versicherer zur folge
Um hier schnellstmöglichen Profit zu erzielen.
Der entscheidene Punkt ist, daß Cataldo den geraden Weg
geht, um den größtmöglichen Profit zu erzielen
Wenn du deine Gegner nicht besiegen kannst, so Verbünde dich mit ihnen;
muß Cataldo wohl denken, denn ein Speicheltest ist in Vorbereitung.
Die Konkurenz schläft nicht und um die ca. 78 Mio$ Einsatz für
den Teststreifen von Caly wieder einzufahren, erfordert es
gerade jetzt hartes Durchsetzungs Vermögen ausreichend Cash sowie
gezielte Werbemaßnahmen mit einem bekannten Schauspieler.
den Cataldo schon engagiert hat.
Cataldo rechnet mit weiteren Investoren, um die Expansion weltweit
voranzutreiben.Cataldo hat Euch noch nicht erzählt, das er die
Aktien von 200 Mio auf 400 Mio Erhöhen will, nur um Kooperationen
sowie Übernahmen dami tätigen will. Um die Produktionsstätten
Auszubauen bzw. sich in eine einzukaufen um die Masse von
Teststreifen zu erreichen, die er braucht um die ganze Welt damit zu
Versorgen
Cataldo kann nicht aus dem „Nähkastchen“ plaudern er würde
dem Kurs nur die Fantasie rauben und Euch die Spannung nehmen
die Ihr Tag ein Tag aus, mit Caly erlebt
Cataldo wird jede noch so kleine News zu einer positiven Ad-hoc
ausbauen um Euch und Euer Geld anzulocken damit sein Traum
von Caly und dem reichtum sich verwirktlich.
Cataldo schließt Vereinbarungen mit Pharmaunternehmen nach
dem Motto – „Zeig mir wer Krank ist und ich Verkauf Ihm mein
Medikament“ der Teststreifen, weltweit im Einsatz würde dieses
möglich machen und die stark gebeutelten Pharmakonzerne die
alle durch Kassenverordnung und der Wirtschaftskrise zu leiden haben,
in nur kurzer Zeit wieder die Kassen auffzüllen.
Cataldo schickt Nancy Katz nach China, Von diesem Treffen erhoffen
sich viele einen weiteren Absatzmarkt in Höhe von mindestens
zwei bis drei hundert Millionen Teststreifen
Cataldo, der sein Ziel verfolgt und seinen Weg mit oder ohne Euch
gehen wird, wird mit allem Ihm zu Verfügung stehenden Mitteln
und Kontakte, Caly wieder an die Nasdaq bringen wollen, um
weitere Aktienkäufer sowie Fonds und Banken anzulocken.
Cataldo, der sicherlich Fonds und Anteile an solchen Pharma-
unternehmen hält, wird Caly schnellstmöglich zum Erfolg
bringen um seine Taschen aufzufüllen mit jeglichen
Beteiligungen die er in der Vergangenheit und Zukunft
getätigt hat.
Cataldo wird auf den Markt reagieren, er wird nichts unversucht
Lassen, aber auch nichts tun, was in irgendeiner weise schädlich
für den Aktienkurs sein wird, deshalb hat er auch den RS zurück
genommen.
Cataldo wird Caly mit oder ohne Euch zum Erfolg bringen,
Anschließend wird er Caly Gewinnbringend abstoßen
und sich aus diesem Geschäft mit weiteren Millionen Dollar
in den Taschen zurückziehen und das nächste Projekt
starten.
In erster Linie ist es ein Leichtes, über das Thema Aids zu schreiben,
und zu Posten sowie zu Reden, wenn man selbst davon nicht betroffen ist.
Wir jagen alle dem Profit hinterher, im Grunde genommen sind wir alle nicht
besser als Cataldo, denn er holt sich das Geld von denen, die eh kaum was
haben, zumal Ihr wißt, wie schwer es ist, an anderer Leute Geld zu kommen.
Sollten wir jetzt Aktien von Condomi kaufen, damit sie weiterhin die Möglich-
keit haben, Kondome an die Armen zu verteilen,um die Ausbreitung von Aids
zu stoppen ? Sollten wir Aktien von allen Firmen meiden, in Zeiten von
Unterschlagung und Korruption ?
Jeder von uns sollte selbst entscheiden und einen Mittelweg finden.
ich werde wohl weiterhin in Caly investiert bleiben, weil ich mich wohl
kaum von all den Menschen die nach Macht und Reichtum streben,
unterscheide nur um mich persönlich zu bereichern und mir
materiellen Wohlstand leisten zu können. ??
Ist es das was wir wollen oder gibt es noch was anderes im Leben,
was uns mehr bedeutet vielleicht, Gesundheit, ein langes Leben,
unsere Familie, Wie lange noch sollen wir dem schnöden Mammon
hinterher laufen, der Eigentlich nur eine angenehme Begleiterscheinung
ist und das Leben einfacher, aber nicht sinnvoller macht.
dies ist meine Persönliche Meinung, dies ist keine Aufforderung zum Kauf
oder Verkauf der Aktie mit der WKN 909402 Calypte, dies ist die Erkenntnis
die ich aus den Gegebenheiten durch Caly und Cataldo in der Vergangenheit
und Gegenwart erfahren habe.
jetzt könnt Ihr mich in der Luft zerreißen, vierteilen oder foltern.
Es bleibt Euch überlassen, mich zu verurteilen und zu kritisieren.
Ich Wünsche allen Kranken auf dieser Erde nur das Beste.
Sollte ich etwas Vergessen haben, so bitte ich um Mittteilung
korriegiert mich zensiert mich alles ist erlaubt denn die Gedanken sind
frei.
Mit freundlichen Grüßen jojo
Caly die Gedanken, sind bei dir
die Gedanken das sind wir
Caly wie weit gehst du noch auf und ab
Caly halt durch und mach nicht schlapp
Caly bald wirst auch du wieder auferstehn
denn wir können schon das Licht am Ende
des Tunnels sehn.
denn Hilfe naht und ist nicht fern,
es braucht Zeit und die geben Wir dir gern
weltweit wirst du Anerkennung finden
und diese wird auch niemals schwinden
auf uns kannst du immer zählen
halt nur durch du wirst schon sehn.
Es wird bald Aufwärts gehn
VON GESTERN
CALY
CALYPTE BIOMEDICAL CP
0.127
0.000 0.00%
Daily Commentary
SELL
Our system recommends SELL as of today. Previous BUY recommendation was made on 10/15/2002 (14) days ago, when the stock price was 0.129. Since then the stock fell -1.55% .
Today the stock closed unchanged, close to its high (sign of strength) with a lower high and a higher low (sign of decrease in volatility). The volume is extremely low. The security price is trending sideways.
Long-term trend is bearish, and the upward move seems to have stopped. An early correction has started which may shortly turn into a bear trap. You may sell this stock now, but be careful!
Candlestick Analysis
Today’s Candlestick Patterns:
Short Black Candlestick
Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation
Stock Quote
Last 0.127
Previous Close 0.127
Change 0.000
% Change 0.00%
Volume 1,039,600
Stock Activity
Open 0.128
Day`s High 0.128
Day`s Low 0.121
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -43.30
6 Month % Change 353.57
12 Month % Change -51.15
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.163
65 Day Volume MA 2,181,614
JS200
CALY
CALYPTE BIOMEDICAL CP
0.127
0.000 0.00%
Daily Commentary
SELL
Our system recommends SELL as of today. Previous BUY recommendation was made on 10/15/2002 (14) days ago, when the stock price was 0.129. Since then the stock fell -1.55% .
Today the stock closed unchanged, close to its high (sign of strength) with a lower high and a higher low (sign of decrease in volatility). The volume is extremely low. The security price is trending sideways.
Long-term trend is bearish, and the upward move seems to have stopped. An early correction has started which may shortly turn into a bear trap. You may sell this stock now, but be careful!
Candlestick Analysis
Today’s Candlestick Patterns:
Short Black Candlestick
Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation
Stock Quote
Last 0.127
Previous Close 0.127
Change 0.000
% Change 0.00%
Volume 1,039,600
Stock Activity
Open 0.128
Day`s High 0.128
Day`s Low 0.121
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -43.30
6 Month % Change 353.57
12 Month % Change -51.15
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.163
65 Day Volume MA 2,181,614
JS200
danke jojo.... für die aufmunterden worte
noch 68min.
gruß
M1
noch 68min.
gruß
M1
ein kleiner Angestellter eines großen Pharmakonzern in Amerika (USA)
bearbeitet die Verkaufszahlen (stellt Diagramme und Statistiken) für das Unternehmen her
um früh genug zu erkennen ob die Machienen die Produktion
steigern oder veringern müssen.
Zu prüfen welche Medikamente auf Lager sind sowie die Nachfrage rechtzeitig zu koordinieren.
stellte einen Absatzsprung der Aidsmedikamente in allen
Bundesstaaten fest (die Ware ist mit einer EAN NR. gekennzeichnet somit läßt sich der Absatz über die Computer schneller ausrechnen)
Bedingt durch die Anschläge in USA sind eine vielzahl von Menschen auf die Idee gekommen sich für den Fall des falles
in zeiten von Terror und Mordanschlägen zu Versichern
das geschieht immer noch !!-- Wer sich Versichern lassen will muß sich erst einen Aids Test unterziehen um nicht als HIV Infizierter durchzugehen.
Dieser kleine Angestellte bemerkte also das die Verkaufszahlen der vielen verschiedenen Aidspräperrate
anstieg, und meldete es seinen Chef.
Dieser gab es an seinem Chef weiter und forschte nach
wie es zu diesem erhöhten Absatz kam.
Er fand heraus das sich das zwangsläufig durch den neu eingeführten Caly teststreifen bei den versicherern
zu stande kam er begang alle nötigen informationen über das Geschehen zu sammeln und ging zum Oberen Boss der auch im Vorstand ist und gab ihm all die Unterlagen mit den nötigen Informationen weiter.
Der natürlich sofort erkannte das der Caly teststreifen
die Leute nicht heilen kann sondern seinen, und all den
anderen Pharmariesen die HIV kranken zu erkennen gab
diese wird sich aber erst am jahresende in den Q Zahlen
der Pharmaindustrie widerspiegeln und zwar mit erhöhten teuren Medikamenten die an soviele neue Aidspatienten
ausgegeben werden.
Folglich ist man zu der Überlegung gekommen sich an Caly zu beteiligen oder sich aufgrund der geringen MK das Geschäft
von Caly unter den Nagel zu reißen.
denn cataldo hat mit hilfe durch Luc Montagnier den
Bekanntheitsgrad von Caly schon erheblich steigern
können hinzu kommt das es auch schon Verträge gibt
das ist erst der Anfang schon in absehbarer Zeit
wird es eine Entscheidung seitens der Pharmaindustrie geben
um hier in schlechten Wirtschaftszeiten nicht eine Fehlinvestition einzugehen muß vorher aber noch
alles bis in`s kleinste geprüft werden
vor zwei Jahren wurden noch Firmen ohne mit der Wimper zu zucken für die doppelte MK eingekauft weil man sich
bei den damaligen BOOM den man für lang anhalten glaubte
sicher war weiterhin Gewinne in Millionen einzufahren
die war aber ein Irrtum der die Kassen nicht nur der Pharmaindustrie schwer zu schaffen machte.
ich warte deshalb auf eine Entscheidung bis spätestens
zum Jahreswechsel und werde meine position bei Caly
weiter ausbauen sowie meine Kontakte zum Ausland weiter pflegen um für den Tag X bereit zu sein denn ich sehe
den Dollar auch wenn er noch in weiter ferne liegen sollte
ich hoffe das alles gut läuft.
mfg jojo
bearbeitet die Verkaufszahlen (stellt Diagramme und Statistiken) für das Unternehmen her
um früh genug zu erkennen ob die Machienen die Produktion
steigern oder veringern müssen.
Zu prüfen welche Medikamente auf Lager sind sowie die Nachfrage rechtzeitig zu koordinieren.
stellte einen Absatzsprung der Aidsmedikamente in allen
Bundesstaaten fest (die Ware ist mit einer EAN NR. gekennzeichnet somit läßt sich der Absatz über die Computer schneller ausrechnen)
Bedingt durch die Anschläge in USA sind eine vielzahl von Menschen auf die Idee gekommen sich für den Fall des falles
in zeiten von Terror und Mordanschlägen zu Versichern
das geschieht immer noch !!-- Wer sich Versichern lassen will muß sich erst einen Aids Test unterziehen um nicht als HIV Infizierter durchzugehen.
Dieser kleine Angestellte bemerkte also das die Verkaufszahlen der vielen verschiedenen Aidspräperrate
anstieg, und meldete es seinen Chef.
Dieser gab es an seinem Chef weiter und forschte nach
wie es zu diesem erhöhten Absatz kam.
Er fand heraus das sich das zwangsläufig durch den neu eingeführten Caly teststreifen bei den versicherern
zu stande kam er begang alle nötigen informationen über das Geschehen zu sammeln und ging zum Oberen Boss der auch im Vorstand ist und gab ihm all die Unterlagen mit den nötigen Informationen weiter.
Der natürlich sofort erkannte das der Caly teststreifen
die Leute nicht heilen kann sondern seinen, und all den
anderen Pharmariesen die HIV kranken zu erkennen gab
diese wird sich aber erst am jahresende in den Q Zahlen
der Pharmaindustrie widerspiegeln und zwar mit erhöhten teuren Medikamenten die an soviele neue Aidspatienten
ausgegeben werden.
Folglich ist man zu der Überlegung gekommen sich an Caly zu beteiligen oder sich aufgrund der geringen MK das Geschäft
von Caly unter den Nagel zu reißen.
denn cataldo hat mit hilfe durch Luc Montagnier den
Bekanntheitsgrad von Caly schon erheblich steigern
können hinzu kommt das es auch schon Verträge gibt
das ist erst der Anfang schon in absehbarer Zeit
wird es eine Entscheidung seitens der Pharmaindustrie geben
um hier in schlechten Wirtschaftszeiten nicht eine Fehlinvestition einzugehen muß vorher aber noch
alles bis in`s kleinste geprüft werden
vor zwei Jahren wurden noch Firmen ohne mit der Wimper zu zucken für die doppelte MK eingekauft weil man sich
bei den damaligen BOOM den man für lang anhalten glaubte
sicher war weiterhin Gewinne in Millionen einzufahren
die war aber ein Irrtum der die Kassen nicht nur der Pharmaindustrie schwer zu schaffen machte.
ich warte deshalb auf eine Entscheidung bis spätestens
zum Jahreswechsel und werde meine position bei Caly
weiter ausbauen sowie meine Kontakte zum Ausland weiter pflegen um für den Tag X bereit zu sein denn ich sehe
den Dollar auch wenn er noch in weiter ferne liegen sollte
ich hoffe das alles gut läuft.
mfg jojo
Kurse ? - Danke - MfG X 99
ommmmmm, ommmmmmmm, ommmmmmmmmm
caly kurs 22uhr mez 0,108€ tendens sinkend ab 0,10€ geht´s dann wieder rauf auf 0,13€ oder so, und so weiter und so weiter.
ich hoffe ich irre mich, sonnst denk ich doch nochmal über das gut alte sparbuch nach
aber sollte jojo.. recht behalten, was wir (alle die investiert sind) hoffen, haben wir bis 31.12.02 kurse um ca.: 0,50€ oder??
wenn da nicht die große unbekannte wäre
gruß
M1
p.s. N8 J.....B
caly kurs 22uhr mez 0,108€ tendens sinkend ab 0,10€ geht´s dann wieder rauf auf 0,13€ oder so, und so weiter und so weiter.
ich hoffe ich irre mich, sonnst denk ich doch nochmal über das gut alte sparbuch nach
aber sollte jojo.. recht behalten, was wir (alle die investiert sind) hoffen, haben wir bis 31.12.02 kurse um ca.: 0,50€ oder??
wenn da nicht die große unbekannte wäre
gruß
M1
p.s. N8 J.....B
Calypte Biomedical Corp.
Date Time Price Volume Exch Type Bid BSize BEx Ask ASize AEx Cond
Vl: BSize: ASize:
30.10.2002 13:30 Best Bid .1240 5000
30.10.2002 13:30 Best Ask .1240 5000 .1300 5000
30.10.2002 15:10 Best Bid .1220 5000 .1300 5000
30.10.2002 15:10 Best Ask .1220 5000 .1300 5000
30.10.2002 15:25 Best Bid .1210 5000 .1300 5000
30.10.2002 15:25 Best Ask .1210 5000 .1250 5000
30.10.2002 15:27 Best Bid .1200 5000 .1250 5000
30.10.2002 15:27 Best Ask .1200 5000 .1250 5000
30.10.2002 15:27 Best Bid .1190 5000 .1250 5000
30.10.2002 15:27 Best Ask .1190 5000 .1250 5000
30.10.2002 15:30 .1250 100 Trade
30.10.2002 15:30 .1190 1000 Trade
30.10.2002 15:30 .1190 800 Trade
30.10.2002 15:30 .1190 12500 Trade
30.10.2002 15:31 .1190 600 Trade
30.10.2002 15:31 .1250 1000 Trade
30.10.2002 15:31 .1250 6500 Trade
30.10.2002 15:32 .1200 6500 Trade
30.10.2002 15:43 .1190 300 Trade
30.10.2002 15:46 .1190 25000 Trade
30.10.2002 15:54 .1190 1000 Trade
30.10.2002 15:54 .1210 1000 Trade
30.10.2002 16:16 .1220 1800 Trade
30.10.2002 16:16 .1190 1800 Trade
30.10.2002 16:22 .1250 5000 Trade
30.10.2002 16:23 .1250 1000 Trade
Date Time Price Volume Exch Type Bid BSize BEx Ask ASize AEx Cond
Vl: BSize: ASize:
30.10.2002 13:30 Best Bid .1240 5000
30.10.2002 13:30 Best Ask .1240 5000 .1300 5000
30.10.2002 15:10 Best Bid .1220 5000 .1300 5000
30.10.2002 15:10 Best Ask .1220 5000 .1300 5000
30.10.2002 15:25 Best Bid .1210 5000 .1300 5000
30.10.2002 15:25 Best Ask .1210 5000 .1250 5000
30.10.2002 15:27 Best Bid .1200 5000 .1250 5000
30.10.2002 15:27 Best Ask .1200 5000 .1250 5000
30.10.2002 15:27 Best Bid .1190 5000 .1250 5000
30.10.2002 15:27 Best Ask .1190 5000 .1250 5000
30.10.2002 15:30 .1250 100 Trade
30.10.2002 15:30 .1190 1000 Trade
30.10.2002 15:30 .1190 800 Trade
30.10.2002 15:30 .1190 12500 Trade
30.10.2002 15:31 .1190 600 Trade
30.10.2002 15:31 .1250 1000 Trade
30.10.2002 15:31 .1250 6500 Trade
30.10.2002 15:32 .1200 6500 Trade
30.10.2002 15:43 .1190 300 Trade
30.10.2002 15:46 .1190 25000 Trade
30.10.2002 15:54 .1190 1000 Trade
30.10.2002 15:54 .1210 1000 Trade
30.10.2002 16:16 .1220 1800 Trade
30.10.2002 16:16 .1190 1800 Trade
30.10.2002 16:22 .1250 5000 Trade
30.10.2002 16:23 .1250 1000 Trade
12:08:55 0.124 5000 OTCBB
11:32:00 0.125 40000 OTCBB
11:30:47 0.125 15000 OTCBB
11:32:00 0.125 40000 OTCBB
11:30:47 0.125 15000 OTCBB
15:42:22 0.127 20000 OTCBB
15:40:04 0.125 100 OTCBB
15:32:59 0.130 30000 OTCBB at Ask
15:30:47 0.128 600 OTCBB at Ask
15:30:47 0.130 600 OTCBB at Ask
15:40:04 0.125 100 OTCBB
15:32:59 0.130 30000 OTCBB at Ask
15:30:47 0.128 600 OTCBB at Ask
15:30:47 0.130 600 OTCBB at Ask
umsatz heute nicht der rede wert
Last: 0.127
High: 0.130
Low: 0.119
Open: 0.125
Change: +0.00
Volume: 563,600
Bid: 0.125
Ask: 0.130
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: 0.0%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Quotes provided by S&P Comstock
10/30/02 - 3:55 p.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
15:42:22 0.127 20000 OTCBB
15:40:04 0.125 100 OTCBB
15:32:59 0.130 30000 OTCBB at Ask
Last: 0.127
High: 0.130
Low: 0.119
Open: 0.125
Change: +0.00
Volume: 563,600
Bid: 0.125
Ask: 0.130
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: 0.0%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Quotes provided by S&P Comstock
10/30/02 - 3:55 p.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
15:42:22 0.127 20000 OTCBB
15:40:04 0.125 100 OTCBB
15:32:59 0.130 30000 OTCBB at Ask
#1812 jojo
Du weißt schon das du dich damit strafbar machst.
Hoffe nur das viele im Board Dein Spiel durchschauen.
Das ist absolut krank!! Du denkst Dir Sachen aus, in der Hoffnung das jemand darauf anspringt. Ich nutze die Threads im Board als Contraindikator. Je mehr Dummies ihren Senf dazugeben, desto eher meide/verkaufe ich die Aktie.
Meine Jahresperformance gibt mir Recht.
Du weißt schon das du dich damit strafbar machst.
Hoffe nur das viele im Board Dein Spiel durchschauen.
Das ist absolut krank!! Du denkst Dir Sachen aus, in der Hoffnung das jemand darauf anspringt. Ich nutze die Threads im Board als Contraindikator. Je mehr Dummies ihren Senf dazugeben, desto eher meide/verkaufe ich die Aktie.
Meine Jahresperformance gibt mir Recht.
16:04:36 0.123 30000 OTCBB
15:57:45 0.127 2000 OTCBB
15:42:10 0.127 20000 OTCBB
15:57:45 0.127 2000 OTCBB
15:42:10 0.127 20000 OTCBB
genau!!!!! jojo verzapf hier nicht so einen blödsinn
Von GESTERN
CALY
CALYPTE BIOMEDICAL CP
0.127
0.000 0.00%
Daily Commentary
WAIT
Our system recommends WAIT as of today. Previous SELL recommendation was made on 10/30/2002 :eek0) days ago, when the stock price was 0.127. Since then the stock gained 0.00% .
Today the stock closed unchanged with a higher high and a lower low (sign of increase in volatility). The volume is extremely low. The security price is trending sideways.
Candlestick Analysis
Today’s Candlestick Patterns:
Spinning Top
Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!
Stock Quote
Last 0.127
Previous Close 0.127
Change 0.000
% Change 0.00%
Volume 595,600
Stock Activity
Open 0.125
Day`s High 0.130
Day`s Low 0.119
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -39.52
6 Month % Change 429.17
12 Month % Change -49.20
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.162
65 Day Volume MA 2,181,042
JS200
CALY
CALYPTE BIOMEDICAL CP
0.127
0.000 0.00%
Daily Commentary
WAIT
Our system recommends WAIT as of today. Previous SELL recommendation was made on 10/30/2002 :eek0) days ago, when the stock price was 0.127. Since then the stock gained 0.00% .
Today the stock closed unchanged with a higher high and a lower low (sign of increase in volatility). The volume is extremely low. The security price is trending sideways.
Candlestick Analysis
Today’s Candlestick Patterns:
Spinning Top
Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!
Stock Quote
Last 0.127
Previous Close 0.127
Change 0.000
% Change 0.00%
Volume 595,600
Stock Activity
Open 0.125
Day`s High 0.130
Day`s Low 0.119
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -39.52
6 Month % Change 429.17
12 Month % Change -49.20
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.162
65 Day Volume MA 2,181,042
JS200
in Berlin geht es auf 0,14 hoch????? warum das Frankfurt 0,12 seltsam einen schönen Tag und JOJO lasse dich nicht nieder machen mfg. MH
@cultom4president
du "Übertrader" zu deinem Posting:
"Je mehr Dummies ihren Senf dazugeben, desto eher meide/verkaufe ich die Aktie.
Meine Jahresperformance gibt mir Recht."
Was willst du dann hier??
gruß
M1
du "Übertrader" zu deinem Posting:
"Je mehr Dummies ihren Senf dazugeben, desto eher meide/verkaufe ich die Aktie.
Meine Jahresperformance gibt mir Recht."
Was willst du dann hier??
gruß
M1
Hallo @cultom4president
In China ist gerade ein Sack Reis umgefallen
ob ich damit Recht haben könnte ????
Habe ich Dir nie erzählt das ich ein Spinner und Hellseher bin ???!!!
wenn der Mond günstig steht überkommt es mich einfach
und ich schreibe nieder was mich Emutional bewegt
ich befinde mich wie in Trance so wie Nostradamus
dem man allerlei Dinge nachsagte.
und wenn große Dinge nicht von kleinen Leuten kommt
dann kommen große Dinge bestimmt von großen Leuten
nur sind Wir nicht alle gleich ????
kann es sein das das Leben manschmal merkwürdige
Wege geht ???
vieleicht sitzt gerade ein kleiner man am Schreibtisch
und vollbringt eine große tat und weis es selber nicht
und wenn alles nicht zutrifft dann hat Cataldo sein Ziel
verfehlt !! denn sein Weg ist das Ziel und wie mache ich aus fünf mio Dollar 50 mio Dollar
und wenn jetzt nicht der richtige Zeitpunkt kommt
dann kommt er später
aber er wird kommen da bin ich mir sicher
mfg jojo
In China ist gerade ein Sack Reis umgefallen
ob ich damit Recht haben könnte ????
Habe ich Dir nie erzählt das ich ein Spinner und Hellseher bin ???!!!
wenn der Mond günstig steht überkommt es mich einfach
und ich schreibe nieder was mich Emutional bewegt
ich befinde mich wie in Trance so wie Nostradamus
dem man allerlei Dinge nachsagte.
und wenn große Dinge nicht von kleinen Leuten kommt
dann kommen große Dinge bestimmt von großen Leuten
nur sind Wir nicht alle gleich ????
kann es sein das das Leben manschmal merkwürdige
Wege geht ???
vieleicht sitzt gerade ein kleiner man am Schreibtisch
und vollbringt eine große tat und weis es selber nicht
und wenn alles nicht zutrifft dann hat Cataldo sein Ziel
verfehlt !! denn sein Weg ist das Ziel und wie mache ich aus fünf mio Dollar 50 mio Dollar
und wenn jetzt nicht der richtige Zeitpunkt kommt
dann kommt er später
aber er wird kommen da bin ich mir sicher
mfg jojo
@jojo...
Das war jetzt aber Zeitverschwendung!.
M1
Das war jetzt aber Zeitverschwendung!.
M1
Hallo Jojo,
wir halten zu Dir!
Denn der "Glaube kann Berge versetzen"!
Wenn wir alle zusammenhalten, dann sind wir wie ein Fels in der Brandung!
Wünsche uns allen viel Glück und Erfolg!
diegutefee
wir halten zu Dir!
Denn der "Glaube kann Berge versetzen"!
Wenn wir alle zusammenhalten, dann sind wir wie ein Fels in der Brandung!
Wünsche uns allen viel Glück und Erfolg!
diegutefee
..mir kommen die tränen ........
@diegutefee
Hi. Hast du mal eine Antwort auf die email bekommen, die du an Donner geschickt hast?
AktieX
Hi. Hast du mal eine Antwort auf die email bekommen, die du an Donner geschickt hast?
AktieX
Needlestick Safety Alliance Announces Four New Members
via CDS
October 31, 2002
The National Alliance for the Primary Prevention of Sharps Injuries (NAPPSI), founded by Venetec International, today announced the addition of four new members: -- Bard Access Systems Inc., a manufacturer of vascular access products; -- Infection Control Today, a journal for infection control professionals; -- The International Association of EMT`s and Paramedics (IAEP), a union for employees in the emergency medical services field; and -- The Association of Perioperative Registered Nurses (AORN), a leading healthcare professional organization. `Having these organizations as members demonstrates NAPPSI`s growing leadership position in sharps injury protection, as a prime force for improving workplace safety.`said Steve Bierman, M.D., NAPPSI`s founder and the CEO and medical director of Venetec International. `Bard Access Systems is a major medical manufacturer that has long been incorporating sharps safety features in its products. The readership of Infection Control Today and the memberships of IAEP and AORN represent vital constituencies that support NAPPSI`s primary prevention message. Our organization`s impact on healthcare has taken a big step forward with these new members on board.`NAPPSI is a non-profit organization dedicated to minimizing sharps injuries in the healthcare workplace. Based in Carlsbad, Calif., the organization promotes primary prevention as the first line of defense for accomplishing this goal. Primary prevention means utilizing technologies and practices that either reduce or eliminate the need to use sharp medical implements. In contrast, secondary prevention renders safer those sharps that must be introduced into the healthcare workplace. NAPPSI supports both approaches, especially when used in a complementary manner -- that is, using primary prevention where possible, and secondary prevention to fill in the gaps. NAPPSI`s membership encompasses professional associations, individual healthcare professionals and medical device makers. Membership is free to individual clinicians. NAPPSI has recently petitioned the Food and Drug Administration (FDA) and the federal Occupation Safety and Health Administration (OSHA) to disseminate the organization`s Needlestick Safety Device List and its Clinician Advisory on healthcare worker safety. About the new members: -- Bard Access Systems Inc., a business unit of healthcare product manufacturer C. R. Bard Inc., offers nine vascular access product lines in more than 800 configurations to meet all vascular access needs. The company also provides comprehensive clinical, educational, and operational support to help institutions meet their specific needs in this area. `Bard has been a leader in the vascular access market, including products with needlestick safety features,`said Paul Blackburn, product manager for PICCS and Midlines. `Joining NAPPSI will help make people more aware of our products and our devotion to clinician safety issues.`For more information, access www.bardaccess.com or call 801/595-0700. -- Infection Control Today is a comprehensive journal for healthcare practitioners who are responsible for purchasing and administering healthcare products in a clean and safe fashion. The journal reports on news, issues and trends that are important to the infection control community; covers best practices in infection control; and provides continuing education for professionals in the field. `We joined NAPPSI to champion awareness and educate healthcare professionals about preventing one of the most common occupational health hazards,`said ICT publisher Bill Eikost. `Our mission is to inform readers about new and upcoming technologies that can prevent these types of injuries and resulting infections, including the technologies NAPPSI advocates.`For more information, access www.infectioncontroltoday.com or call 480/990-1101. -- IAEP, the fastest growing union in the United States, was established in 1992 to deal with job-related problems faced by emergency medical services workers. A division of the National Association of Government Employees, AFL-CIO, the union represents more than 200,000 members in 17 states and is currently organizing in 11 other states. `One of the ways we try to improve the lives of our members is by improving the safety of their work environment, including reducing or eliminating sharps injury risk,`said Matthew Levy, Eastern states coordinator of organizing. One of the most effective ways of accomplishing this is to educate the membership, which NAPPSI does through its e-mail newsletter and other communications to members.`For more information, access www.iaep.org or call 617/376-0220. -- AORN supports registered nurses in achieving optimal outcomes for patients undergoing operative and other invasive procedures. The organization provides a variety of continuing education opportunities for more than 40,000 perioperative nurses in the U.S. and Puerto Rico. `AORN is a strong advocate for the safety of our members and that of the other members of the perioperative team,`said Tom Cooper, AORN`s executive director. `AORN launched a significant workplace safety initiative earlier this year to improve safety conditions in the surgical setting. Preventing sharps injuries is a significant component of this, and something that must be accomplished to ensure healthcare worker safety.`For more information, access www.aorn.org or call 800/755-2676. NAPPSI utilizes its monthly e-mail newsletter, a national speaker`s bureau, public relations, and other activities to inform the media, decision makers, and opinion leaders on the value of primary prevention practices and products. NAPPSI`s Clinician Advisory is widely distributed to clinicians, including members of INS (Infusion Nurses Society), NAVAN (National Association of Vascular Access Networks), AACN (American Association of Critical Care Nurses), NARI (National Association of Residents and Interns); ANFIM (Association of Needle-Free Injection Manufacturers), HIDA (Health Industry Distributors Association) and CINA (Canadian Infusion Nurses Association). NAPPSI`s Safety Device List, which lists products according to primary or secondary prevention attributes, is posted on the Web sites of the states of Tennessee and Alaska, INS, NARI, and NAVAN. Other NAPPSI organizational members include: -- Venetec International, www.Venetec.com, 800/833-3895; -- Cell Robotics International (OTCBB:CRII), www.CellRobotics.com, 505/343-1131; -- Bioject Medical Technologies (Nasdaq:BJCT), www.Bioject.com, 503/639-7221; -- ICU Medical (Nasdaq:ICUI), www.ICUmed.com, 800/824-7890; -- ALARIS Medical Systems Inc. (AMEX:AMI), www.alarismed.com, 858/458-7000; -- Equidyne Systems Inc. (AMEX:IJX), www.equidyne.com, 877/474-6539; -- Calypte Biomedical Inc. (Nasdaq:CALY), www.Calypte.com, 877/CALYPTE (225-9783); -- Arrow International (Nasdaq:ARRO), www.arrowintl.com, 800/233-3187; -- B. Braun Medical, www.BBraunusa.com, 610/691-5400; -- National Association of Residents and Interns, www.NARI-assn.com, 800/221-2168, ext. 5; -- D`Antonio Consultants International Inc., www.dantonioconsultants.com, 315/463-4999; -- Helping Hands Sanctuary of Idaho Inc., www.healthcaretraining.org, 208/221-1611; -- Association of Needle-Free Injection Manufacturers (ANIFM), 315/463-4999; -- Health Industry Distributors Association (HIDA), www.HIDAnetwork.com, 703/549-4432; -- ETHICON Inc., www.EthiconInc.com; -- Abbott Laboratories, www.abbotthosp.com, 800/222-6883; -- The Association of Occupational Health Professionals in Healthcare (AOHP), www.aohp.org, 412/749-7328; -- BD Inc. (Becton Dickinson) (NYSE:BDX), www.bd.com, 201/847-6800; -- The Infusion Nurses Society (INS), www.INS1.org, -- The National Association of Vascular Access Networks (NAVAN), www.navannet.org, 888/57-NAVAN (888/576-2826); -- The American Association of Critical Care Nurses (AACN), www.aacn.org, 800/899-2226; -- Canadian Intravenous Nurses Association (CINA), www.csotcina.com, 416/445-4516; -- StickSafe LLC, www.sticksafe.com, 888/914-9600; -- Phlebotomy West, www.phlebotomywest.com, 925/240-0770; -- Cook Inc., www.cookgroup.com, 800/457-4500; -- Portex Inc., www.portexusa.com, 603/352-3812; -- TransDerm Technologies, www.transdermtech.com www.transdermtech.com, 415/561-2550; -- Hema Metrics Inc., www.hemametrics.com www.hemametrics.com, 800/546-5463 -- Antares Pharma, www.antarespharma.com www.antarespharma.com, 610/458 6200; -- HDC Corp., www.hdccorp.com, 408/942-7340; -- Porex Medical Products Inc. www.porex.com, 800/520-7999. For NAPPSI membership and other information, call 858/350-8623, email info@NAPPSI.org, or access www.NAPPSI.org.
CONTACT: Dowling & Dennis Public Relations
Liz Dowling, 760/942-2544
lizdowling@aol.com
Print story
Current Quote
OBB: CALY
Manufacturing
Last: 0.129
Change: N/A
Volume: N/A
Day High: N/A
Day Low: N/A
First Alert News
Get real-time CALY release alerts by entering your email address below.
JS200
via CDS
October 31, 2002
The National Alliance for the Primary Prevention of Sharps Injuries (NAPPSI), founded by Venetec International, today announced the addition of four new members: -- Bard Access Systems Inc., a manufacturer of vascular access products; -- Infection Control Today, a journal for infection control professionals; -- The International Association of EMT`s and Paramedics (IAEP), a union for employees in the emergency medical services field; and -- The Association of Perioperative Registered Nurses (AORN), a leading healthcare professional organization. `Having these organizations as members demonstrates NAPPSI`s growing leadership position in sharps injury protection, as a prime force for improving workplace safety.`said Steve Bierman, M.D., NAPPSI`s founder and the CEO and medical director of Venetec International. `Bard Access Systems is a major medical manufacturer that has long been incorporating sharps safety features in its products. The readership of Infection Control Today and the memberships of IAEP and AORN represent vital constituencies that support NAPPSI`s primary prevention message. Our organization`s impact on healthcare has taken a big step forward with these new members on board.`NAPPSI is a non-profit organization dedicated to minimizing sharps injuries in the healthcare workplace. Based in Carlsbad, Calif., the organization promotes primary prevention as the first line of defense for accomplishing this goal. Primary prevention means utilizing technologies and practices that either reduce or eliminate the need to use sharp medical implements. In contrast, secondary prevention renders safer those sharps that must be introduced into the healthcare workplace. NAPPSI supports both approaches, especially when used in a complementary manner -- that is, using primary prevention where possible, and secondary prevention to fill in the gaps. NAPPSI`s membership encompasses professional associations, individual healthcare professionals and medical device makers. Membership is free to individual clinicians. NAPPSI has recently petitioned the Food and Drug Administration (FDA) and the federal Occupation Safety and Health Administration (OSHA) to disseminate the organization`s Needlestick Safety Device List and its Clinician Advisory on healthcare worker safety. About the new members: -- Bard Access Systems Inc., a business unit of healthcare product manufacturer C. R. Bard Inc., offers nine vascular access product lines in more than 800 configurations to meet all vascular access needs. The company also provides comprehensive clinical, educational, and operational support to help institutions meet their specific needs in this area. `Bard has been a leader in the vascular access market, including products with needlestick safety features,`said Paul Blackburn, product manager for PICCS and Midlines. `Joining NAPPSI will help make people more aware of our products and our devotion to clinician safety issues.`For more information, access www.bardaccess.com or call 801/595-0700. -- Infection Control Today is a comprehensive journal for healthcare practitioners who are responsible for purchasing and administering healthcare products in a clean and safe fashion. The journal reports on news, issues and trends that are important to the infection control community; covers best practices in infection control; and provides continuing education for professionals in the field. `We joined NAPPSI to champion awareness and educate healthcare professionals about preventing one of the most common occupational health hazards,`said ICT publisher Bill Eikost. `Our mission is to inform readers about new and upcoming technologies that can prevent these types of injuries and resulting infections, including the technologies NAPPSI advocates.`For more information, access www.infectioncontroltoday.com or call 480/990-1101. -- IAEP, the fastest growing union in the United States, was established in 1992 to deal with job-related problems faced by emergency medical services workers. A division of the National Association of Government Employees, AFL-CIO, the union represents more than 200,000 members in 17 states and is currently organizing in 11 other states. `One of the ways we try to improve the lives of our members is by improving the safety of their work environment, including reducing or eliminating sharps injury risk,`said Matthew Levy, Eastern states coordinator of organizing. One of the most effective ways of accomplishing this is to educate the membership, which NAPPSI does through its e-mail newsletter and other communications to members.`For more information, access www.iaep.org or call 617/376-0220. -- AORN supports registered nurses in achieving optimal outcomes for patients undergoing operative and other invasive procedures. The organization provides a variety of continuing education opportunities for more than 40,000 perioperative nurses in the U.S. and Puerto Rico. `AORN is a strong advocate for the safety of our members and that of the other members of the perioperative team,`said Tom Cooper, AORN`s executive director. `AORN launched a significant workplace safety initiative earlier this year to improve safety conditions in the surgical setting. Preventing sharps injuries is a significant component of this, and something that must be accomplished to ensure healthcare worker safety.`For more information, access www.aorn.org or call 800/755-2676. NAPPSI utilizes its monthly e-mail newsletter, a national speaker`s bureau, public relations, and other activities to inform the media, decision makers, and opinion leaders on the value of primary prevention practices and products. NAPPSI`s Clinician Advisory is widely distributed to clinicians, including members of INS (Infusion Nurses Society), NAVAN (National Association of Vascular Access Networks), AACN (American Association of Critical Care Nurses), NARI (National Association of Residents and Interns); ANFIM (Association of Needle-Free Injection Manufacturers), HIDA (Health Industry Distributors Association) and CINA (Canadian Infusion Nurses Association). NAPPSI`s Safety Device List, which lists products according to primary or secondary prevention attributes, is posted on the Web sites of the states of Tennessee and Alaska, INS, NARI, and NAVAN. Other NAPPSI organizational members include: -- Venetec International, www.Venetec.com, 800/833-3895; -- Cell Robotics International (OTCBB:CRII), www.CellRobotics.com, 505/343-1131; -- Bioject Medical Technologies (Nasdaq:BJCT), www.Bioject.com, 503/639-7221; -- ICU Medical (Nasdaq:ICUI), www.ICUmed.com, 800/824-7890; -- ALARIS Medical Systems Inc. (AMEX:AMI), www.alarismed.com, 858/458-7000; -- Equidyne Systems Inc. (AMEX:IJX), www.equidyne.com, 877/474-6539; -- Calypte Biomedical Inc. (Nasdaq:CALY), www.Calypte.com, 877/CALYPTE (225-9783); -- Arrow International (Nasdaq:ARRO), www.arrowintl.com, 800/233-3187; -- B. Braun Medical, www.BBraunusa.com, 610/691-5400; -- National Association of Residents and Interns, www.NARI-assn.com, 800/221-2168, ext. 5; -- D`Antonio Consultants International Inc., www.dantonioconsultants.com, 315/463-4999; -- Helping Hands Sanctuary of Idaho Inc., www.healthcaretraining.org, 208/221-1611; -- Association of Needle-Free Injection Manufacturers (ANIFM), 315/463-4999; -- Health Industry Distributors Association (HIDA), www.HIDAnetwork.com, 703/549-4432; -- ETHICON Inc., www.EthiconInc.com; -- Abbott Laboratories, www.abbotthosp.com, 800/222-6883; -- The Association of Occupational Health Professionals in Healthcare (AOHP), www.aohp.org, 412/749-7328; -- BD Inc. (Becton Dickinson) (NYSE:BDX), www.bd.com, 201/847-6800; -- The Infusion Nurses Society (INS), www.INS1.org, -- The National Association of Vascular Access Networks (NAVAN), www.navannet.org, 888/57-NAVAN (888/576-2826); -- The American Association of Critical Care Nurses (AACN), www.aacn.org, 800/899-2226; -- Canadian Intravenous Nurses Association (CINA), www.csotcina.com, 416/445-4516; -- StickSafe LLC, www.sticksafe.com, 888/914-9600; -- Phlebotomy West, www.phlebotomywest.com, 925/240-0770; -- Cook Inc., www.cookgroup.com, 800/457-4500; -- Portex Inc., www.portexusa.com, 603/352-3812; -- TransDerm Technologies, www.transdermtech.com www.transdermtech.com, 415/561-2550; -- Hema Metrics Inc., www.hemametrics.com www.hemametrics.com, 800/546-5463 -- Antares Pharma, www.antarespharma.com www.antarespharma.com, 610/458 6200; -- HDC Corp., www.hdccorp.com, 408/942-7340; -- Porex Medical Products Inc. www.porex.com, 800/520-7999. For NAPPSI membership and other information, call 858/350-8623, email info@NAPPSI.org, or access www.NAPPSI.org.
CONTACT: Dowling & Dennis Public Relations
Liz Dowling, 760/942-2544
lizdowling@aol.com
Print story
Current Quote
OBB: CALY
Manufacturing
Last: 0.129
Change: N/A
Volume: N/A
Day High: N/A
Day Low: N/A
First Alert News
Get real-time CALY release alerts by entering your email address below.
JS200
Needlestick Safety Alliance Announces Four New Members
via CDS
October 31, 2002
The National Alliance for the Primary Prevention of Sharps Injuries (NAPPSI), founded by Venetec International, today announced the addition of four new members: -- Bard Access Systems Inc., a manufacturer of vascular access products; -- Infection Control Today, a journal for infection control professionals; -- The International Association of EMT`s and Paramedics (IAEP), a union for employees in the emergency medical services field; and -- The Association of Perioperative Registered Nurses (AORN), a leading healthcare professional organization. `Having these organizations as members demonstrates NAPPSI`s growing leadership position in sharps injury protection, as a prime force for improving workplace safety.`said Steve Bierman, M.D., NAPPSI`s founder and the CEO and medical director of Venetec International. `Bard Access Systems is a major medical manufacturer that has long been incorporating sharps safety features in its products. The readership of Infection Control Today and the memberships of IAEP and AORN represent vital constituencies that support NAPPSI`s primary prevention message. Our organization`s impact on healthcare has taken a big step forward with these new members on board.`NAPPSI is a non-profit organization dedicated to minimizing sharps injuries in the healthcare workplace. Based in Carlsbad, Calif., the organization promotes primary prevention as the first line of defense for accomplishing this goal. Primary prevention means utilizing technologies and practices that either reduce or eliminate the need to use sharp medical implements. In contrast, secondary prevention renders safer those sharps that must be introduced into the healthcare workplace. NAPPSI supports both approaches, especially when used in a complementary manner -- that is, using primary prevention where possible, and secondary prevention to fill in the gaps. NAPPSI`s membership encompasses professional associations, individual healthcare professionals and medical device makers. Membership is free to individual clinicians. NAPPSI has recently petitioned the Food and Drug Administration (FDA) and the federal Occupation Safety and Health Administration (OSHA) to disseminate the organization`s Needlestick Safety Device List and its Clinician Advisory on healthcare worker safety. About the new members: -- Bard Access Systems Inc., a business unit of healthcare product manufacturer C. R. Bard Inc., offers nine vascular access product lines in more than 800 configurations to meet all vascular access needs. The company also provides comprehensive clinical, educational, and operational support to help institutions meet their specific needs in this area. `Bard has been a leader in the vascular access market, including products with needlestick safety features,`said Paul Blackburn, product manager for PICCS and Midlines. `Joining NAPPSI will help make people more aware of our products and our devotion to clinician safety issues.`For more information, access www.bardaccess.com or call 801/595-0700. -- Infection Control Today is a comprehensive journal for healthcare practitioners who are responsible for purchasing and administering healthcare products in a clean and safe fashion. The journal reports on news, issues and trends that are important to the infection control community; covers best practices in infection control; and provides continuing education for professionals in the field. `We joined NAPPSI to champion awareness and educate healthcare professionals about preventing one of the most common occupational health hazards,`said ICT publisher Bill Eikost. `Our mission is to inform readers about new and upcoming technologies that can prevent these types of injuries and resulting infections, including the technologies NAPPSI advocates.`For more information, access www.infectioncontroltoday.com or call 480/990-1101. -- IAEP, the fastest growing union in the United States, was established in 1992 to deal with job-related problems faced by emergency medical services workers. A division of the National Association of Government Employees, AFL-CIO, the union represents more than 200,000 members in 17 states and is currently organizing in 11 other states. `One of the ways we try to improve the lives of our members is by improving the safety of their work environment, including reducing or eliminating sharps injury risk,`said Matthew Levy, Eastern states coordinator of organizing. One of the most effective ways of accomplishing this is to educate the membership, which NAPPSI does through its e-mail newsletter and other communications to members.`For more information, access www.iaep.org or call 617/376-0220. -- AORN supports registered nurses in achieving optimal outcomes for patients undergoing operative and other invasive procedures. The organization provides a variety of continuing education opportunities for more than 40,000 perioperative nurses in the U.S. and Puerto Rico. `AORN is a strong advocate for the safety of our members and that of the other members of the perioperative team,`said Tom Cooper, AORN`s executive director. `AORN launched a significant workplace safety initiative earlier this year to improve safety conditions in the surgical setting. Preventing sharps injuries is a significant component of this, and something that must be accomplished to ensure healthcare worker safety.`For more information, access www.aorn.org or call 800/755-2676. NAPPSI utilizes its monthly e-mail newsletter, a national speaker`s bureau, public relations, and other activities to inform the media, decision makers, and opinion leaders on the value of primary prevention practices and products. NAPPSI`s Clinician Advisory is widely distributed to clinicians, including members of INS (Infusion Nurses Society), NAVAN (National Association of Vascular Access Networks), AACN (American Association of Critical Care Nurses), NARI (National Association of Residents and Interns); ANFIM (Association of Needle-Free Injection Manufacturers), HIDA (Health Industry Distributors Association) and CINA (Canadian Infusion Nurses Association). NAPPSI`s Safety Device List, which lists products according to primary or secondary prevention attributes, is posted on the Web sites of the states of Tennessee and Alaska, INS, NARI, and NAVAN. Other NAPPSI organizational members include: -- Venetec International, www.Venetec.com, 800/833-3895; -- Cell Robotics International (OTCBB:CRII), www.CellRobotics.com, 505/343-1131; -- Bioject Medical Technologies (Nasdaq:BJCT), www.Bioject.com, 503/639-7221; -- ICU Medical (Nasdaq:ICUI), www.ICUmed.com, 800/824-7890; -- ALARIS Medical Systems Inc. (AMEX:AMI), www.alarismed.com, 858/458-7000; -- Equidyne Systems Inc. (AMEX:IJX), www.equidyne.com, 877/474-6539; -- Calypte Biomedical Inc. (Nasdaq:CALY), www.Calypte.com, 877/CALYPTE (225-9783); -- Arrow International (Nasdaq:ARRO), www.arrowintl.com, 800/233-3187; -- B. Braun Medical, www.BBraunusa.com, 610/691-5400; -- National Association of Residents and Interns, www.NARI-assn.com, 800/221-2168, ext. 5; -- D`Antonio Consultants International Inc., www.dantonioconsultants.com, 315/463-4999; -- Helping Hands Sanctuary of Idaho Inc., www.healthcaretraining.org, 208/221-1611; -- Association of Needle-Free Injection Manufacturers (ANIFM), 315/463-4999; -- Health Industry Distributors Association (HIDA), www.HIDAnetwork.com, 703/549-4432; -- ETHICON Inc., www.EthiconInc.com; -- Abbott Laboratories, www.abbotthosp.com, 800/222-6883; -- The Association of Occupational Health Professionals in Healthcare (AOHP), www.aohp.org, 412/749-7328; -- BD Inc. (Becton Dickinson) (NYSE:BDX), www.bd.com, 201/847-6800; -- The Infusion Nurses Society (INS), www.INS1.org, -- The National Association of Vascular Access Networks (NAVAN), www.navannet.org, 888/57-NAVAN (888/576-2826); -- The American Association of Critical Care Nurses (AACN), www.aacn.org, 800/899-2226; -- Canadian Intravenous Nurses Association (CINA), www.csotcina.com, 416/445-4516; -- StickSafe LLC, www.sticksafe.com, 888/914-9600; -- Phlebotomy West, www.phlebotomywest.com, 925/240-0770; -- Cook Inc., www.cookgroup.com, 800/457-4500; -- Portex Inc., www.portexusa.com, 603/352-3812; -- TransDerm Technologies, www.transdermtech.com www.transdermtech.com, 415/561-2550; -- Hema Metrics Inc., www.hemametrics.com www.hemametrics.com, 800/546-5463 -- Antares Pharma, www.antarespharma.com www.antarespharma.com, 610/458 6200; -- HDC Corp., www.hdccorp.com, 408/942-7340; -- Porex Medical Products Inc. www.porex.com, 800/520-7999. For NAPPSI membership and other information, call 858/350-8623, email info@NAPPSI.org, or access www.NAPPSI.org.
CONTACT: Dowling & Dennis Public Relations
Liz Dowling, 760/942-2544
lizdowling@aol.com
Print story
Current Quote
OBB: CALY
Manufacturing
Last: 0.129
Change: N/A
Volume: N/A
Day High: N/A
Day Low: N/A
First Alert News
Get real-time CALY release alerts by entering your email address below.
JS200
via CDS
October 31, 2002
The National Alliance for the Primary Prevention of Sharps Injuries (NAPPSI), founded by Venetec International, today announced the addition of four new members: -- Bard Access Systems Inc., a manufacturer of vascular access products; -- Infection Control Today, a journal for infection control professionals; -- The International Association of EMT`s and Paramedics (IAEP), a union for employees in the emergency medical services field; and -- The Association of Perioperative Registered Nurses (AORN), a leading healthcare professional organization. `Having these organizations as members demonstrates NAPPSI`s growing leadership position in sharps injury protection, as a prime force for improving workplace safety.`said Steve Bierman, M.D., NAPPSI`s founder and the CEO and medical director of Venetec International. `Bard Access Systems is a major medical manufacturer that has long been incorporating sharps safety features in its products. The readership of Infection Control Today and the memberships of IAEP and AORN represent vital constituencies that support NAPPSI`s primary prevention message. Our organization`s impact on healthcare has taken a big step forward with these new members on board.`NAPPSI is a non-profit organization dedicated to minimizing sharps injuries in the healthcare workplace. Based in Carlsbad, Calif., the organization promotes primary prevention as the first line of defense for accomplishing this goal. Primary prevention means utilizing technologies and practices that either reduce or eliminate the need to use sharp medical implements. In contrast, secondary prevention renders safer those sharps that must be introduced into the healthcare workplace. NAPPSI supports both approaches, especially when used in a complementary manner -- that is, using primary prevention where possible, and secondary prevention to fill in the gaps. NAPPSI`s membership encompasses professional associations, individual healthcare professionals and medical device makers. Membership is free to individual clinicians. NAPPSI has recently petitioned the Food and Drug Administration (FDA) and the federal Occupation Safety and Health Administration (OSHA) to disseminate the organization`s Needlestick Safety Device List and its Clinician Advisory on healthcare worker safety. About the new members: -- Bard Access Systems Inc., a business unit of healthcare product manufacturer C. R. Bard Inc., offers nine vascular access product lines in more than 800 configurations to meet all vascular access needs. The company also provides comprehensive clinical, educational, and operational support to help institutions meet their specific needs in this area. `Bard has been a leader in the vascular access market, including products with needlestick safety features,`said Paul Blackburn, product manager for PICCS and Midlines. `Joining NAPPSI will help make people more aware of our products and our devotion to clinician safety issues.`For more information, access www.bardaccess.com or call 801/595-0700. -- Infection Control Today is a comprehensive journal for healthcare practitioners who are responsible for purchasing and administering healthcare products in a clean and safe fashion. The journal reports on news, issues and trends that are important to the infection control community; covers best practices in infection control; and provides continuing education for professionals in the field. `We joined NAPPSI to champion awareness and educate healthcare professionals about preventing one of the most common occupational health hazards,`said ICT publisher Bill Eikost. `Our mission is to inform readers about new and upcoming technologies that can prevent these types of injuries and resulting infections, including the technologies NAPPSI advocates.`For more information, access www.infectioncontroltoday.com or call 480/990-1101. -- IAEP, the fastest growing union in the United States, was established in 1992 to deal with job-related problems faced by emergency medical services workers. A division of the National Association of Government Employees, AFL-CIO, the union represents more than 200,000 members in 17 states and is currently organizing in 11 other states. `One of the ways we try to improve the lives of our members is by improving the safety of their work environment, including reducing or eliminating sharps injury risk,`said Matthew Levy, Eastern states coordinator of organizing. One of the most effective ways of accomplishing this is to educate the membership, which NAPPSI does through its e-mail newsletter and other communications to members.`For more information, access www.iaep.org or call 617/376-0220. -- AORN supports registered nurses in achieving optimal outcomes for patients undergoing operative and other invasive procedures. The organization provides a variety of continuing education opportunities for more than 40,000 perioperative nurses in the U.S. and Puerto Rico. `AORN is a strong advocate for the safety of our members and that of the other members of the perioperative team,`said Tom Cooper, AORN`s executive director. `AORN launched a significant workplace safety initiative earlier this year to improve safety conditions in the surgical setting. Preventing sharps injuries is a significant component of this, and something that must be accomplished to ensure healthcare worker safety.`For more information, access www.aorn.org or call 800/755-2676. NAPPSI utilizes its monthly e-mail newsletter, a national speaker`s bureau, public relations, and other activities to inform the media, decision makers, and opinion leaders on the value of primary prevention practices and products. NAPPSI`s Clinician Advisory is widely distributed to clinicians, including members of INS (Infusion Nurses Society), NAVAN (National Association of Vascular Access Networks), AACN (American Association of Critical Care Nurses), NARI (National Association of Residents and Interns); ANFIM (Association of Needle-Free Injection Manufacturers), HIDA (Health Industry Distributors Association) and CINA (Canadian Infusion Nurses Association). NAPPSI`s Safety Device List, which lists products according to primary or secondary prevention attributes, is posted on the Web sites of the states of Tennessee and Alaska, INS, NARI, and NAVAN. Other NAPPSI organizational members include: -- Venetec International, www.Venetec.com, 800/833-3895; -- Cell Robotics International (OTCBB:CRII), www.CellRobotics.com, 505/343-1131; -- Bioject Medical Technologies (Nasdaq:BJCT), www.Bioject.com, 503/639-7221; -- ICU Medical (Nasdaq:ICUI), www.ICUmed.com, 800/824-7890; -- ALARIS Medical Systems Inc. (AMEX:AMI), www.alarismed.com, 858/458-7000; -- Equidyne Systems Inc. (AMEX:IJX), www.equidyne.com, 877/474-6539; -- Calypte Biomedical Inc. (Nasdaq:CALY), www.Calypte.com, 877/CALYPTE (225-9783); -- Arrow International (Nasdaq:ARRO), www.arrowintl.com, 800/233-3187; -- B. Braun Medical, www.BBraunusa.com, 610/691-5400; -- National Association of Residents and Interns, www.NARI-assn.com, 800/221-2168, ext. 5; -- D`Antonio Consultants International Inc., www.dantonioconsultants.com, 315/463-4999; -- Helping Hands Sanctuary of Idaho Inc., www.healthcaretraining.org, 208/221-1611; -- Association of Needle-Free Injection Manufacturers (ANIFM), 315/463-4999; -- Health Industry Distributors Association (HIDA), www.HIDAnetwork.com, 703/549-4432; -- ETHICON Inc., www.EthiconInc.com; -- Abbott Laboratories, www.abbotthosp.com, 800/222-6883; -- The Association of Occupational Health Professionals in Healthcare (AOHP), www.aohp.org, 412/749-7328; -- BD Inc. (Becton Dickinson) (NYSE:BDX), www.bd.com, 201/847-6800; -- The Infusion Nurses Society (INS), www.INS1.org, -- The National Association of Vascular Access Networks (NAVAN), www.navannet.org, 888/57-NAVAN (888/576-2826); -- The American Association of Critical Care Nurses (AACN), www.aacn.org, 800/899-2226; -- Canadian Intravenous Nurses Association (CINA), www.csotcina.com, 416/445-4516; -- StickSafe LLC, www.sticksafe.com, 888/914-9600; -- Phlebotomy West, www.phlebotomywest.com, 925/240-0770; -- Cook Inc., www.cookgroup.com, 800/457-4500; -- Portex Inc., www.portexusa.com, 603/352-3812; -- TransDerm Technologies, www.transdermtech.com www.transdermtech.com, 415/561-2550; -- Hema Metrics Inc., www.hemametrics.com www.hemametrics.com, 800/546-5463 -- Antares Pharma, www.antarespharma.com www.antarespharma.com, 610/458 6200; -- HDC Corp., www.hdccorp.com, 408/942-7340; -- Porex Medical Products Inc. www.porex.com, 800/520-7999. For NAPPSI membership and other information, call 858/350-8623, email info@NAPPSI.org, or access www.NAPPSI.org.
CONTACT: Dowling & Dennis Public Relations
Liz Dowling, 760/942-2544
lizdowling@aol.com
Print story
Current Quote
OBB: CALY
Manufacturing
Last: 0.129
Change: N/A
Volume: N/A
Day High: N/A
Day Low: N/A
First Alert News
Get real-time CALY release alerts by entering your email address below.
JS200
Technologies (Nasdaq:BJCT), www.Bioject.com, 503/639-7221; -- ICU Medical (Nasdaq:ICUI), www.ICUmed.com, 800/824-7890; -- ALARIS Medical Systems Inc. (AMEX:AMI), www.alarismed.com, 858/458-7000; -- Equidyne Systems Inc. (AMEX:IJX), www.equidyne.com, 877/474-6539; -- Calypte Biomedical Inc. (Nasdaq:CALY), www.Calypte.com, 877/CALYPTE (225-9783); -- Arrow International (Nasdaq:ARRO), www.arrowintl.com, 800/233-3187; -- B. Braun Medical, www.BBraunusa.com, 610/691-5400; -- National Association of Residents and Interns, www.NARI-assn.com, 800/221-2168, ext. 5; -- D`Antonio Consultants International Inc.,
JS200
JS200
und...?????? was hat das nun mit Caly zu tun??????
ich dachte die sind da schon lange Mitglied!!
ich dachte die sind da schon lange Mitglied!!
@INTRADER
Scheint nicht so gewesen zu sein, sonst gäbe es keine Aufnahme
JS200
Scheint nicht so gewesen zu sein, sonst gäbe es keine Aufnahme
JS200
Was bringt diese Aufnahme ??????
Was bringt uns die Zukunft ????
JS200
Was bringt uns die Zukunft ????
JS200
allen einen schönen tag.
gruß speku
gruß speku
09:48:27 0.122 3100 OTCBB at Bid
09:38:27 0.122 18300 OTCBB at Bid
09:38:17 0.125 5000 OTCBB
09:35:49 0.126 7000 OTCBB
09:34:57 0.126 5000 OTCBB
09:33:55 0.125 1800 OTCBB at Ask
09:33:55 0.126 5000 OTCBB at Ask
09:33:55 0.126 1200 OTCBB at Ask
09:32:36 0.126 5000 OTCBB at Ask
09:38:27 0.122 18300 OTCBB at Bid
09:38:17 0.125 5000 OTCBB
09:35:49 0.126 7000 OTCBB
09:34:57 0.126 5000 OTCBB
09:33:55 0.125 1800 OTCBB at Ask
09:33:55 0.126 5000 OTCBB at Ask
09:33:55 0.126 1200 OTCBB at Ask
09:32:36 0.126 5000 OTCBB at Ask
Der bekanntheitsgrad von Caly wird immer größer
Oktober 31, 2002
Das nationale Bündnis für die Primärverhinderung der Scharf-Verletzungen (NAPPSI), gegründet von Venetec International, verkündete heute die Hinzufügung von vier neuen Mitgliedern: -- Bard Access Systems Inc., ein Hersteller der Gefäßzugang Produkte; -- Infektion-Steuerung heute, ein Journal für Infektionsteuerfachleute; -- die internationale Verbindung von EMT`s und Paramedics (IAEP), einen Anschluß für Angestellte auf dem Gebiet der Dringlichkeitsärztlichen Bemühungen; und -- die Verbindung von Perioperative registrierte Krankenschwestern (AORN), eine führende healthcare Fachmannorganisation. das `, das diese Organisationen als Mitglieder hat, zeigt NAPPSI`s wachsende Führungposition im Scharfverletzung Schutz, wie eine Hauptkraft für das Verbessern des Arbeitsplatzes safety.`said Steve Bierman, M.D., NAPPSI`s Gründer und der CEO- und medizinische Direktor von Venetec international. ` Barde Zugang Systeme ist ein medizinischer hauptsächlichhersteller, der lang Scharfsicherheit Eigenschaften in seinen Produkten enthalten hat. Die Leserschaft Infektion-Steuerung heute und die Mitgliedschaft IAEP und AORN vertritt lebenswichtige Wahlkreise, die NAPPSI`s von von Primärverhinderunganzeige stützen. Unsere organization`s wirken sich auf healthcare hat unternommen einen grossen Schritt aus, der mit diesen neuen Mitgliedern auf board.`NAPPSI Vorwärts ist, ist eine gemeinnützige Organisation, die herabsetzenscharfverletzungen an dem healthcare Arbeitsplatz eingeweiht wird. Gegründet in Carlsbad, fördert Calif., die Organisation Primärverhinderung wie die erste Verteidigungslinie für das Erreichen dieses Ziels. Primärverhinderung bedeutet das Verwenden von von Technologien und von von Praxis, der entweder die Notwendigkeit verringern Sie oder beseitigen Sie, scharfe medizinische Werkzeuge zu benutzen. Demgegenüber überträgt Sekundärverhinderung sicherer jene Scharfen, die in den healthcare Arbeitsplatz eingeführt werden müssen. NAPPSI stützt beide Annäherungen, besonders wenn es in einer ergänzenden Weise -- das heißt, mit Primärverhinderung wo möglich und Sekundärverhinderung, die Abstände auszufüllen verwendet wird. NAPPSI`s Mitgliedschaft gibt Berufsvereinigungberufsverbände, einzelne healthcare Fachleute und medizinische Vorrichtung Hersteller um. Mitgliedschaft ist zu den einzelnen Klinikern frei. NAPPSI hat vor kurzem die Nahrung und die Droge-Leitung und die Bundesbesetzung Sicherheit und Gesundheit Leitung (OSHA) zu verbreiten die ersucht organization`s Needlestick Sicherheitsvorrichtung-Liste (FDA) und sein Kliniker, der auf healthcare Arbeitersicherheit beratend ist. Über die neuen Mitglieder: -- Bard Access Systems Inc., eine Unternehmenseinheit des healthcare Produktherstellers C. R. Bard Inc., Angebote neun Gefäßzugang Produktserien in mehr als 800 Konfigurationen, zum aller Gefäßzugang Bedürfnisse zu erfüllen. Die Firma stellt auch komplettes klinisches zur Verfügung, pädagogisch, und funktionsfähige Unterstützung zu den Hilfe Anstalten erfüllen ihre spezifischen Bedürfnisse in diesem Bereich. ` Barde ist ein Führer im Gefäßzugang Markt, einschließlich der Produkte mit needlestick Sicherheit Eigenschaften, `said Paul Blackburn, Produktmanager für PICCS und Midlines gewesen. das `, das NAPPSI verbindet, hilft, Leute bewußter zu bilden unsere Produkte und unsere Hingabe zur Klinikersicherheit issues.`For mehr Informationen, Zugang www.bardaccess.com oder Anruf 801/595-0700. -- Infektion-Steuerung ist heute ein komplettes Journal für healthcare Praktiker, die für das Kaufen und das Ausüben der healthcare Produkte auf eine saubere und sichere Art und Weise verantwortlich sind. Das Journal berichtet über Nachrichten, Ausgaben und Tendenzen, die zur Infektionsteuergemeinschaft wichtig sind; Abdeckungen beste Praxis in der Infektionsteuerung; und stellt ständige Weiterbildung für Fachleute auf dem Gebiet zur Verfügung. ` verbanden wir NAPPSI zum Meisterbewußtsein und erziehen healthcare Fachleute über das Verhindern eins der allgemeinsten beruflichen Gesundheitsrisiken, `said ICT Verleger Rechnung Eikost. ` unsere Mission soll Leser über neues informieren und upcoming Technologien, die diese Arten von Verletzungen verhindern können und resultierende Infektion, einschließlich der Technologien NAPPSI advocates.`For mehr Informationen, machen www.infectioncontroltoday.com oder Anruf 480/990-1101 zugänglich. -- IAEP, der schnellste wachsende Anschluß in den Vereinigten Staaten, wurde 1992 hergestellt, um die tätigkeitsbezogenen Probleme zu beschäftigen, die von den Arbeitern der Dringlichkeitsärztlichen Bemühungen gegenübergestellt wurden. Eine Abteilung der nationalen Verbindung der Regierung
Oktober 31, 2002
Das nationale Bündnis für die Primärverhinderung der Scharf-Verletzungen (NAPPSI), gegründet von Venetec International, verkündete heute die Hinzufügung von vier neuen Mitgliedern: -- Bard Access Systems Inc., ein Hersteller der Gefäßzugang Produkte; -- Infektion-Steuerung heute, ein Journal für Infektionsteuerfachleute; -- die internationale Verbindung von EMT`s und Paramedics (IAEP), einen Anschluß für Angestellte auf dem Gebiet der Dringlichkeitsärztlichen Bemühungen; und -- die Verbindung von Perioperative registrierte Krankenschwestern (AORN), eine führende healthcare Fachmannorganisation. das `, das diese Organisationen als Mitglieder hat, zeigt NAPPSI`s wachsende Führungposition im Scharfverletzung Schutz, wie eine Hauptkraft für das Verbessern des Arbeitsplatzes safety.`said Steve Bierman, M.D., NAPPSI`s Gründer und der CEO- und medizinische Direktor von Venetec international. ` Barde Zugang Systeme ist ein medizinischer hauptsächlichhersteller, der lang Scharfsicherheit Eigenschaften in seinen Produkten enthalten hat. Die Leserschaft Infektion-Steuerung heute und die Mitgliedschaft IAEP und AORN vertritt lebenswichtige Wahlkreise, die NAPPSI`s von von Primärverhinderunganzeige stützen. Unsere organization`s wirken sich auf healthcare hat unternommen einen grossen Schritt aus, der mit diesen neuen Mitgliedern auf board.`NAPPSI Vorwärts ist, ist eine gemeinnützige Organisation, die herabsetzenscharfverletzungen an dem healthcare Arbeitsplatz eingeweiht wird. Gegründet in Carlsbad, fördert Calif., die Organisation Primärverhinderung wie die erste Verteidigungslinie für das Erreichen dieses Ziels. Primärverhinderung bedeutet das Verwenden von von Technologien und von von Praxis, der entweder die Notwendigkeit verringern Sie oder beseitigen Sie, scharfe medizinische Werkzeuge zu benutzen. Demgegenüber überträgt Sekundärverhinderung sicherer jene Scharfen, die in den healthcare Arbeitsplatz eingeführt werden müssen. NAPPSI stützt beide Annäherungen, besonders wenn es in einer ergänzenden Weise -- das heißt, mit Primärverhinderung wo möglich und Sekundärverhinderung, die Abstände auszufüllen verwendet wird. NAPPSI`s Mitgliedschaft gibt Berufsvereinigungberufsverbände, einzelne healthcare Fachleute und medizinische Vorrichtung Hersteller um. Mitgliedschaft ist zu den einzelnen Klinikern frei. NAPPSI hat vor kurzem die Nahrung und die Droge-Leitung und die Bundesbesetzung Sicherheit und Gesundheit Leitung (OSHA) zu verbreiten die ersucht organization`s Needlestick Sicherheitsvorrichtung-Liste (FDA) und sein Kliniker, der auf healthcare Arbeitersicherheit beratend ist. Über die neuen Mitglieder: -- Bard Access Systems Inc., eine Unternehmenseinheit des healthcare Produktherstellers C. R. Bard Inc., Angebote neun Gefäßzugang Produktserien in mehr als 800 Konfigurationen, zum aller Gefäßzugang Bedürfnisse zu erfüllen. Die Firma stellt auch komplettes klinisches zur Verfügung, pädagogisch, und funktionsfähige Unterstützung zu den Hilfe Anstalten erfüllen ihre spezifischen Bedürfnisse in diesem Bereich. ` Barde ist ein Führer im Gefäßzugang Markt, einschließlich der Produkte mit needlestick Sicherheit Eigenschaften, `said Paul Blackburn, Produktmanager für PICCS und Midlines gewesen. das `, das NAPPSI verbindet, hilft, Leute bewußter zu bilden unsere Produkte und unsere Hingabe zur Klinikersicherheit issues.`For mehr Informationen, Zugang www.bardaccess.com oder Anruf 801/595-0700. -- Infektion-Steuerung ist heute ein komplettes Journal für healthcare Praktiker, die für das Kaufen und das Ausüben der healthcare Produkte auf eine saubere und sichere Art und Weise verantwortlich sind. Das Journal berichtet über Nachrichten, Ausgaben und Tendenzen, die zur Infektionsteuergemeinschaft wichtig sind; Abdeckungen beste Praxis in der Infektionsteuerung; und stellt ständige Weiterbildung für Fachleute auf dem Gebiet zur Verfügung. ` verbanden wir NAPPSI zum Meisterbewußtsein und erziehen healthcare Fachleute über das Verhindern eins der allgemeinsten beruflichen Gesundheitsrisiken, `said ICT Verleger Rechnung Eikost. ` unsere Mission soll Leser über neues informieren und upcoming Technologien, die diese Arten von Verletzungen verhindern können und resultierende Infektion, einschließlich der Technologien NAPPSI advocates.`For mehr Informationen, machen www.infectioncontroltoday.com oder Anruf 480/990-1101 zugänglich. -- IAEP, der schnellste wachsende Anschluß in den Vereinigten Staaten, wurde 1992 hergestellt, um die tätigkeitsbezogenen Probleme zu beschäftigen, die von den Arbeitern der Dringlichkeitsärztlichen Bemühungen gegenübergestellt wurden. Eine Abteilung der nationalen Verbindung der Regierung
@jojobada,JS222
hier muss ich intrader78 recht geben. Was hat das mit Caly zu tun, bzw. worin liegt die Neuigkeit für Caly? Im letztgenannten Artikel ist Caly garnicht erwähnt. Die neuen Mitglieder sind
-- Bard Access Systems Inc.,
-- Infection Control Today,
-- The International Association of EMT`s and Paramedics (IAEP)
-- The Association of Perioperative Registered Nurses (AORN)
AktieX
hier muss ich intrader78 recht geben. Was hat das mit Caly zu tun, bzw. worin liegt die Neuigkeit für Caly? Im letztgenannten Artikel ist Caly garnicht erwähnt. Die neuen Mitglieder sind
-- Bard Access Systems Inc.,
-- Infection Control Today,
-- The International Association of EMT`s and Paramedics (IAEP)
-- The Association of Perioperative Registered Nurses (AORN)
AktieX
Nicht streiten ! Freut Euch lieber, dass die Gewinnmitnahmen in Amiland beendet zu sein scheinen und es heute (wenn auch bei schwachen Umsätzen) leicht aufwärts geht ! Stellt mir jemand Realtimekurse rein ??? - Danke - MfG X 99
CALY
Date Time Price Volume Exch Type Bid BSize BEx Ask ASize AEx Cond
Vl: BSize: ASize:
31.10.2002 13:30 Best Bid .1250 5000
31.10.2002 13:30 Best Ask .1250 5000 .1270 5000
31.10.2002 14:27 Best Bid .1250 5000 .1270 5000
31.10.2002 14:27 Best Ask .1250 5000 .1290 5000
31.10.2002 15:32 Best Bid .1250 5000 .1290 5000
31.10.2002 15:32 Best Ask .1250 5000 .1300 5000
31.10.2002 15:32 Best Bid .1250 5000 .1300 5000
31.10.2002 15:32 Best Ask .1250 5000 .1260 5000
31.10.2002 15:32 .1260 5000 Trade
31.10.2002 15:34 .1260 5000 Trade
31.10.2002 15:34 Best Bid .1250 5000 .1260 5000
31.10.2002 15:34 Best Ask .1250 5000 .1300 5000
31.10.2002 15:35 .1260 7000 Trade
31.10.2002 15:38 .1250 5000 Trade
31.10.2002 15:38 Best Bid .1220 5000 .1300 5000
31.10.2002 15:38 Best Ask .1220 5000 .1300 5000
31.10.2002 15:38 .1220 18300 Trade
31.10.2002 15:48 .1220 3100 Trade
31.10.2002 15:57 .1300 2000 Trade
31.10.2002 15:57 .1230 2000 Trade
31.10.2002 16:30 .1300 2000 Trade
31.10.2002 16:36 .1300 25000 Trade
31.10.2002 16:36 .1270 5000 Trade
31.10.2002 16:36 .1299 15200 Trade
31.10.2002 16:36 .1270 4800 Trade
31.10.2002 16:37 Best Bid .1280 5000 .1300 5000
31.10.2002 16:37 Best Ask .1280 5000 .1300 5000
31.10.2002 16:44 .1300 300 Trade
31.10.2002 16:44 .1299 300 Trade
31.10.2002 16:45 .1300 5000 Trade
31.10.2002 16:45 .1300 5000 Trade
31.10.2002 16:46 .1300 15000 Trade
31.10.2002 16:46 .1300 5000 Trade
31.10.2002 16:47 .1280 3500 Trade
31.10.2002 16:47 .1300 25000 Trade
31.10.2002 16:47 .1299 5600 Trade
31.10.2002 16:49 .1300 500 Trade
31.10.2002 16:55 .1300 5000 Trade
31.10.2002 17:01 Best Bid .1280 5000 .1300 5000
31.10.2002 17:01 Best Ask .1280 5000 .1330 5000
31.10.2002 17:01 .1300 5000 Trade
31.10.2002 17:10 .1330 700 Trade
31.10.2002 17:10 .1300 700 Trade
Date Time Price Volume Exch Type Bid BSize BEx Ask ASize AEx Cond
Vl: BSize: ASize:
31.10.2002 13:30 Best Bid .1250 5000
31.10.2002 13:30 Best Ask .1250 5000 .1270 5000
31.10.2002 14:27 Best Bid .1250 5000 .1270 5000
31.10.2002 14:27 Best Ask .1250 5000 .1290 5000
31.10.2002 15:32 Best Bid .1250 5000 .1290 5000
31.10.2002 15:32 Best Ask .1250 5000 .1300 5000
31.10.2002 15:32 Best Bid .1250 5000 .1300 5000
31.10.2002 15:32 Best Ask .1250 5000 .1260 5000
31.10.2002 15:32 .1260 5000 Trade
31.10.2002 15:34 .1260 5000 Trade
31.10.2002 15:34 Best Bid .1250 5000 .1260 5000
31.10.2002 15:34 Best Ask .1250 5000 .1300 5000
31.10.2002 15:35 .1260 7000 Trade
31.10.2002 15:38 .1250 5000 Trade
31.10.2002 15:38 Best Bid .1220 5000 .1300 5000
31.10.2002 15:38 Best Ask .1220 5000 .1300 5000
31.10.2002 15:38 .1220 18300 Trade
31.10.2002 15:48 .1220 3100 Trade
31.10.2002 15:57 .1300 2000 Trade
31.10.2002 15:57 .1230 2000 Trade
31.10.2002 16:30 .1300 2000 Trade
31.10.2002 16:36 .1300 25000 Trade
31.10.2002 16:36 .1270 5000 Trade
31.10.2002 16:36 .1299 15200 Trade
31.10.2002 16:36 .1270 4800 Trade
31.10.2002 16:37 Best Bid .1280 5000 .1300 5000
31.10.2002 16:37 Best Ask .1280 5000 .1300 5000
31.10.2002 16:44 .1300 300 Trade
31.10.2002 16:44 .1299 300 Trade
31.10.2002 16:45 .1300 5000 Trade
31.10.2002 16:45 .1300 5000 Trade
31.10.2002 16:46 .1300 15000 Trade
31.10.2002 16:46 .1300 5000 Trade
31.10.2002 16:47 .1280 3500 Trade
31.10.2002 16:47 .1300 25000 Trade
31.10.2002 16:47 .1299 5600 Trade
31.10.2002 16:49 .1300 500 Trade
31.10.2002 16:55 .1300 5000 Trade
31.10.2002 17:01 Best Bid .1280 5000 .1300 5000
31.10.2002 17:01 Best Ask .1280 5000 .1330 5000
31.10.2002 17:01 .1300 5000 Trade
31.10.2002 17:10 .1330 700 Trade
31.10.2002 17:10 .1300 700 Trade
@X99
ich wollte hier auch keine schlechte Stimmung machen. Hab selbst ca. 75K Caly`s im Depot. Aber in der vorliegenden Meldung hab ich halt auch keine positiven oder negativen Aspekte rauslesen können...
AktieX
ich wollte hier auch keine schlechte Stimmung machen. Hab selbst ca. 75K Caly`s im Depot. Aber in der vorliegenden Meldung hab ich halt auch keine positiven oder negativen Aspekte rauslesen können...
AktieX
31.10.2002 17:28 Best Bid .1300 5000 .1330 5000
31.10.2002 17:28 Best Ask .1300 5000 .1330 5000
31.10.2002 17:28 .1300 5000 Trade
31.10.2002 17:28 .1330 10000 Trade
31.10.2002 17:28 .1300 10000 Trade
31.10.2002 17:28 .1300 6200 Trade
31.10.2002 17:30 .1330 25000 Trade
31.10.2002 17:30 .1300 65000 Trade
31.10.2002 17:34 .1330 10000 Trade
31.10.2002 17:37 .1330 25000 Trade
31.10.2002 17:37 .1330 5000 Trade
31.10.2002 17:39 .1330 15000 Trade
31.10.2002 17:39 Best Bid .1320 5000 .1330 5000
31.10.2002 17:39 Best Ask .1320 5000 .1330 5000
31.10.2002 17:40 Best Bid .1320 5000 .1330 5000
31.10.2002 17:40 Best Ask .1320 5000 .1350 5000
31.10.2002 17:40 .1320 15000 Trade
31.10.2002 17:28 Best Ask .1300 5000 .1330 5000
31.10.2002 17:28 .1300 5000 Trade
31.10.2002 17:28 .1330 10000 Trade
31.10.2002 17:28 .1300 10000 Trade
31.10.2002 17:28 .1300 6200 Trade
31.10.2002 17:30 .1330 25000 Trade
31.10.2002 17:30 .1300 65000 Trade
31.10.2002 17:34 .1330 10000 Trade
31.10.2002 17:37 .1330 25000 Trade
31.10.2002 17:37 .1330 5000 Trade
31.10.2002 17:39 .1330 15000 Trade
31.10.2002 17:39 Best Bid .1320 5000 .1330 5000
31.10.2002 17:39 Best Ask .1320 5000 .1330 5000
31.10.2002 17:40 Best Bid .1320 5000 .1330 5000
31.10.2002 17:40 Best Ask .1320 5000 .1350 5000
31.10.2002 17:40 .1320 15000 Trade
31.10.2002 17:59 .1320 15600 Trade
31.10.2002 17:59 Best Bid .1320 5000 .1350 5000
31.10.2002 17:59 Best Ask .1320 5000 .1340 5000
31.10.2002 17:59 Best Bid .1320 5000 .1350 5000
31.10.2002 17:59 Best Ask .1320 5000 .1340 5000
31.10.2002 18:08 .1340 5000 Trade
31.10.2002 18:09 .1320 5000 Trade
31.10.2002 18:09 .1330 10000 Trade
31.10.2002 18:09 Best Bid .1300 5000 .1340 5000
31.10.2002 18:09 Best Ask .1300 5000 .1340 5000
31.10.2002 18:09 .1320 5000 Trade
31.10.2002 18:09 .1330 10000 Trade
31.10.2002 18:09 Best Bid .1300 5000 .1340 5000
31.10.2002 18:09 Best Ask .1300 5000 .1340 5000
31.10.2002 18:12 .1300 200 Trade
31.10.2002 18:14 .1340 10000 Trade
31.10.2002 18:14 .1340 10000 Trade
31.10.2002 18:15 Best Bid .1320 5000 .1340 5000
31.10.2002 18:15 Best Ask .1320 5000 .1340 5000
31.10.2002 18:15 .1340 10000 Trade
So, bin dann weg...
31.10.2002 18:15 Best Ask .1320 5000 .1340 5000
31.10.2002 18:15 .1340 10000 Trade
So, bin dann weg...
hi leute
12:33:04 0.134 10000 OTCBB at Ask
12:25:27 0.134 10000 OTCBB at Ask
12:23:35 0.132 2100 OTCBB at Bid
12:18:59 0.134 25000 OTCBB at Ask
12:33:04 0.134 10000 OTCBB at Ask
12:25:27 0.134 10000 OTCBB at Ask
12:23:35 0.132 2100 OTCBB at Bid
12:18:59 0.134 25000 OTCBB at Ask
12:49:42 0.132 5000 OTCBB at Bid
14:36:31 0.135 2000 OTCBB at Ask
14:36:30 0.132 20000 OTCBB at Bid
14:36:30 0.133 5000 OTCBB
14:36:30 0.133 26100 OTCBB
14:35:03 0.135 8200 OTCBB at Ask
14:14:11 0.135 3000 OTCBB at Ask
Volume: 761,800
Bid: 0.132
Ask: 0.135
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: 6.2%
14:36:30 0.132 20000 OTCBB at Bid
14:36:30 0.133 5000 OTCBB
14:36:30 0.133 26100 OTCBB
14:35:03 0.135 8200 OTCBB at Ask
14:14:11 0.135 3000 OTCBB at Ask
Volume: 761,800
Bid: 0.132
Ask: 0.135
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: 6.2%
ihr faulen säcke könntet euch ja selbst für RT anmelden.....
14:59:54 0.135 2100 OTCBB
14:57:58 0.135 5000 OTCBB
14:59:54 0.135 2100 OTCBB
14:57:58 0.135 5000 OTCBB
2:59pm ET
0.135
0.01 (6.29%)
Day`s Range: 0.122 - 0.135
Day`s Volume: 778,900 zu schwach um hoch zu steigen, leider
Avg. Volume: 2,242,554
JS200
0.135
0.01 (6.29%)
Day`s Range: 0.122 - 0.135
Day`s Volume: 778,900 zu schwach um hoch zu steigen, leider
Avg. Volume: 2,242,554
JS200
@Steffen
Nicht ärgern, ist doch auch ein Zeitvertreib.
JS200
Nicht ärgern, ist doch auch ein Zeitvertreib.
JS200
Das Gap bei 0,136-7 wird noch eine harte NUSS
JS200
JS200
js,
ich ärgere mich doch nicht
für mich gibt es mit caly nur eine richtung - und die ist richtung 1$ PARTY gen NORDEN !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
PS: wo ist jasmin? JASMIN HALLLLLOOOOOOOO
ich ärgere mich doch nicht
für mich gibt es mit caly nur eine richtung - und die ist richtung 1$ PARTY gen NORDEN !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
PS: wo ist jasmin? JASMIN HALLLLLOOOOOOOO
15:43:21 0.130 400 OTCBB
15:34:51 0.133 10000 OTCBB at Ask
15:34:50 0.133 3000 OTCBB at Ask
15:34:19 0.130 17000 OTCBB
15:34:51 0.133 10000 OTCBB at Ask
15:34:50 0.133 3000 OTCBB at Ask
15:34:19 0.130 17000 OTCBB
Tja 0,133 auch nicht schlecht.
Morgen vieleicht 0,14 ?????
JS200
Morgen vieleicht 0,14 ?????
JS200
VON GESTERN
CALY
CALYPTE BIOMEDICAL CP
0.130
+0.003 +2.36%
Daily Commentary
WAIT
Our system recommends WAIT as of today. Previous SELL recommendation was made on 10/30/2002 (1) days ago, when the stock price was 0.127. Since then the stock gained 2.36% .
Today the stock closed higher with a higher high and a higher low. The volume is extremely low. The security price is trending sideways.
Candlestick Analysis
Today’s Candlestick Patterns:
Spinning Top
Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!
Stock Quote
Last 0.130
Previous Close 0.127
Change +0.003
% Change +2.36%
Volume 889,300
Stock Activity
Open 0.126
Day`s High 0.135
Day`s Low 0.122
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -39.53
6 Month % Change 441.67
12 Month % Change -45.83
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.162
65 Day Volume MA 2,191,492
JS200
CALY
CALYPTE BIOMEDICAL CP
0.130
+0.003 +2.36%
Daily Commentary
WAIT
Our system recommends WAIT as of today. Previous SELL recommendation was made on 10/30/2002 (1) days ago, when the stock price was 0.127. Since then the stock gained 2.36% .
Today the stock closed higher with a higher high and a higher low. The volume is extremely low. The security price is trending sideways.
Candlestick Analysis
Today’s Candlestick Patterns:
Spinning Top
Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!
Stock Quote
Last 0.130
Previous Close 0.127
Change +0.003
% Change +2.36%
Volume 889,300
Stock Activity
Open 0.126
Day`s High 0.135
Day`s Low 0.122
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -39.53
6 Month % Change 441.67
12 Month % Change -45.83
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.162
65 Day Volume MA 2,191,492
JS200
@steffen712000,
hab dich nicht vergessen!
hab dich nicht vergessen!
@steffen712000,
hallo
hallo
@steffen712000,
du hast gesagt für dich gibt es nur eine Richtung für Caly 1$, dann könnten wir an so einem Ort eine Party vornehmen.
Ortsangaben:
10:00 und 35° im Schatten.
Gruß Jasmin
du hast gesagt für dich gibt es nur eine Richtung für Caly 1$, dann könnten wir an so einem Ort eine Party vornehmen.
Ortsangaben:
10:00 und 35° im Schatten.
Gruß Jasmin
@steffen712000,
natürlich würden wir vorher solche Luftsprüngen machen.
PSu bist wohl schon im Wochenende, na dann werde ich dies auch tun bis dann.
Gruss Jutta
natürlich würden wir vorher solche Luftsprüngen machen.
PSu bist wohl schon im Wochenende, na dann werde ich dies auch tun bis dann.
Gruss Jutta
Wie geht das mit den smilies??????
Bin glaub`ich zu blond dafür
moon1
DER JETZT ENDLICH WISSEN WILL WIE DAS GEHT! damit ich nicht mehr blond sein muss
Bin glaub`ich zu blond dafür
moon1
DER JETZT ENDLICH WISSEN WILL WIE DAS GEHT! damit ich nicht mehr blond sein muss
@morphoys1,
Entschuldigung habe dich vorhin ganz vergessen!
PS: Du hast Post
Gruss Jasmin
Entschuldigung habe dich vorhin ganz vergessen!
PS: Du hast Post
Gruss Jasmin
Hallo moon1 Post für Dich im Kasten
09:43am ET
0.135
0.01 (3.84%)
Day`s Range: 0.13 - 0.137
Day`s Volume: 99,200
Avg. Volume: 2,242,554
JS200
0.135
0.01 (3.84%)
Day`s Range: 0.13 - 0.137
Day`s Volume: 99,200
Avg. Volume: 2,242,554
JS200
ihr lieben - bitte einmal realtime - danke und gruss fhr
10:58am ET
0.13
0.00 (No Chg)
Day`s Range: 0.13 - 0.137
Day`s Volume: 125,600
Avg. Volume: 2,242,554
JS200
0.13
0.00 (No Chg)
Day`s Range: 0.13 - 0.137
Day`s Volume: 125,600
Avg. Volume: 2,242,554
JS200
nicht viel los hier.
gruß speku
gruß speku
11:53am ET
0.135
0.01 (3.84%)
Day`s Range: 0.13 - 0.137
Day`s Volume: 177,900
Avg. Volume: 2,242,554
JS200
0.135
0.01 (3.84%)
Day`s Range: 0.13 - 0.137
Day`s Volume: 177,900
Avg. Volume: 2,242,554
JS200
hollooo ihr hübschen
da bin ich wieder... danke erstmal, daß ihr so intensiv an mich gedacht habt! "jasmin" -rrrrrrrrrrrrrr
mein 2. monitor war ausgestiegen..hab jetzt nen ersatz! klappt wieder.
realtime:
12:12:49 0.133 1000 OTCBB
12:06:51 0.135 10000 OTCBB
12:05:52 0.135 5000 OTCBB
12:04:11 0.135 5000 OTCBB at Ask
Volume: 219,600
Bid: 0.125
Ask: 0.137
da bin ich wieder... danke erstmal, daß ihr so intensiv an mich gedacht habt! "jasmin" -rrrrrrrrrrrrrr
mein 2. monitor war ausgestiegen..hab jetzt nen ersatz! klappt wieder.
realtime:
12:12:49 0.133 1000 OTCBB
12:06:51 0.135 10000 OTCBB
12:05:52 0.135 5000 OTCBB
12:04:11 0.135 5000 OTCBB at Ask
Volume: 219,600
Bid: 0.125
Ask: 0.137
@Steffen
schön das wir dich haben.
Gruß speku
schön das wir dich haben.
Gruß speku
12:25:30 0.137 10000 OTCBB
12:24:52 0.137 2000 OTCBB at Ask
12:17:21 0.135 12000 OTCBB at Bid
12:17:19 0.137 10000 OTCBB at Ask
12:16:13 0.133 10000 OTCBB
12:24:52 0.137 2000 OTCBB at Ask
12:17:21 0.135 12000 OTCBB at Bid
12:17:19 0.137 10000 OTCBB at Ask
12:16:13 0.133 10000 OTCBB
13:16:50 0.135 100 OTCBB at Bid
12:41:54 0.137 6000 OTCBB at Ask
12:41:54 0.137 6000 OTCBB at Ask
@steffen712000,
bald ist wieder
was meinst du, können wir uns dann schon über einen deutlich höheren Kurs freuen.
Gruss Jasmin
bald ist wieder
was meinst du, können wir uns dann schon über einen deutlich höheren Kurs freuen.
Gruss Jasmin
hallöchen jasmin
ich sage JA! der kurs gefällt mir, das volumen weniger! doch bedenke: kursanstieg unter hohem volumen- kaum konsolidierung, d.h. kaum einer hat verkauft
..außer die pennytrader....
kursziele zu vergeben vermag ich nicht, doch haben wir die 0,30, ist der $ nur noch vom generierten umsatz und bekanntheitsgrad caly`s abhängig!
hast du dich schonmal um deakin financial gekümmert?
RT:
unveränder, letzte festsetzung 13:16:50UHR überseezeit...
ich sage JA! der kurs gefällt mir, das volumen weniger! doch bedenke: kursanstieg unter hohem volumen- kaum konsolidierung, d.h. kaum einer hat verkauft
..außer die pennytrader....
kursziele zu vergeben vermag ich nicht, doch haben wir die 0,30, ist der $ nur noch vom generierten umsatz und bekanntheitsgrad caly`s abhängig!
hast du dich schonmal um deakin financial gekümmert?
RT:
unveränder, letzte festsetzung 13:16:50UHR überseezeit...
14:07:02 0.134 5000 OTCBB at Bid
14:06:59 0.134 5000 OTCBB at Bid
14:02:45 0.135 1600 OTCBB at Bid
13:55:42 0.135 10000 OTCBB
Volume: 304,700
Bid: 0.134
Ask: 0.137
14:06:59 0.134 5000 OTCBB at Bid
14:02:45 0.135 1600 OTCBB at Bid
13:55:42 0.135 10000 OTCBB
Volume: 304,700
Bid: 0.134
Ask: 0.137
@steffen712000,
war in den letzten Tagen in Mobilcom engagiert.
Bin mit 3K noch investiert aber der Run in den letzten Minuten war echt geil.
Ich hoffe ich kann mich bei CALY auch einmal so freuen.
PS: Ich geht heute noch aus, hoffentlich ist dieser Typ wert.
Bis dann
Gruss Jasmin
war in den letzten Tagen in Mobilcom engagiert.
Bin mit 3K noch investiert aber der Run in den letzten Minuten war echt geil.
Ich hoffe ich kann mich bei CALY auch einmal so freuen.
PS: Ich geht heute noch aus, hoffentlich ist dieser Typ wert.
Bis dann
Gruss Jasmin
viel glück jasmin!
irgendwann muß doch dein prinz kommen
ciao
irgendwann muß doch dein prinz kommen
ciao
@steffen712000,
danke für deine guten Gedanken.
Es kann natürlich sein, dass meine Ansprüche zu hoch sind.
Ich wünsche dir ein schönes Wochenende und bei allem was du tust, viel Erfolg
danke für deine guten Gedanken.
Es kann natürlich sein, dass meine Ansprüche zu hoch sind.
Ich wünsche dir ein schönes Wochenende und bei allem was du tust, viel Erfolg
jasmin,
danke,- dir ebenso
RT:
14:32:45 0.137 600 OTCBB at Ask
14:31:21 0.137 10000 OTCBB at Ask
danke,- dir ebenso
RT:
14:32:45 0.137 600 OTCBB at Ask
14:31:21 0.137 10000 OTCBB at Ask
15:42:49 0.136 300 OTCBB
15:42:13 0.136 4700 OTCBB
15:31:09 0.137 19400 OTCBB at Ask
15:21:42 0.137 10000 OTCBB at Ask
15:42:13 0.136 4700 OTCBB
15:31:09 0.137 19400 OTCBB at Ask
15:21:42 0.137 10000 OTCBB at Ask
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
Na dann kann es jetzt ja richtig losgehen!!!
@ALLE
Noch keiner bei Caly hereingeschaut ??????
JS200
Noch keiner bei Caly hereingeschaut ??????
JS200
@js
nö - caly ist doch tot
nö - caly ist doch tot
Caly ist nicht tot. Aber ohne aktuelle News findet der Handel nun mal hauptsächlich in Amiland statt. Die Kursentwicklung sieht doch gar nicht so schlecht aus....
@ak
war doch ein witzle - hier darf doch auch mal gelacht werden - caly ist natürlich noch am leben - gruss fhr
war doch ein witzle - hier darf doch auch mal gelacht werden - caly ist natürlich noch am leben - gruss fhr
@fhr
klar, lachen ist gesund. Aber ohne Gegendarstellung glaubt das irgendeiner auch noch...
klar, lachen ist gesund. Aber ohne Gegendarstellung glaubt das irgendeiner auch noch...
Erster Kurs 0,136 100 Teile
JS200
JS200
Bid 0,10$ und ASK 0,30$
Da wird wohl heut nix abgehn
Latest Quote
Last: 0.137
Close: 0.137
High: 0.137
Low: 0.136
Open: 0.136
Change: +0.00
Volume: 12,600
Bid: 0.100
Ask: 0.300
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: 0.0%
Da wird wohl heut nix abgehn
Latest Quote
Last: 0.137
Close: 0.137
High: 0.137
Low: 0.136
Open: 0.136
Change: +0.00
Volume: 12,600
Bid: 0.100
Ask: 0.300
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.430
52 Wk Low: 0.012
%Change: 0.0%
11:27:58 0.135 10000 OTCBB
11:20:49 0.135 2500 OTCBB
11:20:33 0.135 25000 OTCBB
11:17:47 0.135 5000 OTCBB at Ask
11:17:30 0.135 8000 OTCBB at Ask
Volume: 287,000
Bid: 0.127
Ask: 0.137
11:20:49 0.135 2500 OTCBB
11:20:33 0.135 25000 OTCBB
11:17:47 0.135 5000 OTCBB at Ask
11:17:30 0.135 8000 OTCBB at Ask
Volume: 287,000
Bid: 0.127
Ask: 0.137
wir sind wieder bei 13,7 cent. also + - null...spanne: 13,3 auf 13,7 cent...
@ calypter
Teststreifen nach China ?
Montag, 4. November 2002
Aids-Bekämpfung
China bittet um Hilfe
China hat einem Zeitungsbericht
zufolge um internationale Hilfe bei der
Bekämpfung der
Immunschwächekrankheit Aids
gebeten. "Die HIV/Aids-Bekämpfung
in China befindet sich in einer
kritischen Periode, weil die Krankheit
von Risikogruppen sehr schnell auf
die Normalbevölkerung übergreift",
zitierte die amtliche Tageszeitung "China Daily" den chinesischen
Gesundheitsminister Zhang Wenkang. Das Land benötige dringend Experten.
Mit annähernd 1,3 Milliarden Einwohnern ist China der bevölkerungsreichste
Staat der Welt. Statistiken des Gesundheitsministeriums zufolge sind rund
eine Million Chinesen mit dem HIV-Virus infiziert. Die Zahl der Infizierten
könnte bis 2010 auf zehn Millionen ansteigen, wenn nicht sofort
Gegenmaßnahmen ergriffen würden, sagte Zhang der Zeitung. "Wir dürfen
keine Zeit verlieren."
Die USA hatten China im Juni umgerechnet rund 14,8 Mio. Euro für
Aids-Forschungszwecke in den kommenden fünf Jahren in Aussicht gestellt.
Nach Angaben der Vereinten Nationen sind in China bereits 30.000 Menschen
an der Immunschwächekrankheit gestorben.
Im Oktober hatte UN-Generalsekretär Kofi Annan zentralchinesischen Stadt
Hangzhou erklärt, China stehe "an der Schwelle einer explosiven
Aids-Epidemie" und müsse sofort handeln, um eine potenzielle Katastrophe zu
verhindern. Ausländische Aktivisten werfen Peking seit langem vor, das
Ausmaß der Krankheit verschleiern zu wollen und die Behandlung von
HIV-Infizierten und Aids-Kranken zu vernachlässigen.
Gruß Dr.B
Teststreifen nach China ?
Montag, 4. November 2002
Aids-Bekämpfung
China bittet um Hilfe
China hat einem Zeitungsbericht
zufolge um internationale Hilfe bei der
Bekämpfung der
Immunschwächekrankheit Aids
gebeten. "Die HIV/Aids-Bekämpfung
in China befindet sich in einer
kritischen Periode, weil die Krankheit
von Risikogruppen sehr schnell auf
die Normalbevölkerung übergreift",
zitierte die amtliche Tageszeitung "China Daily" den chinesischen
Gesundheitsminister Zhang Wenkang. Das Land benötige dringend Experten.
Mit annähernd 1,3 Milliarden Einwohnern ist China der bevölkerungsreichste
Staat der Welt. Statistiken des Gesundheitsministeriums zufolge sind rund
eine Million Chinesen mit dem HIV-Virus infiziert. Die Zahl der Infizierten
könnte bis 2010 auf zehn Millionen ansteigen, wenn nicht sofort
Gegenmaßnahmen ergriffen würden, sagte Zhang der Zeitung. "Wir dürfen
keine Zeit verlieren."
Die USA hatten China im Juni umgerechnet rund 14,8 Mio. Euro für
Aids-Forschungszwecke in den kommenden fünf Jahren in Aussicht gestellt.
Nach Angaben der Vereinten Nationen sind in China bereits 30.000 Menschen
an der Immunschwächekrankheit gestorben.
Im Oktober hatte UN-Generalsekretär Kofi Annan zentralchinesischen Stadt
Hangzhou erklärt, China stehe "an der Schwelle einer explosiven
Aids-Epidemie" und müsse sofort handeln, um eine potenzielle Katastrophe zu
verhindern. Ausländische Aktivisten werfen Peking seit langem vor, das
Ausmaß der Krankheit verschleiern zu wollen und die Behandlung von
HIV-Infizierten und Aids-Kranken zu vernachlässigen.
Gruß Dr.B
sorry
Quelle: N-TV.de
Gruß Dr.B
Quelle: N-TV.de
Gruß Dr.B
Investor Alert
A Form 4 regarding Calypte Biomedical Corp. has been filed with the United States Securities and Exchange Commission.
Click on the following hyperlink to view this filing:
http://www.calypte.com/INVESTORS/InvHme.html
Please Note: The hyperlink for the filing may not retrieve the filing if
the address extends to more than one line. If this should occur, please
copy the full text of the address for the filing into the address box in
your web browser.
_________________________________________________________
This email alert service uses proprietary list management software provided by CCBN.
JS200
A Form 4 regarding Calypte Biomedical Corp. has been filed with the United States Securities and Exchange Commission.
Click on the following hyperlink to view this filing:
http://www.calypte.com/INVESTORS/InvHme.html
Please Note: The hyperlink for the filing may not retrieve the filing if
the address extends to more than one line. If this should occur, please
copy the full text of the address for the filing into the address box in
your web browser.
_________________________________________________________
This email alert service uses proprietary list management software provided by CCBN.
JS200
Hallo zusammen
Im moment wenig bewegung
wird es Aufwärts gehen??
müssen aber erst gute Meldungen kommen!
hoffentlich bald
viel glück
kunokuhn
Im moment wenig bewegung
wird es Aufwärts gehen??
müssen aber erst gute Meldungen kommen!
hoffentlich bald
viel glück
kunokuhn
Hat Nancy 4,4 mio Aktien verkauft für 0,08 ?
Warum !
[Choose Font Size]SmallMediumRegular
KATZ NANCY E filed this 4 on 11/04/2002.
SEC Form 4 FORM 4
[ ] Check this box if no longer
subject to Section 16. Form 4 or Form
5 obligations may continue.
See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility
Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
--------------------------------------------------------------------------------
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden
hours per response. . . . . 0.5
1. Name and Address of Reporting Person*
Katz, Nancy
--------------------------------------------------------------------------------
(Last) (First) (Middle)
1265 Harbor Bay Parkway
--------------------------------------------------------------------------------
(Street)
Alameda, CA 94502
--------------------------------------------------------------------------------
(City) (State) (Zip)
2. Issuer Name
and Ticker or Trading Symbol
Calypte BioMedical Corp
Caly
--------------------------------------------------------------------------------
3. I.R.S. Identification
Number of Reporting
Person, if an entity
(voluntary) 4. Statement for
Month/Day/Year
10/31/2002
--------------------------------------------------------------------------------
5. If Amendment,
Date of Original
(Month/Day/Year)
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Description President and CEO
--------------------------------------------------------------------------------
7. Individual or Joint/Group
Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security
(Instr. 3)
2.Transaction
Date
(Month/Day/Year) 2A. Deemed Execution Date, if any
(Month/Day/Year) 3. Transaction
Code
(Instr. 8) 4. Securities Acquired (A) or Disposed Of (D)
(Instr. 3, 4, and 5) 5. Amount of
Securities
Beneficially
Owned Following
Reported Transaction(s)
(Instr. 3 and 4) 6. Owner-
ship
Form:
Direct (D)
or
Indirect (I)
(Instr. 4) 7. Nature of
Indirect
Beneficial
Ownership
(Instr. 4)
Code V Amount A/D Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 2. Conver-
sion or
Exercise
Price of
Deri-
vative
Security 3. Transaction Date
(Month/
Day/
Year) 3A. Deemed Execution Date, if any
(Month/
Day/
Year) 4. Transaction Code
(Instr.8) 5. Number of Derivative
Securities Acquired (A)
or Disposed Of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable(DE) and
Expiration Date(ED)
(Month/Day/Year) 7. Title and Amount of
Underlying Securities
(Instr. 3 and 4) 8. Price
of
Derivative
Security
(Instr.5) 9. Number of
Derivative
Securities
Beneficially
Owned
Following
Reported
Transaction(s)
(Instr.4) 10. Owner-
ship
Form of
Deriv-
ative
Securities:
Direct (D)
or
Indirect (I)
(Instr.4) 11. Nature of
Indirect
Beneficial
Ownership
(Instr.4)
Code V A D DE ED Title Amount or Number of Shares
Incentive Stock Option (right to buy) $0.08 10/31/2002 A 10/31/2002 10/31/2007 Common Stock $ 4,400,000 D
Explanation of Responses:
By:
/s/ Jerrold D. Dotson, attorney in fact 11/04/2002
** Signature of Reporting Person Date
SEC 1474 (8-02)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB Number.
Salut
Warum !
[Choose Font Size]SmallMediumRegular
KATZ NANCY E filed this 4 on 11/04/2002.
SEC Form 4 FORM 4
[ ] Check this box if no longer
subject to Section 16. Form 4 or Form
5 obligations may continue.
See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility
Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
--------------------------------------------------------------------------------
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden
hours per response. . . . . 0.5
1. Name and Address of Reporting Person*
Katz, Nancy
--------------------------------------------------------------------------------
(Last) (First) (Middle)
1265 Harbor Bay Parkway
--------------------------------------------------------------------------------
(Street)
Alameda, CA 94502
--------------------------------------------------------------------------------
(City) (State) (Zip)
2. Issuer Name
and Ticker or Trading Symbol
Calypte BioMedical Corp
Caly
--------------------------------------------------------------------------------
3. I.R.S. Identification
Number of Reporting
Person, if an entity
(voluntary) 4. Statement for
Month/Day/Year
10/31/2002
--------------------------------------------------------------------------------
5. If Amendment,
Date of Original
(Month/Day/Year)
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Description President and CEO
--------------------------------------------------------------------------------
7. Individual or Joint/Group
Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security
(Instr. 3)
2.Transaction
Date
(Month/Day/Year) 2A. Deemed Execution Date, if any
(Month/Day/Year) 3. Transaction
Code
(Instr. 8) 4. Securities Acquired (A) or Disposed Of (D)
(Instr. 3, 4, and 5) 5. Amount of
Securities
Beneficially
Owned Following
Reported Transaction(s)
(Instr. 3 and 4) 6. Owner-
ship
Form:
Direct (D)
or
Indirect (I)
(Instr. 4) 7. Nature of
Indirect
Beneficial
Ownership
(Instr. 4)
Code V Amount A/D Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 2. Conver-
sion or
Exercise
Price of
Deri-
vative
Security 3. Transaction Date
(Month/
Day/
Year) 3A. Deemed Execution Date, if any
(Month/
Day/
Year) 4. Transaction Code
(Instr.8) 5. Number of Derivative
Securities Acquired (A)
or Disposed Of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable(DE) and
Expiration Date(ED)
(Month/Day/Year) 7. Title and Amount of
Underlying Securities
(Instr. 3 and 4) 8. Price
of
Derivative
Security
(Instr.5) 9. Number of
Derivative
Securities
Beneficially
Owned
Following
Reported
Transaction(s)
(Instr.4) 10. Owner-
ship
Form of
Deriv-
ative
Securities:
Direct (D)
or
Indirect (I)
(Instr.4) 11. Nature of
Indirect
Beneficial
Ownership
(Instr.4)
Code V A D DE ED Title Amount or Number of Shares
Incentive Stock Option (right to buy) $0.08 10/31/2002 A 10/31/2002 10/31/2007 Common Stock $ 4,400,000 D
Explanation of Responses:
By:
/s/ Jerrold D. Dotson, attorney in fact 11/04/2002
** Signature of Reporting Person Date
SEC 1474 (8-02)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB Number.
Salut
geht es dabei nicht um optionen 2007 ?
16:22:55 0.137 5000 OTCBB at Ask
15:47:16 0.131 6000 OTCBB at Bid
15:47:00 0.135 5000 OTCBB
15:45:29 0.135 3000 OTCBB
16:22:55 0.137 5000 OTCBB at Ask
15:47:16 0.131 6000 OTCBB at Bid
15:47:00 0.135 5000 OTCBB
15:45:29 0.135 3000 OTCBB
meines erachtens hat nancy 4,4millionen stück optionen bis 2007 zu 0,08$ gezeichnet.....
von verkauf kann ich nichts lesen
ciao
steffen
von verkauf kann ich nichts lesen
ciao
steffen
Moin,
Ich schließe mich der Aussage von steffen an. Kauf-Option 4,4Mio Caly-Shares für 0,08$ zum 31.10.2007
AktieX
Ich schließe mich der Aussage von steffen an. Kauf-Option 4,4Mio Caly-Shares für 0,08$ zum 31.10.2007
AktieX
guten morgen
@all
sorry für die lästige Frage aber hat jemand nen Link für OTC realtimekurse außer reerealtime.com ??
Hab grad Format C: hinter mir!!!
sorry für die lästige Frage aber hat jemand nen Link für OTC realtimekurse außer reerealtime.com ??
Hab grad Format C: hinter mir!!!
@ intrader78
http://host.wallstreetcity.com/wsc2/Free_RT_Quotes.html?temp…
nur noch anmelden .
gruß Dr.B
http://host.wallstreetcity.com/wsc2/Free_RT_Quotes.html?temp…
nur noch anmelden .
gruß Dr.B
Keine NEWS in AUSSICHT ?????
Hier ist alles so ruhig????
JS200
Hier ist alles so ruhig????
JS200
15:43:22 0.148 130000 OTCBB at Ask
na - alle wieder wach
gruss fhr
na - alle wieder wach
gruss fhr
@dr.birdy
vielen Dank genau das hab ich gesucht!!
vielen Dank genau das hab ich gesucht!!
Von Gestern
CALY
CALYPTE BIOMEDICAL CP
0.132
+0.001 +0.76%
Daily Commentary
BUY
Our system recommends BUY as of today. Previous SELL recommendation was made on 10/30/2002 (6) days ago, when the stock price was 0.127. Since then the stock gained 3.94% .
Today the stock closed higher with an unchanged high and a lower low. The volume is extremely low. The security price is trending sideways.
The uptrend is not very strong. You may try your chance once more and buy this stock now, but be careful! Do not expect big profits and you do not have to necessarily wait for the next signal for realization. Cautious investors should stay at the sidelines.
Candlestick Analysis
Today’s Candlestick Patterns:
Long-Legged Doji
Today a Long-Legged Doji formed. The prices traded well above and below the session’s opening level, but closed virtually even with the open. Be careful, this is a sign of a great amount of volatility and indecision; the current trend may be about to stall!
Stock Quote
Last 0.132
Previous Close 0.131
Change +0.001
% Change +0.76%
Volume 427,800
Stock Activity
Open 0.132
Day`s High 0.137
Day`s Low 0.126
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -22.35
6 Month % Change 407.69
12 Month % Change -45.00
Stock Statistics
50 Day Close MA 0.119
200 Day Close MA 0.161
65 Day Volume MA 2,176,612
JS200
CALY
CALYPTE BIOMEDICAL CP
0.132
+0.001 +0.76%
Daily Commentary
BUY
Our system recommends BUY as of today. Previous SELL recommendation was made on 10/30/2002 (6) days ago, when the stock price was 0.127. Since then the stock gained 3.94% .
Today the stock closed higher with an unchanged high and a lower low. The volume is extremely low. The security price is trending sideways.
The uptrend is not very strong. You may try your chance once more and buy this stock now, but be careful! Do not expect big profits and you do not have to necessarily wait for the next signal for realization. Cautious investors should stay at the sidelines.
Candlestick Analysis
Today’s Candlestick Patterns:
Long-Legged Doji
Today a Long-Legged Doji formed. The prices traded well above and below the session’s opening level, but closed virtually even with the open. Be careful, this is a sign of a great amount of volatility and indecision; the current trend may be about to stall!
Stock Quote
Last 0.132
Previous Close 0.131
Change +0.001
% Change +0.76%
Volume 427,800
Stock Activity
Open 0.132
Day`s High 0.137
Day`s Low 0.126
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -22.35
6 Month % Change 407.69
12 Month % Change -45.00
Stock Statistics
50 Day Close MA 0.119
200 Day Close MA 0.161
65 Day Volume MA 2,176,612
JS200
geht es heute ab ?
@SPEKU
WOHIN ?????
JS200
WOHIN ?????
JS200
und warum sollt Caly sich heut bewegen??? gibt es was neues?? mfg. MH
ja!!!
aber warum denn nur???
erwartungsvoller gruß
M1
aber warum denn nur???
erwartungsvoller gruß
M1
das einzige was abgeht - ist in spekus hose
auch ohne caly test
gruss fhr
auch ohne caly test
gruss fhr
warum kauft eigentlich keiner meine stücke zu 0.55 in münchen - würde meinem depot gut stehen
gruss fhr
gruss fhr
Von Gestern
CALY
CALYPTE BIOMEDICAL CP
0.131
-0.001 -0.76%
Daily Commentary
HOLD
Our system recommends HOLD as of today. Previous BUY recommendation was made on 11/6/2002 (0) days ago, when the stock price was 0.131. Since then the stock gained 0.00% .
Today the stock closed lower with a lower high and a higher low (sign of decrease in volatility). The volume is extremely low. The security price is trending up.
Candlestick Analysis
Today’s Candlestick Patterns:
Short Black Candlestick
Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation
Stock Quote
Last 0.131
Previous Close 0.132
Change -0.001
% Change -0.76%
Volume 340,600
Stock Activity
Open 0.132
Day`s High 0.132
Day`s Low 0.128
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -15.48
6 Month % Change 403.85
12 Month % Change -40.45
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.161
65 Day Volume MA 2,165,231
JS200
CALY
CALYPTE BIOMEDICAL CP
0.131
-0.001 -0.76%
Daily Commentary
HOLD
Our system recommends HOLD as of today. Previous BUY recommendation was made on 11/6/2002 (0) days ago, when the stock price was 0.131. Since then the stock gained 0.00% .
Today the stock closed lower with a lower high and a higher low (sign of decrease in volatility). The volume is extremely low. The security price is trending up.
Candlestick Analysis
Today’s Candlestick Patterns:
Short Black Candlestick
Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation
Stock Quote
Last 0.131
Previous Close 0.132
Change -0.001
% Change -0.76%
Volume 340,600
Stock Activity
Open 0.132
Day`s High 0.132
Day`s Low 0.128
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -15.48
6 Month % Change 403.85
12 Month % Change -40.45
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.161
65 Day Volume MA 2,165,231
JS200
hi calypter...
schaut mal auf blink models [875656], da tut sich was
PS: nur so`n tip......
schaut mal auf blink models [875656], da tut sich was
PS: nur so`n tip......
hallo Jojo, morphoys, David,JasminB, Bittermoon...
wo seid ihr alle.
Schade das mann so wenig mehr von euch sieht!.
Seid Ihr nicht mehr in Caly inv?.
Gebt mal ein Lebenszeichen von Euch
Der Amberger
wo seid ihr alle.
Schade das mann so wenig mehr von euch sieht!.
Seid Ihr nicht mehr in Caly inv?.
Gebt mal ein Lebenszeichen von Euch
Der Amberger
Press Release Source: OraSure Technologies, Inc.
OraSure Receives FDA Approval for OraQuick Rapid HIV-1 Test
Thursday November 7, 1:05 pm ET
Investor Conference Call and Press Conference at 2:15 P.M. Eastern Time
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 7, 2002--OraSure Technologies, Inc. (Nasdaq:OSUR - News), the market leader in oral fluid diagnostics, announced today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its OraQuick® Rapid HIV-1 Antibody Test.
OraSure Receives FDA Approval for OraQuick Rapid HIV-1 Test
Thursday November 7, 1:05 pm ET
Investor Conference Call and Press Conference at 2:15 P.M. Eastern Time
BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 7, 2002--OraSure Technologies, Inc. (Nasdaq:OSUR - News), the market leader in oral fluid diagnostics, announced today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its OraQuick® Rapid HIV-1 Antibody Test.
@ DerAmberger
Bin weiter investiert und bleibe auch bis zum bitteren Ende.
Leider hab ich zur Zeit viel Arbeit und kann nicht immer
vor dem PC sitzen.
Werde mich aber wieder melden!
Gruss an alle.
David
Bin weiter investiert und bleibe auch bis zum bitteren Ende.
Leider hab ich zur Zeit viel Arbeit und kann nicht immer
vor dem PC sitzen.
Werde mich aber wieder melden!
Gruss an alle.
David
Investor Alert
A Form 5 regarding Calypte Biomedical Corp. has been filed with the United States Securities and Exchange Commission.
Click on the following hyperlink to view this filing:
http://www.calypte.com/INVESTORS/InvHme.html
Please Note: The hyperlink for the filing may not retrieve the filing if
the address extends to more than one line. If this should occur, please
copy the full text of the address for the filing into the address box in
your web browser.
_________________________________________________________
JS200
A Form 5 regarding Calypte Biomedical Corp. has been filed with the United States Securities and Exchange Commission.
Click on the following hyperlink to view this filing:
http://www.calypte.com/INVESTORS/InvHme.html
Please Note: The hyperlink for the filing may not retrieve the filing if
the address extends to more than one line. If this should occur, please
copy the full text of the address for the filing into the address box in
your web browser.
_________________________________________________________
JS200
@amberger
müssen wohl alle die Verluste wieder reinarbeiten!!
müssen wohl alle die Verluste wieder reinarbeiten!!
14:09:48 0.130 5000 OTCBB at Ask
14:09:15 0.130 5000 OTCBB at Ask
14:08:33 0.130 10000 OTCBB at Ask
14:08:11 0.130 5000 OTCBB at Ask
14:03:27 0.127 15600 OTCBB
14:01:27 0.130 1000 OTCBB at Ask
13:53:59 0.130 10000 OTCBB at Ask
13:43:34 0.126 100 OTCBB at Bid
13:39:24 0.129 5000 OTCBB at Ask
13:39:24 0.130 5000 OTCBB at Ask
Volume: 296,900
Bid: 0.126
Ask: 0.130
%Change: -0.8%
14:09:15 0.130 5000 OTCBB at Ask
14:08:33 0.130 10000 OTCBB at Ask
14:08:11 0.130 5000 OTCBB at Ask
14:03:27 0.127 15600 OTCBB
14:01:27 0.130 1000 OTCBB at Ask
13:53:59 0.130 10000 OTCBB at Ask
13:43:34 0.126 100 OTCBB at Bid
13:39:24 0.129 5000 OTCBB at Ask
13:39:24 0.130 5000 OTCBB at Ask
Volume: 296,900
Bid: 0.126
Ask: 0.130
%Change: -0.8%
chapter 11
shit!!!!!!!!!!!!!
shit!!!!!!!!!!!!!
@steffen
Wo steht das ?
Gruß
Wo steht das ?
Gruß
Was ist denn bei Caly LOS ???????
JS200
JS200
nischt is los......
hab mich nur so einsam gefühlt!
hab mich nur so einsam gefühlt!
Hallo Steffen nicht weinen
bin doch auch noch da habe viel um die Ohren aber wenn Ihr möchtet und nicht mehr Böse auf mich seit werde ich wieder
etwas Stimmung in diesen Thread bringen !!???
mfg jojo
Eines Tages Ihr werdet es sehn wird Caly wieder hoch am Himmel stehn !!
habet Gedukd es dauert nicht mehr lang dann ist auch Caly wieder mit steigen dran
Caly ist schon Längst zur Kultaktie mutiert !!!!!!
Gut News werden in nicht alt zu langer Ferne kommen
denn Ihr habt was Übersehn
bin doch auch noch da habe viel um die Ohren aber wenn Ihr möchtet und nicht mehr Böse auf mich seit werde ich wieder
etwas Stimmung in diesen Thread bringen !!???
mfg jojo
Eines Tages Ihr werdet es sehn wird Caly wieder hoch am Himmel stehn !!
habet Gedukd es dauert nicht mehr lang dann ist auch Caly wieder mit steigen dran
Caly ist schon Längst zur Kultaktie mutiert !!!!!!
Gut News werden in nicht alt zu langer Ferne kommen
denn Ihr habt was Übersehn
Caly vollzieht bei 0,12 eine seitwärtsbewegung ca. 4 handelstage noch dann klettert sie wieder hoch auf 0,15
um von da aus neue hürden zu erklimmen !!!!
LANDAU MARTIN files Form 5, Annual Statement of Changes in Beneficial Ownership of CALYPTE BIOMEDICAL CORP
--------------------------------------------------------------------------------
SEC Form 5 FORM 5
[X] Check this box if no longer
subject to Section 16. Form 4 or Form 5 obligations may continue.
See Instruction 1(b).
[ ] Form 3 Holdings Reported
[ ] Form 4 Transactions Reported UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility
Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
OMB APPROVAL
--------------------------------------------------------------------------------
OMB Number: 3235-0362
Expires: January 31, 2005
Estimated average burden
hours per response. . . . . 1.0
1. Name and Address of Reporting Person *
Landau, Martin
--------------------------------------------------------------------------------
(Last) (First) (Middle)
1265 Harbor Bay Parkway
--------------------------------------------------------------------------------
(Street)
Alameda, CA 94502
--------------------------------------------------------------------------------
(City) (State) (Zip)
2. Issuer Name
and Ticker or Trading Symbol
Calypte BioMedical Corp
Caly
--------------------------------------------------------------------------------
3. I.R.S. Identification
Number of Reporting
Person, if an entity
(voluntary) 4. Statement for
Month/Day/Year
11/05/2002
--------------------------------------------------------------------------------
5. If Amendment,
Date of Original
(Month/Day/Year)
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
Description
--------------------------------------------------------------------------------
7. Individual or Joint/Group
Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security
(Instr. 3)
2.Transaction
Date
(Month/Day/Year) 3. Transaction
Code
(Instr. 8) 4. Securities Acquired (A) or Disposed Of (D)
(Instr. 3, 4, and 5)
--------------------------------------------------------------------------------
Amount / A/D / Price 5. Amount of
Securities
Beneficially
Owned at end of
Issuer`s Fiscal Year
(Instr. 3 and 4) 6. Owner-
ship
Form:
Direct (D)
or
Indirect (I)
(Instr. 4) 7. Nature of
Indirect
Beneficial
Ownership
(Instr. 4)
/ / $
--------------------------------------------------------------------------------
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 2. Conver-
sion or
Exercise
Price of
Deri-
vative
Security 3. Transaction Date
(Month/
Day/
Year) 4. Transaction Code
(Instr.8) 5. Number of Derivative
Securities Acquired (A)
or Disposed Of (D)
(Instr. 3, 4 and 5)
--------------------------------------------------------------------------------
A or D 6. Date Exercisable(DE) and
Expiration Date(ED)
(Month/Day/Year)
--------------------------------------------------------------------------------
DE / ED 7. Title and Amount of
Underlying Securities
(Instr. 3 and 4)
--------------------------------------------------------------------------------
Title / Amount or Number of Shares 8. Price
of
Derivative
Security
(Instr.5) 9. Number of
Derivative
Securities
Beneficially
Owned
at End of Year
Reported
Transaction(s)
(Instr.4) 10. Owner-
ship
Form of
Deriv-
ative
Securities:
Direct (D)
or
Indirect (I)
(Instr.4) 11. Nature of
Indirect
Beneficial
Ownership
(Instr.4)
$ / / $
Explanation of Responses:
By:
/s/ Jerrold D. Dotson, attorney-in-fact 11/07/2002
** Signature of Reporting Person Date
SEC 2270 (7-02)
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB Number.
--------------------------------------------------------------------------------
End of News Created by: EDGARPro.com
Copyright 2002, EDGAR Online, Inc. All rights reserved. Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
um von da aus neue hürden zu erklimmen !!!!
LANDAU MARTIN files Form 5, Annual Statement of Changes in Beneficial Ownership of CALYPTE BIOMEDICAL CORP
--------------------------------------------------------------------------------
SEC Form 5 FORM 5
[X] Check this box if no longer
subject to Section 16. Form 4 or Form 5 obligations may continue.
See Instruction 1(b).
[ ] Form 3 Holdings Reported
[ ] Form 4 Transactions Reported UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility
Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
OMB APPROVAL
--------------------------------------------------------------------------------
OMB Number: 3235-0362
Expires: January 31, 2005
Estimated average burden
hours per response. . . . . 1.0
1. Name and Address of Reporting Person *
Landau, Martin
--------------------------------------------------------------------------------
(Last) (First) (Middle)
1265 Harbor Bay Parkway
--------------------------------------------------------------------------------
(Street)
Alameda, CA 94502
--------------------------------------------------------------------------------
(City) (State) (Zip)
2. Issuer Name
and Ticker or Trading Symbol
Calypte BioMedical Corp
Caly
--------------------------------------------------------------------------------
3. I.R.S. Identification
Number of Reporting
Person, if an entity
(voluntary) 4. Statement for
Month/Day/Year
11/05/2002
--------------------------------------------------------------------------------
5. If Amendment,
Date of Original
(Month/Day/Year)
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
Description
--------------------------------------------------------------------------------
7. Individual or Joint/Group
Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security
(Instr. 3)
2.Transaction
Date
(Month/Day/Year) 3. Transaction
Code
(Instr. 8) 4. Securities Acquired (A) or Disposed Of (D)
(Instr. 3, 4, and 5)
--------------------------------------------------------------------------------
Amount / A/D / Price 5. Amount of
Securities
Beneficially
Owned at end of
Issuer`s Fiscal Year
(Instr. 3 and 4) 6. Owner-
ship
Form:
Direct (D)
or
Indirect (I)
(Instr. 4) 7. Nature of
Indirect
Beneficial
Ownership
(Instr. 4)
/ / $
--------------------------------------------------------------------------------
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 2. Conver-
sion or
Exercise
Price of
Deri-
vative
Security 3. Transaction Date
(Month/
Day/
Year) 4. Transaction Code
(Instr.8) 5. Number of Derivative
Securities Acquired (A)
or Disposed Of (D)
(Instr. 3, 4 and 5)
--------------------------------------------------------------------------------
A or D 6. Date Exercisable(DE) and
Expiration Date(ED)
(Month/Day/Year)
--------------------------------------------------------------------------------
DE / ED 7. Title and Amount of
Underlying Securities
(Instr. 3 and 4)
--------------------------------------------------------------------------------
Title / Amount or Number of Shares 8. Price
of
Derivative
Security
(Instr.5) 9. Number of
Derivative
Securities
Beneficially
Owned
at End of Year
Reported
Transaction(s)
(Instr.4) 10. Owner-
ship
Form of
Deriv-
ative
Securities:
Direct (D)
or
Indirect (I)
(Instr.4) 11. Nature of
Indirect
Beneficial
Ownership
(Instr.4)
$ / / $
Explanation of Responses:
By:
/s/ Jerrold D. Dotson, attorney-in-fact 11/07/2002
** Signature of Reporting Person Date
SEC 2270 (7-02)
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB Number.
--------------------------------------------------------------------------------
End of News Created by: EDGARPro.com
Copyright 2002, EDGAR Online, Inc. All rights reserved. Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
hi jojo
was denn übersehn ?????
16:09:11 0.128 30000 OTCBB
16:01:21 0.122 5000 OTCBB at Ask
16:01:50 0.121 134000 OTCBB
16:00:40 0.122 1000 OTCBB at Ask
16:00:23 0.122 15000 OTCBB
16:00:56 0.122 25000 OTCBB
15:59:31 0.123 10000 OTCBB at Ask
15:59:06 0.123 1000 OTCBB at Ask
15:59:46 0.123 6000 OTCBB at Ask
15:59:46 0.123 5000 OTCBB at Ask
%Change: -6.2%
Bid: 0.121
Ask: 0.122
JS200
CALY
CALYPTE BIOMEDICAL CP
0.123
-0.008 -6.11%
Daily Commentary
SELL
Our system recommends SELL as of today. Previous BUY recommendation was made on 11/6/2002 (1) days ago, when the stock price was 0.131. Since then the stock fell -6.11% .
Today the stock closed lower, at its low (sign of weakness) with a lower high and a lower low. The volume is extremely low. The security price is trending sideways.
There is a strong downward move that turned down all the moving averages. This may be a sign of a new downtrend. It is still not too late to sell this stock.
Candlestick Analysis
Today’s Candlestick Patterns:
Black Candlestick
Today a Black Candlestick formed. Sellers were in control but the selling pressure was not very strong.
Stock Quote
Last 0.123
Previous Close 0.131
Change -0.008
% Change -6.11%
Volume 785,500
Stock Activity
Open 0.130
Day`s High 0.131
Day`s Low 0.123
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -25.45
6 Month % Change 310.00
12 Month % Change -44.09
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.161
65 Day Volume MA 2,165,906
JS200
CALY
CALYPTE BIOMEDICAL CP
0.123
-0.008 -6.11%
Daily Commentary
SELL
Our system recommends SELL as of today. Previous BUY recommendation was made on 11/6/2002 (1) days ago, when the stock price was 0.131. Since then the stock fell -6.11% .
Today the stock closed lower, at its low (sign of weakness) with a lower high and a lower low. The volume is extremely low. The security price is trending sideways.
There is a strong downward move that turned down all the moving averages. This may be a sign of a new downtrend. It is still not too late to sell this stock.
Candlestick Analysis
Today’s Candlestick Patterns:
Black Candlestick
Today a Black Candlestick formed. Sellers were in control but the selling pressure was not very strong.
Stock Quote
Last 0.123
Previous Close 0.131
Change -0.008
% Change -6.11%
Volume 785,500
Stock Activity
Open 0.130
Day`s High 0.131
Day`s Low 0.123
52 Week High 0.370
52 Week Low 0.024
Stock Price History
3 Month % Change -25.45
6 Month % Change 310.00
12 Month % Change -44.09
Stock Statistics
50 Day Close MA 0.118
200 Day Close MA 0.161
65 Day Volume MA 2,165,906
JS200
Hallo Leute,
melde mich auch mal wieder zu Wort, leider schläft die Konkurrenz von Caly nicht:
Freitag, 8. November 2002
Ergebnis nach 20 Minuten
Schneller Aids-Test genehmigt
Die US-Gesundheitsbehörden haben einen neuen Aids-Schnelltest genehmigt, der bereits nach zwanzig Minuten ein verlässliches Ergebnis liefert.
Wie die US-amerikanische Gesundheitsbehörde FDA in Washington mitteilte, erreicht das neue Produkt "OraQuick" eine Ergebnisgenauigkeit von 96,6 Prozent.
Ähnliche HIV-Schnelltests galten bisher als nicht zuverlässig, Tests, die verlässliche Ergebnisse liefern, brauchen üblicherweise mehrere Tage.
Quelle: http://www.n-tv.de/3078602.html
Steht leider nix über den Hersteller drin.
melde mich auch mal wieder zu Wort, leider schläft die Konkurrenz von Caly nicht:
Freitag, 8. November 2002
Ergebnis nach 20 Minuten
Schneller Aids-Test genehmigt
Die US-Gesundheitsbehörden haben einen neuen Aids-Schnelltest genehmigt, der bereits nach zwanzig Minuten ein verlässliches Ergebnis liefert.
Wie die US-amerikanische Gesundheitsbehörde FDA in Washington mitteilte, erreicht das neue Produkt "OraQuick" eine Ergebnisgenauigkeit von 96,6 Prozent.
Ähnliche HIV-Schnelltests galten bisher als nicht zuverlässig, Tests, die verlässliche Ergebnisse liefern, brauchen üblicherweise mehrere Tage.
Quelle: http://www.n-tv.de/3078602.html
Steht leider nix über den Hersteller drin.
Hier der Link zur Firma!!!
www.mirates.com
www.mirates.com
urintest wird von den zu prüfenden bevorzugt! das ist fakt...
vom speicheltest (oraltest-ORASURE,ORAQUICK) habe ich keine ahnung...
außerdem ist der markt so groß, daß caly allemal mit dem urintest, der schneller werden soll, genug absatz finden sollte! (siehe china, westafrika...)
ciao
steffen
vom speicheltest (oraltest-ORASURE,ORAQUICK) habe ich keine ahnung...
außerdem ist der markt so groß, daß caly allemal mit dem urintest, der schneller werden soll, genug absatz finden sollte! (siehe china, westafrika...)
ciao
steffen
Falsche Firma!!!Nicht Mirates sonders ORASURE!
WKN: 881351
Ich persönlich finde einen Speicheltest jedenfalls noch angenehmer als in einen Becher zu pinkeln. Eigentlich schade, hatte mir von Caly mehr versprochen!!!
Was meint ihr????
WKN: 881351
Ich persönlich finde einen Speicheltest jedenfalls noch angenehmer als in einen Becher zu pinkeln. Eigentlich schade, hatte mir von Caly mehr versprochen!!!
Was meint ihr????
Ausserdem haben die einen finanzkräftigen Partner wie Abbott Laboratories dahinterstehen. Warum hat sich Abbott nicht für Caly entschieden???
Dow Jones Business News
FDA Approves OraSure`s New Rapid HIV Test Kit
Thursday November 7, 4:09 pm ET
By Otesa Middleton
Dow Jones Newswires
WASHINGTON -- A new, 20-minute HIV test kit received Food and Drug Administration approval Thursday.
The OraQuick Rapid HIV-1 antibody test, made by OraSure Technologies Inc. (NasdaqNM:OSUR - News) , Bethlehem, Pa., requires no special equipment, can be stored at room temperature and may later be approved for use outside the doctor`s office.
U.S. Health and Human Services Secretary Tommy Thompson announced the approval of the test, which uses a finger stick device similar to the type used by diabetics to test blood sugar.
OraSure Technologies said it is seeking further authorization to sell the HIV test kits to clinics and counseling centers, in addition to laboratories and physicians` offices.
OraSure`s test, which requires only one drop of blood from a finger prick, is 99.6% effective. The FDA approved the test for use in the 40,000 locations certified to perform these types of tests. The company said it has asked the FDA to review its plans for testing the device so it can be used in a wider range of centers. The Centers for Medicare and Medicaid will have to approve such a waiver.
HHS Secretary Thompson urged OraSure to apply for the waiver at a press conference Thursday. "Please ask for this waiver [so the test can] be given in more places," he said.
The first 50,000 OraQuick devices will be sold to Abbott Laboratories for distribution within 45 days, said Mike Gausling, OraSure`s chief executive.
The OraQuick test requires users to prick their finger, take a drop of blood and dip it in a solution. A testing strip then is placed in the solution. One line indicates the person is HIV-negative, and two lines mean the person is HIV- positive. If the test is done incorrectly, no lines appear.
Like other tests, OraQuick doesn`t directly test for the virus. Instead, the device looks for antibodies, whose presence are an indication that the body`s immune system is trying to fight off the infection. It takes up to three months for the body to produce a detectable amount of antibodies.
The 20-minute OraQuick test is considered simpler than the currently approved rapid test from Murex Diagnostics Inc., Norcross, Ga.
Up to one-quarter of people who come in for HIV testing balk at the two-week wait for results and never come back, Mr. Gausling said. Health officials hope OraQuick can help prevent transmission of the virus by giving quick and easy results.
"This test adds an extra dimension to our armamentarium," said Dr. Anthony Fauci, director of the National Institutes of Health`s Institute of Allergy and Infectious Diseases.
Expectant mothers can be tested in the delivery room so drugs can be administered to prevent mother-to-child HIV transmission. Also, health workers who accidentally stick themselves with possibly contaminated needles can almost immediately determine a patient`s HIV status in order to determine if preventive therapy needs to be started, Dr. Fauci said.
Mr. Gausling said OraQuick`s price will be competitive with those of tests given at public health centers, which he said run about $20.
Next, the company plans to seek approval of an even simpler saliva HIV test.
-By Otesa Middleton, Dow Jones Newswires; 202-862-6654; otesa.middleton@ dowjones.com
Dow Jones Business News
FDA Approves OraSure`s New Rapid HIV Test Kit
Thursday November 7, 4:09 pm ET
By Otesa Middleton
Dow Jones Newswires
WASHINGTON -- A new, 20-minute HIV test kit received Food and Drug Administration approval Thursday.
The OraQuick Rapid HIV-1 antibody test, made by OraSure Technologies Inc. (NasdaqNM:OSUR - News) , Bethlehem, Pa., requires no special equipment, can be stored at room temperature and may later be approved for use outside the doctor`s office.
U.S. Health and Human Services Secretary Tommy Thompson announced the approval of the test, which uses a finger stick device similar to the type used by diabetics to test blood sugar.
OraSure Technologies said it is seeking further authorization to sell the HIV test kits to clinics and counseling centers, in addition to laboratories and physicians` offices.
OraSure`s test, which requires only one drop of blood from a finger prick, is 99.6% effective. The FDA approved the test for use in the 40,000 locations certified to perform these types of tests. The company said it has asked the FDA to review its plans for testing the device so it can be used in a wider range of centers. The Centers for Medicare and Medicaid will have to approve such a waiver.
HHS Secretary Thompson urged OraSure to apply for the waiver at a press conference Thursday. "Please ask for this waiver [so the test can] be given in more places," he said.
The first 50,000 OraQuick devices will be sold to Abbott Laboratories for distribution within 45 days, said Mike Gausling, OraSure`s chief executive.
The OraQuick test requires users to prick their finger, take a drop of blood and dip it in a solution. A testing strip then is placed in the solution. One line indicates the person is HIV-negative, and two lines mean the person is HIV- positive. If the test is done incorrectly, no lines appear.
Like other tests, OraQuick doesn`t directly test for the virus. Instead, the device looks for antibodies, whose presence are an indication that the body`s immune system is trying to fight off the infection. It takes up to three months for the body to produce a detectable amount of antibodies.
The 20-minute OraQuick test is considered simpler than the currently approved rapid test from Murex Diagnostics Inc., Norcross, Ga.
Up to one-quarter of people who come in for HIV testing balk at the two-week wait for results and never come back, Mr. Gausling said. Health officials hope OraQuick can help prevent transmission of the virus by giving quick and easy results.
"This test adds an extra dimension to our armamentarium," said Dr. Anthony Fauci, director of the National Institutes of Health`s Institute of Allergy and Infectious Diseases.
Expectant mothers can be tested in the delivery room so drugs can be administered to prevent mother-to-child HIV transmission. Also, health workers who accidentally stick themselves with possibly contaminated needles can almost immediately determine a patient`s HIV status in order to determine if preventive therapy needs to be started, Dr. Fauci said.
Mr. Gausling said OraQuick`s price will be competitive with those of tests given at public health centers, which he said run about $20.
Next, the company plans to seek approval of an even simpler saliva HIV test.
-By Otesa Middleton, Dow Jones Newswires; 202-862-6654; otesa.middleton@ dowjones.com
marleen,
ansichtssache!
meines erachtens ist durch den speicheltest immernoch der direkte kontakt mit dem teststreifen! direkte kontakte mit nadeln (es sind in der verhangenheit ja auch schon infektionen durch -versehentliche?- mehrfachbenutzung vorgekommen, ich denke daß weißt du...) sind EIN grund für die inakzeptanz des bluttests.
think about...
ich selbst würde im falle eines tests lieber in einen "becher pinkeln" statt mir mit einem -wahrscheinlich- unbenutzten streifen im mund rumgiegeln zu lassen.
PS: man beachte das volumen, unter dem caly gefallen ist! nicht der rede wert (im schnitt 300K - 800K). man nennt dies auch konsolidierung. unter der teppich sollte man auch die prognose von 25-50% revenueplus nicht kehren, diese prognose kann man nicht machen, wenn nicht schon dementsprechen aufträge in der pipeline wäre...
steffen (der nicht pumpen muß)
ansichtssache!
meines erachtens ist durch den speicheltest immernoch der direkte kontakt mit dem teststreifen! direkte kontakte mit nadeln (es sind in der verhangenheit ja auch schon infektionen durch -versehentliche?- mehrfachbenutzung vorgekommen, ich denke daß weißt du...) sind EIN grund für die inakzeptanz des bluttests.
think about...
ich selbst würde im falle eines tests lieber in einen "becher pinkeln" statt mir mit einem -wahrscheinlich- unbenutzten streifen im mund rumgiegeln zu lassen.
PS: man beachte das volumen, unter dem caly gefallen ist! nicht der rede wert (im schnitt 300K - 800K). man nennt dies auch konsolidierung. unter der teppich sollte man auch die prognose von 25-50% revenueplus nicht kehren, diese prognose kann man nicht machen, wenn nicht schon dementsprechen aufträge in der pipeline wäre...
steffen (der nicht pumpen muß)
@ calys
sieht nicht gut aus .......gar nicht gut
Last:
0.106
High:
0.115
Low:
0.106
Open:
0.112
Change:
-0.02
Volume:
773,300
Bid:
0.100
Ask:
0.107
Bid/Ask Size:
5,000 / 5,000
52 Wk High:
0.430
52 Wk Low:
0.012
%Change:
-13.9%
Market Cap:
N/A
Price/Sales:
N/A
EPS:
$0.00
P/E Ratio:
N/A
Quotes provided by S&P Comstock
11/08/02 - 10:11 a.m. Eastern -- No Quote Delay.
Last 10 trades
Time
Price
Volume
Exchange
Info
10:11:52
0.106
20000
OTCBB
at Ask
10:11:52
0.107
20000
OTCBB
at Ask
10:10:19
0.106
1000
OTCBB
10:09:40
0.106
10000
OTCBB
10:09:21
0.106
3000
OTCBB
10:09:21
0.107
3000
OTCBB
10:07:59
0.108
6300
OTCBB
10:05:32
0.109
5000
OTCBB
10:05:21
0.109
5000
OTCBB
10:04:44
0.109
5000
OTCBB
sieht nicht gut aus .......gar nicht gut
Last:
0.106
High:
0.115
Low:
0.106
Open:
0.112
Change:
-0.02
Volume:
773,300
Bid:
0.100
Ask:
0.107
Bid/Ask Size:
5,000 / 5,000
52 Wk High:
0.430
52 Wk Low:
0.012
%Change:
-13.9%
Market Cap:
N/A
Price/Sales:
N/A
EPS:
$0.00
P/E Ratio:
N/A
Quotes provided by S&P Comstock
11/08/02 - 10:11 a.m. Eastern -- No Quote Delay.
Last 10 trades
Time
Price
Volume
Exchange
Info
10:11:52
0.106
20000
OTCBB
at Ask
10:11:52
0.107
20000
OTCBB
at Ask
10:10:19
0.106
1000
OTCBB
10:09:40
0.106
10000
OTCBB
10:09:21
0.106
3000
OTCBB
10:09:21
0.107
3000
OTCBB
10:07:59
0.108
6300
OTCBB
10:05:32
0.109
5000
OTCBB
10:05:21
0.109
5000
OTCBB
10:04:44
0.109
5000
OTCBB
10:14:48
0.103
5000
OTCBB
10:12:46
0.103
2000
OTCBB
10:12:46
0.105
2000
OTCBB
10:12:46
0.103
10000
OTCBB
10:12:46
0.105
10000
OTCBB
10:12:59
0.105
5000
OTCBB
10:11:12
0.106
10000
OTCBB
10:11:52
0.106
20000
OTCBB
at Ask
10:11:52
0.107
20000
OTCBB
at Ask
10:10:19
0.106
1000
OTCBB
0.103
5000
OTCBB
10:12:46
0.103
2000
OTCBB
10:12:46
0.105
2000
OTCBB
10:12:46
0.103
10000
OTCBB
10:12:46
0.105
10000
OTCBB
10:12:59
0.105
5000
OTCBB
10:11:12
0.106
10000
OTCBB
10:11:52
0.106
20000
OTCBB
at Ask
10:11:52
0.107
20000
OTCBB
at Ask
10:10:19
0.106
1000
OTCBB
@ calys
falls das noch jemanden interessiert
glaube nicht das 0,10 $ halten
Last:
0.100
High:
0.115
Low:
0.100
Open:
0.112
Change:
-0.03
Volume:
1,061,900
Bid:
0.050
Ask:
0.140
Bid/Ask Size:
5,000 / 5,000
52 Wk High:
0.430
52 Wk Low:
0.012
%Change:
-18.7%
Market Cap:
N/A
Price/Sales:
N/A
EPS:
$0.00
P/E Ratio:
N/A
falls das noch jemanden interessiert
glaube nicht das 0,10 $ halten
Last:
0.100
High:
0.115
Low:
0.100
Open:
0.112
Change:
-0.03
Volume:
1,061,900
Bid:
0.050
Ask:
0.140
Bid/Ask Size:
5,000 / 5,000
52 Wk High:
0.430
52 Wk Low:
0.012
%Change:
-18.7%
Market Cap:
N/A
Price/Sales:
N/A
EPS:
$0.00
P/E Ratio:
N/A
Tja, die Nachricht wirkt sich wohl doch negativer auf Caly aus als gedacht.
diese nachricht ist unser ende. bin damals zu 26 cent rein. die sehe ich nie wieder. lieber mit 70% verlust verkaufen, als gar nicht mehr...
wir haben leider alle auf das falsche pferd gesetzt!!!!
außer caly zieht jetzt nach und präsentiert einen finanzkräftigen investor!!!
wir haben leider alle auf das falsche pferd gesetzt!!!!
außer caly zieht jetzt nach und präsentiert einen finanzkräftigen investor!!!
wers kapiert hat, was seit Monaten bzw. Jahren hier abläuft macht doch ganz gut Kohle mit Caly.....anstiegt +100% und mehr...dann voller Einbruch auf alte Kurse und nach ein paar Wochen oder Monaten wieder 100% und mehr....
Man muß einfach nur im richtigen Moment kaufen und verkaufen. Mehr taugt diese Scheis Aktie nicht!!!
Wenn die noch lange so rumblödeln ist die Konkurenz schneller und bringt ein mindestens gleichwertiges Produkt auf dem Markt. Das wird dann auch besser vermarktet wird weil Sie mehr Kohle reinstecken können.
Schon ist diese klitsche wertlos......
Cataldo wird das eh scheis egal sein...Er hat ja seine Stücke zu 0,01$ gekauft......wenn er sie bei 0,05 raushaut hat er sogar noch 400% gemacht und kann beruhigt gehen!!!
Wenn das wirklich so aussichtsreich wäre wie hier viele denken.....warum müss dann der Kurs über 70% gedrückt werden (0,42$--0.08$) um überhaupt einen Investor zu finden. Jetzt sind die Investoren drin und was passiert---- genau NIX!!!!!!! das alte Spiel!!!
Welcher seriöse Investor investiert den da schon.
Zigg Conference Calls bzw. Investor conference wurden angehalten....und ERGEBNIS!!!!!!!!
Also nicht jammern...Caly taugt nur zum ZOCKEN...das muss doch langsam jeder begreifen.
Ich hoffe nur noch das es irgendwann mal richtig nachhaltig aufwärts geht...glauben kann ich leider nicht mehr dran!!!
Viel Spaß noch.....nexte Wochen wieder 0.06-0.08 $
10:33am ET
0.099
0.02 (19.51%)
Day`s Range: 0.099 - 0.115
Day`s Volume: 1,519,800
Avg. Volume: 2,226,342
JS200
0.099
0.02 (19.51%)
Day`s Range: 0.099 - 0.115
Day`s Volume: 1,519,800
Avg. Volume: 2,226,342
JS200
@joelu
tja diese Caly Hirnies haben ja lange genug Zeit gehabt um Ihr Produkt boomen zu lassen.
FDA Zulassung und 99.98% Sicherheit
das ich nicht lache.......und dann nicht mal an den Mann bzw. Frau bringen ist doch mangelhaft oder einfach DUMM!!!
tja diese Caly Hirnies haben ja lange genug Zeit gehabt um Ihr Produkt boomen zu lassen.
FDA Zulassung und 99.98% Sicherheit
das ich nicht lache.......und dann nicht mal an den Mann bzw. Frau bringen ist doch mangelhaft oder einfach DUMM!!!
verkauft nur alle
ende 4.quartal kauft ihr alle wieder nach .....
und wech (wie wäre es mit goldaktien?)
ende 4.quartal kauft ihr alle wieder nach .....
und wech (wie wäre es mit goldaktien?)
@ steffen
welches Jahr ( 4.Quartal) ?????
du meinst doch nicht 2002 oder ???
sarkasmusmusseinus
hab ja selber welche
Gruß Dr.B
welches Jahr ( 4.Quartal) ?????
du meinst doch nicht 2002 oder ???
sarkasmusmusseinus
hab ja selber welche
Gruß Dr.B
oh oh
da waren`s nur noch
Last:
0.097
High:
0.115
Low:
0.097
Open:
0.112
Change:
-0.026
Volume:
2,558,000
da waren`s nur noch
Last:
0.097
High:
0.115
Low:
0.097
Open:
0.112
Change:
-0.026
Volume:
2,558,000
Tagchen
kann mir mal einer genau erklären was genau in der news stand.
Mfg
1048
kann mir mal einer genau erklären was genau in der news stand.
Mfg
1048
11:27:54 0.102 7700 OTCBB
11:25:20 0.100 1000 OTCBB
11:25:05 0.102 20000 OTCBB
Volume: 2,670,000
11:25:20 0.100 1000 OTCBB
11:25:05 0.102 20000 OTCBB
Volume: 2,670,000
12:00:34 0.102 55000 OTCBB
12:00:21 0.100 5000 OTCBB at Bid
11:59:18 0.102 5000 OTCBB
11:45:11 0.100 6500 OTCBB
12:00:21 0.100 5000 OTCBB at Bid
11:59:18 0.102 5000 OTCBB
11:45:11 0.100 6500 OTCBB
Ich finde das krank, nur weil Orasure ein schnell HIV
Test hat, soll Caly gleich in die Knie gehen.
Hier kann man erkennen, wie kleinkariert manche Leute sind. Orasure hat ein Speicheltest, Caly ein Pinkeltest.
Caly Test ist 100%-tig, Orasure Test 96,6%-tig.
Caly ist dabei gleichzeitig Hepatitistest durch Urin Proben zu erkennen. Orasure nicht.
Verträgt Ihr keine Konkurenz?
Konkurenz belebt das Geschäft!
Bleibe weiter bei Caly investiert.
david1
Test hat, soll Caly gleich in die Knie gehen.
Hier kann man erkennen, wie kleinkariert manche Leute sind. Orasure hat ein Speicheltest, Caly ein Pinkeltest.
Caly Test ist 100%-tig, Orasure Test 96,6%-tig.
Caly ist dabei gleichzeitig Hepatitistest durch Urin Proben zu erkennen. Orasure nicht.
Verträgt Ihr keine Konkurenz?
Konkurenz belebt das Geschäft!
Bleibe weiter bei Caly investiert.
david1
Seid Ihr sicher das Orasure das ja Wort für den Test bekommen hat?
Orasure steigt nur 7% nicht gerade berauschend oder ?
Mal sehen was Caly in nächster Zeit für News bringt
Mfg
1048
Orasure steigt nur 7% nicht gerade berauschend oder ?
Mal sehen was Caly in nächster Zeit für News bringt
Mfg
1048
Orasure hat sich mehr als verdoppelt in den letzten Tagen
bei 21 Mio aktien
Wau
Caly ist damit Tot weil Orasure einen Bluttest haben ähnlich dem Blutzuckertest.
Kurzer picks und 20 Min später das Ergebnis mit kleinen mobilen testgerät
Ehefrauen und betrogene Freundinnen,versicherungen werden auch beim Testen zuschauen statt auf dem Klo auf ´Steifen pinkeln.
Erster test der öffentlich und ohne Lobor auskommt
Caly hat verloren
Gruß
Marco
bei 21 Mio aktien
Wau
Caly ist damit Tot weil Orasure einen Bluttest haben ähnlich dem Blutzuckertest.
Kurzer picks und 20 Min später das Ergebnis mit kleinen mobilen testgerät
Ehefrauen und betrogene Freundinnen,versicherungen werden auch beim Testen zuschauen statt auf dem Klo auf ´Steifen pinkeln.
Erster test der öffentlich und ohne Lobor auskommt
Caly hat verloren
Gruß
Marco
marco,
orasure mit bluttest - hää?????? hat orasure nicht den speicheltest? daher "ORA" von oral ?
pickser in die zunge oder was?????
klär mich auf..........
orasure mit bluttest - hää?????? hat orasure nicht den speicheltest? daher "ORA" von oral ?
pickser in die zunge oder was?????
klär mich auf..........
ok, ein bluttest! gäääähn
-hab mal nachgeschaut...
aber:
Mr. Gausling said he did not know what the test would cost!
ups.......
-hab mal nachgeschaut...
aber:
Mr. Gausling said he did not know what the test would cost!
ups.......
New HIV Test Tells Results In Minutes
Newsday - 08 Nov 2002
Washington - The government approved a new 20-minute HIV test yesterday that promises
to let more Americans than ever before learn on-the-spot if they`re ...
FDA Approves Quick HIV Test
Wired News - 08 Nov 2002
By Associated Press Page 1 of 1. The government on Thursday approved
a 20-minute HIV test that AIDS experts say is so easy to use ...
New 20-Minute AIDS Test Approved
Discovery Channel - 08 Nov 2002
Nov. 8 — A new diagnostic device allowing to detect the AIDS virus
in as little as 20 minutes has received government approval ...
FDA Approves OraSure`s New Rapid HIV Test Kit
Smart Money - 08 Nov 2002
By Otesa Middleton. The OraQuick Rapid HIV-1 antibody test, made by
OraSure Technologies Inc. (OSUR), Bethlehem, Pa., requires no ...
FDA Approves OraSure`s New Rapid HIV Test Kit
Smart Money - 08 Nov 2002
By Otesa Middleton. The OraQuick Rapid HIV-1 antibody test, made by
OraSure Technologies Inc. (OSUR), Bethlehem, Pa., requires no ...
New Aids test is superquick
News24, South Africa - 08 Nov 2002
Washington - A new diagnostic device allowing medics to detect the Aids virus in
as little as 20 minutes has received government approval in the United States ...
FDA approves simplified test for HIV
Boston Globe, MA - 08 Nov 2002
By Associated Press, 11/8/2002. ASHINGTON - The government yesterday
approved a 20-minute HIV test, one easy enough to use that AIDS ...
US OKs 20-Minute AIDS Test
Voice of America - 08 Nov 2002
US regulators have approved a simple blood test that can signal the presence of the
virus that causes AIDS in just 20 minutes, instead of the usual two weeks. ...
US Approves Test for Rapid Diagnosis of HIV
Voice of America - 07 Nov 2002
The US government has approved a rapid new test to diagnose HIV in
minutes instead of up to two weeks, as current tests require. ...
US government`s FDA approves easy-to-use 20-minute HIV test
Canada.com, Canada - 07 Nov 2002
WASHINGTON (AP) - The government approved a 20-minute HIV test Thursday, one so
easy to use AIDS experts predict it will greatly cut the number of people who ...
US FDA Approves Orasure 20-Minute HIV Test
Reuters, UK - 07 Nov 2002
By Lisa Richwine. WASHINGTON (Reuters) - An HIV test that delivers results in
as little as 20 minutes from a drop of blood won US approval on Thursday. ...
FDA Approves HIV Test That Gives Results in Minutes
Reuters, UK - 07 Nov 2002
By Brian Reid. WASHINGTON (Reuters Health) - The US Food and Drug Administration
(FDA) said Thursday that it has cleared for marketing ...
FDA approves easy-to-use 20-minute HIV test
San Francisco Chronicle, CA - 07 Nov 2002
People will soon be able to learn before leaving the doctor`s office if they`re
infected with the AIDS virus. It`s not the first rapid HIV test. ...
US FDA Approves Orasure 20-Minute HIV Test
Reuters, UK - 07 Nov 2002
By Lisa Richwine. WASHINGTON (Reuters) - An HIV test that delivers results in
as little as 20 minutes from a drop of blood won US approval on Thursday. ...
FDA Approves 20-Minute HIV Test
ABC News - 07 Nov 2002
WASHINGTON, Nov. 7 — The government approved a 20-minute HIV test
Thursday, one so easy to use that AIDS experts predict it will ...
FDA Approves 20-Minute HIV Test
ABC News - 07 Nov 2002
Nov. 7 — The government approved a 20-minute HIV test Thursday, one
so easy to use that AIDS experts predict it will greatly cut ...
FDA approves new rapid AIDS test
United Press International - 07 Nov 2002
By Katrina Woznicki. WASHINGTON, Nov. 7 (UPI) -- The federal government
announced Thursday that the Food and Drug Administration ...
OraSure HIV Test Cleared
TheStreet.com, NY - 07 Nov 2002
OraSure Technologies (OSUR:Nasdaq - news - commentary - research - analysis), a
maker of medical testing equipment, saw its shares climb 14% to $6.60 after ...
US Approves OraSure`s Rapid HIV Blood Test
Reuters, UK - 07 Nov 2002
WASHINGTON (Reuters) - US officials have approved OraSure Technologies Inc.`s OraQuick
HIV test, a blood test that delivers results in as little as 20 minutes ...
FDA approves easy-to-use 20-minute HIV test
San Francisco Chronicle, CA - 07 Nov 2002
The government approved a new 20-minute HIV test on Thursday that promises to let
more Americans than ever before learn on-the-spot if they`re infected with ...
New HIV test offers rapid results
MSNBC - 07 Nov 2002
WASHINGTON, Nov. 7 — The government approved a new HIV test on Thursday
that provides results within 20 minutes and promises to ...
FDA Approves 20-Minute HIV Test
ABC News - 07 Nov 2002
WASHINGTON, Nov. 7 — The government approved a new 20-minute HIV
test on Thursday that promises to let more Americans than ever ...
FDA Approves 20-Minute HIV Test
ABC News - 07 Nov 2002
Nov. 7 — The government approved a new 20-minute HIV test on Thursday
that promises to let more Americans than ever before learn ...
New HIV Test is Fast and Accurate
WKRN, TN - 08 Nov 2002
The FDA has approved a new HIV test, one that only takes twenty-minutes
for a result. Experts say the test, called "Oraquick", is ...
New 20-minute HIV test gives reliable results
The Straits Times, Singapore - 08 Nov 2002
WASHINGTON - The Food and Drug Administration (FDA) has approved a test that can
detect whether someone is infected with HIV, the virus that causes Aids, in as ...
FDA Approves New AIDS Test
The Data Lounge - 08 Nov 2002
WASHINGTON -- The Food and Drug Administration on Thursday approved a new 20-minute
HIV test that promises on-the-spot diagnosis of HIV-infection. ...
New HIV testing needs only a drop of blood
Channel News Asia, Singapore - 08 Nov 2002
The US Food and Drug Administration has given its thumbs up to a new,
faster HIV testing method which only requires a drop of blood. ...
US Approves 20-Minute HIV Test
Gay.com UK, UK - 08 Nov 2002
by T Musbach for Gay.com/PlanetOut.com Network. The US Food and Drug
Administration approved a quick HIV test on Thursday that reduces ...
Rapid HIV Test Gains US Gov`t Approval
365 Gay.com - 07 Nov 2002
by Doreen Brandt. (Washington, DC) A new HIV test that gives results within
20 minutes has been approved for use by the Food and Drug Administration. ...
FDA approves quick, easy-to-use HIV test
Dayton Daily News, OH - 07 Nov 2002
WASHINGTON | People will soon be able to learn before leaving the
doctor’s office if they’re infected with the AIDS virus. It ...
JS200
Newsday - 08 Nov 2002
Washington - The government approved a new 20-minute HIV test yesterday that promises
to let more Americans than ever before learn on-the-spot if they`re ...
FDA Approves Quick HIV Test
Wired News - 08 Nov 2002
By Associated Press Page 1 of 1. The government on Thursday approved
a 20-minute HIV test that AIDS experts say is so easy to use ...
New 20-Minute AIDS Test Approved
Discovery Channel - 08 Nov 2002
Nov. 8 — A new diagnostic device allowing to detect the AIDS virus
in as little as 20 minutes has received government approval ...
FDA Approves OraSure`s New Rapid HIV Test Kit
Smart Money - 08 Nov 2002
By Otesa Middleton. The OraQuick Rapid HIV-1 antibody test, made by
OraSure Technologies Inc. (OSUR), Bethlehem, Pa., requires no ...
FDA Approves OraSure`s New Rapid HIV Test Kit
Smart Money - 08 Nov 2002
By Otesa Middleton. The OraQuick Rapid HIV-1 antibody test, made by
OraSure Technologies Inc. (OSUR), Bethlehem, Pa., requires no ...
New Aids test is superquick
News24, South Africa - 08 Nov 2002
Washington - A new diagnostic device allowing medics to detect the Aids virus in
as little as 20 minutes has received government approval in the United States ...
FDA approves simplified test for HIV
Boston Globe, MA - 08 Nov 2002
By Associated Press, 11/8/2002. ASHINGTON - The government yesterday
approved a 20-minute HIV test, one easy enough to use that AIDS ...
US OKs 20-Minute AIDS Test
Voice of America - 08 Nov 2002
US regulators have approved a simple blood test that can signal the presence of the
virus that causes AIDS in just 20 minutes, instead of the usual two weeks. ...
US Approves Test for Rapid Diagnosis of HIV
Voice of America - 07 Nov 2002
The US government has approved a rapid new test to diagnose HIV in
minutes instead of up to two weeks, as current tests require. ...
US government`s FDA approves easy-to-use 20-minute HIV test
Canada.com, Canada - 07 Nov 2002
WASHINGTON (AP) - The government approved a 20-minute HIV test Thursday, one so
easy to use AIDS experts predict it will greatly cut the number of people who ...
US FDA Approves Orasure 20-Minute HIV Test
Reuters, UK - 07 Nov 2002
By Lisa Richwine. WASHINGTON (Reuters) - An HIV test that delivers results in
as little as 20 minutes from a drop of blood won US approval on Thursday. ...
FDA Approves HIV Test That Gives Results in Minutes
Reuters, UK - 07 Nov 2002
By Brian Reid. WASHINGTON (Reuters Health) - The US Food and Drug Administration
(FDA) said Thursday that it has cleared for marketing ...
FDA approves easy-to-use 20-minute HIV test
San Francisco Chronicle, CA - 07 Nov 2002
People will soon be able to learn before leaving the doctor`s office if they`re
infected with the AIDS virus. It`s not the first rapid HIV test. ...
US FDA Approves Orasure 20-Minute HIV Test
Reuters, UK - 07 Nov 2002
By Lisa Richwine. WASHINGTON (Reuters) - An HIV test that delivers results in
as little as 20 minutes from a drop of blood won US approval on Thursday. ...
FDA Approves 20-Minute HIV Test
ABC News - 07 Nov 2002
WASHINGTON, Nov. 7 — The government approved a 20-minute HIV test
Thursday, one so easy to use that AIDS experts predict it will ...
FDA Approves 20-Minute HIV Test
ABC News - 07 Nov 2002
Nov. 7 — The government approved a 20-minute HIV test Thursday, one
so easy to use that AIDS experts predict it will greatly cut ...
FDA approves new rapid AIDS test
United Press International - 07 Nov 2002
By Katrina Woznicki. WASHINGTON, Nov. 7 (UPI) -- The federal government
announced Thursday that the Food and Drug Administration ...
OraSure HIV Test Cleared
TheStreet.com, NY - 07 Nov 2002
OraSure Technologies (OSUR:Nasdaq - news - commentary - research - analysis), a
maker of medical testing equipment, saw its shares climb 14% to $6.60 after ...
US Approves OraSure`s Rapid HIV Blood Test
Reuters, UK - 07 Nov 2002
WASHINGTON (Reuters) - US officials have approved OraSure Technologies Inc.`s OraQuick
HIV test, a blood test that delivers results in as little as 20 minutes ...
FDA approves easy-to-use 20-minute HIV test
San Francisco Chronicle, CA - 07 Nov 2002
The government approved a new 20-minute HIV test on Thursday that promises to let
more Americans than ever before learn on-the-spot if they`re infected with ...
New HIV test offers rapid results
MSNBC - 07 Nov 2002
WASHINGTON, Nov. 7 — The government approved a new HIV test on Thursday
that provides results within 20 minutes and promises to ...
FDA Approves 20-Minute HIV Test
ABC News - 07 Nov 2002
WASHINGTON, Nov. 7 — The government approved a new 20-minute HIV
test on Thursday that promises to let more Americans than ever ...
FDA Approves 20-Minute HIV Test
ABC News - 07 Nov 2002
Nov. 7 — The government approved a new 20-minute HIV test on Thursday
that promises to let more Americans than ever before learn ...
New HIV Test is Fast and Accurate
WKRN, TN - 08 Nov 2002
The FDA has approved a new HIV test, one that only takes twenty-minutes
for a result. Experts say the test, called "Oraquick", is ...
New 20-minute HIV test gives reliable results
The Straits Times, Singapore - 08 Nov 2002
WASHINGTON - The Food and Drug Administration (FDA) has approved a test that can
detect whether someone is infected with HIV, the virus that causes Aids, in as ...
FDA Approves New AIDS Test
The Data Lounge - 08 Nov 2002
WASHINGTON -- The Food and Drug Administration on Thursday approved a new 20-minute
HIV test that promises on-the-spot diagnosis of HIV-infection. ...
New HIV testing needs only a drop of blood
Channel News Asia, Singapore - 08 Nov 2002
The US Food and Drug Administration has given its thumbs up to a new,
faster HIV testing method which only requires a drop of blood. ...
US Approves 20-Minute HIV Test
Gay.com UK, UK - 08 Nov 2002
by T Musbach for Gay.com/PlanetOut.com Network. The US Food and Drug
Administration approved a quick HIV test on Thursday that reduces ...
Rapid HIV Test Gains US Gov`t Approval
365 Gay.com - 07 Nov 2002
by Doreen Brandt. (Washington, DC) A new HIV test that gives results within
20 minutes has been approved for use by the Food and Drug Administration. ...
FDA approves quick, easy-to-use HIV test
Dayton Daily News, OH - 07 Nov 2002
WASHINGTON | People will soon be able to learn before leaving the
doctor’s office if they’re infected with the AIDS virus. It ...
JS200
Ist dieser Artikel Schuld am Kurssturz ?????
The Calypte Biomedical Corporation, which sells a urine test for the virus that causes AIDS, announced in April that it was winding down and preparing to file for bankruptcy. "We had gone as far as to box up the company," said Richard D. Brounstein, the chief financial officer.
But a month later, it got a new chairman, who has attracted more than $6 million to the company. Calypte, based in Alameda, has hired back most of its top management and is making its product again, though at the end of the third quarter its cash reserve was down again, to only $19,000.
JS200
The Calypte Biomedical Corporation, which sells a urine test for the virus that causes AIDS, announced in April that it was winding down and preparing to file for bankruptcy. "We had gone as far as to box up the company," said Richard D. Brounstein, the chief financial officer.
But a month later, it got a new chairman, who has attracted more than $6 million to the company. Calypte, based in Alameda, has hired back most of its top management and is making its product again, though at the end of the third quarter its cash reserve was down again, to only $19,000.
JS200
@ALLE
Ich habe vergessen zu schreiben wo die Info stand:
WWW.news.google.com
Hier noch was
New HIV Test Tells Results In Minutes
Newsday - and 96 related »
JS200
Ich habe vergessen zu schreiben wo die Info stand:
WWW.news.google.com
Hier noch was
New HIV Test Tells Results In Minutes
Newsday - and 96 related »
JS200
@ js
is ja nix neues, daß CALY wieder kein geld mehr hat.
aber bitte geht´s genauer mit der artikelquelle, bitte nen link oder zumind. die überschrift?
im übrigen warte ich ja immer noch auf den quartalsbericht
is ja nix neues, daß CALY wieder kein geld mehr hat.
aber bitte geht´s genauer mit der artikelquelle, bitte nen link oder zumind. die überschrift?
im übrigen warte ich ja immer noch auf den quartalsbericht
@LOSS_PRO
Hier stehts drin auf Seite 3
In NEW YORK TIMES stand dieses
Companies That Seek Cures Now Fight for Life
By ANDREW POLLACK
HEN the terror attacks halted air traffic last year, an exception was made for a private jet flying from Southern California to Washington. It carried sheets of human skin cells to treat people burned at the Pentagon.
Now the manufacturer of that biotechnology product, Advanced Tissue Sciences, is itself in need of emergency aid. The company, based in San Diego, filed for bankruptcy protection last month and is still operating, although it has been unable to raise money.
Advertisement
Look out Big Foot, this binocular takes pictures!
If your eyes have changed... shouldn’t your light?
If you are still sleeping on old spring mattress technology, try Verflex® with an in-home trial
Get a zero impact workout while flying through the air
It’s time to put all of your photos onto your computer
Bring this incredibly portable digital camera everywhere!
Don’t let your guests sleep on this bed-they may not leave!
Natural de-icer means you’ll have to shovel less this winter
"What we ran into was the change in the investment climate," said Abe Wischnia, the senior director for investor relations at Advanced Tissue Sciences. "A year or two ago, we would have had no trouble raising additional money."
The biotechnology industry is facing one of its worst financial squeezes ever. The prices of many biotechnology stocks have plummeted, and Wall Street`s vaults have snapped nearly shut, making it almost impossible for capital-hungry companies to finance themselves.
As a result, many companies are now fighting for their lives. About 35 percent of publicly traded biotechnology companies have less than a year`s worth of cash left at their current spending levels, according to a recent survey by Merrill Lynch. Since the beginning of July, at least 45 biotechnology companies in the United States and Europe have announced layoffs or other cutbacks, according to BioCentury, a newsletter.
Among the companies in the most precarious positions are those whose research breakthroughs have attracted much attention in the past. Such technology often tends to be not only far-reaching, but also far out — in terms of the time when it will start making money. These are exactly the types of businesses that risk-averse investors are now shunning.
The Alliance Pharmaceutical Corporation, just down the road from Advanced Tissue Sciences, was the subject of a front-page article two years ago in USA Today for its work developing a blood substitute, a chemical that could deliver oxygen to a patient`s tissues when there was no blood available for a transfusion.
Today, Alliance is virtually out of money, unable to resume its clinical trials, down to 90 employees from 180 at its peak and delisted from the Nasdaq National Market. Desperate for cash, it recently borrowed $3 million — at an annual interest rate of 100 percent.
Four years ago, the stock of Entremed soared to $85 a share after The New York Times reported that its experimental drugs had eradicated cancer in mice by cutting off the blood supply to their tumors. Now the stock is trading at $1.69, and the company, based in Rockville, Md., said in September that it had enough cash to last only through the end of the year.
But grabbing headlines does not always translate into business success. Sales have been slow for Advanced Tissue Sciences` artificial skin, which costs up to $600 a sheet and competes with ordinary bandages. Alliance halted a clinical trial of its blood substitute last year because some patients developed strokes, although the company says the product was not at fault. Entremed`s drugs have not shown the same astounding results in people as they did in mice. Indeed, many of the companies hit hardest have spent tens or hundreds of millions of dollars on drugs and business plans that have failed, but only now are facing the day of reckoning.
Still, some analysts and executives say that if many companies fold, some useful technology may never be developed.
The recent bear market, of course, has been hard on many industries. But few depend as much as biotechnology does on investors willing to bet huge sums on technology that may not pay off for years, if ever.
"I see the biotechnology industry as always struggling, always fighting for capital," said Kevin W. Sharer, the chief executive of Amgen, the biggest company in the field and one of the relatively few that are profitable and therefore not that dependent on continually raising money from investors. In the future, he said, "it`ll be a lot of losers and not very many winners."
Among the more troubled areas is one that has received much political and public attention in the last year — stem cells and other aspects of "regenerative medicine," involving the regrowth of damaged organs. Despite the technology`s long-term promise, profits are not expected for years, and some of the pioneers are ailing.
Organogenesis, of Canton, Mass., a competitor of Advanced Tissue Sciences in the artificial-skin business, filed for bankruptcy protection a few weeks ago. Nexell Therapeutics, of Irvine, Calif., which was working largely on blood stem cells, is liquidating itself. The Geron Corporation, the widely acknowledged leader in human embryonic stem cells, laid off 43 people, or 30 percent of its work force, in June.
STEM cells has been a hot area with regard to the press, but it has not been a hot area with regard to investors," said Clayton I. Duncan, the chief executive of Incara Pharmaceuticals, a company based in Research Triangle Park, N.C., that worked on using liver stem cells to regrow diseased livers.
Companies That Seek Cures Now Fight for Life
(Page 2 of 3)
Incara, which had two drugs fail in clinical trials, ran out of cash at the end of September but has continued to operate. Two weeks ago, to save itself, Incara sold its liver stem cell business to concentrate on more traditional drugs.
Another sector that has suffered is bioinformatics, which uses computers to analyze masses of genetic data. Several young companies have gone out of business or been acquired for a pittance after sales did not meet expectations.
Advertisement
Companies pursuing another futuristic field — tailoring medicines to patients by testing their genes — have also fallen on hard times. Shares of Genaissance Pharmaceuticals, Variagenics and Interleukin Genetics are all selling at around $1; Interleukin has said that its existing cash will last only until January.
The biotechnology industry periodically goes through money droughts, but some say this one is the worst. "This is the first time we`ve had a bear market on top of a tough environment for biotech," said Jim Scopa, co-head of health care investment banking at Thomas Weisel Partners in San Francisco.
Many companies, however, have withstood the famine because they raised huge sums in 2000, when investors were in a frenzy about the deciphering of the human genome. The industry as a whole raised more than $30 billion that year, several times as much as in any previous year.
"The last stop at the gas station was two years ago, and people filled up their tanks very well," said Stelios Papadopoulos, a health care investment banker and vice chairman of S. G. Cowen Securities.
Still, the feeling of wealth led some companies to spend profligately. Like Internet start-ups, some biotechnology companies decided to spend heavily to build their business while ignoring the need for profits.
So now, even companies in no immediate danger of running out of money are slowing their "burn rate" — the speed at which they go through cash — in case the market downturn lasts for years.
DeCode Genetics, a company searching disease-causing genes in the relatively homogeneous population of Iceland, its home, cut 200 employees in September — on the same day that it announced a collaboration with Merck & Company worth up to $90 million. In Alameda, Calif., Avigen, which is developing gene therapy to treat hemophilia, cut 28 percent of its work force last month so that its cash will last for four or five years instead of three, said John Monahan, the chief executive. Even Human Genome Sciences, with $1.5 billion in cash, and Abgenix, with $464 million, are facing investor pressure to preserve cash.
THE biggest shortage of financing has been from public investors. In the first three quarters this year, there were only five initial public offerings of stock by biotechnology companies worldwide and only 10 secondary offerings, according to Recombinant Capital, a consulting and research firm in Walnut Creek, Calif. Together, the stock sales raised $870 million, less than half the $1.9 billion raised in the first three quarters of 2001 and just a small fraction of the more than $12 billion in the same period of 2000.
The drought has shown some signs of easing. Four companies — Trimeris, Tularik, Telik and NPS Pharmaceuticals — have completed secondary stock offerings since late September, raising more than $300 million combined.
But all those companies have what most biotechnology companies lack: drugs that are close to reaching the market, and possible profits. Indeed, drug development companies are held in relatively good stead by investors compared with companies pursuing genomics, cell therapies or other exotic technologies.
With the public markets virtually closed, public companies can still raise money by selling stock privately to investors, though often on onerous terms. And venture capitalists still have ample money to invest in privately held start-ups.
But venture capitalists make their returns when those start-ups go public. With the market for public offerings effectively closed, venture capitalists are starting to cut back as well on the amounts of money they offer to companies.
"We`re starting to see values fall pretty aggressively," said Brian G. Atwood, a managing director at Versant Ventures in Menlo Park, Calif. He added, "Almost every private company I know is considering doing a layoff."
In some cases, venture capitalists must now put additional money into companies in their portfolios that would normally have gone public by now, leaving less for new companies. And with the valuations of publicly traded companies so low, some venture firms are tempted to invest in public companies rather than private ones.
For public companies, raising money is difficult because their stock prices have been driven down, in part by a series of failures in clinical trials of drugs. About 16 percent of public biotechnology companies have market valuations lower than their cash on hand, according to Merrill Lynch, meaning that investors effectively assign no value to their technology. About 25 percent of biotechnology stocks have sold for less than $1 a share in the past year, according to Burrill & Company, an investment firm in San Francisco.
Companies That Seek Cures Now Fight for Life
(Page 3 of 3)
With prices so low, some stocks are being delisted or threatened with delisting by Nasdaq, making it even harder for companies to attract investors. Nasdaq is considering lowering its listing standards because so many stocks, not just biotechnology, have fallen so far.
Cygnus, which has never been profitable in its 17-year history, finally achieved what it thought was a breakthrough earlier this year when it began selling its GlucoWatch Biographer, a device worn by diabetics that continually monitors their blood sugar levels. But last month, Nasdaq told the company, based in Redwood City, Calif., that its stock would be delisted for trading at too low a price.
Advertisement
It’s time to put all of your photos onto your computer
If your eyes have changed... shouldn’t your light?
Scientists adapt NASA technology to create "smart bed" sleep surface
Atomic accuracy in any U.S. time zone
Warm up to this dual oscillating ceramic heater
Why spend hundreds on a bigger monitor… enlarge the one you have
Motion sensor technology creates low cost surveillance system
Look out Big Foot, this binocular takes pictures!
"There is a dichotomy," said John C. Hodgman, the chief executive of the company, which said it plans to appeal. "You`re the strongest you`ve ever been, but you don`t meet the requirements for remaining listed on the trading board."
Analysts said that they expect more companies to close or be acquired. "There was a massive overinvestment in the industry, and there is going to have to be a workout period where some companies fail," said Mark N. Lampert, who runs the Biotechnology Value Fund, an investment company in San Francisco.
Still, biotechnology companies often manage to hang on for years, even with a skeleton staff, hoping for a recovery like that of Amylin Pharmaceuticals of San Diego. Four years ago, Amylin laid off 80 percent of its employees and nearly closed after running into problems with its first drug. But two months ago, it licensed the rights to its second experimental drug, for diabetes, to Eli Lilly & Company in a deal that could bring Amylin up to $325 million.
MANAGEMENT teams and founders are so passionate about what they are doing that they never believe it is going away," said Peter J. Crowley, the head of health care investment banking at CIBC World Markets. "They will stay at it until someone absolutely turns the lights out."
The Calypte Biomedical Corporation, which sells a urine test for the virus that causes AIDS, announced in April that it was winding down and preparing to file for bankruptcy. "We had gone as far as to box up the company," said Richard D. Brounstein, the chief financial officer.
But a month later, it got a new chairman, who has attracted more than $6 million to the company. Calypte, based in Alameda, has hired back most of its top management and is making its product again, though at the end of the third quarter its cash reserve was down again, to only $19,000.
The artificial-skin products of Advanced Tissue Sciences are being acquired by its marketing partner, Smith & Nephew of Britain, for $10 million plus the assumption of debt, so the technology will live on. Smith & Nephew hired 110 Advanced Tissue employees. An additional 70 were laid off, leaving 35 at the company.
The board of Advanced Tissue will decide soon whether the company should stay in business or shut down. If it stays open, Mr. Wischnia said, "this time the company is going to do it in a way that makes money."
JS200
Hier stehts drin auf Seite 3
In NEW YORK TIMES stand dieses
Companies That Seek Cures Now Fight for Life
By ANDREW POLLACK
HEN the terror attacks halted air traffic last year, an exception was made for a private jet flying from Southern California to Washington. It carried sheets of human skin cells to treat people burned at the Pentagon.
Now the manufacturer of that biotechnology product, Advanced Tissue Sciences, is itself in need of emergency aid. The company, based in San Diego, filed for bankruptcy protection last month and is still operating, although it has been unable to raise money.
Advertisement
Look out Big Foot, this binocular takes pictures!
If your eyes have changed... shouldn’t your light?
If you are still sleeping on old spring mattress technology, try Verflex® with an in-home trial
Get a zero impact workout while flying through the air
It’s time to put all of your photos onto your computer
Bring this incredibly portable digital camera everywhere!
Don’t let your guests sleep on this bed-they may not leave!
Natural de-icer means you’ll have to shovel less this winter
"What we ran into was the change in the investment climate," said Abe Wischnia, the senior director for investor relations at Advanced Tissue Sciences. "A year or two ago, we would have had no trouble raising additional money."
The biotechnology industry is facing one of its worst financial squeezes ever. The prices of many biotechnology stocks have plummeted, and Wall Street`s vaults have snapped nearly shut, making it almost impossible for capital-hungry companies to finance themselves.
As a result, many companies are now fighting for their lives. About 35 percent of publicly traded biotechnology companies have less than a year`s worth of cash left at their current spending levels, according to a recent survey by Merrill Lynch. Since the beginning of July, at least 45 biotechnology companies in the United States and Europe have announced layoffs or other cutbacks, according to BioCentury, a newsletter.
Among the companies in the most precarious positions are those whose research breakthroughs have attracted much attention in the past. Such technology often tends to be not only far-reaching, but also far out — in terms of the time when it will start making money. These are exactly the types of businesses that risk-averse investors are now shunning.
The Alliance Pharmaceutical Corporation, just down the road from Advanced Tissue Sciences, was the subject of a front-page article two years ago in USA Today for its work developing a blood substitute, a chemical that could deliver oxygen to a patient`s tissues when there was no blood available for a transfusion.
Today, Alliance is virtually out of money, unable to resume its clinical trials, down to 90 employees from 180 at its peak and delisted from the Nasdaq National Market. Desperate for cash, it recently borrowed $3 million — at an annual interest rate of 100 percent.
Four years ago, the stock of Entremed soared to $85 a share after The New York Times reported that its experimental drugs had eradicated cancer in mice by cutting off the blood supply to their tumors. Now the stock is trading at $1.69, and the company, based in Rockville, Md., said in September that it had enough cash to last only through the end of the year.
But grabbing headlines does not always translate into business success. Sales have been slow for Advanced Tissue Sciences` artificial skin, which costs up to $600 a sheet and competes with ordinary bandages. Alliance halted a clinical trial of its blood substitute last year because some patients developed strokes, although the company says the product was not at fault. Entremed`s drugs have not shown the same astounding results in people as they did in mice. Indeed, many of the companies hit hardest have spent tens or hundreds of millions of dollars on drugs and business plans that have failed, but only now are facing the day of reckoning.
Still, some analysts and executives say that if many companies fold, some useful technology may never be developed.
The recent bear market, of course, has been hard on many industries. But few depend as much as biotechnology does on investors willing to bet huge sums on technology that may not pay off for years, if ever.
"I see the biotechnology industry as always struggling, always fighting for capital," said Kevin W. Sharer, the chief executive of Amgen, the biggest company in the field and one of the relatively few that are profitable and therefore not that dependent on continually raising money from investors. In the future, he said, "it`ll be a lot of losers and not very many winners."
Among the more troubled areas is one that has received much political and public attention in the last year — stem cells and other aspects of "regenerative medicine," involving the regrowth of damaged organs. Despite the technology`s long-term promise, profits are not expected for years, and some of the pioneers are ailing.
Organogenesis, of Canton, Mass., a competitor of Advanced Tissue Sciences in the artificial-skin business, filed for bankruptcy protection a few weeks ago. Nexell Therapeutics, of Irvine, Calif., which was working largely on blood stem cells, is liquidating itself. The Geron Corporation, the widely acknowledged leader in human embryonic stem cells, laid off 43 people, or 30 percent of its work force, in June.
STEM cells has been a hot area with regard to the press, but it has not been a hot area with regard to investors," said Clayton I. Duncan, the chief executive of Incara Pharmaceuticals, a company based in Research Triangle Park, N.C., that worked on using liver stem cells to regrow diseased livers.
Companies That Seek Cures Now Fight for Life
(Page 2 of 3)
Incara, which had two drugs fail in clinical trials, ran out of cash at the end of September but has continued to operate. Two weeks ago, to save itself, Incara sold its liver stem cell business to concentrate on more traditional drugs.
Another sector that has suffered is bioinformatics, which uses computers to analyze masses of genetic data. Several young companies have gone out of business or been acquired for a pittance after sales did not meet expectations.
Advertisement
Companies pursuing another futuristic field — tailoring medicines to patients by testing their genes — have also fallen on hard times. Shares of Genaissance Pharmaceuticals, Variagenics and Interleukin Genetics are all selling at around $1; Interleukin has said that its existing cash will last only until January.
The biotechnology industry periodically goes through money droughts, but some say this one is the worst. "This is the first time we`ve had a bear market on top of a tough environment for biotech," said Jim Scopa, co-head of health care investment banking at Thomas Weisel Partners in San Francisco.
Many companies, however, have withstood the famine because they raised huge sums in 2000, when investors were in a frenzy about the deciphering of the human genome. The industry as a whole raised more than $30 billion that year, several times as much as in any previous year.
"The last stop at the gas station was two years ago, and people filled up their tanks very well," said Stelios Papadopoulos, a health care investment banker and vice chairman of S. G. Cowen Securities.
Still, the feeling of wealth led some companies to spend profligately. Like Internet start-ups, some biotechnology companies decided to spend heavily to build their business while ignoring the need for profits.
So now, even companies in no immediate danger of running out of money are slowing their "burn rate" — the speed at which they go through cash — in case the market downturn lasts for years.
DeCode Genetics, a company searching disease-causing genes in the relatively homogeneous population of Iceland, its home, cut 200 employees in September — on the same day that it announced a collaboration with Merck & Company worth up to $90 million. In Alameda, Calif., Avigen, which is developing gene therapy to treat hemophilia, cut 28 percent of its work force last month so that its cash will last for four or five years instead of three, said John Monahan, the chief executive. Even Human Genome Sciences, with $1.5 billion in cash, and Abgenix, with $464 million, are facing investor pressure to preserve cash.
THE biggest shortage of financing has been from public investors. In the first three quarters this year, there were only five initial public offerings of stock by biotechnology companies worldwide and only 10 secondary offerings, according to Recombinant Capital, a consulting and research firm in Walnut Creek, Calif. Together, the stock sales raised $870 million, less than half the $1.9 billion raised in the first three quarters of 2001 and just a small fraction of the more than $12 billion in the same period of 2000.
The drought has shown some signs of easing. Four companies — Trimeris, Tularik, Telik and NPS Pharmaceuticals — have completed secondary stock offerings since late September, raising more than $300 million combined.
But all those companies have what most biotechnology companies lack: drugs that are close to reaching the market, and possible profits. Indeed, drug development companies are held in relatively good stead by investors compared with companies pursuing genomics, cell therapies or other exotic technologies.
With the public markets virtually closed, public companies can still raise money by selling stock privately to investors, though often on onerous terms. And venture capitalists still have ample money to invest in privately held start-ups.
But venture capitalists make their returns when those start-ups go public. With the market for public offerings effectively closed, venture capitalists are starting to cut back as well on the amounts of money they offer to companies.
"We`re starting to see values fall pretty aggressively," said Brian G. Atwood, a managing director at Versant Ventures in Menlo Park, Calif. He added, "Almost every private company I know is considering doing a layoff."
In some cases, venture capitalists must now put additional money into companies in their portfolios that would normally have gone public by now, leaving less for new companies. And with the valuations of publicly traded companies so low, some venture firms are tempted to invest in public companies rather than private ones.
For public companies, raising money is difficult because their stock prices have been driven down, in part by a series of failures in clinical trials of drugs. About 16 percent of public biotechnology companies have market valuations lower than their cash on hand, according to Merrill Lynch, meaning that investors effectively assign no value to their technology. About 25 percent of biotechnology stocks have sold for less than $1 a share in the past year, according to Burrill & Company, an investment firm in San Francisco.
Companies That Seek Cures Now Fight for Life
(Page 3 of 3)
With prices so low, some stocks are being delisted or threatened with delisting by Nasdaq, making it even harder for companies to attract investors. Nasdaq is considering lowering its listing standards because so many stocks, not just biotechnology, have fallen so far.
Cygnus, which has never been profitable in its 17-year history, finally achieved what it thought was a breakthrough earlier this year when it began selling its GlucoWatch Biographer, a device worn by diabetics that continually monitors their blood sugar levels. But last month, Nasdaq told the company, based in Redwood City, Calif., that its stock would be delisted for trading at too low a price.
Advertisement
It’s time to put all of your photos onto your computer
If your eyes have changed... shouldn’t your light?
Scientists adapt NASA technology to create "smart bed" sleep surface
Atomic accuracy in any U.S. time zone
Warm up to this dual oscillating ceramic heater
Why spend hundreds on a bigger monitor… enlarge the one you have
Motion sensor technology creates low cost surveillance system
Look out Big Foot, this binocular takes pictures!
"There is a dichotomy," said John C. Hodgman, the chief executive of the company, which said it plans to appeal. "You`re the strongest you`ve ever been, but you don`t meet the requirements for remaining listed on the trading board."
Analysts said that they expect more companies to close or be acquired. "There was a massive overinvestment in the industry, and there is going to have to be a workout period where some companies fail," said Mark N. Lampert, who runs the Biotechnology Value Fund, an investment company in San Francisco.
Still, biotechnology companies often manage to hang on for years, even with a skeleton staff, hoping for a recovery like that of Amylin Pharmaceuticals of San Diego. Four years ago, Amylin laid off 80 percent of its employees and nearly closed after running into problems with its first drug. But two months ago, it licensed the rights to its second experimental drug, for diabetes, to Eli Lilly & Company in a deal that could bring Amylin up to $325 million.
MANAGEMENT teams and founders are so passionate about what they are doing that they never believe it is going away," said Peter J. Crowley, the head of health care investment banking at CIBC World Markets. "They will stay at it until someone absolutely turns the lights out."
The Calypte Biomedical Corporation, which sells a urine test for the virus that causes AIDS, announced in April that it was winding down and preparing to file for bankruptcy. "We had gone as far as to box up the company," said Richard D. Brounstein, the chief financial officer.
But a month later, it got a new chairman, who has attracted more than $6 million to the company. Calypte, based in Alameda, has hired back most of its top management and is making its product again, though at the end of the third quarter its cash reserve was down again, to only $19,000.
The artificial-skin products of Advanced Tissue Sciences are being acquired by its marketing partner, Smith & Nephew of Britain, for $10 million plus the assumption of debt, so the technology will live on. Smith & Nephew hired 110 Advanced Tissue employees. An additional 70 were laid off, leaving 35 at the company.
The board of Advanced Tissue will decide soon whether the company should stay in business or shut down. If it stays open, Mr. Wischnia said, "this time the company is going to do it in a way that makes money."
JS200
@LOSS_PRO
Companies That Seek Cures Now Fight for Life
New York Times - 07 Nov 2002
... They will stay at it until someone absolutely turns the lights out." The Calypte
Biomedical Corporation, which sells a urine test for the virus that causes ...
JS200
Companies That Seek Cures Now Fight for Life
New York Times - 07 Nov 2002
... They will stay at it until someone absolutely turns the lights out." The Calypte
Biomedical Corporation, which sells a urine test for the virus that causes ...
JS200
@LOOS_PRO
Schöner Titel
Sie werden dabei bleiben, bis jemand die Lichter absolut ausmacht. Der Calypte
Biomedical Corporation, die eine Urinprüfung für den Virus verkauft, der verursacht,...
JS200
Schöner Titel
Sie werden dabei bleiben, bis jemand die Lichter absolut ausmacht. Der Calypte
Biomedical Corporation, die eine Urinprüfung für den Virus verkauft, der verursacht,...
JS200
@LOSS_PRO
Genügt diese Info ??????
JS200
Genügt diese Info ??????
JS200
Kann mir jemand ein Übersetzungs-Programm hier reinstellen?
Babel-Fish funktioniert nicht.
Danke David
Babel-Fish funktioniert nicht.
Danke David
@ david
http://reversonet.lycos.de/
@ js
danke, fraglich bleibt jetzt noch das datum? bei dir steht 7., bei mir 6.(bei google) und schließlich 3. bei der NYT?
zudem fraglich, ob so ´ne "nebensatz"-erwähnung mit bekannten daten so ein volumen auslöst? ich glaub eher die sind wieder pleite.
was kommt wohl eher der quartalbericht oder die winding-down-meldung?
http://reversonet.lycos.de/
@ js
danke, fraglich bleibt jetzt noch das datum? bei dir steht 7., bei mir 6.(bei google) und schließlich 3. bei der NYT?
zudem fraglich, ob so ´ne "nebensatz"-erwähnung mit bekannten daten so ein volumen auslöst? ich glaub eher die sind wieder pleite.
was kommt wohl eher der quartalbericht oder die winding-down-meldung?
@LOSS_PRO
Ich glaube eher, dass dieses eine gut geführte Werbekampagne von OSUR war.
Fast 100 Beiträge am Freitag waren einfach zuviel für CALY
11/08/2002 (16:44 ET) Text: Faster Results Available from Newly Approved HIV Test Kit -
11/08/2002 (09:46 ET) VOLUME(+): OSUR Volume 164% > 20-adsv, Stock +12.43% - Knobias
11/08/2002 (09:46 ET) GAP-UP: Opening Higher MTWV, RIMM, CICI, OSUR - Knobias
11/08/2002 (08:32 ET) PREMARKET: OraSure Gets FDA Approval for OraQuick - Knobias
11/08/2002 (07:00 ET) CLOSER(+): Upward Close INIV, WFMI, NXTL, KRON, OVTI - Knobias
JS200
Ich glaube eher, dass dieses eine gut geführte Werbekampagne von OSUR war.
Fast 100 Beiträge am Freitag waren einfach zuviel für CALY
11/08/2002 (16:44 ET) Text: Faster Results Available from Newly Approved HIV Test Kit -
11/08/2002 (09:46 ET) VOLUME(+): OSUR Volume 164% > 20-adsv, Stock +12.43% - Knobias
11/08/2002 (09:46 ET) GAP-UP: Opening Higher MTWV, RIMM, CICI, OSUR - Knobias
11/08/2002 (08:32 ET) PREMARKET: OraSure Gets FDA Approval for OraQuick - Knobias
11/08/2002 (07:00 ET) CLOSER(+): Upward Close INIV, WFMI, NXTL, KRON, OVTI - Knobias
JS200
@LOSS_PRO
Searched news for OraSure Technologies. (BETA) Results 1 - 10 of about 81. Search took 1.84 seconds
81 Gegenangriffe innerhalb 2 TAGE ist zuviel
JS200
Searched news for OraSure Technologies. (BETA) Results 1 - 10 of about 81. Search took 1.84 seconds
81 Gegenangriffe innerhalb 2 TAGE ist zuviel
JS200
@ Loss_Pro
Danke!
david1
Danke!
david1
Ich habe das Gefühl, dass hier ein faules Ei ins Nest gesetzt wurde.
Was meint Ihr?
david1
Was meint Ihr?
david1
Selbst die Amis sind nicht so skeptisch.
------------------------------------------------------------------------------------------------------------------------
it`s good to see you back. I`ve always
appreciated contrarian views-- particularly
yours--to keep a broader perspective. I don`t believe there is mutual exclusivity in regards to Orasure and CALY. IMO CALY will most definitely have FDA approval by this time next year. Both companies will play their parts. The bottom line for CALY, however, as we all know, is sales and having enough cash to keep us afloat until the rapid test is approved. For the first time since I`ve owned this stock (about 4 years now)I`m absolutely confident that the company will secure the cash they need.
david1
------------------------------------------------------------------------------------------------------------------------
it`s good to see you back. I`ve always
appreciated contrarian views-- particularly
yours--to keep a broader perspective. I don`t believe there is mutual exclusivity in regards to Orasure and CALY. IMO CALY will most definitely have FDA approval by this time next year. Both companies will play their parts. The bottom line for CALY, however, as we all know, is sales and having enough cash to keep us afloat until the rapid test is approved. For the first time since I`ve owned this stock (about 4 years now)I`m absolutely confident that the company will secure the cash they need.
david1
Und noch was.
Orasure hat schon mal vor ca. zwei Jahren versucht Caly schlecht zu machen. Ist allerdings nicht ganz gelungen.
Ich dachte immer, Orasure hat ein Speichel Rapid-Test.
So wie ich jetzt überalle lese, ist das ein Blut
Rapid-Test.
Ist ja klar, dass die Angst haben, wer kauft schon heute ein Blut-Test, wenn das mit pinkeln besser geht und ist auch noch billiger.
david1
Orasure hat schon mal vor ca. zwei Jahren versucht Caly schlecht zu machen. Ist allerdings nicht ganz gelungen.
Ich dachte immer, Orasure hat ein Speichel Rapid-Test.
So wie ich jetzt überalle lese, ist das ein Blut
Rapid-Test.
Ist ja klar, dass die Angst haben, wer kauft schon heute ein Blut-Test, wenn das mit pinkeln besser geht und ist auch noch billiger.
david1
@DAVID 1
Und wieder
WJXX
Drug Agency Approves a Quick Test for H.I.V.
New York Times - 3 hours ago
WASHINGTON, Nov. 7 The Food and Drug Administration approved a test today that can detect whether someone is infected with H.I.V., the virus that causes AIDS, in as little as 20 minutes. Experts said that advance might prompt thousands more ...
New HIV test promises rapid results Pakistan Frontier Post
Government Approves Quick and Easy HIV Test GWBlitz
Newsday - Wired News - Smart Money - OfficialSpin - and 50 related »
JS200
Und wieder
WJXX
Drug Agency Approves a Quick Test for H.I.V.
New York Times - 3 hours ago
WASHINGTON, Nov. 7 The Food and Drug Administration approved a test today that can detect whether someone is infected with H.I.V., the virus that causes AIDS, in as little as 20 minutes. Experts said that advance might prompt thousands more ...
New HIV test promises rapid results Pakistan Frontier Post
Government Approves Quick and Easy HIV Test GWBlitz
Newsday - Wired News - Smart Money - OfficialSpin - and 50 related »
JS200
@js200
Klar, müssen die agresive Werbung machen.
Wenn Caly mit Urin Rapid Test kommt, ist der Erfolg mit Blut vorbei.
Rechne Anfang 2003 mit der Caly - FDA Zulassung.
david1
Klar, müssen die agresive Werbung machen.
Wenn Caly mit Urin Rapid Test kommt, ist der Erfolg mit Blut vorbei.
Rechne Anfang 2003 mit der Caly - FDA Zulassung.
david1
CNN
Bill Gates hands out millions to fight AIDS in India
CNN - 10 minutes ago
Microsoft Corp Chairman Bill Gates has announced a $100 million grant to battle HIV/AIDS in India, which has the world`s second largest number of victims of the deadly disease.
Gates group gives $100 million for India AIDS fight Seattle Post Intelligencer
Gates on India Aids mission BBC
The Register - Ananova - Ireland Online - Rediff - and 125 related »
JS200
Bill Gates hands out millions to fight AIDS in India
CNN - 10 minutes ago
Microsoft Corp Chairman Bill Gates has announced a $100 million grant to battle HIV/AIDS in India, which has the world`s second largest number of victims of the deadly disease.
Gates group gives $100 million for India AIDS fight Seattle Post Intelligencer
Gates on India Aids mission BBC
The Register - Ananova - Ireland Online - Rediff - and 125 related »
JS200
Bill Gates hands out millions to fight AIDS in India
Monday, November 11, 2002 Posted: 5:15 PM HKT (0915 GMT)
Bill Gates is the world`s richest man, and has many Indian engineers working for him
--------------------------------------------------------------------------------
Story Tools
--------------------------------------------------------------------------------
RELATED
• HIV epidemic could triple by 2010
• Proteins may stop replication of HIV
• China frees AIDS activist
• China AIDS a "titanic peril`
RESOURCES
• Map: World HIV and AIDS statistics
• Animation: How HIV infects cells
--------------------------------------------------------------------------------
Gallery: AIDS in Asia
NEW DELHI, India (Reuters) -- Microsoft Corp Chairman Bill Gates has announced a $100 million grant to battle HIV/AIDS in India, which has the world`s second largest number of victims of the deadly disease.
The announcement on Monday came at the start of a four-day visit by Gates to India. The donation was the largest single-country grant by his charity, the Bill & Melinda Gates Foundation, a foundation spokeswoman told Reuters.
A foundation statement said the India AIDS Initiative would work to provide mobile populations better access to proven HIV-prevention interventions.
The drive would target truck drivers and migrant laborers, among others, who are seen as vulnerable to HIV infection.
India has four million HIV-positive cases, the highest after South Africa. Some reports estimate the number of people afflicted in India could reach 20 million by 2010.
Some 20 percent of Microsoft`s engineers are of Indian origin and Gates said in a recent interview the company took a special interest in the country because of that.
Earlier, Gates met patients suffering from HIV/AIDS at Naz Foundation, an Indian volunteer group working to heighten awareness about the disease.
Gates, the richest man in the world and whose company dominates the personal computer software market, will also meet Indian leaders, business people and technology experts during the four-day trip.
A government spokesman said Gates met Prime Minister Atal Behari Vajpayee and briefed him about his charity`s efforts to spread AIDS awareness in India.
Vajpayee assured Gates the government would cooperate with the charity in its programmes, the spokesman said.
Gates, on his third Indian visit in five years, is also expected to announce that Microsoft is stepping up its Indian software involvement, a source close to the company told Reuters.
Microsoft has a software centre in the southern Indian city of Hyderabad, one of the few outside the United States.
Gates is due to meet Indian President A.P.J. Abdul Kalam, who is keen to harness software for use by India`s masses.
--------------------------------------------------------------------------------
Copyright 2002 Reuters. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
JS200
Monday, November 11, 2002 Posted: 5:15 PM HKT (0915 GMT)
Bill Gates is the world`s richest man, and has many Indian engineers working for him
--------------------------------------------------------------------------------
Story Tools
--------------------------------------------------------------------------------
RELATED
• HIV epidemic could triple by 2010
• Proteins may stop replication of HIV
• China frees AIDS activist
• China AIDS a "titanic peril`
RESOURCES
• Map: World HIV and AIDS statistics
• Animation: How HIV infects cells
--------------------------------------------------------------------------------
Gallery: AIDS in Asia
NEW DELHI, India (Reuters) -- Microsoft Corp Chairman Bill Gates has announced a $100 million grant to battle HIV/AIDS in India, which has the world`s second largest number of victims of the deadly disease.
The announcement on Monday came at the start of a four-day visit by Gates to India. The donation was the largest single-country grant by his charity, the Bill & Melinda Gates Foundation, a foundation spokeswoman told Reuters.
A foundation statement said the India AIDS Initiative would work to provide mobile populations better access to proven HIV-prevention interventions.
The drive would target truck drivers and migrant laborers, among others, who are seen as vulnerable to HIV infection.
India has four million HIV-positive cases, the highest after South Africa. Some reports estimate the number of people afflicted in India could reach 20 million by 2010.
Some 20 percent of Microsoft`s engineers are of Indian origin and Gates said in a recent interview the company took a special interest in the country because of that.
Earlier, Gates met patients suffering from HIV/AIDS at Naz Foundation, an Indian volunteer group working to heighten awareness about the disease.
Gates, the richest man in the world and whose company dominates the personal computer software market, will also meet Indian leaders, business people and technology experts during the four-day trip.
A government spokesman said Gates met Prime Minister Atal Behari Vajpayee and briefed him about his charity`s efforts to spread AIDS awareness in India.
Vajpayee assured Gates the government would cooperate with the charity in its programmes, the spokesman said.
Gates, on his third Indian visit in five years, is also expected to announce that Microsoft is stepping up its Indian software involvement, a source close to the company told Reuters.
Microsoft has a software centre in the southern Indian city of Hyderabad, one of the few outside the United States.
Gates is due to meet Indian President A.P.J. Abdul Kalam, who is keen to harness software for use by India`s masses.
--------------------------------------------------------------------------------
Copyright 2002 Reuters. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
JS200
#1977
für 100 Mille hätte er auch Caly kaufen können
für 100 Mille hätte er auch Caly kaufen können
derzeit recht starke käufe. ist das nur ein tech. rebound, oder kommen doch noch news. sonst stagniert der kurs immer um die "mittagszeit"!!!
derzeit 11,2 cent oder 12% im plus. 685.300 stücke gehandelt bei 69 trades...
derzeit 11,2 cent oder 12% im plus. 685.300 stücke gehandelt bei 69 trades...
Aus dem Ami Board
Company Contact: Investor Relations Contact:
Richard Brounstein, Brendan Lahiff/Kirsten Chapman
Chief Financial Officer Lippert/Heilshorn & Associates
(510) 749-5156 (415) 433-3777
email:rbrounstein@calypte.com email:brendan@lhai-sf.com
To: Calypte Followers
From: Calypte Investor Relations
Date: November 11, 2002
Re: Calypte Executive Chairman Interviewed on BioBusiness
Network: www.biobn.com
Anthony Cataldo Emphasizes Benefits of Urine-Based Testing and
Provides Background on Calypte`s Recent Progress and Milestones
On the heels of the excitement over a new rapid blood test gaining FDA
approval, Anthony Cataldo, Calypte`s Executive Chairman, discussed the
benefits of the company`s products and its own progress toward a safe,
completely non-invasive urine-based rapid HIV test with BioBusiness
Network.
Interested parties can access the interview on the Internet at
www.biobn.com, and search for "Calypte." The interview will be
available for the next few days, and is part of the company`s
continuing efforts to gain exposure within the medical and investment
communities.
David
Company Contact: Investor Relations Contact:
Richard Brounstein, Brendan Lahiff/Kirsten Chapman
Chief Financial Officer Lippert/Heilshorn & Associates
(510) 749-5156 (415) 433-3777
email:rbrounstein@calypte.com email:brendan@lhai-sf.com
To: Calypte Followers
From: Calypte Investor Relations
Date: November 11, 2002
Re: Calypte Executive Chairman Interviewed on BioBusiness
Network: www.biobn.com
Anthony Cataldo Emphasizes Benefits of Urine-Based Testing and
Provides Background on Calypte`s Recent Progress and Milestones
On the heels of the excitement over a new rapid blood test gaining FDA
approval, Anthony Cataldo, Calypte`s Executive Chairman, discussed the
benefits of the company`s products and its own progress toward a safe,
completely non-invasive urine-based rapid HIV test with BioBusiness
Network.
Interested parties can access the interview on the Internet at
www.biobn.com, and search for "Calypte." The interview will be
available for the next few days, and is part of the company`s
continuing efforts to gain exposure within the medical and investment
communities.
David
hi alle, hier die Übersetzung von Lycos
Anthony Cataldo betont Nutzen Der urin-gegründeten Prüfung
und versorgt Hintergrund auf Calypte ` s Neuer(jüngster)
Fortschritt und Meilensteine Auf den Fersen der Aufregung
über einer neuen schnellen Blutprobe, die FDA Billigung,
Anthony Cataldo, Calypte ` s Exekutivvorsitzender erreicht,
besprach den Nutzen der Firma ` s Produkte und sein eigener
Fortschritt zu einem Safe, vollkommen nichtangreifender
urin-gegründeter schneller HIV Test mit BioBusiness-Netzwerk.
Interessenten können auf das Interview auf dem Internet an
www.biobn.com zugreifen, und " Calypte suchen.
" Das Interview wird für die nächsten einigen Tage
vorhanden sein, und ist Teil der Firma ` s weitermachende
Bemühungen, Aussetzung innerhalb der medizinischen
Investitionsgemeinschaften zu erreichen.
Anthony Cataldo betont Nutzen Der urin-gegründeten Prüfung
und versorgt Hintergrund auf Calypte ` s Neuer(jüngster)
Fortschritt und Meilensteine Auf den Fersen der Aufregung
über einer neuen schnellen Blutprobe, die FDA Billigung,
Anthony Cataldo, Calypte ` s Exekutivvorsitzender erreicht,
besprach den Nutzen der Firma ` s Produkte und sein eigener
Fortschritt zu einem Safe, vollkommen nichtangreifender
urin-gegründeter schneller HIV Test mit BioBusiness-Netzwerk.
Interessenten können auf das Interview auf dem Internet an
www.biobn.com zugreifen, und " Calypte suchen.
" Das Interview wird für die nächsten einigen Tage
vorhanden sein, und ist Teil der Firma ` s weitermachende
Bemühungen, Aussetzung innerhalb der medizinischen
Investitionsgemeinschaften zu erreichen.
wow, ist das tot hier...wie bei einer beerdigung...keine meinungen mehr, kein interesse??? schafft caly die wende und somit eher seine tests an den mann zu bringen als der konkurrent???
es müßte doch mal eine stellungnahme von caly erfolgen, sonst schlafen die umsätze bald auch ein...
es müßte doch mal eine stellungnahme von caly erfolgen, sonst schlafen die umsätze bald auch ein...
Keine Angst joelu, Caly geht bald wieder ab.
Caly hat keine Konkurenz, auch wenn Orasure schnelle mit FDA war. Blut Test ist für die Zukunft Kacke.
david
Caly hat keine Konkurenz, auch wenn Orasure schnelle mit FDA war. Blut Test ist für die Zukunft Kacke.
david
Habt Ihr alle verkauft, warum meldet sich hier keiner?
david
david
@DAVID
Ich habe meine noch
OSUR, hat noch nicht alle Staaten unter Vertrag, Vorteil von Caly
OSUR, welcher Afrikaner lässt sich schon gerne Blut nehmen, wenn Pinkeln genügt
Caly ist mit Sicherheit billiger
JS200
Ich habe meine noch
OSUR, hat noch nicht alle Staaten unter Vertrag, Vorteil von Caly
OSUR, welcher Afrikaner lässt sich schon gerne Blut nehmen, wenn Pinkeln genügt
Caly ist mit Sicherheit billiger
JS200
@ js200
Das mit dem Blut ist sowieso absolute Kacke, weil:
A) Es ist zu teuer.
B) Man muss Spritzen und Nadeln sorgfältig entsorgen.
Urin kannst Du in jeder beliebige Toilette wegspülen .
c) Es gibt verschiedene Glaubens Gemeinschaften oder Sekten wie Jehova usw., die lassen sich kein Blut abnehmen, auch wenn es um eigene Gesundheit geht.
D) Was meinst Du, wenn Caly die Zulassung hat, geht Osur baden.
David
Das mit dem Blut ist sowieso absolute Kacke, weil:
A) Es ist zu teuer.
B) Man muss Spritzen und Nadeln sorgfältig entsorgen.
Urin kannst Du in jeder beliebige Toilette wegspülen .
c) Es gibt verschiedene Glaubens Gemeinschaften oder Sekten wie Jehova usw., die lassen sich kein Blut abnehmen, auch wenn es um eigene Gesundheit geht.
D) Was meinst Du, wenn Caly die Zulassung hat, geht Osur baden.
David
hab meine auch noch!
"weil zu geldgeil"
außerdem gönn ich uns allen mal noch nen gewinn!
außerdem sollen die, die es noch nicht wissen, es möglich schmerzlos erfahren!
der "positive" test ist schon hart genug!
M1
"weil zu geldgeil"
außerdem gönn ich uns allen mal noch nen gewinn!
außerdem sollen die, die es noch nicht wissen, es möglich schmerzlos erfahren!
der "positive" test ist schon hart genug!
M1
Investor Alert
A Form 8-K regarding Calypte Biomedical Corp. has been filed with the United States Securities and Exchange Commission.
Click on the following hyperlink to view this filing:
http://www.calypte.com/INVESTORS/InvHme.html
Please Note: The hyperlink for the filing may not retrieve the filing if
the address extends to more than one line. If this should occur, please
copy the full text of the address for the filing into the address box in
your web browser.
_________________________________________________________
JS200
A Form 8-K regarding Calypte Biomedical Corp. has been filed with the United States Securities and Exchange Commission.
Click on the following hyperlink to view this filing:
http://www.calypte.com/INVESTORS/InvHme.html
Please Note: The hyperlink for the filing may not retrieve the filing if
the address extends to more than one line. If this should occur, please
copy the full text of the address for the filing into the address box in
your web browser.
_________________________________________________________
JS200
CALYPTE BIOMEDICAL CORP filed this 8-K on 11/12/2002.
Outline Printer Friendly
Next Page »
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------------------------------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported) November 8, 2002
CALYPTE BIOMEDICAL CORPORATION.
Exact name of Registrant as specified in its Charter)
DELAWARE
(State or other jurisdiction of incorporation)
000-20985 06-1226727
Commission File No. I.R.S. Employer Identification
1265 Harbor Bay Parkway, Alameda, CA 94502
Address of principal executive offices Zip Code
(510) 749-5100
Registrant’s telephone number, including area code
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
ITEM 5. OTHER EVENTS
As previously disclosed, in May of 2002, the Registrant (the “Company”) entered into an arrangement with Cataldo Investment Group, a group of non-affiliated investors, referred to under the acronym (“CIG”) to arrange for up to $5,000,000 in financing for the Company on or before May 17, 2003. At the present time, financing in excess of $5,000,000 attributed to CIG has been obtained. Annexed hereto as Exhibit 10.115 is a copy of the CIG arrangement. In that regard, the Company incorporates, by reference, its 8-K Report filed on July 17, 2002 and its 10-Q Report for the period ending June 30, 2002, with respect to the financing arrangements previously attributed to CIG.
· In addition to the previously reported financing transactions and supplementing the CIG commitment, on September 12, 2002 the Company entered into a financing agreement with Mercator Momentum Fund LP (“Mercator”). The Mercator Agreement provided for a credit facility up to the sum of $2,000,000 at 12% interest per annum due on September 12, 2004 or in the event of sale or merger of the Company. In connection with the Mercator financing agreement, a convertible promissory note issued to Mercator further provides for a conversion feature wherein Mercator can convert principal and interest due on the debt obligation to shares of common stock of the Company at the average of the lowest three inter-day trading prices over the twenty (20) consecutive trading days immediately prior to the conversion. The conversion price will be equal to eighty-five percent (85%) of the trading market price, with a floor of $.05 per share.
The terms of financing further provided for the Company to pay a commitment fee of ten percent (10%) of the total credit facility on closing of the initial $550,000 traunch. Additionally, the Company further granted registration rights for the underlying shares of the debenture and agreed to file a Registration Statement within 45 days, registering 200% of the amount of common stock necessary for conversion of the initial funding ($550,000). The Agreement also provided that, in the event of a default with respect to the Company’s failure to file a Registration Statement,
--------------------------------------------------------------------------------
which Registration Statement is not approved within 90 days thereafter, the Company shall issue to Mercator 10,000 shares of the Company’s common stock a day for the time of the default until said default is corrected up to the lower of 18% per annum or the highest rate permitted by law. The Company subsequently amended the Mercator Debenture to extend the default in the registration provision for 45 days.
The Company issued 500,000 shares of its restricted common stock on closing to Mercator as part of the funding costs, and also agreed to register the shares without cost to Mercator. Annexed hereto and marked as Exhibit 10.116 is a copy of the Mercator Term Sheet and form of Registration Rights Agreement.
· On August 28, 2002, an aggregate of $400,000 was invested in the Company by Caledonia Corporate Group, Ltd. (“Caledonia”) and Careen Ltd. (“Careen”). Caledonia purchased 4,000,000 restricted shares of common stock of the Company at $.05 per share in a Regulation S transaction, and Careen purchased 4,000,000 restricted shares of the Company’s common stock at $.05 per share in a Regulation S transaction. In connection with the transactions, the Company agreed to pay Brigand Capital Corp. a ten percent (10%) financial consulting fee or the sum of $40,000, and granted cost-free registration rights to Caledonia and Careen. The form of the subscription agreement is annexed hereto as Exhibit 10.117.
· On June 17, 2002, the Company sold a $100,000 8% convertible debenture to Ms. Su So in a Regulation S transaction that was subsequently converted into 1,100,000 shares of restricted common stock. On July 3, 2002, the Company sold a $100,000 8% convertible debenture to Mr. Jason Arasheben in a Regulation S transaction that was subsequently converted into 474,493 shares of restricted common stock. The Company agreed to pay a finder’s fee of ten percent (10%) for each transaction to Mr. Blake Ransom. The Company granted cost-free best efforts registration rights to the purchasers.
--------------------------------------------------------------------------------
· In connection with the previously reported 8% convertible note transactions on Form 8-K (July 17, 2002) totaling $2,625,000, the Company reported in its Form 10-Q for the quarter ended June 30, 2002 that it had issued an additional $250,000 of such notes. On August 21, 2002, the Company issued an additional $250,000 of such notes, so that as of November 8, 2002, the Company had issued a total of $3,125,000 of 8% convertible notes. In conjunction with these transactions, the Company paid a 15% finder’s fee to Bi-Coastal Consulting Corporation (“Bi-Coastal”) or the sum of $418,750. Annexed hereto as Exhibit 10.118 is a copy of the subscription agreement.
· The Company further incorporates by reference prior reports filed with respect to the Townsbury, Ltd. (“Townsbury”) equity credit line transaction. In connection with the Townsbury equity credit line, the Company paid finder’s fee of five percent (5%) or $70,000 to Bi-Coastal, as a result of the draw-down on the Company’s equity credit line with Townsbury.
· As previously reported in the Company’s Form 10-Q for the period ended June 30, 2002, the Company issued a ten percent (10%) convertible promissory note to BNC Bach International Ltd. in a Regulation S transaction. A finder’s fee of ten percent (10%) was paid to Bi-Coastal in connection with this transaction.
EXHIBITS
10.115 Investment Commitment Arrangement with Cataldo Investment Group;
10.116 Term Sheet for Mercator Momentum Fund LP and Registration Rights Agreement;
10.117 Form of Subscription Agreement under Regulation S for Caledonia Corporate Group Ltd. and Careen Ltd.
10.118 Bi-Coastal Consulting, Inc. Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant
--------------------------------------------------------------------------------
has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: Alameda, California
November 12, 2002
CALYPTE BIOMEDICAL CORPORATION
--------------------------------------------------------------------------------
(Registrant)
/S/ ANTHONY J. CATALDO
--------------------------------------------------------------------------------
ANTHONY J. CATALDO
Executive Chairman
Exhibit 10.115
CATALDO INVESTMENT GROUP
Calypte Biomedical Corporation
1265 Harbor Bay Parkway
Alameda, CA 94502
Re: Cataldo Investment Group (“CIG”)
With Calypte Biomedical Corporation
(“CALY” or the “Company”)
Dear Ms. Katz:
The within is to confirm that as of May 9, 2002, the terms of the independent CIG investment proposal will be amended as stated herein:
CIG is agreeable to arranging for an aggregate of $1,400,000 within 90 days of May 10, 2002 as a combination of equity investments and/or convertible debentures from accredited investors for the express purpose of utilizing said funds to continue the operation of the Company’s business.
It is understood that the Company has issued a press release announcing that the Company is in danger of shutting down its operations and may be compelled to close its doors. Resultantly, the within amended proposal is subject to the following:
a) An aggregate of $5,000,000 to be invested in CALY prior to May 10, 2003, subject to terms negotiated in separate independent arms-length transactions with accredited investors;
b) Mr. Anthony Cataldo to serve as Executive Chairman of the Company with authority to utilize the services of financial business or management consultants and/or professionals, accountants, attorneys etc. as he may deem necessary to accomplish the goal of re-starting and continuing the Company’s business operations going forward;
--------------------------------------------------------------------------------
c) Mr. Cataldo, to obtain authority from the Board to disburse investment funds attributed to CIG; and
d) Mr. Cataldo, to have the right to appoint new directors, which directors may constitute a majority of the Board, within 30 days of the date hereof. The current Board of Directors will continue to serve during the interim period and, thereafter, continue to work with Mr. Cataldo in the interest of the Company and its stockholders.
e) The within amendment to supercede any prior understandings or agreements whether oral or written.
If the foregoing is agreeable, please acknowledge your consent to the within and provide a confirmation of an Officer’s Certificate and/or Board Resolution concerning the amendment.
Very truly yours,
CATALDO INVESTMENT GROUP
By: /s/ ANTHONY J. CATALDO
--------------------------------------------------------------------------------
ANTHONY J. CATALDO
AGREED TO AS OF MAY 9, 2002:
CALYPTE BIOMEDICAL CORPORATION
By: /s/ NANCY E. KATZ
--------------------------------------------------------------------------------
NANCY KATZ, President and CEO
Exhibit 10.116
Mercator Momentum Fund, LP.
TERM SHEET
This Term Sheet is intended as an outline of the basic terms upon which Mercator Momentum Fund, LP (“Mercator” or “Lender”) would be willing to consider the extension of credit to Calypte Biomedical Corporation (“Borrower” or “Company”). This Term Sheet should not be construed as an offer to lend based upon such terms or as a binding commitment. The terms set forth herein are based on limited information provided by Borrower and are subject to change pending the completion of due diligence and the approval of Mercator’s loan committee. Until the parties have executed a definite loan agreement and related documentation, neither Mercator nor its partners shall have any obligation to fund the loan outlined herein.
September 12, 2002
Borrower: Calypte Biomedical Corporation
1265 Harbor BayParkway
Alameda, CA 94502
Tel: (510) 749-5100
Fax: (510) 526-5381
Lender: Mercator Momentum Fund, LP and/or other participants from time to time (collectively referred to as “Lender”).
Total Credit Facility: $2,000,000
Debenture Tranche Funding $550,000 for 1st Debenture funding, $500,000 Debenture funding thereafter per 30 day subject to conditions as set forth herein.
Availability: Immediately upon the signing of a definitive agreement reflecting the Terms set forth herein.
Conditions Precedent: N/A.
Market Price: Market Price shall mean the average of the lowest three inter-day trading prices (which need not occur on consecutive Trading Days) during the twenty Trading Days immediately preceding the applicable Conversion Date (which may include Trading Days prior to the Original Issue Date), provided, that such thirty Trading Day period shall be extended for the number of Trading Days during such period in which (A) trading in the Common Stock is suspended by, or not traded on, the pink sheets or a Subsequent Market on which the Common Stock is then listed, or (B) after the date declared effective by the Commission, the Underlying Shares Registration Statement is either not effective or the Prospectus included in the Underlying Shares Registration Statement may not be used by the Holder for the resale of Underlying Shares.
--------------------------------------------------------------------------------
Repayment: Monthly interest, principal on maturity. Interest shall accrue until Maturity or paid in kind upon conversion.
Rate: 12% APR
Commitment Fee: The Company shall pay a Commitment Fee equal to 10% of the Total Credit Facility. The entire Commitment Fee will be net funded from upon initial debenture funding.
Maturity: The earlier of September 12, 2004 (the “Maturity Date”), the Borrower’s next equity event, or a sale or merger.
Conversion: The Note shall be convertible at the Lender’s sole discretion in part or in whole at a price equal to 85% of the Market Price. Notwithstanding the foregoing, the Lender will not convert should the Market Price of Company be below $0.05
Registration: Upon the initial debenture funding of $550,000, the Company shall have a Registration Statement submitted to the SEC within 45 Days registering 200% of the common stock of the company available for conversion immediately after the initial funding. Furthermore, the Registration Statement must be deemed effective by the SEC for the Company to receive any additional Debenture tranches. Such tranches will be available to Company in 30 day increments.
Default: At an event of Default (failure to make interest and/or principle payment(s) when due, failure to submit Registration statement within 45 Days, and/or failure to have Registration statement approved within 90 Days thereafter) the Company shall issue to the Lender 10,000 shares of Company’s common stock per day from the time of Default until Default is corrected and the lower of 18% APR or the highest rate of interest permitted by law. The corresponding Registration statement shall be amended immediately by Company to include the Default shares, if any.
Common Stock: For the first Debenture in the amount of $550,000, the Company shall issue the Lender 500,000 shares of common stock of Company. Such stock shall be included in a Registration Statement. For each Debenture thereafter the Lender will also receive additional common stock of the Company as agreed by both parties.
Extension: N/A
Collateral: N/A
Debt Subordination: N/A
Warrants: N/A
Financial None; provided, however, the proceeds of the Credit Facility shall not be
--------------------------------------------------------------------------------
Covenants: available to reduce or retire any insider note or convertible debt.
Reporting: Monthly Financials
Documentation: Lender’s standard documents, including: conditions to advances, representations and warranties on company status, legal compliance, liens, legal compliance; covenants on investments, liens, debt, dispositions, insurance; remedies, jury waiver and California law provisions.
Expenses: Borrower to reimburse Lender for all out of pocket costs in connection with the underwriting, legal, documentation and funding of the Credit facility.
Deposit: N/A
Confidentiality: This Term Sheet is confidential and proprietary to Lender. Please treat it with the same respect that we treat your private information and do not disclose it to any third parties.
To confirm your agreement with these basic terms, and to permit us to proceed with our due diligence, please fax an executed copy of this Term Sheet to our office (213.533.8285) and deliver the executed original and the Deposit to our office via courier by 5:30 p.m. September 12, 2002:
Mercator Momentum Fund, LP.
555 South Flower Street, Suite 4500
Los Angeles, CA 90071
THIS TERM SHEET EXPIRES AT
5:30 p.m. (PST) on September 12, 2002.
MERCATOR MOMENTUM FUND, LP.
--------------------------------------------------------------------------------
/s/ ANSHUMAN “ANDY” DUBE
--------------------------------------------------------------------------------
Anshuman “Andy” Dube
General Partner
Agreed and confirmed:
Calypte Biomedical Corporation
By: /s/ ANTHONY J. CATALDO
Title: Executive Chairman
Date: September 12, 2002
--------------------------------------------------------------------------------
REGISTRATION RIGHTS AGREEMENT
AGREEMENT dated as of the 12th day of September, 2002, between the person whose name and address appears in the convertible debenture (individually, a “Holder” or, collectively with the holders of the Securities issued in the Offering, each as defined below, the “Holders”), and CALYPTE BIOMEDICAL CORPORATION., a Delaware corporation having its principal executive office at 1265 Harbor Bay Parkway, Alameda, CA 94502 (the “Company”).
WHEREAS, the Holders have previously subscribed to a convertible debenture (the “Debenture”) with the Company in the principal amount of U.S. $550,000 (the “Offering”). The Holders, upon conversion of the debenture may own up to a maximum of 11,000,000 Units (the “Units”), each Unit consisting of one share of Common Stock, $.001 par value (the “Common Stock”) of the Company.
WHEREAS, the Company desires to grant to the Holder the registration rights set forth herein with respect to the Shares;
NOW, THEREFORE, the parties hereto mutually agree as follows:
1. Registrable Securities. As used herein the term “Registrable Security” means each of the shares of Common Stock included in the Units; provided, however, that with respect to any particular Registrable Security, such security shall cease to be a Registrable Security when, as of the date of determination, (i) it has been effectively registered under the Securities Act of 1933, as amended (the “Securities Act”) and disposed of pursuant thereto, or (ii) registration under the Securities Act is no longer required for the immediate public distribution of such security. The term “Registrable Securities” means any and/or all of the securities falling within the foregoing definition of a “Registrable Security.” In the event of any merger, reorganization, consolidation, recapitalization or other change in corporate structure affecting the Common Stock, such adjustment shall be made in the definition of “Registrable Security” as is appropriate in order to prevent any dilution or enlargement of the rights granted pursuant to this Section 1.
2. Registration. The Company agrees to file a registration statement (a “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) within 45 days of the completion of the Offering in order to register the resale of the Registrable Securities under the Securities Act. Once effective, the Company will be required to maintain the effectiveness of the Registration Statement until the earlier of (i) the date that all of the Registrable Securities have been sold, or (ii) the date that the Company receives an opinion of counsel to the Company that all of the Registrable Securities may be freely traded without registration under the Securities Act, under Rule 144 promulgated under the Securities Act or otherwise.
3. Covenants of the Company With Respect to Registration.
--------------------------------------------------------------------------------
The Company covenants and agrees as follows:
(1) connection with any registration filed pursuant hereto, the Company shall use its best efforts to cause the Registration Statement to become effective as promptly as possible and, if any stop order shall be issued by the Commission in connection therewith, to use its reasonable efforts to obtain the removal of such order. Following the effective date of a Registration Statement, the Company shall, upon the request of the Holder, forthwith supply such reasonable number of copies of the Registration Statement, preliminary prospectus and prospectus meeting the requirements of the Securities Act, and other documents necessary or incidental to the public offering of the Registrable Securities, as shall be reasonably requested by the Holder to permit the Holder to make a public distribution of the Holder’s Registrable Securities. The obligations of the Company hereunder with respect to the Holder’s Registrable Securities are subject to the Holder’s furnishing to the Company such appropriate information concerning the Holder, the Holder’s Registrable Securities and the terms of the Holder’s offering of such Registrable Securities as the Company may reasonably request in writing.
(2) The Company shall pay all costs, fees and expenses in connection with all Registration Statements filed pursuant to Section 2 hereof including, without limitation, the Company’s legal and accounting fees, printing expenses, and blue sky fees and expenses; provided, however, that the Holder shall be solely responsible for the fees of any counsel retained by the Holder in connection with such registration and any transfer taxes or underwriting discounts, commissions or fees applicable to the Registrable Securities sold by the Holder pursuant thereto.
(3) The Company will take all necessary action which may be required in qualifying or registering the Registrable Securities included in a Registration Statement for offering and sale under the securities or blue sky laws of such states as are reasonably requested by the holders of such securities, provided that the Company shall not be obligated to execute or file any general consent to service of process or to qualify as a foreign corporation to do business under the laws of any such jurisdiction.
4. Additional Terms.
(1) The Company shall indemnify and hold harmless the Holder and each underwriter, within the meaning of the Securities Act, who may purchase from or sell for the Holder, any Registrable Securities, from and against any and all losses, claims, damages and liabilities caused by any untrue statement of a material fact contained in the Registration Statement, any other registration statement filed by the Company under the Securities Act with respect to the registration of the Registrable Securities, any post-effective amendment to such registration statements, or any prospectus included therein or caused by any omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission based upon information furnished or required to be furnished in writing to the Company by the Holder or underwriter expressly for use therein, which indemnification shall include each person, if any, who controls either the Holder or underwriter
--------------------------------------------------------------------------------
within the meaning of the Securities Act and each officer, director, employee and agent of the Holder and underwriter; provided, however, that the indemnification in this Section 5(a) with respect to any prospectus shall not inure to the benefit of the Holder or underwriter (or to the benefit of any person controlling the Holder or underwriter) on account of any such loss, claim, damage or liability arising from the sale of Registrable Securities by the Holder or underwriter, if a copy of a subsequent prospectus correcting the untrue statement or omission in such earlier prospectus was provided to the Holder or underwriter by the Company prior to the subject sale and the subsequent prospectus was not delivered or sent by the Holder or underwriter to the purchaser prior to such sale and provided further, that the Company shall not be obligated to so indemnify the Holder or any such underwriter or other person referred to above unless the Holder or underwriter or other person, as the case may be, shall at the same time indemnify the Company, its directors, each officer signing the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act, from and against any and all losses, claims, damages and liabilities caused by any untrue statement of a material fact contained in the Registration Statement, any registration statement or any prospectus required to be filed or furnished by reason of this Agreement or caused by any omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, insofar as such losses, claims, damages or liabilities are caused by any untrue statement or omission based upon information furnished in writing to the Company by the Holder or underwriter expressly for use therein.
(2) If for any reason the indemnification provided for in the preceding section is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, claim, damage, liability or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect not only the relative benefits received by the indemnified party and the indemnifying party, but also the relative fault of the indemnified party and the indemnifying party, as well as any other relevant equitable considerations.
(3) Neither the filing of a Registration Statement by the Company pursuant to this Agreement nor the making of any request for prospectuses by the Holder shall impose upon the Holder any obligation to sell the Holder’s Registrable Securities.
(4) The Holder, upon receipt of notice from the Company that an event has occurred which requires a Post-Effective Amendment to the Registration Statement or a supplement to the prospectus included therein, shall promptly discontinue the sale of Registrable Securities until the Holder receives a copy of a supplemented or amended prospectus from the Company, which the Company shall provide as soon as practicable after such notice.
(5) If the Company fails to keep the Registration Statement referred to above continuously effective during the requisite period, then the Company shall, promptly upon the request of the Holders of at least a majority of the unsold Registrable Securities, use its best efforts to update the Registration Statement or file a new registration statement covering the Registrable Securities remaining unsold, subject to the terms and provisions hereof.
--------------------------------------------------------------------------------
(6) The Holder agrees to provide the Company with any information or undertakings reasonably requested by the Company in order for the Company to include any appropriate information concerning the Holder in the Registration Statement or in order to promote compliance by the Company or the Holders with the Securities Act.
5. Governing Law. The Registrable Securities will be, if and when issued, delivered in California. This Agreement shall be deemed to have been made and delivered in the State of California and shall be governed as to validity, interpretation, construction, effect and in all other respects by the internal substantive laws of the State of California, without giving effect to the choice of law rules thereof.
6. Amendment. This Agreement may only be amended by a written instrument executed by the Company and the Holder.
7. Entire Agreement. This Agreement constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.
8. Execution in Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same document.
9. Notices. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed duly given when delivered by hand or mailed by registered or certified mail, postage prepaid, return receipt requested, as follows:
If to the Holder, to his, her or its address set forth in the Purchaser Questionnaire.
If to the Company, to the address set forth on the first page of this Agreement.
10. Binding Effect; Benefits. The Holder may assign his, her or its rights hereunder. This Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their respective heirs, legal representatives and successors. Nothing herein contained, express or implied, is intended to confer upon any person other than the parties hereto and their respective heirs, legal representatives and successors, any rights or remedies under or by reason of this Agreement.
--------------------------------------------------------------------------------
11. Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.
12. Severability. Any provision of this Agreement which is held by a court of competent jurisdiction to be prohibited or unenforceable in any jurisdiction(s) shall be, as to such jurisdiction(s), ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.
IN WITNESS WHEREOF, this Agreement has been executed and delivered by the parties hereto as of the date first above written.
CALYPTE BIOMEDICAL CORPORATION.
By:
Name:
--------------------------------------------------------------------------------
Its:
--------------------------------------------------------------------------------
HOLDER:
MERCATOR MOMENTUM FUND, LP
By:
Its:
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
November 7, 2002
VIA E-Mail and First Class Mail
Mr. Anthony J. Cataldo
Executive Chairman
Calypte Biomedical Corp.
1265 Harbor Bay Parkway
Alameda, CA 94502
Re: Registration Rights Agreement—Waiver of Default—Amendment.
Dear Tony:
Please permit the within to confirm our prior understanding and agreement with respect to our waiver of the provision requiring Calypte Biomedical Corporation to file a Registration Statement (as defined in the Registration Rights Agreement dated as of the 12th day of September, 2002 (the “Agreement”)). The requirement to file a Registration Statement is hereby extended an additional forty five (45) days through December 11, 2002. All other terms and conditions of the Agreement remain in full force and effect unless modified in writing with the mutual consent of both parties. Please countersign this letter acknowledging your agreement to the waiver and amendment and forward a fully executed copy of this letter back to me at our office.
Should you have any questions, please call me.
Kindest Regards,
Mercator Group, LLC.
/s/ DAVID FIRESTONE
David Firestone
Managing Partner
Agreed to:
Calypte Biomedical Corporation
/s/ ANTHONY J. CATALDO
--------------------------------------------------------------------------------
Anthony J. Cataldo
Executive Chairman
EXHIBIT 10.117
SUBSCRIPTION AGREEMENT
, 2002
Dear Subscriber:
You, together with other subscribers (each a “Subscriber”) hereby agree to purchase, and Calypte Biomedical Corporation, a Delaware corporation (the “Company”), hereby agrees to issue and to sell to the Subscriber, Shares of the Company’s $.001 par value common stock (the “Company Shares”) for the consideration as set forth on the signature page hereof (“Purchase Price”). (The Company Shares are sometimes referred to herein as the “Shares”, “Common Shares”, “Securities”, or “Common Stock”). Upon acceptance of this Agreement by the Subscriber, the Company shall issue and deliver the Shares against payment, by federal funds wire transfer, or bank, or certified check of the Purchase Price.
The following terms and conditions shall apply to this Subscription.
1. Subscriber’s Representations and Warranties. The Subscriber hereby represents and warrants to and agrees with the Company that:
(a) Information on Company. The Subscriber has been furnished with the Company’s Form 10-K and 10-K/A for the year ended December 31, 2001 as filed with the Securities and Exchange Commission (the “Commission”) together with all subsequently filed forms 10-Q, 8-K, Preliminary Proxy Statement, and pending Form S-2 Registration Statement Amendment I, and other publicly available filings made with the Commission (hereinafter referred to collectively as the “Reports”). In addition, the Subscriber has received from the Company such other information concerning its operations, financial condition and other matters as the Subscriber has requested (such information in writing is collectively, the “Other Written Information”), and considered all factors the Subscriber deems material in deciding on the advisability of investing in the Shares of Common Stock.
(b) Information on Subscriber. The Subscriber is and was not a “U.S. person”, as defined in Regulation S promulgated under the Securities Act of 1933 at the time the offer or sale of the Shares of Common Stock is made. Additionally, Subscriber is an “accredited investor”, as such term is defined in Regulation D promulgated by the Commission under the Securities Act of 1933, as amended (the “1933 Act”), is experienced in investments and business matters, has made investments of a speculative nature and has purchased securities of United States publicly-owned companies in private placements in the past and, with its representatives, has such knowledge and experience in financial, tax and other business matters as to enable the Subscriber to utilize the information made available by the Company to evaluate the merits and risks of and to make an informed investment decision with respect to the proposed purchase, which represents a speculative investment. The Subscriber has the authority and is duly and legally qualified to purchase and own the Shares of Common Stock. The Subscriber is able to bear the risk of such investment for an indefinite period and to afford a complete loss thereof. The information set forth on the signature page hereto regarding the Subscriber is accurate.
(c) Purchase of Shares. On the Closing Date, the Subscriber will purchase the Company Stock for its own account and not with a view to any distribution thereof
--------------------------------------------------------------------------------
and that the purchase of the Common Stock is intended to be made as an “Offshore Transaction” as defined in Regulation S.
(d) Compliance with Securities Act. The Subscriber understands and agrees that the Shares have not been registered under the 1933 Act, by reason of their issuance in a transaction that does not require registration under the 1933 Act (based in part on the accuracy of the representations and warranties of Subscriber contained herein), and that such Shares of Common Stock must be held unless a subsequent disposition is registered under the 1933 Act or is exempt from such registration.
(e) Company Shares Legend. The Company Shares shall bear the following legend, unless same shall have been included in an effective registration statement under the 1933 Act:
“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THESE SHARES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO CALYPTE BIOMEDICAL CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED”.
(f) Communication of Offer. The offer to sell the Shares of Common Stock was directly communicated to the Subscriber. At no time was the Subscriber presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement, or any other form of general advertising or solicited or invited to attend a promotional meeting otherwise than in connection and concurrently with such communicated offer.
(g) Correctness of Representations. The Subscriber represents that the foregoing representations and warranties are true and correct as of the date hereof and, unless the Subscriber otherwise notifies the Company prior to the Closing Date (as hereinafter defined), shall be true and correct as of the Closing Date. The foregoing representations and warranties shall survive the Closing Date.
2. Company Representations and Warranties. The Company represents and warrants to and agrees with the Subscriber that:
(a) Due Incorporation. The Company and each of its subsidiaries, if any, is a corporation duly organized, validly existing and in good standing under the laws of the respective jurisdictions of their incorporation and have the requisite corporate power to own their properties and to carry on their business as now being conducted. The Company and each of its subsidiaries is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary, other than those jurisdictions in which the failure to so qualify would not have a material adverse effect on the business, operations or financial condition of the Company.
--------------------------------------------------------------------------------
(b) Outstanding Stock. All issued and outstanding shares of capital stock of the Company and each of its subsidiaries has been duly authorized and validly issued and are fully paid and non-assessable.
(c) Authority; Enforceability. This Agreement and other agreements delivered together with this Agreement or in connection herewith have been duly authorized, executed and delivered by the Company and are valid and binding agreements enforceable in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights generally and to general principles of equity; and the Company has full corporate power and authority necessary to enter into this Agreement, and such other agreements and to perform its obligations hereunder and under all other agreements entered into by the Company relating hereto.
(d) Additional Issuances. Except as set forth on Schedule 2(d), there are no outstanding agreements or preemptive or similar rights affecting the Company’s common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or other equity interest in any of the subsidiaries of the Company except as described in the Reports or Other Written Information.
(e) Consents. No consent, approval, authorization or order of any court, governmental agency or body or arbitrator having jurisdiction over the Company, or any of its affiliates, the National Association of Securities Dealers, Inc. (“NASD”), NASDAQ or the Company’s Shareholders is required for execution of this Agreement, and all other agreements entered into by the Company relating thereto, including, without limitation, the issuance and sale of the Securities, and the performance of the Company’s obligations hereunder and under all such other agreements.
(f) No Violation or Conflict. Assuming the representations and warranties of the Subscriber in Paragraph 1 are true and correct and the Subscriber complies with its obligations under this Agreement, neither the issuance and sale of the Shares of Common Stock nor the performance of the Company’s obligations under this Agreement and all other agreements entered into by the Company relating thereto by the Company will:
(i) violate, conflict with, result in a breach of, or constitute a default (or an event which with the giving of notice or the lapse of time or both would be reasonably likely to constitute a default) under (A) the certificate of incorporation, charter or bylaws of the Company, (B) to the Company’s knowledge, any decree, judgment, order, law, treaty, rule, regulation or determination applicable to the Company of any court, governmental agency or body, or arbitrator having jurisdiction over the Company or any of its affiliates or over the properties or assets of the Company or any of its affiliates, (C) the terms of any bond, debenture, note or any other evidence of indebtedness, or any agreement, stock option or other similar plan, indenture, lease, mortgage, deed of trust or other instrument to which the Company or any of its affiliates is a party, by which the Company or any of its affiliates is bound, or to which any of the properties of the Company or any of its affiliates is subject, or (D) the terms of any “lock-up” or similar provision of any underwriting or similar agreement to which the Company, or any of its affiliates is a party except the violation, conflict, breach, or default of which would not have a material adverse effect on the Company; or
--------------------------------------------------------------------------------
(ii) result in the creation or imposition of any lien, charge or encumbrance upon the Shares of Common Stock or any of the assets of the Company, its subsidiaries or any of its affiliates.
(g) The Shares of Common Stock. The Shares upon issuance:
(i) are, or will be, free and clear of any security interests, liens, claims or other encumbrances, subject to restrictions upon transfer under the 1933 Act and State laws;
(ii) have been, or will be, duly and validly authorized and on the date of issuance and on the Closing Date, as hereinafter defined, and will be duly and validly issued, fully paid and nonassessable (and if registered pursuant to the 1933 Act, and resold pursuant to an effective Registration Statement will be free trading and unrestricted, provided that the Subscriber complies with the Prospectus delivery requirements);
(iii) will not have been issued or sold in violation of any preemptive or other similar rights of the holders of any Shares of Common Stock of the Company; and
(iv) will not subject the holders thereof to personal liability by reason of being such holders.
(h) Litigation. There is no pending or, to the best knowledge of the Company, threatened action, suit, proceeding or investigation before any court, governmental agency or body, or arbitrator having jurisdiction over the Company, or any of its affiliates that would affect the execution by the Company or the performance by the Company of its obligations under this Agreement, and all other agreements entered into by the Company relating hereto. Except as disclosed in the Securities and Exchange Commission filings, Reports or Other Written Information, there is no pending or, to the best knowledge of the Company, threatened action, suit, proceeding or investigation before any court, governmental agency or body, or arbitrator having jurisdiction over the Company, or any of its affiliates which litigation if adversely determined could have a material adverse effect on the Company.
(i) Reporting Company. The Company is a publicly-held company subject to reporting obligations pursuant to Sections 15(d) and 13 of the Securities Exchange Act of 1934, as amended (the “1934 Act”) and has a class of common shares registered pursuant to Section 12(g) of the 1934 Act. The Company’s common stock is listed for trading on the OTC Bulletin Board (“Bulletin Board”). Pursuant to the provisions of the 1934 Act, the Company has filed all reports and other materials required to be filed thereunder with the Securities and Exchange Commission during the preceding twelve months.
(j) No Market Manipulation. The Company has not taken, and will not take, directly or indirectly, any action designed to, or that might reasonably be expected to, cause or result in stabilization or manipulation of the price of the common stock of the Company to facilitate the sale or resale of the Shares of Common Stock or affect the price at which the Shares may be issued or resold.
(k) Information Concerning Company. The Reports contain all material information relating to the Company and its operations and financial condition as of their
--------------------------------------------------------------------------------
respective dates which information is required to be disclosed therein. Since the date of the financial statements included in the Reports, and except as modified in the Other Written Information or in the Schedule hereto, there has been no material adverse change in the Company’s business, financial condition or affairs not disclosed in the Reports. The Reports do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances when made.
(l) Dilution. The Company’s executive officers and directors have studied and fully understand the nature of the Stock being sold hereby and recognize that they have a potential dilutive effect. The board of directors of the Company has concluded, in its good faith business judgment, that such issuance is in the best interests of the Company. The Company specifically acknowledges that its obligation to issue the Shares upon payment is binding upon the Company and enforceable, except as otherwise described in this Subscription Agreement, regardless of the dilution such issuance may have on the ownership interests of other shareholders of the Company.
(m) Stop Transfer. The Shares of Common Stock are restricted securities as of the date of this Agreement. The Company will not issue any stop transfer order or other order impeding the sale, resale or delivery of the Stock, except as may be required by federal securities laws.
(n) Defaults. To the best of the Company’s knowledge, neither the Company nor any of its subsidiaries is in violation of its Certificate of Incorporation or ByLaws. Neither the Company nor any of its subsidiaries is (i) in default under or in violation of any other material agreement or instrument to which it is a party or by which it or any of its properties are bound or affected, which default or violation would have a material adverse effect on the Company, (ii) in default with respect to any order of any court, arbitrator or governmental body or subject to or party to any order of any court or governmental authority arising out of any action, suit or proceeding under any statute or other law respecting antitrust, monopoly, restraint of trade, unfair competition or similar matters, or (iii) to its knowledge in violation of any statute, rule or regulation of any governmental authority which violation would have a material adverse effect on the Company.
(o) No Integrated Offering. The Company believes that neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would cause the offer of the Shares of Common Stock pursuant to this Agreement to be integrated with prior offerings by the Company for purposes of the 1933 Act or any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of the Bulletin Board nor will the Company or any of its affiliates or subsidiaries take any action or steps that would cause the offering of the Common Stock to be integrated with other offerings. The Company has not conducted and will not conduct any offer other than the transactions contemplated hereby that will be integrated with the offer or issuance of the Common Stock. Subscribers warrant and represent to the Company that each Subscriber has not taken any action that would cause a violation of the integration regulation as promulgated by Federal Law as made and provided.
(p) No General Solicitation. Neither the Company, nor any of its affiliates, nor to its knowledge, any person acting on its or their behalf, has engaged in any form
--------------------------------------------------------------------------------
of general solicitation or general advertising (within the meaning of Regulation S or D under the Act) in connection with the offer or sale of the Common Stock.
(q) Listing. The Company’s Common Stock is quoted on, and listed for trading on the Bulletin Board. The Company has not received any oral or written notice that its Common Stock will be delisted from the Bulletin Board or that the Company’s Common Stock does not meet all requirements for the continuation of such listing.
(r) No Undisclosed Liabilities. The Company has no liabilities or obligations which are material, individually or in the aggregate, which are not disclosed in the Reports, Securities and Exchange Commission filings, and Other Written Information, other than those incurred in the ordinary course of the Company’s businesses since December 31, 2001 and which, individually or in the aggregate, would not reasonably be expected to have a material adverse effect on the Company’s financial condition.
(s) No Undisclosed Events or Circumstances. Since December 31, 2001, no event or circumstance has occurred or exists with respect to the Company or its businesses, properties, operations or financial condition, that, under applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof by the Company but which has not been so publicly announced or disclosed in the Reports.
(t) Capitalization. The authorized and outstanding capital stock of the Company as of the date of this Agreement and the Closing Date are set forth on Schedule 2(t) hereto. Except as set forth in the Reports and Other Written Information and Securities and Exchange Commission filings, there are no options, warrants, or rights to subscribe to, securities, rights or obligations convertible into or exchangeable for or giving any right to subscribe for any shares of capital stock of the Company. All of the outstanding shares of Common Stock of the Company have been duly and validly authorized and issued and are fully paid and nonassessable.
(u) Correctness of Representations. The Company represents that the foregoing representations and warranties are true and correct as of the date hereof in all material respects, and, unless the Company otherwise notifies the Subscriber prior to the Closing Date, shall be true and correct in all material respects as of the Closing Date. The foregoing representations and warranties shall survive the Closing Date.
3. Regulation S Offering. This Offering is being made pursuant to the exemption from the registration provisions of the Securities Act of 1933, as amended, afforded by Regulation S promulgated there under. On the Closing Date, the Company will provide an opinion from the Company’s legal counsel based upon the representation of Subscribers opining on the availability of the Regulation S exemption as it relates to the offer and issuance of the Shares of Common Stock.
4. Reissuance of Shares of Common Stock. The Company agrees to reissue certificates representing the Shares of Common Stock without the legend set forth in Sections 1(e) above at such time as (a) the holder thereof is permitted to and disposes of such Shares of Common Stock pursuant to Rule 144(d) and/or Rule 144(k) under the 1933 Act or Regulation “S” in the opinion of counsel reasonably satisfactory to the Company, or (b) upon resale subject to an effective registration statement after the Shares are registered under the 1933 Act. The Company agrees to cooperate with the Subscriber in connection with all resales pursuant to Rule 144(d) and Rule 144(k) and provide legal opinions necessary to allow such resales provided the Company and its counsel receive requested written representations from the Subscriber and selling broker,
--------------------------------------------------------------------------------
if any. Provided the Subscriber provides required certifications and representation letters, if any, if the Company fails to remove any legend as required by this Section 4 (a “Legend Removal Failure”), then beginning on the tenth (10th) day following the date that the Subscriber has requested the removal of the legend and delivered all items reasonably required by the Company to be delivered by the Subscriber, the Company continues to fail to remove such legend, the Company shall pay to each Subscriber or assignee holding Shares, subject to a Legend Removal Failure, as liquidated damages and not a penalty an amount equal to one percent (1%) of the Purchase Price of the Shares subject to a Legend Removal Failure per day that such failure continues. If during any twelve (12) month period, the Company fails to remove any legend as required by this Section 4 for an aggregate of thirty (30) days, each Subscriber or assignee holding Shares subject to a Legend Removal Failure may, at its option, require the Company to purchase all or any portion of the Shares subject to a Legend Removal Failure held by such Subscriber or assignee at a price per share equal to 120% of the applicable Purchase Price.
5. Regulation D. In the event that a Subscriber does not qualify under Regulation S and qualifies under Regulation D, the Company covenants and agrees that if the Company fails to file a Registration Statement for Company Shares within ninety (90) days from the Closing Date pursuant to Section 10.1(iv) below, then for so long as such registration statement is not effective and as any of the Company Shares remain outstanding and continue to be “restricted Shares” within the meaning of Rule 144, the Company shall, in order to permit resales of any of the Company Shares pursuant to Rule 144 under the 1933 Act, (a) continue to file all material required to be filed pursuant to Section 13(a) or 15(d) of the 1934 Act.
6. Indemnification. The Company on the one hand, and the Subscriber on the other hand, agree to indemnify the other against and hold the other harmless from any and all liabilities to any other persons claiming brokerage commissions or finder’s fees other than Careen Limited on account of services purported to have been rendered on behalf of the indemnifying party in connection with this Agreement or the transactions contemplated hereby and arising out of such party’s actions. The Company and the Subscriber represent to each other that there are no other parties entitled to receive fees, commissions, or similar payments in connection with the offering described in the Subscription Agreement.
7. Covenants of the Company. The Company covenants and agrees with the Subscriber as follows:
(a) The Company will advise the Subscriber, promptly after it receives notice of issuance by the Securities and Exchange Commission, any state securities commission or any other regulatory authority of any stop order or of any order preventing or suspending any offering of any securities of the Company, or of the suspension of the qualification of the Common Stock of the Company for offering or sale in any jurisdiction, or the initiation of any proceeding for any such purpose.
(b) The Company will maintain the listing of its Common Stock on the NASDAQ SmallCap Market, NASDAQ National Market System, NASD OTC Bulletin Board, or New York Exchange, or Pink Sheet Trading Market (whichever of the foregoing is at the time the principal trading exchange or market for the Common Stock (the “Principal Market”), and will use its best efforts to comply, in all respects, with the Company’s reporting, filing and other obligations under the bylaws or rules of the National Association of Securities Dealers (“NASD”) and such exchanges, as applicable. The Company will provide the Subscriber copies of all notices it receives notifying the Company of the threatened and actual delisting of the Common Stock from any Principal Market.
--------------------------------------------------------------------------------
(c) The Company shall notify the Commission, NASD, the Principal Market and applicable state authorities, in accordance with their requirements, if any, of the transactions contemplated by this Agreement, and shall take all other necessary action and proceedings as may be required and permitted by applicable law, rule and regulation, for the legal and valid issuance of the Shares of Common Stock to the Subscriber and promptly provide copies thereof to Subscriber.
(d) From the Closing Date and until at least one (1) year after the effectiveness of the Registration Statement on Form S-2 or such other Registration Statement described in Section 10.1(iv) hereof, the Company will (i) cause its Common Stock to continue to be registered under Sections 12(b) or 12(g) of the Exchange Act, (ii) comply in all respects with its reporting and filing obligations under the Exchange Act, (iii) comply with all reporting requirements that are applicable to an issuer with a class of Shares registered pursuant to Section 12(g) of the Exchange Act, and (iv) comply with all requirements related to any registration statement filed pursuant to this Agreement. The Company will use its best efforts not to take any action or file any document (whether or not permitted by the Act or the Exchange Act or the rules thereunder) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under said Acts until one (1) year after the actual effective date of the Registration Statement on Form S-2 or other Registration Statement described in Section 10.1(iv) hereof. Until the resale of the Company Shares by the Subscriber, the Company will use its best efforts to continue the listing of the Common Stock on the Bulletin Board and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of Bulletin Board.
8. Covenants of the Company and Subscriber Regarding Indemnification.
(a) The Company agrees to indemnify, hold harmless, reimburse and defend Subscriber, Subscriber’s officers, directors, agents, affiliates, control persons, and principal shareholders, against any claim, cost, expense, liability, obligation, loss or damage (including reasonable legal fees) of any nature, incurred by or imposed upon Subscriber or any such person which results, arises out of or is based upon (i) any material misrepresentation by Company or breach of any warranty by Company in this Agreement or in any Exhibits or Schedules attached hereto, or other agreement delivered pursuant hereto; or (ii) after any applicable notice and/or cure periods, any breach or default in performance by the Company of any covenant or undertaking to be performed by the Company hereunder, or any other agreement entered into by the Company and Subscribers relating hereto.
(b) Subscriber agrees to indemnify, hold harmless, reimburse and defend the Company and each of the Company’s officers, directors, agents, affiliates, control persons against any claim, cost, expense, liability, obligation, loss or damage (including reasonable legal fees) of any nature, incurred by or imposed upon the Company or any such person which results, arises out of or is based upon (i) any material misrepresentation by Subscriber in this Agreement or in any Exhibits or Schedules attached hereto, or other agreement delivered pursuant hereto; or (ii) after any applicable notice and/or cure periods, any breach or default in performance by Subscriber of any covenant or undertaking to be performed by Subscriber hereunder, or any other agreement entered into by the Company and Subscribers relating hereto.
--------------------------------------------------------------------------------
(c) The procedures set forth herein shall apply to the indemnifications set forth in Sections 8(a) and 8(b) above.
10.1. Registration Rights. The Company hereby grants the following registration rights to holders of the Shares of Common Stock.
(a) The Company hereby agrees to register the Shares of Common Stock herein on a Form S-2 or any other applicable Form with the Securities and Exchange Commission within ninety (90) days of the date hereof, and it is further agreed that, should the Company not file a Registration Statement, as provided for herein, within the said 90 day period, that the Company will pay any liquidated damage penalty in the amount of up to 250,000 Common Shares for each ten (10) days that the Company fails to file the Registration Statement, as stated herein. It is understood that the liquidated damages will be calculated on a pro rata basis based upon the number of shares purchased by Subscribers. Subscribers agree that the registration will be on an optional piggy-back or single registration basis at the option of the Company, and that the Company will bear all costs and expenses of the registration.
(b) The Company agrees to give ten (10) days written notice to all Subscribers of the filing of the Registration Statement, and Subscribers agree that each will cooperate with the Company in providing the necessary information required by each Subscriber to file a Registration Statement on that Subscriber’s behalf.
(c) Each Subscriber agrees to execute the within Agreement and to subscribe for the number of Shares of Common Stock as agreed to by Subscriber.
10.2. Registration Procedures. If and whenever the Company is required by the provisions hereof to effect the registration of any Shares of Common Stock under the Act, the Company will, as expeditiously as possible:
(a) prepare and file with the Commission a Registration Statement with respect to such Shares of Common Stock and use its best efforts to cause such Registration Statement to become and remain effective for the period of the distribution contemplated thereby (determined as herein provided), and promptly provide to the holders of Shares of Common Stock (“Sellers”) copies of all filings with the Commission;
(b) prepare and file with the Commission such amendments and supplements to such Registration Statement and the prospectus used in connection therewith as may be necessary to keep such Registration Statement effective until the latest of: (i) 180 days following the effective date of the Registration Statement;
(c) furnish to the Seller, such number of copies of the Registration Statement and the prospectus included therein (including each preliminary prospectus) as such Seller reasonably may request in order to facilitate the public sale or their disposition of the securities covered by such Registration Statement;
(d) use its best efforts to register or qualify the Seller’s Shares of Common Stock covered by such Registration Statement under the securities or “blue sky” laws of such jurisdictions as the Seller shall reasonably designate, provided, however, that the Company shall not for any such purpose be required to qualify generally to transact business as a
--------------------------------------------------------------------------------
foreign corporation in any jurisdiction where it is not so qualified or to consent to general s
Outline Printer Friendly
Next Page »
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------------------------------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported) November 8, 2002
CALYPTE BIOMEDICAL CORPORATION.
Exact name of Registrant as specified in its Charter)
DELAWARE
(State or other jurisdiction of incorporation)
000-20985 06-1226727
Commission File No. I.R.S. Employer Identification
1265 Harbor Bay Parkway, Alameda, CA 94502
Address of principal executive offices Zip Code
(510) 749-5100
Registrant’s telephone number, including area code
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
ITEM 5. OTHER EVENTS
As previously disclosed, in May of 2002, the Registrant (the “Company”) entered into an arrangement with Cataldo Investment Group, a group of non-affiliated investors, referred to under the acronym (“CIG”) to arrange for up to $5,000,000 in financing for the Company on or before May 17, 2003. At the present time, financing in excess of $5,000,000 attributed to CIG has been obtained. Annexed hereto as Exhibit 10.115 is a copy of the CIG arrangement. In that regard, the Company incorporates, by reference, its 8-K Report filed on July 17, 2002 and its 10-Q Report for the period ending June 30, 2002, with respect to the financing arrangements previously attributed to CIG.
· In addition to the previously reported financing transactions and supplementing the CIG commitment, on September 12, 2002 the Company entered into a financing agreement with Mercator Momentum Fund LP (“Mercator”). The Mercator Agreement provided for a credit facility up to the sum of $2,000,000 at 12% interest per annum due on September 12, 2004 or in the event of sale or merger of the Company. In connection with the Mercator financing agreement, a convertible promissory note issued to Mercator further provides for a conversion feature wherein Mercator can convert principal and interest due on the debt obligation to shares of common stock of the Company at the average of the lowest three inter-day trading prices over the twenty (20) consecutive trading days immediately prior to the conversion. The conversion price will be equal to eighty-five percent (85%) of the trading market price, with a floor of $.05 per share.
The terms of financing further provided for the Company to pay a commitment fee of ten percent (10%) of the total credit facility on closing of the initial $550,000 traunch. Additionally, the Company further granted registration rights for the underlying shares of the debenture and agreed to file a Registration Statement within 45 days, registering 200% of the amount of common stock necessary for conversion of the initial funding ($550,000). The Agreement also provided that, in the event of a default with respect to the Company’s failure to file a Registration Statement,
--------------------------------------------------------------------------------
which Registration Statement is not approved within 90 days thereafter, the Company shall issue to Mercator 10,000 shares of the Company’s common stock a day for the time of the default until said default is corrected up to the lower of 18% per annum or the highest rate permitted by law. The Company subsequently amended the Mercator Debenture to extend the default in the registration provision for 45 days.
The Company issued 500,000 shares of its restricted common stock on closing to Mercator as part of the funding costs, and also agreed to register the shares without cost to Mercator. Annexed hereto and marked as Exhibit 10.116 is a copy of the Mercator Term Sheet and form of Registration Rights Agreement.
· On August 28, 2002, an aggregate of $400,000 was invested in the Company by Caledonia Corporate Group, Ltd. (“Caledonia”) and Careen Ltd. (“Careen”). Caledonia purchased 4,000,000 restricted shares of common stock of the Company at $.05 per share in a Regulation S transaction, and Careen purchased 4,000,000 restricted shares of the Company’s common stock at $.05 per share in a Regulation S transaction. In connection with the transactions, the Company agreed to pay Brigand Capital Corp. a ten percent (10%) financial consulting fee or the sum of $40,000, and granted cost-free registration rights to Caledonia and Careen. The form of the subscription agreement is annexed hereto as Exhibit 10.117.
· On June 17, 2002, the Company sold a $100,000 8% convertible debenture to Ms. Su So in a Regulation S transaction that was subsequently converted into 1,100,000 shares of restricted common stock. On July 3, 2002, the Company sold a $100,000 8% convertible debenture to Mr. Jason Arasheben in a Regulation S transaction that was subsequently converted into 474,493 shares of restricted common stock. The Company agreed to pay a finder’s fee of ten percent (10%) for each transaction to Mr. Blake Ransom. The Company granted cost-free best efforts registration rights to the purchasers.
--------------------------------------------------------------------------------
· In connection with the previously reported 8% convertible note transactions on Form 8-K (July 17, 2002) totaling $2,625,000, the Company reported in its Form 10-Q for the quarter ended June 30, 2002 that it had issued an additional $250,000 of such notes. On August 21, 2002, the Company issued an additional $250,000 of such notes, so that as of November 8, 2002, the Company had issued a total of $3,125,000 of 8% convertible notes. In conjunction with these transactions, the Company paid a 15% finder’s fee to Bi-Coastal Consulting Corporation (“Bi-Coastal”) or the sum of $418,750. Annexed hereto as Exhibit 10.118 is a copy of the subscription agreement.
· The Company further incorporates by reference prior reports filed with respect to the Townsbury, Ltd. (“Townsbury”) equity credit line transaction. In connection with the Townsbury equity credit line, the Company paid finder’s fee of five percent (5%) or $70,000 to Bi-Coastal, as a result of the draw-down on the Company’s equity credit line with Townsbury.
· As previously reported in the Company’s Form 10-Q for the period ended June 30, 2002, the Company issued a ten percent (10%) convertible promissory note to BNC Bach International Ltd. in a Regulation S transaction. A finder’s fee of ten percent (10%) was paid to Bi-Coastal in connection with this transaction.
EXHIBITS
10.115 Investment Commitment Arrangement with Cataldo Investment Group;
10.116 Term Sheet for Mercator Momentum Fund LP and Registration Rights Agreement;
10.117 Form of Subscription Agreement under Regulation S for Caledonia Corporate Group Ltd. and Careen Ltd.
10.118 Bi-Coastal Consulting, Inc. Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant
--------------------------------------------------------------------------------
has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: Alameda, California
November 12, 2002
CALYPTE BIOMEDICAL CORPORATION
--------------------------------------------------------------------------------
(Registrant)
/S/ ANTHONY J. CATALDO
--------------------------------------------------------------------------------
ANTHONY J. CATALDO
Executive Chairman
Exhibit 10.115
CATALDO INVESTMENT GROUP
Calypte Biomedical Corporation
1265 Harbor Bay Parkway
Alameda, CA 94502
Re: Cataldo Investment Group (“CIG”)
With Calypte Biomedical Corporation
(“CALY” or the “Company”)
Dear Ms. Katz:
The within is to confirm that as of May 9, 2002, the terms of the independent CIG investment proposal will be amended as stated herein:
CIG is agreeable to arranging for an aggregate of $1,400,000 within 90 days of May 10, 2002 as a combination of equity investments and/or convertible debentures from accredited investors for the express purpose of utilizing said funds to continue the operation of the Company’s business.
It is understood that the Company has issued a press release announcing that the Company is in danger of shutting down its operations and may be compelled to close its doors. Resultantly, the within amended proposal is subject to the following:
a) An aggregate of $5,000,000 to be invested in CALY prior to May 10, 2003, subject to terms negotiated in separate independent arms-length transactions with accredited investors;
b) Mr. Anthony Cataldo to serve as Executive Chairman of the Company with authority to utilize the services of financial business or management consultants and/or professionals, accountants, attorneys etc. as he may deem necessary to accomplish the goal of re-starting and continuing the Company’s business operations going forward;
--------------------------------------------------------------------------------
c) Mr. Cataldo, to obtain authority from the Board to disburse investment funds attributed to CIG; and
d) Mr. Cataldo, to have the right to appoint new directors, which directors may constitute a majority of the Board, within 30 days of the date hereof. The current Board of Directors will continue to serve during the interim period and, thereafter, continue to work with Mr. Cataldo in the interest of the Company and its stockholders.
e) The within amendment to supercede any prior understandings or agreements whether oral or written.
If the foregoing is agreeable, please acknowledge your consent to the within and provide a confirmation of an Officer’s Certificate and/or Board Resolution concerning the amendment.
Very truly yours,
CATALDO INVESTMENT GROUP
By: /s/ ANTHONY J. CATALDO
--------------------------------------------------------------------------------
ANTHONY J. CATALDO
AGREED TO AS OF MAY 9, 2002:
CALYPTE BIOMEDICAL CORPORATION
By: /s/ NANCY E. KATZ
--------------------------------------------------------------------------------
NANCY KATZ, President and CEO
Exhibit 10.116
Mercator Momentum Fund, LP.
TERM SHEET
This Term Sheet is intended as an outline of the basic terms upon which Mercator Momentum Fund, LP (“Mercator” or “Lender”) would be willing to consider the extension of credit to Calypte Biomedical Corporation (“Borrower” or “Company”). This Term Sheet should not be construed as an offer to lend based upon such terms or as a binding commitment. The terms set forth herein are based on limited information provided by Borrower and are subject to change pending the completion of due diligence and the approval of Mercator’s loan committee. Until the parties have executed a definite loan agreement and related documentation, neither Mercator nor its partners shall have any obligation to fund the loan outlined herein.
September 12, 2002
Borrower: Calypte Biomedical Corporation
1265 Harbor BayParkway
Alameda, CA 94502
Tel: (510) 749-5100
Fax: (510) 526-5381
Lender: Mercator Momentum Fund, LP and/or other participants from time to time (collectively referred to as “Lender”).
Total Credit Facility: $2,000,000
Debenture Tranche Funding $550,000 for 1st Debenture funding, $500,000 Debenture funding thereafter per 30 day subject to conditions as set forth herein.
Availability: Immediately upon the signing of a definitive agreement reflecting the Terms set forth herein.
Conditions Precedent: N/A.
Market Price: Market Price shall mean the average of the lowest three inter-day trading prices (which need not occur on consecutive Trading Days) during the twenty Trading Days immediately preceding the applicable Conversion Date (which may include Trading Days prior to the Original Issue Date), provided, that such thirty Trading Day period shall be extended for the number of Trading Days during such period in which (A) trading in the Common Stock is suspended by, or not traded on, the pink sheets or a Subsequent Market on which the Common Stock is then listed, or (B) after the date declared effective by the Commission, the Underlying Shares Registration Statement is either not effective or the Prospectus included in the Underlying Shares Registration Statement may not be used by the Holder for the resale of Underlying Shares.
--------------------------------------------------------------------------------
Repayment: Monthly interest, principal on maturity. Interest shall accrue until Maturity or paid in kind upon conversion.
Rate: 12% APR
Commitment Fee: The Company shall pay a Commitment Fee equal to 10% of the Total Credit Facility. The entire Commitment Fee will be net funded from upon initial debenture funding.
Maturity: The earlier of September 12, 2004 (the “Maturity Date”), the Borrower’s next equity event, or a sale or merger.
Conversion: The Note shall be convertible at the Lender’s sole discretion in part or in whole at a price equal to 85% of the Market Price. Notwithstanding the foregoing, the Lender will not convert should the Market Price of Company be below $0.05
Registration: Upon the initial debenture funding of $550,000, the Company shall have a Registration Statement submitted to the SEC within 45 Days registering 200% of the common stock of the company available for conversion immediately after the initial funding. Furthermore, the Registration Statement must be deemed effective by the SEC for the Company to receive any additional Debenture tranches. Such tranches will be available to Company in 30 day increments.
Default: At an event of Default (failure to make interest and/or principle payment(s) when due, failure to submit Registration statement within 45 Days, and/or failure to have Registration statement approved within 90 Days thereafter) the Company shall issue to the Lender 10,000 shares of Company’s common stock per day from the time of Default until Default is corrected and the lower of 18% APR or the highest rate of interest permitted by law. The corresponding Registration statement shall be amended immediately by Company to include the Default shares, if any.
Common Stock: For the first Debenture in the amount of $550,000, the Company shall issue the Lender 500,000 shares of common stock of Company. Such stock shall be included in a Registration Statement. For each Debenture thereafter the Lender will also receive additional common stock of the Company as agreed by both parties.
Extension: N/A
Collateral: N/A
Debt Subordination: N/A
Warrants: N/A
Financial None; provided, however, the proceeds of the Credit Facility shall not be
--------------------------------------------------------------------------------
Covenants: available to reduce or retire any insider note or convertible debt.
Reporting: Monthly Financials
Documentation: Lender’s standard documents, including: conditions to advances, representations and warranties on company status, legal compliance, liens, legal compliance; covenants on investments, liens, debt, dispositions, insurance; remedies, jury waiver and California law provisions.
Expenses: Borrower to reimburse Lender for all out of pocket costs in connection with the underwriting, legal, documentation and funding of the Credit facility.
Deposit: N/A
Confidentiality: This Term Sheet is confidential and proprietary to Lender. Please treat it with the same respect that we treat your private information and do not disclose it to any third parties.
To confirm your agreement with these basic terms, and to permit us to proceed with our due diligence, please fax an executed copy of this Term Sheet to our office (213.533.8285) and deliver the executed original and the Deposit to our office via courier by 5:30 p.m. September 12, 2002:
Mercator Momentum Fund, LP.
555 South Flower Street, Suite 4500
Los Angeles, CA 90071
THIS TERM SHEET EXPIRES AT
5:30 p.m. (PST) on September 12, 2002.
MERCATOR MOMENTUM FUND, LP.
--------------------------------------------------------------------------------
/s/ ANSHUMAN “ANDY” DUBE
--------------------------------------------------------------------------------
Anshuman “Andy” Dube
General Partner
Agreed and confirmed:
Calypte Biomedical Corporation
By: /s/ ANTHONY J. CATALDO
Title: Executive Chairman
Date: September 12, 2002
--------------------------------------------------------------------------------
REGISTRATION RIGHTS AGREEMENT
AGREEMENT dated as of the 12th day of September, 2002, between the person whose name and address appears in the convertible debenture (individually, a “Holder” or, collectively with the holders of the Securities issued in the Offering, each as defined below, the “Holders”), and CALYPTE BIOMEDICAL CORPORATION., a Delaware corporation having its principal executive office at 1265 Harbor Bay Parkway, Alameda, CA 94502 (the “Company”).
WHEREAS, the Holders have previously subscribed to a convertible debenture (the “Debenture”) with the Company in the principal amount of U.S. $550,000 (the “Offering”). The Holders, upon conversion of the debenture may own up to a maximum of 11,000,000 Units (the “Units”), each Unit consisting of one share of Common Stock, $.001 par value (the “Common Stock”) of the Company.
WHEREAS, the Company desires to grant to the Holder the registration rights set forth herein with respect to the Shares;
NOW, THEREFORE, the parties hereto mutually agree as follows:
1. Registrable Securities. As used herein the term “Registrable Security” means each of the shares of Common Stock included in the Units; provided, however, that with respect to any particular Registrable Security, such security shall cease to be a Registrable Security when, as of the date of determination, (i) it has been effectively registered under the Securities Act of 1933, as amended (the “Securities Act”) and disposed of pursuant thereto, or (ii) registration under the Securities Act is no longer required for the immediate public distribution of such security. The term “Registrable Securities” means any and/or all of the securities falling within the foregoing definition of a “Registrable Security.” In the event of any merger, reorganization, consolidation, recapitalization or other change in corporate structure affecting the Common Stock, such adjustment shall be made in the definition of “Registrable Security” as is appropriate in order to prevent any dilution or enlargement of the rights granted pursuant to this Section 1.
2. Registration. The Company agrees to file a registration statement (a “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) within 45 days of the completion of the Offering in order to register the resale of the Registrable Securities under the Securities Act. Once effective, the Company will be required to maintain the effectiveness of the Registration Statement until the earlier of (i) the date that all of the Registrable Securities have been sold, or (ii) the date that the Company receives an opinion of counsel to the Company that all of the Registrable Securities may be freely traded without registration under the Securities Act, under Rule 144 promulgated under the Securities Act or otherwise.
3. Covenants of the Company With Respect to Registration.
--------------------------------------------------------------------------------
The Company covenants and agrees as follows:
(1) connection with any registration filed pursuant hereto, the Company shall use its best efforts to cause the Registration Statement to become effective as promptly as possible and, if any stop order shall be issued by the Commission in connection therewith, to use its reasonable efforts to obtain the removal of such order. Following the effective date of a Registration Statement, the Company shall, upon the request of the Holder, forthwith supply such reasonable number of copies of the Registration Statement, preliminary prospectus and prospectus meeting the requirements of the Securities Act, and other documents necessary or incidental to the public offering of the Registrable Securities, as shall be reasonably requested by the Holder to permit the Holder to make a public distribution of the Holder’s Registrable Securities. The obligations of the Company hereunder with respect to the Holder’s Registrable Securities are subject to the Holder’s furnishing to the Company such appropriate information concerning the Holder, the Holder’s Registrable Securities and the terms of the Holder’s offering of such Registrable Securities as the Company may reasonably request in writing.
(2) The Company shall pay all costs, fees and expenses in connection with all Registration Statements filed pursuant to Section 2 hereof including, without limitation, the Company’s legal and accounting fees, printing expenses, and blue sky fees and expenses; provided, however, that the Holder shall be solely responsible for the fees of any counsel retained by the Holder in connection with such registration and any transfer taxes or underwriting discounts, commissions or fees applicable to the Registrable Securities sold by the Holder pursuant thereto.
(3) The Company will take all necessary action which may be required in qualifying or registering the Registrable Securities included in a Registration Statement for offering and sale under the securities or blue sky laws of such states as are reasonably requested by the holders of such securities, provided that the Company shall not be obligated to execute or file any general consent to service of process or to qualify as a foreign corporation to do business under the laws of any such jurisdiction.
4. Additional Terms.
(1) The Company shall indemnify and hold harmless the Holder and each underwriter, within the meaning of the Securities Act, who may purchase from or sell for the Holder, any Registrable Securities, from and against any and all losses, claims, damages and liabilities caused by any untrue statement of a material fact contained in the Registration Statement, any other registration statement filed by the Company under the Securities Act with respect to the registration of the Registrable Securities, any post-effective amendment to such registration statements, or any prospectus included therein or caused by any omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission based upon information furnished or required to be furnished in writing to the Company by the Holder or underwriter expressly for use therein, which indemnification shall include each person, if any, who controls either the Holder or underwriter
--------------------------------------------------------------------------------
within the meaning of the Securities Act and each officer, director, employee and agent of the Holder and underwriter; provided, however, that the indemnification in this Section 5(a) with respect to any prospectus shall not inure to the benefit of the Holder or underwriter (or to the benefit of any person controlling the Holder or underwriter) on account of any such loss, claim, damage or liability arising from the sale of Registrable Securities by the Holder or underwriter, if a copy of a subsequent prospectus correcting the untrue statement or omission in such earlier prospectus was provided to the Holder or underwriter by the Company prior to the subject sale and the subsequent prospectus was not delivered or sent by the Holder or underwriter to the purchaser prior to such sale and provided further, that the Company shall not be obligated to so indemnify the Holder or any such underwriter or other person referred to above unless the Holder or underwriter or other person, as the case may be, shall at the same time indemnify the Company, its directors, each officer signing the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act, from and against any and all losses, claims, damages and liabilities caused by any untrue statement of a material fact contained in the Registration Statement, any registration statement or any prospectus required to be filed or furnished by reason of this Agreement or caused by any omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, insofar as such losses, claims, damages or liabilities are caused by any untrue statement or omission based upon information furnished in writing to the Company by the Holder or underwriter expressly for use therein.
(2) If for any reason the indemnification provided for in the preceding section is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, claim, damage, liability or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect not only the relative benefits received by the indemnified party and the indemnifying party, but also the relative fault of the indemnified party and the indemnifying party, as well as any other relevant equitable considerations.
(3) Neither the filing of a Registration Statement by the Company pursuant to this Agreement nor the making of any request for prospectuses by the Holder shall impose upon the Holder any obligation to sell the Holder’s Registrable Securities.
(4) The Holder, upon receipt of notice from the Company that an event has occurred which requires a Post-Effective Amendment to the Registration Statement or a supplement to the prospectus included therein, shall promptly discontinue the sale of Registrable Securities until the Holder receives a copy of a supplemented or amended prospectus from the Company, which the Company shall provide as soon as practicable after such notice.
(5) If the Company fails to keep the Registration Statement referred to above continuously effective during the requisite period, then the Company shall, promptly upon the request of the Holders of at least a majority of the unsold Registrable Securities, use its best efforts to update the Registration Statement or file a new registration statement covering the Registrable Securities remaining unsold, subject to the terms and provisions hereof.
--------------------------------------------------------------------------------
(6) The Holder agrees to provide the Company with any information or undertakings reasonably requested by the Company in order for the Company to include any appropriate information concerning the Holder in the Registration Statement or in order to promote compliance by the Company or the Holders with the Securities Act.
5. Governing Law. The Registrable Securities will be, if and when issued, delivered in California. This Agreement shall be deemed to have been made and delivered in the State of California and shall be governed as to validity, interpretation, construction, effect and in all other respects by the internal substantive laws of the State of California, without giving effect to the choice of law rules thereof.
6. Amendment. This Agreement may only be amended by a written instrument executed by the Company and the Holder.
7. Entire Agreement. This Agreement constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.
8. Execution in Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same document.
9. Notices. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed duly given when delivered by hand or mailed by registered or certified mail, postage prepaid, return receipt requested, as follows:
If to the Holder, to his, her or its address set forth in the Purchaser Questionnaire.
If to the Company, to the address set forth on the first page of this Agreement.
10. Binding Effect; Benefits. The Holder may assign his, her or its rights hereunder. This Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their respective heirs, legal representatives and successors. Nothing herein contained, express or implied, is intended to confer upon any person other than the parties hereto and their respective heirs, legal representatives and successors, any rights or remedies under or by reason of this Agreement.
--------------------------------------------------------------------------------
11. Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.
12. Severability. Any provision of this Agreement which is held by a court of competent jurisdiction to be prohibited or unenforceable in any jurisdiction(s) shall be, as to such jurisdiction(s), ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.
IN WITNESS WHEREOF, this Agreement has been executed and delivered by the parties hereto as of the date first above written.
CALYPTE BIOMEDICAL CORPORATION.
By:
Name:
--------------------------------------------------------------------------------
Its:
--------------------------------------------------------------------------------
HOLDER:
MERCATOR MOMENTUM FUND, LP
By:
Its:
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
November 7, 2002
VIA E-Mail and First Class Mail
Mr. Anthony J. Cataldo
Executive Chairman
Calypte Biomedical Corp.
1265 Harbor Bay Parkway
Alameda, CA 94502
Re: Registration Rights Agreement—Waiver of Default—Amendment.
Dear Tony:
Please permit the within to confirm our prior understanding and agreement with respect to our waiver of the provision requiring Calypte Biomedical Corporation to file a Registration Statement (as defined in the Registration Rights Agreement dated as of the 12th day of September, 2002 (the “Agreement”)). The requirement to file a Registration Statement is hereby extended an additional forty five (45) days through December 11, 2002. All other terms and conditions of the Agreement remain in full force and effect unless modified in writing with the mutual consent of both parties. Please countersign this letter acknowledging your agreement to the waiver and amendment and forward a fully executed copy of this letter back to me at our office.
Should you have any questions, please call me.
Kindest Regards,
Mercator Group, LLC.
/s/ DAVID FIRESTONE
David Firestone
Managing Partner
Agreed to:
Calypte Biomedical Corporation
/s/ ANTHONY J. CATALDO
--------------------------------------------------------------------------------
Anthony J. Cataldo
Executive Chairman
EXHIBIT 10.117
SUBSCRIPTION AGREEMENT
, 2002
Dear Subscriber:
You, together with other subscribers (each a “Subscriber”) hereby agree to purchase, and Calypte Biomedical Corporation, a Delaware corporation (the “Company”), hereby agrees to issue and to sell to the Subscriber, Shares of the Company’s $.001 par value common stock (the “Company Shares”) for the consideration as set forth on the signature page hereof (“Purchase Price”). (The Company Shares are sometimes referred to herein as the “Shares”, “Common Shares”, “Securities”, or “Common Stock”). Upon acceptance of this Agreement by the Subscriber, the Company shall issue and deliver the Shares against payment, by federal funds wire transfer, or bank, or certified check of the Purchase Price.
The following terms and conditions shall apply to this Subscription.
1. Subscriber’s Representations and Warranties. The Subscriber hereby represents and warrants to and agrees with the Company that:
(a) Information on Company. The Subscriber has been furnished with the Company’s Form 10-K and 10-K/A for the year ended December 31, 2001 as filed with the Securities and Exchange Commission (the “Commission”) together with all subsequently filed forms 10-Q, 8-K, Preliminary Proxy Statement, and pending Form S-2 Registration Statement Amendment I, and other publicly available filings made with the Commission (hereinafter referred to collectively as the “Reports”). In addition, the Subscriber has received from the Company such other information concerning its operations, financial condition and other matters as the Subscriber has requested (such information in writing is collectively, the “Other Written Information”), and considered all factors the Subscriber deems material in deciding on the advisability of investing in the Shares of Common Stock.
(b) Information on Subscriber. The Subscriber is and was not a “U.S. person”, as defined in Regulation S promulgated under the Securities Act of 1933 at the time the offer or sale of the Shares of Common Stock is made. Additionally, Subscriber is an “accredited investor”, as such term is defined in Regulation D promulgated by the Commission under the Securities Act of 1933, as amended (the “1933 Act”), is experienced in investments and business matters, has made investments of a speculative nature and has purchased securities of United States publicly-owned companies in private placements in the past and, with its representatives, has such knowledge and experience in financial, tax and other business matters as to enable the Subscriber to utilize the information made available by the Company to evaluate the merits and risks of and to make an informed investment decision with respect to the proposed purchase, which represents a speculative investment. The Subscriber has the authority and is duly and legally qualified to purchase and own the Shares of Common Stock. The Subscriber is able to bear the risk of such investment for an indefinite period and to afford a complete loss thereof. The information set forth on the signature page hereto regarding the Subscriber is accurate.
(c) Purchase of Shares. On the Closing Date, the Subscriber will purchase the Company Stock for its own account and not with a view to any distribution thereof
--------------------------------------------------------------------------------
and that the purchase of the Common Stock is intended to be made as an “Offshore Transaction” as defined in Regulation S.
(d) Compliance with Securities Act. The Subscriber understands and agrees that the Shares have not been registered under the 1933 Act, by reason of their issuance in a transaction that does not require registration under the 1933 Act (based in part on the accuracy of the representations and warranties of Subscriber contained herein), and that such Shares of Common Stock must be held unless a subsequent disposition is registered under the 1933 Act or is exempt from such registration.
(e) Company Shares Legend. The Company Shares shall bear the following legend, unless same shall have been included in an effective registration statement under the 1933 Act:
“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THESE SHARES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO CALYPTE BIOMEDICAL CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED”.
(f) Communication of Offer. The offer to sell the Shares of Common Stock was directly communicated to the Subscriber. At no time was the Subscriber presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement, or any other form of general advertising or solicited or invited to attend a promotional meeting otherwise than in connection and concurrently with such communicated offer.
(g) Correctness of Representations. The Subscriber represents that the foregoing representations and warranties are true and correct as of the date hereof and, unless the Subscriber otherwise notifies the Company prior to the Closing Date (as hereinafter defined), shall be true and correct as of the Closing Date. The foregoing representations and warranties shall survive the Closing Date.
2. Company Representations and Warranties. The Company represents and warrants to and agrees with the Subscriber that:
(a) Due Incorporation. The Company and each of its subsidiaries, if any, is a corporation duly organized, validly existing and in good standing under the laws of the respective jurisdictions of their incorporation and have the requisite corporate power to own their properties and to carry on their business as now being conducted. The Company and each of its subsidiaries is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary, other than those jurisdictions in which the failure to so qualify would not have a material adverse effect on the business, operations or financial condition of the Company.
--------------------------------------------------------------------------------
(b) Outstanding Stock. All issued and outstanding shares of capital stock of the Company and each of its subsidiaries has been duly authorized and validly issued and are fully paid and non-assessable.
(c) Authority; Enforceability. This Agreement and other agreements delivered together with this Agreement or in connection herewith have been duly authorized, executed and delivered by the Company and are valid and binding agreements enforceable in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights generally and to general principles of equity; and the Company has full corporate power and authority necessary to enter into this Agreement, and such other agreements and to perform its obligations hereunder and under all other agreements entered into by the Company relating hereto.
(d) Additional Issuances. Except as set forth on Schedule 2(d), there are no outstanding agreements or preemptive or similar rights affecting the Company’s common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or other equity interest in any of the subsidiaries of the Company except as described in the Reports or Other Written Information.
(e) Consents. No consent, approval, authorization or order of any court, governmental agency or body or arbitrator having jurisdiction over the Company, or any of its affiliates, the National Association of Securities Dealers, Inc. (“NASD”), NASDAQ or the Company’s Shareholders is required for execution of this Agreement, and all other agreements entered into by the Company relating thereto, including, without limitation, the issuance and sale of the Securities, and the performance of the Company’s obligations hereunder and under all such other agreements.
(f) No Violation or Conflict. Assuming the representations and warranties of the Subscriber in Paragraph 1 are true and correct and the Subscriber complies with its obligations under this Agreement, neither the issuance and sale of the Shares of Common Stock nor the performance of the Company’s obligations under this Agreement and all other agreements entered into by the Company relating thereto by the Company will:
(i) violate, conflict with, result in a breach of, or constitute a default (or an event which with the giving of notice or the lapse of time or both would be reasonably likely to constitute a default) under (A) the certificate of incorporation, charter or bylaws of the Company, (B) to the Company’s knowledge, any decree, judgment, order, law, treaty, rule, regulation or determination applicable to the Company of any court, governmental agency or body, or arbitrator having jurisdiction over the Company or any of its affiliates or over the properties or assets of the Company or any of its affiliates, (C) the terms of any bond, debenture, note or any other evidence of indebtedness, or any agreement, stock option or other similar plan, indenture, lease, mortgage, deed of trust or other instrument to which the Company or any of its affiliates is a party, by which the Company or any of its affiliates is bound, or to which any of the properties of the Company or any of its affiliates is subject, or (D) the terms of any “lock-up” or similar provision of any underwriting or similar agreement to which the Company, or any of its affiliates is a party except the violation, conflict, breach, or default of which would not have a material adverse effect on the Company; or
--------------------------------------------------------------------------------
(ii) result in the creation or imposition of any lien, charge or encumbrance upon the Shares of Common Stock or any of the assets of the Company, its subsidiaries or any of its affiliates.
(g) The Shares of Common Stock. The Shares upon issuance:
(i) are, or will be, free and clear of any security interests, liens, claims or other encumbrances, subject to restrictions upon transfer under the 1933 Act and State laws;
(ii) have been, or will be, duly and validly authorized and on the date of issuance and on the Closing Date, as hereinafter defined, and will be duly and validly issued, fully paid and nonassessable (and if registered pursuant to the 1933 Act, and resold pursuant to an effective Registration Statement will be free trading and unrestricted, provided that the Subscriber complies with the Prospectus delivery requirements);
(iii) will not have been issued or sold in violation of any preemptive or other similar rights of the holders of any Shares of Common Stock of the Company; and
(iv) will not subject the holders thereof to personal liability by reason of being such holders.
(h) Litigation. There is no pending or, to the best knowledge of the Company, threatened action, suit, proceeding or investigation before any court, governmental agency or body, or arbitrator having jurisdiction over the Company, or any of its affiliates that would affect the execution by the Company or the performance by the Company of its obligations under this Agreement, and all other agreements entered into by the Company relating hereto. Except as disclosed in the Securities and Exchange Commission filings, Reports or Other Written Information, there is no pending or, to the best knowledge of the Company, threatened action, suit, proceeding or investigation before any court, governmental agency or body, or arbitrator having jurisdiction over the Company, or any of its affiliates which litigation if adversely determined could have a material adverse effect on the Company.
(i) Reporting Company. The Company is a publicly-held company subject to reporting obligations pursuant to Sections 15(d) and 13 of the Securities Exchange Act of 1934, as amended (the “1934 Act”) and has a class of common shares registered pursuant to Section 12(g) of the 1934 Act. The Company’s common stock is listed for trading on the OTC Bulletin Board (“Bulletin Board”). Pursuant to the provisions of the 1934 Act, the Company has filed all reports and other materials required to be filed thereunder with the Securities and Exchange Commission during the preceding twelve months.
(j) No Market Manipulation. The Company has not taken, and will not take, directly or indirectly, any action designed to, or that might reasonably be expected to, cause or result in stabilization or manipulation of the price of the common stock of the Company to facilitate the sale or resale of the Shares of Common Stock or affect the price at which the Shares may be issued or resold.
(k) Information Concerning Company. The Reports contain all material information relating to the Company and its operations and financial condition as of their
--------------------------------------------------------------------------------
respective dates which information is required to be disclosed therein. Since the date of the financial statements included in the Reports, and except as modified in the Other Written Information or in the Schedule hereto, there has been no material adverse change in the Company’s business, financial condition or affairs not disclosed in the Reports. The Reports do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances when made.
(l) Dilution. The Company’s executive officers and directors have studied and fully understand the nature of the Stock being sold hereby and recognize that they have a potential dilutive effect. The board of directors of the Company has concluded, in its good faith business judgment, that such issuance is in the best interests of the Company. The Company specifically acknowledges that its obligation to issue the Shares upon payment is binding upon the Company and enforceable, except as otherwise described in this Subscription Agreement, regardless of the dilution such issuance may have on the ownership interests of other shareholders of the Company.
(m) Stop Transfer. The Shares of Common Stock are restricted securities as of the date of this Agreement. The Company will not issue any stop transfer order or other order impeding the sale, resale or delivery of the Stock, except as may be required by federal securities laws.
(n) Defaults. To the best of the Company’s knowledge, neither the Company nor any of its subsidiaries is in violation of its Certificate of Incorporation or ByLaws. Neither the Company nor any of its subsidiaries is (i) in default under or in violation of any other material agreement or instrument to which it is a party or by which it or any of its properties are bound or affected, which default or violation would have a material adverse effect on the Company, (ii) in default with respect to any order of any court, arbitrator or governmental body or subject to or party to any order of any court or governmental authority arising out of any action, suit or proceeding under any statute or other law respecting antitrust, monopoly, restraint of trade, unfair competition or similar matters, or (iii) to its knowledge in violation of any statute, rule or regulation of any governmental authority which violation would have a material adverse effect on the Company.
(o) No Integrated Offering. The Company believes that neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would cause the offer of the Shares of Common Stock pursuant to this Agreement to be integrated with prior offerings by the Company for purposes of the 1933 Act or any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of the Bulletin Board nor will the Company or any of its affiliates or subsidiaries take any action or steps that would cause the offering of the Common Stock to be integrated with other offerings. The Company has not conducted and will not conduct any offer other than the transactions contemplated hereby that will be integrated with the offer or issuance of the Common Stock. Subscribers warrant and represent to the Company that each Subscriber has not taken any action that would cause a violation of the integration regulation as promulgated by Federal Law as made and provided.
(p) No General Solicitation. Neither the Company, nor any of its affiliates, nor to its knowledge, any person acting on its or their behalf, has engaged in any form
--------------------------------------------------------------------------------
of general solicitation or general advertising (within the meaning of Regulation S or D under the Act) in connection with the offer or sale of the Common Stock.
(q) Listing. The Company’s Common Stock is quoted on, and listed for trading on the Bulletin Board. The Company has not received any oral or written notice that its Common Stock will be delisted from the Bulletin Board or that the Company’s Common Stock does not meet all requirements for the continuation of such listing.
(r) No Undisclosed Liabilities. The Company has no liabilities or obligations which are material, individually or in the aggregate, which are not disclosed in the Reports, Securities and Exchange Commission filings, and Other Written Information, other than those incurred in the ordinary course of the Company’s businesses since December 31, 2001 and which, individually or in the aggregate, would not reasonably be expected to have a material adverse effect on the Company’s financial condition.
(s) No Undisclosed Events or Circumstances. Since December 31, 2001, no event or circumstance has occurred or exists with respect to the Company or its businesses, properties, operations or financial condition, that, under applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof by the Company but which has not been so publicly announced or disclosed in the Reports.
(t) Capitalization. The authorized and outstanding capital stock of the Company as of the date of this Agreement and the Closing Date are set forth on Schedule 2(t) hereto. Except as set forth in the Reports and Other Written Information and Securities and Exchange Commission filings, there are no options, warrants, or rights to subscribe to, securities, rights or obligations convertible into or exchangeable for or giving any right to subscribe for any shares of capital stock of the Company. All of the outstanding shares of Common Stock of the Company have been duly and validly authorized and issued and are fully paid and nonassessable.
(u) Correctness of Representations. The Company represents that the foregoing representations and warranties are true and correct as of the date hereof in all material respects, and, unless the Company otherwise notifies the Subscriber prior to the Closing Date, shall be true and correct in all material respects as of the Closing Date. The foregoing representations and warranties shall survive the Closing Date.
3. Regulation S Offering. This Offering is being made pursuant to the exemption from the registration provisions of the Securities Act of 1933, as amended, afforded by Regulation S promulgated there under. On the Closing Date, the Company will provide an opinion from the Company’s legal counsel based upon the representation of Subscribers opining on the availability of the Regulation S exemption as it relates to the offer and issuance of the Shares of Common Stock.
4. Reissuance of Shares of Common Stock. The Company agrees to reissue certificates representing the Shares of Common Stock without the legend set forth in Sections 1(e) above at such time as (a) the holder thereof is permitted to and disposes of such Shares of Common Stock pursuant to Rule 144(d) and/or Rule 144(k) under the 1933 Act or Regulation “S” in the opinion of counsel reasonably satisfactory to the Company, or (b) upon resale subject to an effective registration statement after the Shares are registered under the 1933 Act. The Company agrees to cooperate with the Subscriber in connection with all resales pursuant to Rule 144(d) and Rule 144(k) and provide legal opinions necessary to allow such resales provided the Company and its counsel receive requested written representations from the Subscriber and selling broker,
--------------------------------------------------------------------------------
if any. Provided the Subscriber provides required certifications and representation letters, if any, if the Company fails to remove any legend as required by this Section 4 (a “Legend Removal Failure”), then beginning on the tenth (10th) day following the date that the Subscriber has requested the removal of the legend and delivered all items reasonably required by the Company to be delivered by the Subscriber, the Company continues to fail to remove such legend, the Company shall pay to each Subscriber or assignee holding Shares, subject to a Legend Removal Failure, as liquidated damages and not a penalty an amount equal to one percent (1%) of the Purchase Price of the Shares subject to a Legend Removal Failure per day that such failure continues. If during any twelve (12) month period, the Company fails to remove any legend as required by this Section 4 for an aggregate of thirty (30) days, each Subscriber or assignee holding Shares subject to a Legend Removal Failure may, at its option, require the Company to purchase all or any portion of the Shares subject to a Legend Removal Failure held by such Subscriber or assignee at a price per share equal to 120% of the applicable Purchase Price.
5. Regulation D. In the event that a Subscriber does not qualify under Regulation S and qualifies under Regulation D, the Company covenants and agrees that if the Company fails to file a Registration Statement for Company Shares within ninety (90) days from the Closing Date pursuant to Section 10.1(iv) below, then for so long as such registration statement is not effective and as any of the Company Shares remain outstanding and continue to be “restricted Shares” within the meaning of Rule 144, the Company shall, in order to permit resales of any of the Company Shares pursuant to Rule 144 under the 1933 Act, (a) continue to file all material required to be filed pursuant to Section 13(a) or 15(d) of the 1934 Act.
6. Indemnification. The Company on the one hand, and the Subscriber on the other hand, agree to indemnify the other against and hold the other harmless from any and all liabilities to any other persons claiming brokerage commissions or finder’s fees other than Careen Limited on account of services purported to have been rendered on behalf of the indemnifying party in connection with this Agreement or the transactions contemplated hereby and arising out of such party’s actions. The Company and the Subscriber represent to each other that there are no other parties entitled to receive fees, commissions, or similar payments in connection with the offering described in the Subscription Agreement.
7. Covenants of the Company. The Company covenants and agrees with the Subscriber as follows:
(a) The Company will advise the Subscriber, promptly after it receives notice of issuance by the Securities and Exchange Commission, any state securities commission or any other regulatory authority of any stop order or of any order preventing or suspending any offering of any securities of the Company, or of the suspension of the qualification of the Common Stock of the Company for offering or sale in any jurisdiction, or the initiation of any proceeding for any such purpose.
(b) The Company will maintain the listing of its Common Stock on the NASDAQ SmallCap Market, NASDAQ National Market System, NASD OTC Bulletin Board, or New York Exchange, or Pink Sheet Trading Market (whichever of the foregoing is at the time the principal trading exchange or market for the Common Stock (the “Principal Market”), and will use its best efforts to comply, in all respects, with the Company’s reporting, filing and other obligations under the bylaws or rules of the National Association of Securities Dealers (“NASD”) and such exchanges, as applicable. The Company will provide the Subscriber copies of all notices it receives notifying the Company of the threatened and actual delisting of the Common Stock from any Principal Market.
--------------------------------------------------------------------------------
(c) The Company shall notify the Commission, NASD, the Principal Market and applicable state authorities, in accordance with their requirements, if any, of the transactions contemplated by this Agreement, and shall take all other necessary action and proceedings as may be required and permitted by applicable law, rule and regulation, for the legal and valid issuance of the Shares of Common Stock to the Subscriber and promptly provide copies thereof to Subscriber.
(d) From the Closing Date and until at least one (1) year after the effectiveness of the Registration Statement on Form S-2 or such other Registration Statement described in Section 10.1(iv) hereof, the Company will (i) cause its Common Stock to continue to be registered under Sections 12(b) or 12(g) of the Exchange Act, (ii) comply in all respects with its reporting and filing obligations under the Exchange Act, (iii) comply with all reporting requirements that are applicable to an issuer with a class of Shares registered pursuant to Section 12(g) of the Exchange Act, and (iv) comply with all requirements related to any registration statement filed pursuant to this Agreement. The Company will use its best efforts not to take any action or file any document (whether or not permitted by the Act or the Exchange Act or the rules thereunder) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under said Acts until one (1) year after the actual effective date of the Registration Statement on Form S-2 or other Registration Statement described in Section 10.1(iv) hereof. Until the resale of the Company Shares by the Subscriber, the Company will use its best efforts to continue the listing of the Common Stock on the Bulletin Board and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of Bulletin Board.
8. Covenants of the Company and Subscriber Regarding Indemnification.
(a) The Company agrees to indemnify, hold harmless, reimburse and defend Subscriber, Subscriber’s officers, directors, agents, affiliates, control persons, and principal shareholders, against any claim, cost, expense, liability, obligation, loss or damage (including reasonable legal fees) of any nature, incurred by or imposed upon Subscriber or any such person which results, arises out of or is based upon (i) any material misrepresentation by Company or breach of any warranty by Company in this Agreement or in any Exhibits or Schedules attached hereto, or other agreement delivered pursuant hereto; or (ii) after any applicable notice and/or cure periods, any breach or default in performance by the Company of any covenant or undertaking to be performed by the Company hereunder, or any other agreement entered into by the Company and Subscribers relating hereto.
(b) Subscriber agrees to indemnify, hold harmless, reimburse and defend the Company and each of the Company’s officers, directors, agents, affiliates, control persons against any claim, cost, expense, liability, obligation, loss or damage (including reasonable legal fees) of any nature, incurred by or imposed upon the Company or any such person which results, arises out of or is based upon (i) any material misrepresentation by Subscriber in this Agreement or in any Exhibits or Schedules attached hereto, or other agreement delivered pursuant hereto; or (ii) after any applicable notice and/or cure periods, any breach or default in performance by Subscriber of any covenant or undertaking to be performed by Subscriber hereunder, or any other agreement entered into by the Company and Subscribers relating hereto.
--------------------------------------------------------------------------------
(c) The procedures set forth herein shall apply to the indemnifications set forth in Sections 8(a) and 8(b) above.
10.1. Registration Rights. The Company hereby grants the following registration rights to holders of the Shares of Common Stock.
(a) The Company hereby agrees to register the Shares of Common Stock herein on a Form S-2 or any other applicable Form with the Securities and Exchange Commission within ninety (90) days of the date hereof, and it is further agreed that, should the Company not file a Registration Statement, as provided for herein, within the said 90 day period, that the Company will pay any liquidated damage penalty in the amount of up to 250,000 Common Shares for each ten (10) days that the Company fails to file the Registration Statement, as stated herein. It is understood that the liquidated damages will be calculated on a pro rata basis based upon the number of shares purchased by Subscribers. Subscribers agree that the registration will be on an optional piggy-back or single registration basis at the option of the Company, and that the Company will bear all costs and expenses of the registration.
(b) The Company agrees to give ten (10) days written notice to all Subscribers of the filing of the Registration Statement, and Subscribers agree that each will cooperate with the Company in providing the necessary information required by each Subscriber to file a Registration Statement on that Subscriber’s behalf.
(c) Each Subscriber agrees to execute the within Agreement and to subscribe for the number of Shares of Common Stock as agreed to by Subscriber.
10.2. Registration Procedures. If and whenever the Company is required by the provisions hereof to effect the registration of any Shares of Common Stock under the Act, the Company will, as expeditiously as possible:
(a) prepare and file with the Commission a Registration Statement with respect to such Shares of Common Stock and use its best efforts to cause such Registration Statement to become and remain effective for the period of the distribution contemplated thereby (determined as herein provided), and promptly provide to the holders of Shares of Common Stock (“Sellers”) copies of all filings with the Commission;
(b) prepare and file with the Commission such amendments and supplements to such Registration Statement and the prospectus used in connection therewith as may be necessary to keep such Registration Statement effective until the latest of: (i) 180 days following the effective date of the Registration Statement;
(c) furnish to the Seller, such number of copies of the Registration Statement and the prospectus included therein (including each preliminary prospectus) as such Seller reasonably may request in order to facilitate the public sale or their disposition of the securities covered by such Registration Statement;
(d) use its best efforts to register or qualify the Seller’s Shares of Common Stock covered by such Registration Statement under the securities or “blue sky” laws of such jurisdictions as the Seller shall reasonably designate, provided, however, that the Company shall not for any such purpose be required to qualify generally to transact business as a
--------------------------------------------------------------------------------
foreign corporation in any jurisdiction where it is not so qualified or to consent to general s
11/12/2002 (17:25 ET) New 8-K just released for CALY - Edgar
10/28/2002 (12:08 ET) MOVER(-): Calypte Biomedical Trading Lower In Session - Knobias
10/24/2002 (09:27 ET) CALY Conference Call Today at 11:00 AM ET - Knobias
10/24/2002 (09:20 ET) CALY Reports Q3 EPS (2c) vs (5c) Last Yr. on Rev $493K - Knobias
10/24/2002 (07:01 ET) Calypte Announces Third Quarter and Nine-Month Financial Results; Management Expects Sequential Fourth Quarter Revenue Growth of at Least 50 to 75% - Business Wire
JS200
10/28/2002 (12:08 ET) MOVER(-): Calypte Biomedical Trading Lower In Session - Knobias
10/24/2002 (09:27 ET) CALY Conference Call Today at 11:00 AM ET - Knobias
10/24/2002 (09:20 ET) CALY Reports Q3 EPS (2c) vs (5c) Last Yr. on Rev $493K - Knobias
10/24/2002 (07:01 ET) Calypte Announces Third Quarter and Nine-Month Financial Results; Management Expects Sequential Fourth Quarter Revenue Growth of at Least 50 to 75% - Business Wire
JS200
Ob das alles gut geht 12% Kreditzinsen ?
Wo zum Teufel haben die diese Kredite unterschrieben ?
Ich dachte in Amerika stehen die Darlehenszinsen bei 1,75 .
Bei der Verwässerung und bei solchen Krediten sind die schneller als wir glauben Pleite.
Salut
Wo zum Teufel haben die diese Kredite unterschrieben ?
Ich dachte in Amerika stehen die Darlehenszinsen bei 1,75 .
Bei der Verwässerung und bei solchen Krediten sind die schneller als wir glauben Pleite.
Salut
State Farm Bank®
Money Market
$0 - $99 0.00% 0.00%
$100 - $999 1.53% 1.54%
$1,000 - $4,999 1.93% 1.95%
$5,000 - $24,999 2.23% 2.25%
$25,000+ 2.28% 2.31%
Certificates of Deposit
less than $100,000
90 days 1.91% 1.93%
180 days 2.06% 2.08%
1 year 2.30% 2.33%
2 years 2.83% 2.87%
3 years 3.25% 3.30%
5 years 4.13% 4.22%
$100,000 or more
90 days 2.06% 2.08%
180 days 2.21% 2.23%
1 year 2.45% 2.48%
2 years 2.98% 3.02%
3 years 3.40% 3.46%
5 years 4.28% 4.37%
Individual Retirement Account (IRA) and
Coverdell Education Savings Account (ESA)
Certificates of Deposit
less than $100,000
1 year 2.30% 2.33%
2 years 2.83% 2.87%
3 years 3.25% 3.30%
5 years 4.13% 4.22%
$100,000 or more
1 year 2.45% 2.48%
2 years 2.98% 3.02%
3 years 3.40% 3.46%
5 years 4.28% 4.37%
Salut
Money Market
$0 - $99 0.00% 0.00%
$100 - $999 1.53% 1.54%
$1,000 - $4,999 1.93% 1.95%
$5,000 - $24,999 2.23% 2.25%
$25,000+ 2.28% 2.31%
Certificates of Deposit
less than $100,000
90 days 1.91% 1.93%
180 days 2.06% 2.08%
1 year 2.30% 2.33%
2 years 2.83% 2.87%
3 years 3.25% 3.30%
5 years 4.13% 4.22%
$100,000 or more
90 days 2.06% 2.08%
180 days 2.21% 2.23%
1 year 2.45% 2.48%
2 years 2.98% 3.02%
3 years 3.40% 3.46%
5 years 4.28% 4.37%
Individual Retirement Account (IRA) and
Coverdell Education Savings Account (ESA)
Certificates of Deposit
less than $100,000
1 year 2.30% 2.33%
2 years 2.83% 2.87%
3 years 3.25% 3.30%
5 years 4.13% 4.22%
$100,000 or more
1 year 2.45% 2.48%
2 years 2.98% 3.02%
3 years 3.40% 3.46%
5 years 4.28% 4.37%
Salut
@ lux
du glaubst doch nicht, daß die ihre RegS shares alle noch haben?
außerdem geht dir wohl ein grundlegendes verständnis ab: je größer das risiko, desto größer die prämie(hier:zins; auch wenn es darauf eigentlich gar nicht ankommt )
soviele financings und trotzdem blank am quartalsende; wenn der quartalsbericht endlich rauskommt, werden es wohl mittlerweile 120mio+ shares sein...
du glaubst doch nicht, daß die ihre RegS shares alle noch haben?
außerdem geht dir wohl ein grundlegendes verständnis ab: je größer das risiko, desto größer die prämie(hier:zins; auch wenn es darauf eigentlich gar nicht ankommt )
soviele financings und trotzdem blank am quartalsende; wenn der quartalsbericht endlich rauskommt, werden es wohl mittlerweile 120mio+ shares sein...
Kredit bei 12 % ?
Also ich verstehe das so:
Wenn eine Bank schon einen Kredit vergibt, dann muss doch was dahinter sein. Welche Bank vergibt denn schon Geld, wenn die Zahlung dessen in Frage steht?
Würde mich nicht wundern, wenn das in Amiland als vertrauensbeweis gilt und der Kurs steigt.
Grüße
Chartwaechter
Also ich verstehe das so:
Wenn eine Bank schon einen Kredit vergibt, dann muss doch was dahinter sein. Welche Bank vergibt denn schon Geld, wenn die Zahlung dessen in Frage steht?
Würde mich nicht wundern, wenn das in Amiland als vertrauensbeweis gilt und der Kurs steigt.
Grüße
Chartwaechter
Aber warum 12% zahlen wenn man es für 5% bekommen kann ?
Ich denke mal das Risiko ist einfach zu hoch.
Salut
Ich denke mal das Risiko ist einfach zu hoch.
Salut
@ charti
immer schön überprüfen was andere da schreiben, es geht hier natürlich nicht um einen bankkredit, sondern wie aus dem 8K ersichtlich, mal wieder um eine schuldverschreibung, die durch ausgabe von shares unterlegt ist. mehr oder weniger das gleiche wie vorher mit TIL. nur mit anderen SEC forms, damit es den anschein hat, als ob TCs aussage, ab sofort keine shares mehr zu verkaufen (wir erinnern uns, daß dies imho im zusammenhang mit dem china deal gesagt wurde), wahr wäre.
also: aktienverkauf weit unter marktpreis, nix kredit.
immer schön überprüfen was andere da schreiben, es geht hier natürlich nicht um einen bankkredit, sondern wie aus dem 8K ersichtlich, mal wieder um eine schuldverschreibung, die durch ausgabe von shares unterlegt ist. mehr oder weniger das gleiche wie vorher mit TIL. nur mit anderen SEC forms, damit es den anschein hat, als ob TCs aussage, ab sofort keine shares mehr zu verkaufen (wir erinnern uns, daß dies imho im zusammenhang mit dem china deal gesagt wurde), wahr wäre.
also: aktienverkauf weit unter marktpreis, nix kredit.
alles wird gut
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
224 | ||
124 | ||
105 | ||
64 | ||
55 | ||
39 | ||
38 | ||
35 | ||
27 | ||
26 |
Wertpapier | Beiträge | |
---|---|---|
21 | ||
21 | ||
20 | ||
18 | ||
18 | ||
17 | ||
17 | ||
17 | ||
16 | ||
16 |